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Objectives: To assess the clinical effectiveness 
and cost-effectiveness of topotecan as second-line 
treatment for small cell lung cancer (SCLC).
Data sources:  Bibliographic databases were searched 
from 1990 to February 2009, including the Cochrane 
library, MEDLINE (Ovid), EMBASE (Ovid), PREMEDLINE 
In-Process & Other Non-Indexed Citations. 
Bibliographies of related papers were assessed and 
experts were contacted to identify additional references 
and the manufacturer’s submission to NICE was also 
searched. 
Review methods: Two reviewers independently 
screened titles and abstracts for eligibility. Inclusion 
criteria were applied to the full text of retrieved papers 
using a standard form. For the clinical effectiveness 
review, the studies were randomised controlled 
trials (RCTs), which included adult participants with 
relapsed SCLC who responded to first-line treatment 
and for whom re-treatment with first-line therapy 
was inappropriate. The treatment was topotecan 
(oral or intravenous, i.v.) compared with one another, 
best supportive care (BSC) or other chemotherapy 
regimens. Outcomes included measures of response 
or disease progression and measures of survival. For 
the cost-effectiveness review studies were eligible for 
inclusion if they reported cost-effectiveness, cost–utility, 
cost–benefit or cost–consequence analyses. Data 
extraction and quality assessment of included studies 
was undertaken by one reviewer and checked by a 
second. Studies were synthesised through a narrative 
review with full tabulation of results. An independent 
economic model estimated the cost-effectiveness of 
topotecan (oral or i.v.) compared with BSC. The model 
used survival analysis methods to derive estimates of 
mean survival for patients treated with topotecan or 
receiving BSC alone. These were combined with quality 
of life (QoL) weights to derive estimates of mean 
quality-adjusted life expectancy for patients receiving 
BSC alone or topotecan plus BSC. Categories of costs 
included in the model included drug use, chemotherapy 
administration and on-treatment monitoring, 
management of adverse events, monitoring for disease 
progression and palliative care. 
Results: A total of 434 references were identified of 
which five were included in the clinical effectiveness 
review. In these trials topotecan was compared with 
BSC, CAV [cyclophosphamide, Adriamycin (doxorubicin) 
and vincristine] or amrubicin, or oral topotecan was 
compared with i.v. topotecan.  No economic evaluations 
were identified. There were no statistically significant 
differences between groups when i.v. topotecan was 
compared with either CAV or oral topotecan for 
overall response rate (ORR). Response rate was 
significantly better in participants receiving i.v. amrubicin 
than in those receiving a low dose of i.v. topotecan 
(38% versus 13%, respectively, p = 0.039). There was a 
statistically significant benefit in favour of oral topotecan 
compared with BSC (HR 0.61, 95% CI 0.43 to 0.87, 
p = 0.01). Drug acquisition costs for four cycles of 
treatment were estimated at £2550 for oral topotecan 
and £5979 for i.v. topotecan. Non-drug treatment costs 
accounted for an additional £1097 for oral topotecan 
and £4289 for i.v. topotecan. Total costs for the 
modelled time horizon of 5 years were £4854 for BSC, 
£11,048 for oral topotecan and between £16,914 and 
£17,369 for i.v. topotecan (depending on assumptions 
regarding time progression). Life expectancy was 0.4735, 
0.7984 and 0.7784 years for BSC, oral topotecan and i.v. 
topotecan respectively. Total quality-adjusted life-years 
(QALYs) were 0.2247 and 0.4077, for BSC and oral 
topotecan respectively, resulting in an incremental cost-
effectiveness ratio (ICER) of £33,851 per QALY gained. 
Total QALYs for i.v. topotecan were between 0.3875 
and 0.4157 (depending on assumptions regarding time 
progression) resulting in an ICER between £74,074 and 
£65,507 per QALY gained.
Conclusions: Topotecan appeared to be better than 
BSC alone in terms of improved survival, and was as 
Abstract
The clinical effectiveness and cost-effectiveness of 
topotecan for small cell lung cancer: a systematic 
review and economic evaluation
E Loveman,* J Jones, D Hartwell, A Bird, P Harris, K Welch and A Clegg
Southampton Health Technology Assessments Centre (SHTAC), UK
*Corresponding authorAbstract
iv
effective as CAV and less favourable than i.v. amrubicin 
in terms of response. Oral topotecan and i.v. topotecan 
were similar in efficacy. Topotecan offers additional 
benefit over BSC, but at increased cost. ICERs for i.v. 
topotecan, compared with BSC, were high and suggest 
that it is unlikely to be a cost-effective option. The ICER 
for oral topotecan is at the upper extreme of the range 
conventionally regarded as cost-effective from an NHS 
decision-making perspective. Further research into the 
QoL of patients with relapsed SCLC could identify the 
impacts of disease progression and treatment response.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Objectives
The aim of this systematic review and economic 
evaluation was to assess the clinical effectiveness 
and cost-effectiveness of topotecan as second-line 
treatment for small cell lung cancer (SCLC).
Epidemiology and 
background
Lung cancer is one of the most common cancers, 
with SCLC accounting for approximately 10–20% 
of all lung cancers. Without treatment, SCLC has 
an aggressive clinical course, with life expectancy of 
between 6 weeks and 3.5 months. However, SCLC 
is initially very sensitive to chemotherapy and this 
is reflected in prolonged median survival rates. 
Second-line chemotherapy is offered to patients at 
relapse, and depends on the response and duration 
of response to first-line therapy, but generally 
consists of a repeat of the first-line chemotherapy 
regimen. However, for some relapsed patients, 
this may not be considered appropriate due to 
the development of resistance, contraindications 
or adverse events. In these patients, alternative 
chemotherapy regimens can be used. This 
assessment considers topotecan, used within its 
licensed indication as second-line treatment for 
patients with relapsed SCLC, compared to other 
chemotherapy regimens or best supportive care 
(BSC) on measures of disease progression and 
survival.
Methods
Data sources
A sensitive search strategy was designed 
and applied to 11 electronic bibliographic 
databases (including MEDLINE, EMBASE and 
the Cochrane library) from 1990 to February 
2009. Bibliographies of related papers were 
screened, key cancer resources and symposia were 
searched, and experts were contacted to identify 
additional published and unpublished references. 
Manufacturer submissions to the National Institute 
for Health and Clinical Excellence (NICE) were 
also searched.
Study selection
Titles and abstracts were screened for eligibility 
by two independent reviewers. Inclusion criteria 
were defined a priori and applied to the full text of 
retrieved papers by two reviewers using a standard 
form. Studies were included if the participants 
were adults (≥ 18 years) with relapsed SCLC who 
responded to first-line treatment and for whom re-
treatment with first-line therapy was not considered 
appropriate; the treatment was topotecan [oral 
or intravenous (i.v.)] compared to one another, 
BSC or other chemotherapy regimens; the 
outcomes included measures of response or disease 
progression and measures of survival; the studies 
were randomised controlled trials.
Data extraction and quality 
assessment
Data extraction and assessment of methodological 
quality was undertaken by one reviewer and 
checked by a second. Differences in opinion were 
resolved through discussion or recourse to a third 
reviewer at each stage. Authors of all the trials were 
contacted to clarify if participants met the licensed 
indication of topotecan.
Data synthesis
The trials were reviewed in a narrative synthesis 
with full tabulation of the results of all included 
studies. Meta-analysis was not undertaken due to 
clinical heterogeneity in the patient groups and 
comparator treatments.
Economic model
An independent economic model was developed to 
estimate the cost-effectiveness of topotecan (oral or 
i.v.) compared with BSC for patients with relapsed 
SCLC, for whom re-treatment with the first-line 
regimen was not considered appropriate, from the 
perspective of the National Health Service (NHS) 
and Personal Social Services (PSS). The model used 
survival analysis methods to derive estimates of 
mean survival for patients treated with topotecan 
or receiving BSC alone, which were combined with 
quality of life (QoL) weights to derive estimates of 
mean quality-adjusted life expectancy for patients 
Executive summaryExecutive summary
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receiving BSC alone or topotecan plus BSC. The 
model includes an estimate of time to disease 
progression (TTP) for patients receiving topotecan, 
to take account of the reduction in QoL following 
disease progression.
Categories of costs included in the model include 
drug use, chemotherapy administration and on-
treatment monitoring, management of adverse 
events, monitoring for disease progression and 
palliative care. Resource use in the model was 
estimated from included RCTs, other published 
sources and advice from clinical experts. Drug 
costs were unit costs taken for the British National 
Formulary (BNF). Other unit costs were taken from 
published sources (including NHS Reference Costs) 
and from Southampton University Hospitals Trust.
The base-case model has a 5-year time horizon. 
Costs and health outcomes in the model are 
discounted at 3.5%. The estimated costs, life-years 
and quality-adjusted life-years (QALYs) for relapsed 
patients with SCLC receiving topotecan plus BSC 
and BSC alone in the model are presented. Results 
are reported as incremental cost per life-year 
gained and incremental cost per QALY gained.
Results
Quantity and quality of studies
A total of 434 references were identified. Ten 
publications describing five randomised controlled 
trials (RCTs) were included in the review of clinical 
effectiveness. One RCT compared oral topotecan 
plus BSC versus BSC alone; one trial compared 
i.v. topotecan against CAV [cyclophosphamide, 
Adriamycin (doxorubicin) and vincristine]; 
two studies evaluated oral topotecan versus i.v. 
topotecan and one RCT compared i.v. topotecan 
with i.v. amrubicin. Assessment of methodological 
reporting and quality varied between the included 
studies. In three trials the risk of selection bias 
was uncertain due to a lack of reporting of 
the methods of generating the randomisation 
sequence and allocation concealment, while there 
was a risk of detection bias in all of the studies. 
Overall, methodological quality was judged to be 
good in two trials and unknown in three trials. 
For two trials, uncertainty remains as to whether 
the included participants fully met the licensed 
indication for topotecan and, as such, caution 
is needed when interpreting the results as the 
population groups may be slightly different than 
those eligible for topotecan according to the 
marketing authorisation.
Systematic searches identified no fully published 
economic evaluations of oral or i.v. topotecan for 
the treatment of relapsed SCLC in patients who 
were not considered appropriate for re-treatment 
with their first-line regimen, and only limited 
information on QoL/utilities in patients with 
relapsed SCLC. The manufacturer’s submission 
(MS) in support of topotecan, which included an 
economic evaluation of oral topotecan plus BSC 
compared with BSC alone, was reviewed.
Summary of clinical 
effectiveness
There were no statistically significant differences 
between groups when i.v. topotecan was compared 
with either CAV or oral topotecan for overall 
response rate (ORR), the primary outcome in four 
RCTs. Response rate was seen to be significantly 
better in participants receiving i.v. amrubicin 
compared with i.v. topotecan (38% versus 13%, 
respectively, p = 0.039), although it should be 
noted that the dose of topotecan used (1.0 mg/
m2) was lower than the UK recommended dose 
(1.5 mg/m2). In the trial assessing oral topotecan 
against BSC, response was measured only in 
those in the topotecan group, as measurement 
of this outcome in the comparator (BSC alone) 
was not appropriate. Where reported, there were 
no statistically significant differences in TTP for 
i.v. topotecan compared with either CAV or oral 
topotecan.
In one RCT with overall survival (OS) as the 
primary outcome, there was a statistically 
significant benefit in favour of oral topotecan plus 
BSC compared with BSC alone [median difference 
12 weeks; HR 0.61, 95% confidence interval (CI) 
0.43 to 0.87, p = 0.01]. None of the remaining four 
RCTs showed any statistically significant differences 
in OS between treatment arms.
Only two trials measured QoL as a secondary 
outcome. QoL data showed a smaller decline 
in health status for those receiving topotecan in 
addition to BSC, although these results should be 
viewed with caution owing to issues surrounding 
the data reported. One of the trials comparing 
oral versus i.v. topotecan reported no statistical 
differences between groups, although no data were 
presented.
Generally, rates of adverse events were observed to 
be comparable across treatments in the included 
studies. Some haematological toxicities occurred 
significantly more frequently in the topotecan DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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group compared with CAV, whereas rates of 
haematological toxicities in the topotecan versus 
amrubicin trial varied between arms. Toxicities 
observed with oral and i.v. topotecan were similar. 
Rates of adverse events and toxicities were not 
tested for statistical significance in the studies.
Summary of costs
Drug acquisition costs for four cycles of treatment 
(the mean number of cycles in trials of oral and 
i.v. topotecan), assuming a patient BSA of 1.8 m2, 
were estimated at £2550 for oral topotecan and 
£5979 for i.v. topotecan. Non-drug treatment costs 
(for chemotherapy administration and monitoring 
while on treatment) accounted for an additional 
£1097 for oral topotecan [30% of total treatment 
costs, of which £743 (68%) is for chemotherapy 
administration] and £4289 for i.v. topotecan [42% 
of total treatment costs, of which £3936 (92%) is for 
chemotherapy administration].
Further costs are associated with the management 
of adverse events, which amount to £1584 for oral 
topotecan (30% of total treatment cost) and £1149 
for i.v. topotecan (10% of total treatment cost). In 
both cases the majority of adverse event costs are 
associated with haematological toxicity.
Summary of cost-effectiveness
The manufacturer’s economic model, based on 
individual patient data from one RCT, compared 
oral topotecan plus BSC with BSC alone. The 
QALY gain with oral topotecan plus BSC was 
estimated at 0.211 in the base-case analysis. The 
cost difference was £5671, giving an incremental 
cost-effectiveness ratio (ICER) of £26,833 per 
QALY gained. Subgroup analyses suggested that 
oral topotecan may be more cost-effective in 
patients whose TTP from prior therapy was ≤ 60 
days, in women and in those patients without liver 
metastases. Treatment with oral topotecan plus 
BSC also appeared to be more cost-effective for 
patients with a performance status of 2, as opposed 
to those with performance status of 0 or 1.
In the independent model the gain in discounted 
life expectancy associated with the addition of oral 
topotecan to BSC was 0.33 years (approximately 
16.9 weeks) and the discounted QALY gain 
was 0.1830 QALYs. The incremental cost was 
approximately £6194, resulting in an ICER of 
£33,851 per QALY with the addition of oral 
topotecan to BSC.
The gain in discounted life expectancy associated 
with i.v. topotecan, compared with BSC, in the 
independent model was 0.30 years (approximately 
15.9 weeks) – 1 week shorter than the base-case 
analysis for oral topotecan. The discounted 
QALY gain is between 0.1628 and 0.1910 QALYs, 
depending on assumptions regarding TTP, while 
the incremental cost is approximately £12,000, 
resulting in an ICER between £65,507 and £74,074 
per QALY gained, for i.v. topotecan compared with 
BSC. Compared with oral topotecan, i.v. topotecan 
is strictly dominated or is associated with a very 
high ICER.
Sensitivity analyses
In a deterministic sensitivity analysis using the 
manufacturer’s model, the results were sensitive to 
methods of estimating QoL, drug administration 
costs and adverse event costs. Using a parametric 
cost-effectiveness acceptability curve, the MS 
reported a probability of oral topotecan plus BSC 
being cost-effective, compared with BSC alone, 
of 22% at a willingness to pay (WTP) threshold of 
£20,000 per QALY and 60% at a WTP threshold of 
£30,000 per QALY.
In a deterministic sensitivity analysis using the 
independent model, the cost-effectiveness results 
for oral topotecan plus BSC were generally robust 
to variation in parameters values. The results were 
most sensitive to assumptions over the form of 
survival functions adopted and variation in values 
of parameters in the survival functions, variation in 
utility estimates applied in the model and the cost 
of outpatient attendance for the administration 
of oral chemotherapy. In a probabilistic sensitivity 
analysis the probability of oral topotecan plus BSC 
being cost-effective, compared with BSC alone, was 
estimated at 0% using a WTP threshold of £20,000 
and a 20% probability using a WTP threshold 
of £30,000 per QALY. A probabilistic sensitivity 
analysis for i.v. topotecan showed zero or very low 
probability of being cost-effective, compared with 
BSC alone, at WTP thresholds up to £50,000.
Conclusions
In summary, the clinical evidence indicates that 
topotecan is better than BSC alone in terms of 
improved survival, is as effective as CAV, and less 
favourable than i.v. amrubicin in terms of response. 
Oral topotecan and i.v. topotecan were shown to 
be similar in efficacy. It remains uncertain whether Executive summary
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topotecan is more or less toxic than comparator 
interventions.
The cost-effectiveness analysis showed that, for 
patients with relapsed SCLC, topotecan offers 
additional benefit over BSC, but at increased cost. 
Costs for i.v. topotecan are substantially higher 
than for oral topotecan, while health benefits 
are largely equivalent. ICERs for i.v. topotecan, 
compared with BSC, are high and suggest that 
it is unlikely to be a cost-effective option for this 
group of patients. Oral topotecan is associated with 
a lower ICER than BSC, although this remains at 
the upper extreme of the range conventionally 
regarded as cost-effective from an NHS decision-
making perspective. Sensitivity analyses suggest 
the exact value of the ICER is highly dependent 
on assumptions regarding QoL for patients 
with relapsed SCLC and who are receiving oral 
topotecan.
Recommendations for 
further research
It is unlikely that any further RCTs of topotecan 
compared with BSC will be ethically acceptable, 
nor is it likely for there to be a need to undertake 
a further comparison with CAV therapy, and there 
is little to be gained from undertaking further 
evidence of the effectiveness of intravenous versus 
oral topotecan. However, given the ongoing RCTs 
of topotecan versus amrubicin it would be desirable 
to update the current review when these report.
Further research is required into the QoL of 
patients with relapsed SCLC, to identify the impact 
of disease progression on QoL. In the case of 
patients receiving active treatment, further research 
is required on the impact of response [complete 
response (CR) or partial response (PR)] and the 
impact of treatment-related adverse events on QoL.
Further research on the impact of active treatment 
on resource use for palliative care would improve 
cost-effectiveness models for topotecan. Data 
collection on resource use in the RCT by O’Brien 
and colleagues was not comprehensive. It is 
difficult to determine whether the lower proportion 
of patients receiving radiotherapy and palliative 
medication (in the topotecan plus BSC arm) 
indicates a genuine reduction in palliative care 
interventions or a postponement until disease 
progression occurs.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Description of underlying 
health problem
Lung cancer can be categorised into four major 
cell types: small cell lung cancer (SCLC), squamous 
cell carcinoma (SCC), adenocarcinoma (AC) and 
large cell carcinoma.1 The last three cell types are 
most often described as ‘non-small cell lung cancer’ 
(NSCLC). SCLCs are usually centrally located, 
with extensive mediastinal involvement, tend to 
grow rapidly and spread quickly to distant sites 
(metastases).2 SCLC is typically classified using a 
two-stage system: limited-stage disease and extensive-
stage disease, according to the level of progression 
of the disease. Limited-stage disease is generally 
confined to one hemithorax and its regional 
lymph nodes, in the absence of malignant effusion, 
and can be encompassed in one radiotherapy 
port. Extensive-stage disease is disease beyond 
the confines of the thorax at diagnosis, with the 
presence of systemic metastases, and cannot be 
encompassed safely in one radiotherapy port.3 The 
prognosis for patients with extensive-stage disease 
is much poorer than for those with limited-stage 
disease. Most SCLCs present with metastases – a 
recent review found that two-thirds of patients have 
extensive disease on presentation.4
In most patients the disease is symptomatic on 
presentation. In some, there are non-specific 
symptoms such as fatigue, anorexia, and weight 
loss, whereas in others there are more direct 
signs and symptoms, such as breathlessness, 
chest discomfort and haemoptysis (blood-stained 
sputum).2 SCLC is also associated with systemic 
symptoms that are related to paraneoplastic 
syndromes.5 These are caused by the release of 
bioactive substances produced by the tumour, or 
in response to the tumour,2 and include endocrine 
syndromes and neurological syndromes.5 The 
most common endocrine syndrome in SCLC is 
inappropriate secretion of antidiuretic hormone 
(leading to water retention), hyponatraemia 
(low sodium), and hypotension (low blood 
pressure). Digital clubbing and hypertrophic 
pulmonary osteoarthropathy are common skeletal 
manifestations.2
Small cell lung cancer is initially very sensitive 
to chemotherapy, with 60–90% of patients with 
limited-stage disease responding to first-line 
therapy, and 40–70% of patients achieving a 
complete response (CR) (no further evidence 
of disease).6 For extensive-stage disease, 
approximately 50–85% of patients respond to first-
line therapy.7
Aetiology
Risk factors for lung cancer include tobacco 
exposure, occupational exposure, gender, diet 
and chronic lung disease. Smoking is the leading 
cause of lung cancer, accounting for approximately 
80–90% of cases,8,9 although it is likely that the 
cause of lung cancer is multifactorial and involves 
more than a simple association with smoking.10 
When compared with people who have never 
smoked, those who have smoked without quitting 
successfully have a 20-fold increase in lung cancer 
risk.11 The risk for lung cancer among cigarette 
smokers increases with the duration of smoking 
and the number of cigarettes smoked per day.11 
The association with smoking has been shown 
to be much stronger in SCLC than NSCLCs in 
a meta-analysis.12 Passive smoking [referred to 
as environmental tobacco smoke (ETS)] is also 
associated with lung cancer, albeit more weakly 
than active smoking.8
Lung cancer was initially seen at higher rates in 
males, being associated with an earlier start of 
smoking tobacco and the higher quantities of 
tobacco smoked.8,10 However, the disease has been 
declining in recent years in males, but increasing 
in women, most likely due to changes in smoking 
practices.10,12 Whether men and women differ in 
their susceptibility to the carcinogens in tobacco 
smoke remains the focus of controversy. Some 
studies report that women who smoke have a 
significantly larger relative increase in lung cancer 
risk than men.13 Other studies, however, have 
found that there do not appear to be differences 
between men and women in their susceptibility 
to lung cancer, given comparable smoking 
histories.12,14 A recent cohort study13 of 279,214 
men and 184,623 women, for example, suggests 
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that women are not more susceptible than men to 
the carcinogenic effects of cigarette smoking.
Occupational exposure to compounds such as 
asbestos, radon, chromium and nickel has also been 
recognised to be a risk factor for lung cancer.15 A 
diet that is rich in fruits and vegetables is associated 
with a reduced risk of lung cancer in smokers, 
ex-smokers and those who have never smoked.8,16 
Some studies have also shown an association 
between dietary beta-carotene intake and a lower 
risk of lung cancer.8 However, intervention trials of 
beta-carotene supplementation have either shown 
no effect, or an increased risk of lung cancer.16 
Other dietary factors that may have an association 
with a higher risk of lung cancer are high fat and 
cholesterol content, meat consumption, high 
intakes of dairy products and high consumption of 
alcohol.16 However, because tobacco smoking has 
such an overwhelming contribution to the risk of 
lung cancer, it is often difficult to assess whether 
dietary factors independently are risk factors for 
lung cancer.8,16
An increased susceptibility to lung cancer may also 
result from the presence of previous lung disease.10 
Associations have been noted in the literature, but, 
as with the association with dietary factors, these 
are also possibly confounded by tobacco smoking 
and therefore findings are contestable.8 Chronic 
obstructive pulmonary disease (COPD) has been 
shown to be an independent predictor of lung 
cancer risk in some studies, however.10
Diagnosis and staging
Lung cancer is usually suspected on the basis of 
an initial clinical assessment – taking into account 
the patients’ symptoms, history and a physical 
examination – in addition to an abnormal chest 
radiograph. Confirmation of the diagnosis is 
then achieved using histological and cytological 
tests. Patients with SCLC are generally staged by 
clinical evaluation and computerised tomography 
(CT) scan of the chest and abdomen.3,17 The 
TNM (tumour, node, metastases) stage scores 
are not usually relevant in SCLC due to the high 
proportion of patients presenting with metastases 
and its poor prediction of survival.4,17 As previously 
mentioned, SCLC is classified as limited-stage 
disease or extensive-stage disease, classified 
according to the level of progression of disease. 
Selection of the most appropriate treatment is 
determined primarily by the stage of disease (see 
Current service provision).
Performance status
Measurement of the functional status of a patient 
is often described in terms of the World Health 
Organization/Eastern Cooperative Oncology Group 
(WHO/ECOG) performance status scores.18 This 
scale rates the effect on daily living on a scale of 
0–5, where 0 is ‘fully active, able to carry on all 
pre-disease performance without restriction’, 4 is 
‘completely disabled, cannot carry out any self-care, 
totally confined to bed or chair’ and 5 is ‘dead’ 
(see Appendix 1). The Karnofsky performance 
status scale, can also be used to measure functional 
status in SCLC. This is a 100-point scale, rating 
performance from death (0), through inability to 
care for self, to able to carry on normal activity with 
no evidence of disease (100)19 (for full details, see 
Appendix 1).
Epidemiology
Lung cancer is one of the most common cancers 
in England, accounting for some 15% of all 
malignancies in males and 11% in females in 
2005.20 Lung cancer is the most common cause of 
death from cancer worldwide.21–23 The proportion 
of lung cancer cases classified as small cell type has 
been steadily falling over the years. The reasons 
for this are unclear, but it has been attributed to 
changing smoking habits.8,12,24 Cancer statistics do 
not appear to distinguish between the different 
histological types of lung cancer in their rates. 
However, estimates suggest that small cell lung 
cancers account for approximately 10–20% of 
lung cancers, with rates in more recent estimates 
reflecting the lower end of this range.3,25,26 
Therefore, crude estimates of the epidemiology of 
SCLC can be generated from the overall rates of 
lung cancer.
There were 33,181 new cases of lung cancer in 
England and Wales in 2005,20,27 with more cases 
in males than in females (19,261 males, 13,920 
females). European age-standardised incidence 
rates of lung cancer in England in 2005 were 72.9 
per 100,000 in males and 50.6 per 100,000 in 
females.20 The corresponding rates in Wales in 
2005 were 62.5 per 100,000 (males) and 39.5 per 
100,000 (females).27 In 2006, estimates of the age-
standardised incidence rates of lung cancer in the 
UK were lower than estimates for all European 
Union countries for males (57.1 per 100,000 
compared with 71.8 per 100,000), but higher 
for females (34.6 per 100,000 versus 21.7 per 
100,000).21 Taking a range of 10–20% for SCLC, 
an estimate of the number of new cases of SCLC 
per year (using 2005 estimates for England and DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Wales20,27) would be in the region of 3300–6600 for 
England and Wales.
The incidence of lung cancer rises with increasing 
age. Very few people are diagnosed under the age 
of 40 years, and the incidence shows a peak in 
rates around ages 75–84 years. Most cases occur 
in people over the age of 60 years.28 Time trends 
in the incidence of lung cancer show an overall 
decline in rates between 1995 and 2004.28 Recently, 
the National Lung Cancer Audit was set up in 
England and Wales to collect information on lung 
cancer, with the aim of understanding incidence, 
treatments, and outcomes and to explore regional 
variations. The report for the period 2006–726 
presents data derived from the National Lung 
Cancer Data Audit (LUCADA) database in England 
and via the Cancer Network Information System 
Cymru (CANISC) in Wales, and includes data 
from 93% of trusts from these countries. This 
showed that the incidence of lung cancer is clearly 
associated with the degree of deprivation; there 
was more than a twofold difference in incidence 
between the most affluent groups and the most 
deprived groups.26 The report confirms the positive 
association between deprivation and levels of 
smoking, which may account for much of this 
difference.
Prognosis
Lung cancer is the most common cause of death 
from cancer in both men and women.22,23 The 
survival rate has improved in recent years,29 
although deaths from lung cancer remain high 
(5-year age-standardised survival rate of 5.8% 
and 6.4% in males and females, respectively, 
from 1996–9) in the UK.29 This is partly owing to 
diagnosis often being at a late stage, when curative 
treatments are not possible.30 SCLCs tend to grow 
rapidly and have a greater tendency to widely 
metastasise.10 An important predictor of prognosis 
in SCLC is the extent of disease progression. 
Without treatment, SCLC has an aggressive clinical 
course, with life expectancy of about 3.5 months 
for limited-stage disease and 6 weeks for extensive-
stage disease.31 With treatment, median survival 
for patients with limited-stage disease is 16 to 22 
months; for those with extensive-stage disease 
median survival is 10 months.32 Approximately 
20–40% of patients with limited-stage SCLC 
and fewer than 5% of patients with extensive-
stage SCLC survive for 2 years.33 Survivors often 
continue to relapse up to, and occasionally after, 
5 years. However, for those surviving long term, 
relapse after 5–6 years appears to be a rare event,34 
although in one study, longer-term survivors 
appeared to be at high risk of a second primary 
cancer.34
Prognostic factors have been reported by a 
number of studies in the literature and while 
comparisons are not necessarily easy to make 
between these different studies, a number of key 
variables do appear to be consistently identified 
as having an effect on prognosis. In a review for 
the Lung Cancer Subcommittee of the United 
Kingdom Coordinating Committee on Cancer 
Research (UKCCCR) in 1990, Rawson and Peto35 
identified a number of variables which contributed 
significantly to the prediction of likely survival 
over the 6 months after starting treatment. 
They demonstrated that performance status, 
alkaline phosphatase and disease stage were the 
most important prognostic factors. More recent 
epidemiological studies show similar results. 
Lassen and colleagues36 studied prognostic factors 
that correlated with survival after 18-months in a 
retrospective review of 1714 patients with SCLC. 
The extent of disease and the performance status 
were found to be of prognostic significance. 
In limited-stage disease, an elevated lactate 
dehydrogenase (LDH) (an enzyme that is often 
raised in cancers and can be used as a marker of 
disease) was considered unfavourable. In this study, 
gender appeared to have no significant influence 
on survival.36 Similar findings were observed in an 
analysis by the Southwest Oncology Group in the 
USA, although in this study female gender was 
seen to be an additional independent favourable 
predictor.37 In this latter study, predictors of 
survival in those with extensive-stage SCLC 
were the number of metastatic sites, with lower 
numbers of sites being related to better prognosis. 
In an exploratory analysis of patients from four 
European clinical trials, characteristics that were 
associated with a higher objective response rate 
included higher performance status, limited-
stage disease, and absence of brain metastases.38 
This study also found that women fared better 
than men,38 as did an analysis of prognostic 
factors from a 5-year randomised controlled trial 
(RCT).39 Prominent prognostic factors among all 
patients with SCLC in this latter study were also 
extent of disease, LDH levels and weight loss.39 
SCLC is frequently associated with paraneoplastic 
syndromes (above), which can be caused by either 
ectopic hormone production or antibody-mediated 
tissue destruction.33 Ectopic hormone production 
is the synthesis and secretion of a hormone by a 
tumour of a tissue that does not normally produce 
the particular hormone, and it has been associated Background
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with extensive-stage SCLC and a poorer outcome.40 
Antibody-mediated paraneoplastic syndromes 
are, however, associated with more favourable 
outcomes.33,40
Current service provision
Selection of the most appropriate first-line 
treatment for SCLC is determined primarily by the 
stage of disease. Treatments include chemotherapy, 
radiotherapy or a combination of these treatments, 
with increased survival attributed to combination 
therapy.41 The majority of patients with SCLC are 
inoperable,42 as the disease is often widespread at 
the time of diagnosis.5
The current National Institute for Health and 
Clinical Excellence (NICE) guidelines3 recommend 
that patients with SCLC should be offered a 
multidrug platinum-based chemotherapy as first-
line therapy. Those with limited-stage disease 
should be offered radiation concurrently with the 
first or second cycle, or following completion if 
a good partial response (PR) is seen within the 
thorax. Their initial treatment is usually followed 
by prophylactic cranial irradiation, in order 
to reduce the risk of cerebral metastases.26 For 
those with extensive-stage disease, prophylactic 
cranial radiation should be considered following 
chemotherapy if there has been a CR at distant 
sites and at least a good PR in the thorax.43
The platinum-based treatment combinations 
for first-line therapy that are offered (and 
recommended by NICE) are either cisplatin or 
carboplatin with etoposide. Other active agents 
include anthracyclines (doxorubicin, epirubicin), 
alkylating agents (cyclophosphamide, ifosfamide), 
vinca alkaloids (vindesine, vincristine) and taxanes 
(paclitaxel).
While guidelines for rapid referral of patients 
exist, there are many routes of patient referral.26 
Only 48% of patients are directly referred to 
specialist lung cancer teams via their GP, possibly 
due to the non-specific nature of lung cancer 
symptoms.26 The majority of trusts in England and 
Wales now have rapid access clinics, managed by 
a multidisciplinary team (MDT).26 The national 
lung cancer audit report 2006–7 asserts that 
outcomes for patients with lung cancer in the 
UK vary widely across the country and are poor 
when compared to many other countries.26 The 
specialist nature of cancer treatments means that 
patients are often treated by more than one trust.26 
Despite NICE’s recommendation that all patients 
are reviewed, figures suggest that this occurs in 
only 86% of cases.26 Specific anticancer treatment 
– such as chemotherapy and radiotherapy – as 
first-line treatment are suggested to remain low 
by international standards.26 In addition, the 
likelihood of receiving chemotherapy in the 
UK declines rapidly for anyone over 75 years of 
age.26 The report suggests that while prognosis 
for patients with lung cancer has remained poor 
with little improvement in long-term survival, 
applying best practice could provide a considerate 
improvement in outcomes.26
Objective tumour response is assessed by 
radiograph or CT scan. A response requires 
the tumour to reduce by at least 30% using a 
unidimensional measure such as the Response 
Evaluation Criteria In Solid Tumors (RECIST) 
or 50% using a bidimensional measure (WHO), 
with reduction maintained for at least 4 weeks (see 
Appendix 1). Response to first-line therapy for 
SCLC can be categorised as ‘sensitive’, ‘resistant’ or 
‘refractory’.6 ‘Sensitive’ refers to a tumour response 
of more than 90 days, ‘resistant’ to tumour 
recurrence within 90 days and ‘refractory’ to 
tumours that either never responded or progressed 
during first-line therapy. It is generally thought 
that those with a sensitive response will have the 
greatest potential for second-line therapy.6
Second-line treatment decisions depend on the 
response to first-line therapy and the duration 
of that response.3,44 Evidence suggests that the 
best results from second-line chemotherapy 
are achieved in those with at least 3 months 
between response and progression.4 On relapse, 
re-treatment with the same chemotherapy 
regimen is reasonable if a durable first-line 
response is achieved. For other patients, this may 
not be appropriate due to a short duration of 
response, the development of resistance or other 
contraindications.45 In these patients, alternative 
chemotherapy regimens can be used.46
Intravenous topotecan has been assessed by 
the Scottish Medicines Consortium (SMC) 
[which makes recommendations to the National 
Health Service (NHS) in Scotland], but was not 
recommended for the treatment of patients with 
relapsed SCLC, ‘for whom re-treatment with the 
first-line regimen is not considered appropriate’.47 
In contrast, the All Wales Medicines Strategy 
Group (AWMSG) has recommended i.v. topotecan 
for ‘use within NHS Wales for the treatment of 
patients with relapsed small SCLC for whom DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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re-treatment with the first-line regimen is not 
considered appropriate’.48 However, the AWMSG 
also noted that topotecan should be initiated only 
by specialists who are experienced in the treatment 
of SCLC and it was not recommended for shared 
care.
UK research, using a 4-year retrospective patient-
chart analysis, determined the average cost for the 
treatment of patients with SCLC using a variety 
of sources.49 The calculated cost per patient from 
a cohort of 109 patients was £11,556, with the 
most expensive element through all phases of the 
disease being hospitalisation.49 The average patient 
cost for first-line treatment was estimated at £6128 
(48.7% of total costs), with 28% of the total costs 
down to recurrence of the disease until death. The 
average cost per patient for second-line treatment 
was around £5008.49
Description of new 
intervention
Topotecan is an anticancer treatment that acts by 
the inhibiting the enzyme topoisomerase I, which 
is required for DNA replication. This leads to cell 
death.
Topotecan is indicated for patients as a second-
line therapy in those patients with relapsed SCLC 
for whom re-treatment with the first-line regimen 
is not considered appropriate. The marketing 
authorisation for i.v. therapy was granted in the UK 
in 2006, and, more recently, a licence was granted 
for oral therapy (2008). The recommended dose 
for i.v. treatment is 1.5 mg/m2 of body surface area/
day in a 30-minute infusion for 5 consecutive 
days, in a 21-day cycle. The cost of i.v. topotecan is 
£97.65 per milligram, which equates to £147.47 m2/
day.50 For oral treatment the recommended dose is 
2.3 mg/m2/day, administered for 5 consecutive days, 
in 21-day cycles. The cost of oral topotecan is £30 
per milligram, which equates to £69 m2/day.51 Each 
oral capsule contains topotecan hydrochloride 
equivalent to 0.25 mg or 1 mg of topotecan. 
The advantage of the oral form of topotecan 
is that it does not need specialist preparation 
and administration, and can therefore be self-
administered.52 However, no guidance advising 
which form may provide the better treatment has 
been identified.
Treatment may continue until disease progression 
if the treatment is well tolerated. Oral topotecan 
can be self-administered on an outpatient basis. 
Intravenous topotecan is administered in secondary 
or tertiary care settings, usually on a day-case basis.
Topotecan is contraindicated in patients who 
have a history of hypersensitivity to the active 
substance, are breastfeeding or already have 
severe bone marrow depression prior to starting 
the first course. Haematological toxicity may 
occur, and a full blood count (FBC) including 
platelets should be monitored regularly. As with 
other anticancer therapies, topotecan can cause 
severe myelosuppression, which can lead to 
sepsis. Other potential adverse effects include 
nausea and vomiting, diarrhoea, alopecia and 
fatigue. Topotecan rarely causes life-threatening 
neutropenic colitis. Topotecan is produced by 
GlaxoSmithKline (GSK) and trades under the 
name ‘Hycamtin’.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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T
he a priori methods for systematically 
reviewing the evidence of clinical and 
cost-effectiveness are described in the research 
protocol (Appendix 2), which was sent to experts 
for comment. No comments were received which 
identified specific problems with the methods of 
the review. The methods outlined in the protocol 
are briefly summarised below. The methods of 
the SHTAC (Southampton Health Technology 
Assessments Centre) economic evaluation can be 
seen in Chapter 4 (Methods for economic analysis).
Search strategy
The search strategy was developed, tested 
and refined by an experienced information 
scientist. Separate searches were conducted to 
identify studies of clinical effectiveness, cost-
effectiveness, quality of life (QoL), resource use/
costs and epidemiology/natural history. Sources 
of information and search terms are provided in 
Appendix 3.
Searches for clinical and cost-effectiveness 
literature were undertaken from 1990 to August 
2008. Given that marketing authorisation for 
topotecan was first granted in 1996, it was deemed 
unlikely that there would be any trials before 
1990 for topotecan for any indication. Electronic 
databases searched included the Cochrane 
Database of Systematic Reviews (CDSR), the 
Cochrane Central Register of Controlled Trials, 
CRD (University of York) Database of Abstracts 
of Reviews of Effectiveness (DARE), the NHS 
Economic Evaluation Database (NHS EED) 
and the Health Technology Assessment (HTA) 
database, MEDLINE (OVID), EMBASE (OVID), 
PREMEDLINE In-Process & Other Non-Indexed 
Citations; Web of Knowledge Science Citation 
Index (SCI); Web of Knowledge ISI Proceedings; 
PsycInfo (EBSCO), Biosis, CINAHL (EBSCO), 
NIHR Clinical Research Network Portfolio, Current 
Controlled Trials, ClinicalTrials.gov and Cancer 
Research UK trials. Key cancer resources including 
the American Society of Clinical Oncology (ASCO) 
and relevant cancer symposia, including the 
12th World Lung Cancer Conference, were also 
searched. Updated searches were carried out in 
February 2009.
The searches were restricted to English language. 
Bibliographies of related papers were screened for 
relevant studies, and the manufacturer’s submission 
(MS) to NICE was assessed for any additional 
studies [see Appendix 4 for a critique of the clinical 
effectiveness section of the MS, and Chapter 
4 (Methods for economic analysis) for further 
discussion of the cost-effectiveness section]. Experts 
who were contacted for advice and peer review 
were also asked to identify additional published 
and unpublished references. The authors of the 
five included studies were contacted to establish 
whether the patient populations in the trials met 
the review inclusion criteria with regard to being 
inappropriate for re-treatment with first-line 
therapy.
Inclusion and data 
extraction process
Titles and abstracts identified by the search 
strategy for the clinical effectiveness section of the 
review were assessed for possible eligibility by two 
independent reviewers. The full texts of relevant 
papers were then obtained, and inclusion criteria 
were applied by one reviewer and checked by a 
second reviewer. Any disagreements over eligibility 
were resolved by consensus or by recourse to a third 
reviewer. Data were extracted by one reviewer using 
a standardised data extraction form and checked by 
a second reviewer.
Titles and abstracts identified by the search 
strategy for the cost-effectiveness section of the 
review were assessed for potential eligibility by 
two health economists. Economic evaluations were 
considered for inclusion if they reported both 
health service costs and effectiveness, or presented 
a systematic review of such evaluations. Full papers 
were formally assessed for inclusion by one health 
economist.
Quality assessment
The quality of included RCTs and systematic 
reviews was assessed using criteria recommended 
by the Centre for Reviews and Dissemination 
(CRD)53 (Appendix 5). Quality criteria were applied 
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by one reviewer and checked by a second reviewer. 
At each stage, any differences in opinion were 
resolved through discussion or consultation with a 
third reviewer.
Inclusion criteria
Population
•  Adults (≥ 18 years) with relapsed SCLC who 
responded to first-line treatment and for 
whom re-treatment with first-line therapy 
is not considered appropriate (due to 
contraindications, adverse effects).
•  Patients may have had limited-stage disease or 
extensive-stage disease.
•  Response to initial treatment may have been 
either CR or PR.
•  Patients who did not respond to first-line 
therapy (including patients whose tumours did 
not respond, or who progressed, during first-
line treatment) were not included.
•  Studies with a mix of untreated and previously 
treated patients (or responders and non-
responders) were not included unless the 
groups were reported separately.
Intervention
•  Intravenous topotecan (administered as 
second-line treatment).
•  Oral topotecan (administered as second-line 
treatment).
•  Studies with a focus on first-line treatment were 
not included.
•  Effectiveness data for oral and i.v. topotecan 
were not combined.
Comparators
•  Intravenous and oral topotecan compared with 
each other.
•  Best supportive care (BSC) (including 
radiotherapy).
•  CAV (cyclophosphamide, doxorubicin, 
vincristine).
•  Other chemotherapy regimens.
Outcomes
Studies reporting one or more of the following 
outcomes were included:
•  time to disease progression (TTP)
•  progression-free survival (PFS)
•  response rate (see below)
•  response duration
•  overall survival (OS)
•  symptom control
•  health-related QoL (using a validated measure)
•  cost-effectiveness (incremental cost per life-year 
gained) or cost–utility [incremental cost per 
quality-adjusted life-year (QALY) gained].
Adverse effects of treatments were reported if 
available within trials that met the prespecified 
inclusion criteria above.
Understanding the definition of treatment 
‘response’ used within the studies is important. Two 
criteria have been identified, which appear to be 
widely reported in oncology research – the WHO 
criteria54 and the RECIST guidelines.55 These 
are summarised in Appendix 1. Where a clinical 
trial documents which criteria were used to define 
treatment response and related outcomes, this 
is reported in the current review. Where it is not 
certain what the definition of response was, this is 
similarly noted.
Types of studies
RCTs were included. Studies published as abstracts 
or conference presentations were included only 
if sufficient details were presented to allow an 
appraisal of the methodology and the assessment 
of results to be undertaken. Systematic reviews were 
used only as a source of references.
For the systematic review of cost-effectiveness, 
studies were only eligible for inclusion if they 
reported the results of full economic evaluations 
[cost-effectiveness analyses (reporting cost per life-
year gained), cost–utility analyses or cost–benefit 
analyses].
Data synthesis
Data were synthesised through a narrative review, 
with tabulation of results of all included studies. 
Full data extraction forms are presented in 
Appendix 6. It was not considered appropriate to 
combine the included RCTs in a meta-analysis due 
to clinical heterogeneity in the patient groups and 
comparator treatments.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Quantity and quality of 
research available
Included studies
Searches identified 395 references, after removal 
of duplicates. After initial screening of titles and 
abstracts, 385 references were excluded. Ten full 
copies of articles were retrieved, with four excluded 
on further inspection. In addition, 22 abstracts 
were identified on searches of the proceedings of 
ASCO, with 21 of these being excluded during the 
screening process. The included ASCO abstract 
later became available as a fully published article. 
Two (out of nine) abstracts were also identified 
from the 12th World Lung Cancer Conference 
2007, which were linked to one of the included 
studies. Eight studies were identified in the 
updated searches, but none were included. The 
total number of published papers included at each 
stage of the systematic review is shown in the flow 
chart in Figure 1, and the list of excluded studies 
can be seen in Appendix 7. The level of agreement 
between reviewers assessing study eligibility was 
high.
Ten publications describing five RCTs appeared to 
meet the inclusion criteria of the review.56–65 Five 
of the articles were either earlier abstracts60–62 or 
abstracts presenting additional results64,65 linked 
to full publications,56,57,59,63 leaving five RCTs to be 
evaluated. Only one trial appeared to fully meet 
the inclusion criteria of the review on inspection 
of the published article,57 and this was confirmed 
in correspondence with the author (participants 
were inappropriate for re-treatment with their 
original first-line chemotherapy for reasons such 
as contraindication, toxicity and refusal). The 
remaining four RCTs did not appear to fully 
meet the inclusion criteria of having participants 
for whom re-treatment with their first-line 
chemotherapy regimen was not appropriate, as per 
the licensed indication for topotecan. Authors of all 
of these publications were contacted to clarify this 
aspect of our inclusion criteria. Response from one 
author established that two of the included trials58,59 
did meet this aspect of the inclusion criteria. In the 
correspondence with the author from a third trial,63 
it was reported that participants were not required 
to have a ‘contraindication’ to re-treatment with 
their first-line therapy to meet the study protocol. 
Chapter 3  
Clinical effectiveness
Total identified on searching (after 
de-duplication) n = 434a 
References for retrieval 
and screening n = 19 
Excluded 
n = 415 
Excluded 
n = 10 
Total included references n = 10b
(5 RCTS reported in 10 publications)
Titles and abstracts 
inspected 
FIGURE 1  Flow chart of identification of studies for inclusion in the review.a Includes total number of studies identified in searches of 
ASCO, 12th World Lung Cancer Conference and updated search in addition to main search.b One identified ASCO abstract subsequently 
published as a full publication.Clinical effectiveness
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TABLE 1  Studies included in the review, by intervention
Study Intervention Comparator
O’Brien et al. 200657,64,65 Oral topotecan + BSC BSC alone
von Pawel et al. 199959,61 Intravenous topotecan CAV
aEckardt et al. 200756,60 Oral topotecan Intravenous topotecan
von Pawel et al. 200158 Oral topotecan Intravenous topotecan
aInoue et al. 200862,63 Intravenous topotecan Intravenous amrubicin
a  There is some uncertainty that the population groups in these trials fully reflect those covered in the marketing 
authorisation.
Whether there were other reasons that would have 
deemed participants as being inappropriate for 
re-treatment, or whether all participants could 
have been appropriate for re-treatment, however, 
is not clear. No reply was received from the 
author of one other study,56 so it remains unclear 
whether the included participants fully met the 
licensed indication for topotecan. Despite these 
uncertainties, these last two studies were included, 
although we emphasise the need for caution in 
the interpretation of results, as the population 
groups may be slightly different than those 
eligible for topotecan according to the marketing 
authorisation. In summary, five trials were included 
in this review (Table 1).
Description of the included 
studies
Four56–59 of the included studies were international, 
multicentre RCTs, varying between 31 and 83 
centres (numbers not reported in one59). The fifth 
study63 was a multicentre RCT carried out in 12 
centres in Japan. Two of the studies were phase II 
trials.58,63 Four of the trials were sponsored by the 
drug manufacturers,56–59 whereas financial support 
was reported to be provided by two of the authors 
in the trial by Inoue and colleagues.63
The study of O’Brien and colleagues (2006)57 
investigated oral topotecan plus BSC versus 
BSC alone in a population of participants who 
were considered to be unsuitable for further 
i.v. chemotherapy. The study initially excluded 
participants with a treatment-free interval (TFI) 
of > 90 days for whom treatment with BSC was 
not acceptable. This changed during the trial 
and some participants with sensitive SCLC, who 
were unsuitable for standard i.v. chemotherapy 
due to co-morbidities or who had refused i.v. 
chemotherapy due to the risk of toxicity, became 
eligible for inclusion in the study. The study 
protocol was amended to allow the inclusion of 
such patients. In the topotecan plus BSC group, 
participants received 2.3 mg/m2 of oral topotecan 
on days 1–5 every 21 days. A minimum of four 
treatment cycles were recommended, but delays 
and dose adjustments were anticipated in the study 
protocol. BSC was defined as including measures 
such as ‘analgesics, antibiotics, corticosteroids, 
appetite stimulants, antidepressants, red blood 
cell transfusions, deep relaxation therapy, and 
palliative radiotherapy or surgical procedures’. 
Both treatment groups had equal access to these 
treatments.
A study by von Pawel and colleagues (1999)59 
compared i.v. topotecan with CAV in a population 
of participants with limited- or extensive-stage 
SCLC, with a CR or PR to first-line chemotherapy 
and who had relapsed ≥ 60 days after cessation 
of first-line therapy. Participants who were 
contraindicated to re-treatment with CAV were 
specifically excluded from this study and therefore 
the participants may not be those that would 
normally be eligible for topotecan. The i.v. 
topotecan group received 1.5 mg/m2 as a 30-minute 
infusion for 5 days every 21 days, whereas the 
CAV group received an infusion of 1000 mg/m2 
(maximum 2000 mg) of cyclophosphamide, 45 mg/
m2 (maximum 100 mg) of doxorubicin and 2 mg 
of vincristine, all on day 1 of each 21-day course. 
Second-line treatment duration was dependent 
on response to second-line treatment. Participants 
with stable disease received a minimum of four 
treatment cycles, whereas patients with a CR or PR 
received at least six.
Two studies56,58 compared oral topotecan with i.v. 
topotecan, in a population of participants with 
limited- or extensive-stage relapsed SCLC who 
had CR or PR to first-line therapy with disease 
recurrence after ≥ 90 days. In both studies, 
participants received 2.3 mg/m2 of oral topotecan DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
11
compared with 1.5 mg/m2 of i.v. topotecan for 5 
days every 21 days. Treatment duration depended 
on response, but in both studies participants with 
stable disease received at least four treatment 
cycles. Protocol-specified dose adjustments were 
permitted in both trials.
The trial by Inoue and colleagues63 compared i.v. 
topotecan with i.v. amrubicin (an anthracycline) 
in a population of participants with SCLC, who 
were previously treated with platinum-containing 
chemotherapy and who had either sensitive 
(relapse ≥ 90 days after cessation of first-line 
therapy) or refractory relapse (defined as no 
response to first-line chemotherapy or relapse 
within 90 days after cessation of first-line therapy). 
The study suggested that the latter category may 
also include participants who never responded to 
first-line treatment, although whether this is the 
case or what proportion this includes is unknown. 
The majority of participants were sensitive to the 
first-line therapy. Participants received 40 mg/m2 
of amrubicin as a 5-minute infusion on days 1–3 
every 3 weeks. Topotecan was administered as a 
30-minute infusion on days 1–5 every 3 weeks 
at a dose of 1.0 mg/m2, which is the approved 
dosage in Japan. This is lower than the UK 
recommended dose (1.5 mg/m2/day) given in the 
other studies.56,58,59
The key characteristics of the RCTs are shown in 
Table 2. The numbers of participants ranged from 
59 in the Inoue and colleagues trial63 to 309 in the 
Eckardt and colleagues trial.56 The age ranges of 
the participants in four of the studies was similar 
(the mean ages were not reported consistently 
across studies), whereas the fifth study provided 
no information about the age of the participants.59 
All studies had a higher percentage of male 
participants in both treatment arms (male range 
57–83%, female range 17–43%). Where reported, 
studies had a higher proportion of participants 
with extensive-stage disease and these were 
similar across treatment groups. The percentage 
of participants with extensive disease was similar 
in three studies,56–58 at 61–72%, higher in a fourth 
study59 at 83–85%, and not reported by the fifth 
study.63
The proportion of participants with a performance 
status of zero was lowest in the O’Brien and 
colleagues study57 (~10%), higher in three 
trials,56,58,59 ranging from 17% to 33%, whereas 
the trial by Inoue and colleagues63 had a much 
higher proportion (48–57%). Four trials had 
similar proportions of participants (55–65%) 
with a performance status of one,56–59 with the 
exception of the i.v. topotecan group in the von 
Pawel and colleagues (2001) trial58, which was 
lower (39%). This was similar to the proportions 
in both treatment groups (30–34%) in the study 
by Inoue and colleagues (2008).63 When grouping 
together performance status zero and one, all 
trials had similar numbers of good performance 
status participants (70–80%). The percentage of 
participants with a performance status of two were 
mixed between studies. Within two studies,56,63 
the proportion was low and similar across arms 
(12–17%). In a third study,59 percentages were 
slightly higher (19–24%), and in a fourth trial57 
percentages were higher still (27–33%), but similar 
across treatment arms. In the trial by von Pawel 
and colleagues (2001),58 there were almost twice as 
many participants with a performance status of two 
in the i.v. topotecan group (28%) compared with 
the oral topotecan group (15%).
Liver metastases were present in around 30% of 
participants in two studies,56,58 but higher in both 
treatment groups (~40%) in the study by von 
Pawel and colleagues (1999).59 In the O’Brien 
and colleagues’ study,57 liver metastases were 
present in a greater proportion of topotecan 
participants (28%) compared to BSC (20%), 
although the authors do not report that this is a 
statistically significant difference. Presence of liver 
metastases was not reported in the trial by Inoue 
and colleagues.63 Duration of response to first-
line chemotherapy was 6 months or more for the 
majority of patients in both treatment groups for 
two studies,56,58 and around a median of 23–24 
weeks in another study.59 Inoue and colleagues63 
did not report these data. In the study by O’Brien 
and colleagues,57 this was reported as median TTP 
after first-line chemotherapy, and was 84 days in 
the topotecan arm and 90 days in the BSC arm.
Four RCTs56,58,59,63 reported response rate as the 
primary outcome measure, with the two trials by 
von Pawel and colleagues also reporting duration of 
response58,59 and TTP.58 OS and toxicities/symptoms 
were reported as secondary outcomes in these four 
studies. O’Brien and colleagues57 reported OS as 
the primary outcome and response rate, TTP and 
adverse effects/toxicities as secondary outcome 
measures. Two trials56,57 reported health-related 
QoL.
Quality assessment of included 
studies
The methodological quality of reporting in the 
included studies was assessed using criteria set by Clinical effectiveness
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the CRD at the University of York,53 and varied 
across studies (Table 3). Two trials57,59 described an 
adequate randomisation procedure that ensured 
both true random assignment to treatment groups 
and adequate concealment of allocation. The 
other three studies56,58,63 provided no details of 
the methods of generating the randomisation 
sequence, nor the allocation procedure used, 
and, consequently, are rated as unknown on 
these quality factors. Without adequate published 
information it is not possible to assess whether 
there is a risk of selection bias in these studies, with 
the allocation sequence being open to possible 
manipulation.
All the trials reported eligibility criteria adequately 
and participants appeared similar at baseline on 
key demographic and prognostic characteristics, 
although in some cases supporting statistical 
comparisons were not provided. None of the RCTs 
reported if either the caregivers or participants 
were blinded to the treatment. However, given 
the disparity in the treatment interventions, 
blinding of participants or care providers may 
have not been possible in some trials, but the 
studies did not discuss this. Details of blinding 
for outcome assessors were partially reported 
by three trials,56,58,59 inadequately reported in 
one trial57 and unknown in one trial.63 This may 
lead to detection bias, particularly for subjective 
outcomes such as QoL assessments. Outcomes were 
reported adequately in four trials,56–59 and partially 
in one.63 An appropriate intention-to-treat (ITT) 
data analysis was reported to be undertaken and 
assessed as adequate in only three trials.57–59 In two 
trials,56,63 the analysis was not true ITT, as it was 
based on all of those who received treatment, not 
on all of those who were randomised. Reasons for 
withdrawals were adequately explained by three 
trials,56,57,63 partially reported by one,59 and classed 
as inadequate for another trial, as there was no 
discussion of numbers or reasons for any attrition.58 
Overall, methodological quality was judged to be 
reasonably good in two trials, and unknown in 
three trials.
Assessment of clinical 
effectiveness
Oral topotecan plus BSC versus 
BSC alone
Survival
One trial (O’Brien and colleagues57) was included, 
which compared oral topotecan plus BSC with BSC 
alone. Overall survival was the primary outcome 
in this study. The median survival was reported 
to be 25.9 [95% confidence interval (CI) 18.3 to 
31.6] weeks in the oral topotecan plus BSC-treated 
participants and 13.9 (95% CI 11.1 to 18.6) weeks 
in those with BSC alone. This was not tested for 
statistical significance. Six-month survival rates 
were 49% versus 26% for the oral topotecan plus 
BSC, and BSC groups, respectively (Table 4). Using 
Kaplan–Meier analysis, the hazard ratio (HR) for 
OS was 0.64 (95% CI 0.45 to 0.90) in favour of oral 
topotecan. With adjustment for covariates, the HR 
was reported to be 0.61 (95% CI 0.43 to 0.87). This 
showed a statistically significant benefit for the oral 
topotecan plus BSC group, compared with BSC 
alone (log-rank p = 0.01).
Data were presented on subgroup analyses of 
survival according to the various stratification 
factors (gender, performance status, TTP, presence 
of liver metastases). However, the HRs and 95% CI 
were only presented in a figure and hence are not 
reported in detail here. Estimates of these rates can 
be seen, however, in Appendix 6. Overall, the data 
indicate a survival trend favouring oral topotecan 
plus BSC for all subgroups analysed. However, 
the 95% CI cross 1.0 for TTP > 60 days, male 
gender, PS 0/1, and liver metastases on the figures 
presented in the paper. It is also not clear whether 
the study was powered for these analyses.
Participant dropout rates differed between the 
study arms (30% topotecan plus BSC, 47% BSC), 
although the study reports that an ITT principle to 
the analyses of data were applied. No participants 
crossed over, although there were a number of 
participants in both groups who received additional 
chemotherapy and/or radiotherapy post-study. It is 
not clear whether this may have had an impact on 
the OS rates shown, but the proportions receiving 
post-study chemotherapy are observed to be similar 
between treatment arms (18.6% and 18.3% for the 
topotecan plus BSC and BSC arms, respectively).
Progression-free survival was not reported in the 
O’Brien and colleagues57 study.
Response
The overall response rate (ORR) (classified as 
either CR or PR, although only PRs were seen) 
was measured in 60 out of the 71 participants 
randomised to oral topotecan plus BSC. This was 
measured using WHO criteria and was reported 
to be 7% (95% CI 2.33 to 15.67). The study also 
reports a subgroup analysis according to one 
stratification factor (TTP) for response, but these 
data are not reported here, as they were only for 
the oral topotecan plus BSC group.Clinical effectiveness
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Eckardt et al. 200756,60 Un Un Rep Ad Par Un Un Ad In Ad
Inoue et al. 200862,63 Un Un Rep Ad Un Un Un Par In Ad
O’Brien et al. 200657 Ad Ad Rep Ad In Un Un Ad Ad Ad
von Pawel et al.199959,61 Ad Ad Rep Ad Par Un Un Ad Ad Par
von Pawel et al. 200158 Un Un Rep Ad Par Un Un Ad Ad In
Ad, adequate; In, inadequate; Par, partial; Rep, reported; Un, unknown.
TABLE 4  Overall survival (oral topotecan plus BSC versus BSC)
Study: O’Brien et al. 200657
Treatment arms
p-value
Oral topotecan + BSC 
(n = 71)
BSC  
(n = 70)
OS, median (weeks) 25.9 (95% CI 18.3 to 31.6) 13.9 (95% CI 11.1 to 18.6) Not reported
6-month survival rate (%) 49 26 Not reported
Duration of response
The median time to progressive disease in the oral 
topotecan plus BSC group was 16.3 weeks (95% 
CI 12.9 to 20.0). Those in the BSC group were 
already in a progressive disease state and hence 
no comparison was made in the study report. It 
was also reported that 83% (n = 59) of the oral 
topotecan plus BSC group experienced progression 
and 34% (n = 24) reached progressive disease (by 
WHO criteria). Some 44% (n = 31) of participants 
had achieved stable disease. It is unclear in 
the study report at what point these data were 
collected.
Quality of life
The study of O’Brien and colleagues57 reports the 
rate of deterioration of QoL (per 3-month period) 
as measured by the EuroQol 5 dimension health 
questionnaire (EQ-5D) (lower score indicates 
worse QoL). Baseline EQ-5Ds were completed by 
68 (96%) participants in the oral topotecan plus 
BSC group and 65 (93%) participants in the BSC 
group. At least one postbaseline questionnaire 
was completed by 63 (89%) participants in the 
oral topotecan plus BSC group and 49 (70%) 
participants in the BSC group. No baseline 
scores were presented (see Appendix 11). The 
results showed a difference between treatment 
arms, favouring the oral topotecan plus BSC arm 
(topotecan + BSC: –0.05, 95% CI –0.11 to 0.02; 
BSC: –0.20, 95% CI –0.27 to –0.12, difference 0.15, 
95% CI 0.05 to 0.25).
The Chen and colleagues (2007)64 abstract 
reported additional QoL data on the EQ-5D index 
as well as the visual analogue scale [(VAS) – lower 
score indicates poorer imaginable health state]. 
The mean change from baseline in both the EQ-5D 
index and VAS for the pooled and last evaluation 
analyses was statistically significantly different 
between groups (Table 5), indicating a smaller 
decline in health status for those receiving oral 
topotecan plus BSC. It should be noted that the 
high proportion of participants reported to have 
completed at least one postbaseline questionnaire 
does not necessarily reflect the number of 
participants in the pooled and last evaluation 
analyses. In the pooled estimate, there will be a 
number of participants who were tested a number 
of times (depending on, for example, survival, 
inability or refusal to complete the questionnaire) 
with the results of multiple assessments averaged; 
in the last evaluation analysis, it is possible that 
results from some participants were missing for the DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 5  Quality of life (oral topotecan plus BSC versus BSC)
Study: O’Brien et al. 200657,64
Treatment arms
p-value
Oral topotecan + BSC 
(n = 71)
BSC  
(n = 70)
EQ-5D, rate of deterioration per 3-month 
interval
–0.05
(95% CI –0.11 to 0.02)
–0.20
(95% CI –0.27 to –0.12)
Difference 0.15
(95% CI 0.05 to 0.25)
EQ-5D index (pooled analysisa), mean 
change from baseline
–0.03 –0.12 Difference 0.09
(p = 0.0036)
EQ-5D index (changeb), mean change from 
baseline
–0.10 –0.30 Difference 0.2
(p = 0.0034)
EQ-5D VAS (pooled analysisa), mean 
change from baseline
0.30 –7.41 Difference 7.71
(p < 0.0001)
EQ-5D VAS (changeb), mean change from 
baseline
–3.98 –14.46 Difference 10.48
(p = 0.0025)
a  Change from baseline to averaged on-treatment assessments.
b  Change from baseline to last evaluation analysis.
same reasons, but these numbers are not known. 
Also caution should be taken in interpreting the 
results as the data are reported in abstract form 
only.
Symptoms
O’Brien and colleagues57 also report participant 
symptoms based on a self-reported measure, 
the patient symptom assessment (PSA) scale, 
which evaluates the degree to which participants 
experience nine symptoms, rating from 1 (no 
symptom) to 4 (very severe symptoms). The 
results are presented as odds ratios (ORs) of the 
likelihood of symptom improvement with oral 
topotecan plus BSC relative to BSC alone. The ORs 
presented for each individual symptom suggest 
that shortness of breath (OR 2.18, 95% CI 1.09 to 
4.38), sleep disturbance (OR 2.16, 95% CI 1.15 to 
4.06) and fatigue (OR 2.29, 95% CI 1.25 to 4.19) 
may be improved in those with oral topotecan 
plus BSC (all p < 0.05). The other symptoms were 
not found to be statistically significantly different 
between the two treatment arms (individual 
symptoms can be seen in Table 6). For this measure, 
baseline questionnaires were completed by 70 
participants in the topotecan plus BSC group and 
67 participants in the BSC group. The numbers of 
participants with sufficient data to be included in 
the analyses varied for the symptom scores between 
47 and 48 for the BSC group, and between 60 and 
61 for the topotecan plus BSC group. In addition, 
although this scale is reported to resemble a well-
validated lung cancer symptom scale (LCSS), it is 
unclear whether the PSA scale has been validated, 
therefore the outcomes should be cautiously 
interpreted. A more recent abstract (2007) by 
O’Brien and colleagues65 presents a subgroup 
analysis of the association between baseline PSA 
total scores and performance status according to 
PR or stable disease for the oral topotecan plus 
BSC group only, but the data have neither been 
extracted nor reported here.
Adverse events and toxicity
Rates of adverse events between those in the oral 
topotecan plus BSC arm and those in the BSC 
alone arm were reported for non-sepsis infection, 
sepsis, diarrhoea, fatigue, vomiting, dyspnoea 
and cough in the O’Brien and colleagues study,57 
and can be seen in Table 7. From this it can be 
observed that rates were generally low and similar 
across groups, with the exception of diarrhoea and 
dyspnoea, which are slightly different between 
the groups. None of these was tested for statistical 
significance, and it is not clear whether the 
definitions of these symptoms differ from those 
used in the PSA as reported above. All-cause 
mortality within 30 days of randomisation was 7% 
in the oral topotecan plus BSC arm and 13% in the 
BSC alone arm.
Treatment-related toxicity was also presented for 
the oral topotecan-treated group and is shown 
in Table 8. From this it can be seen that 61% had 
grade 3 or 4 neutropenia, with 3% of participants 
(n = 2) observed to have febrile neutropenia. 
Grade 3 or 4 thrombocytopenia was seen in 38% 
of participants, and anaemia in 25%. It is unclear, Clinical effectiveness
20
TABLE 6  Symptoms (oral topotecan plus BSC versus BSC)
Study: O’Brien et al. 200657
Odds ratio: oral 
topotecan–BSC 95% CI p-value
Improvement in PSA scores
Shortness of breath 2.18 1.09 to 4.38 p < 0.05
Cough 1.35 0.68 to 2.66 NS
Chest pain 2.07 1.00 to 4.28 NS
Coughing blood 1.95 0.46 to 8.27 NS
Loss of appetite 1.02 0.57 to 1.84 NS
Interference of sleep 2.16 1.15 to 4.06 p < 0.05
Hoarseness 1.35 0.63 to 2.87 NS
Fatigue 2.29 1.25 to 4.19 p < 0.05
Interference with daily activity 1.70 0.95 to 3.03 NS
NS, not significant.
TABLE 7  Adverse events (oral topotecan plus BSC versus BSC)
Study: O’Brien et al. 200657
Treatment arms:
Oral topotecan + BSC (n = 71) BSC (n = 70)
Non-sepsis infection ≥ grade 2 10 (14%) 8 (12%)
Sepsis 3 (4%) 1 (1%)
Diarrhoea 6% 0
Fatigue 4% 4%
Vomiting 3% 0
Dyspnoea 3% 9%
Cough 0 2%
TABLE 8  Toxicities (oral topotecan plus BSC versus BSC)
Study: O’Brien et al. 200657 Topotecan + BSC (n = 71)
Treatment-related toxicity (%)
Grade 3/4 neutropenia 61
Grade 3/4 thrombocytopenia 38
Grade 3/4 anaemia 25
Febrile neutropenia 3
because of the nature of the study, what the impact 
of these rates of toxicities may be taken to mean 
as there can be no comparator data. Toxic deaths 
occurred in 4 (6%) participants, three of which were 
due to haematological toxicity.
Summary of effectiveness of oral 
topotecan plus BSC versus BSC alone
In this one RCT of reasonable quality, there 
appears to be an OS benefit to having oral 
topotecan in addition to BSC. The HR, adjusted 
for baseline covariates, was favourable to oral 
topotecan. OS was the primary outcome in this 
study. Response was measured in only those in 
the oral topotecan group, as no comparator was 
appropriate. In those who were assessed, QoL was 
better in those who were given oral topotecan in 
addition to BSC. Rates of adverse events appeared 
to be similar between the two groups. Toxicities 
were reported, but, due to the nature of the DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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comparator intervention, cannot be placed into 
context in this study alone.
Intravenous topotecan versus 
CAV
Survival
The von Pawel and colleagues (1999) trial59 was 
the only trial that compared i.v. topotecan with 
CAV. The median OS was reported to be 25.0 
weeks (range 0.4–90.7) for participants who were 
given topotecan and 24.7 weeks (range 1.3–101.3) 
for participants given CAV (Table 9). The Cox 
regression model for survival showed no statistically 
significant difference between treatment groups 
(p = 0.795), with a risk ratio (RR) of topotecan–CAV 
of 1.039. At the time of analysis, 11.2% and 12.5% 
of topotecan and CAV participants, respectively, 
were censored for survival. The 6- and 12-month 
survival rates, calculated using Kaplan–Meier 
analysis, were similar between treatment groups 
and can be seen in Table 9.
Subgroup analyses (see Appendix 6 for full data) of 
the two stratification factors, baseline performance 
status and extent of disease, found that these 
were statistically significant prognostic factors for 
survival (p < 0.001). In addition to the stratification 
factors, gender, baseline liver metastases and 
baseline brain metastases were also found to be 
TABLE 9  Overall survival (i.v. topotecan versus CAV)
Study: von Pawel et al. 199959
Treatment arms
p-value
Intravenous topotecan 
(n = 107)
CAV  
(n = 104)
OS (weeks), median (range)  25 (0.4–90.7)a 24.7 (1.3–101.3) p = 0.795
Survival rate (%)
6 months 46.7 45.2 Not reported
12 months 14.2 14.4 Not reported
a  Includes censored events.
TABLE 10  Response (i.v. topotecan versus CAV)
Study: von Pawel et al. 
199959
Treatment arms
p-value, 95% CI
Intravenous topotecan 
(n = 107)
CAV  
(n = 104)
ORR, n (%) 26 (24.3), 95% CI 16.2 to 32.4 19 (18.3), 95% CI 10.8 to 25.7 p = 0.285, difference 6.0% 
(95% CI 6 to 18a) – CR 0 1 (1)
– PR 26 (24.3) 18 (17.3)
Response duration (weeks), 
median (range)
n = 26
14.4 (9.4–50.1)
n = 19
15.3 (8.6–69.9)b p = 0.300
Time to response (weeks), 
median (range)
n = 26
6 (2.4–15.7)
n = 19
6.1 (5.4–18.1) p = 0.953
Non-responders, n (%)
– overall 81 (75.7) 85 (81.7) Not reported
– stable disease 21 (19.6) 12 (11.5) Not reported
– progressive disease 49 (45.8) 55 (52.9) Not reported
– not assessable 11 (10.3) 18 (17.3) Not reported
a  Possible error in reporting of 95% CI in this study.
b  Includes censored events.Clinical effectiveness
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significant factors for survival (p < 0.05). However, 
after adjustment for the covariates, the effect 
of treatment was still not statistically significant 
(RR 1.17, p = 0.322). It should be noted that it is 
unclear if the study was powered for the subgroup 
analyses and results should be interpreted with 
caution.
Progression-free survival was not reported in the 
von Pawel and colleagues (1999) study.59
Response
Response rate and duration of response were the 
primary outcomes in this study, and response 
rates were determined using the WHO criteria. 
The ORR was 24.3% (95% CI 16.2 to 32.4) for 
participants who received topotecan compared with 
18.3% (95% CI 10.8 to 25.7) for participants who 
received CAV (p = 0.285), with a difference in the 
rates of response of 6.0% (95% CI 6 to 18) (Table 
10). A CR was achieved in only one participant 
(CAV); 24.3% and 17.3% of topotecan and CAV 
participants, respectively, achieved a PR. A logistic 
regression model (evaluating the effect of baseline 
characteristics) identified presence of baseline 
liver metastases and gender as significant factors 
in determining response (p = 0.043 and p = 0.008, 
respectively – see Appendix 6). It should be noted 
that the authors only presented data for the factors 
that were shown to be statistically significant. After 
adjusting for the covariates, it is reported that 
those treated with topotecan showed a greater 
propensity to respond than did those treated 
with CAV, although the result was not statistically 
significant (OR 1.24, p = 0.557). Subgroup analyses 
for males and females, and for those experiencing 
relapse 60–90 days after completion of first-line 
chemotherapy, were reported, but not tested, for 
statistical significance (see Appendix 6).
Duration of response and time to 
response
High proportions of participants in each treatment 
group did not respond to treatment. The 
proportion of non-responders reported to have 
stable or progressive disease (according to WHO 
criteria) or who were not assessable are shown in 
Table 10. On the whole, the proportions appear 
similar between treatment groups, although slightly 
more in the topotecan arm were classed as having 
stable disease. However, no statistical comparison 
was reported. The median duration of response was 
14.4 weeks (range 9.4–50.1) in the topotecan group 
and 15.3 weeks (range 8.6–69.9) in the CAV group, 
with no statistically significant difference between 
groups (p = 0.300). Similarly, the median time to 
response was not statistically different between 
treatments (p = 0.953) and was approximately 6 
weeks in each arm.
Time to progression
No statistically significant difference was found 
between topotecan and CAV for median TTP (13.3 
weeks versus 12.3 weeks, respectively, p = 0.552) 
(Table 11).
Quality of life
Quality of life was not reported in the von Pawel 
and colleagues (1999) study.59
Symptoms
von Pawel and colleagues (1999)59 used a symptom-
specific SCLC questionnaire to measure participant 
symptoms. Patient symptom assessments were 
scored on a four-point ordinal scale (1, not at 
all; 2, a little bit; 3, quite a bit; 4, very much), 
and improvement had to be sustained for two 
consecutive courses. Symptom evaluation also 
included the time to symptom worsening as 
defined by the interval from the first dose of study 
medication until the first evidence of worsening in 
the postbaseline assessment.
Using Pearson’s uncorrected chi-squared statistic 
to compare treatment groups, greater symptomatic 
improvement was seen in participants who received 
topotecan for symptoms of dyspnoea (p = 0.002), 
anorexia (p = 0.042), hoarseness (p = 0.043) and 
fatigue (p = 0.032), as well as for interference with 
daily activity (p = 0.023). The other symptoms 
TABLE 11  Time to disease progression (i.v. topotecan versus CAV)
Study: von Pawel et al. 199959
Treatment arms
p-value
Intravenous topotecan 
(n = 107)
CAV  
(n = 104)
TTP (weeks), median (range) 13.3 (0.4–55.1) 12.3 (0.1–75.3)a p = 0.552
a  Includes censored events.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 12  Symptoms (i.v. topotecan versus CAV)
Study: von Pawel et al. 199959
Treatment arms:
p-value
Intravenous topotecan 
(n = 107)
CAV  
(n = 104)
Improvement in disease-related symptoms, n/Na (%)
Dyspnoea 19/68 (27.9) 4/61 (6.6) 0.002b
Cough 17/69 (24.6) 9/61 (14.8) 0.160
Chest pain 11/44 (25.0) 7/41 (17.1) 0.371
Haemoptysis 4/15 (26.7) 4/12 (33.3) 0.706
Anorexia 18/56 (32.1) 9/57 (15.8) 0.042b
Insomnia 19/57 (33.3) 10/53 (18.9) 0.085
Hoarseness 13/40 (32.5) 5/38 (13.2) 0.043b
Fatigue 16/70 (22.9) 6/65 (9.2) 0.032b
Interference with daily activity 18/67 (26.9) 7/63 (11.1) 0.023b
a  Number of patients with baseline and at least one postbaseline assessment; symptom improvement defined as two 
consecutive postbaseline assessments.
b  p < 0.05.
(Table 12) were not found to be statistically 
significantly different between the two treatment 
arms. For this measure, the number of participants 
with sufficient data to be included in the analyses 
(i.e. baseline and at least one postbaseline 
assessment) varied for the symptom scores between 
15 and 70 for topotecan, and between 12 and 
65 for CAV. The study also reported significant 
differences in the length of time to worsening of 
dyspnoea (p = 0.046) and anorexia (p = 0.003), with 
symptoms progressing more slowly in the topotecan 
group. However, data were not presented for any 
symptom for this latter outcome. It should also be 
noted that the symptom-specific questionnaire used 
in this study was not a validated instrument, and it 
is therefore unclear how reliable the results are.
Toxicity and adverse events
Adverse events of all grades, which were related, 
or possibly related, to treatment, and which 
occurred in more than 10% of participants, were 
reported for the two treatment groups, and can 
be seen in Table 13 (see Appendix 6 for rates of 
adverse events of grades 1/2 and 3/4). The most 
frequently reported adverse events were nausea, 
fatigue, vomiting, anorexia and alopecia. Overall, 
the groups appeared comparable for all reported 
adverse events, although in participants receiving 
topotecan the incidence of fatigue was lower and 
the incidence of alopecia was higher than in those 
receiving CAV. The trial did not report a statistical 
comparison between treatment groups. Six deaths 
(5.6%) in the topotecan group and four deaths 
(3.8%) in the CAV group were related, or possibly 
related, to treatment. Of the 10 deaths, seven 
(four topotecan, three CAV) were associated with 
therapy-induced myelosuppression with sepsis/
infection.
The incidence of haematological toxicities are 
presented in Table 14. Grade 4 neutropenia 
occurred significantly more frequently in the 
topotecan group than CAV (p < 0.001) for 
treatment courses (see Appendix 6), but this was 
not statistically significant for the participant 
analysis. In addition, the incidence of grade 4 
thrombocytopenia (p < 0.001) and grade 3/4 
anaemia (p < 0.001) was significantly higher 
in participants receiving topotecan. Infectious 
complications were reported to be similar between 
treatment groups.
Summary of effectiveness of i.v. 
topotecan versus CAV
In the one RCT identified, topotecan and CAV 
were not found to be statistically significantly 
different for the primary outcomes of response 
and duration of response. Furthermore, there 
were neither significant differences between 
groups for OS nor TTP. QoL was not reported. 
Greater symptomatic improvement was seen in 
participants who received topotecan for four 
symptoms as well as interference with daily activity, 
and symptoms progressed significantly more slowly Clinical effectiveness
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TABLE 13  Adverse events (i.v. topotecan versus CAV)
Study: von Pawel et al. 199959
Treatment arms
Intravenous topotecan 
(n = 107)
CAV  
(n = 104)
Adverse events (all grades) occurring in > 10% of patients, n (%)
Nausea 42 (39.3) 42 (40.4)
Alopeciaa 38 (35.5) 23 (22.1)
Fatigue 28 (26.2) 35 (33.7)
Vomiting 26 (24.3) 25 (24.0)
Anorexia 20 (18.7) 23 (22.1)
Stomatitis 15 (14.0) 13 (12.5)
Diarrhoea 13 (12.1) 13 (12.5)
Feverb 13 (12.1) –
Constipation – 16 (15.4)
Asthenia – 14 (13.5)
Treatment-related deaths 4 3
Deaths possibly related or related to therapy 2 1
a  Reflects the number of patients who developed alopecia on study, approximately 30% in each arm presented to study 
with alopecia secondary to prior chemotherapy.
b  Excludes febrile neutropenia.
TABLE 14  Toxicities (i.v. topotecan versus CAV)
Study: von Pawel et al. 
1999,59 haematological 
toxicities, n/Na (%)
Treatment arms
Intravenous topotecan (n = 107) CAV (n = 104)
Grade 3 Grade 4 Grade 3 Grade 4
Leucopenia
Neutropenia
Thrombocytopenia
Anaemia
57/104 (54.8)
19/104 (18.3)
30/104 (28.8)
41/104 (39.4)c
33/104 (31.7)
73/104 (70.2)
30/104 (28.8)b
3/104 (2.9)c
38/101 (37.6)
15/99 (15.2)
10/101 (9.9)
18/101 (17.8)c
44/101 (43.6)
71/99 (71.7)
5/101 (5.0)b
2/101 (2.0)c
a  Represents the total number of patients with laboratory data available.
b  p < 0.001.
c  p < 0.001 only when data for grades 3 and 4 were combined.
in the topotecan group for two out of the eight 
symptoms evaluated. However, the symptom-
specific questionnaire used in this study was not 
a validated instrument. Overall, the treatment 
groups were comparable for rates of adverse events, 
although the incidence of some haematological 
toxicities occurred significantly more frequently in 
the topotecan group than in the CAV group. The 
trial was judged to be of reasonable methodological 
quality.
Oral versus i.v. topotecan
Survival
Two RCTs56,58 compared oral and i.v. topotecan. In 
both trials, no statistically significant differences 
in OS were found between treatment groups (Table 
15). Eckardt and colleagues56 reported a median 
survival of 33.0 weeks (range 0.3–185.3) for oral 
participants and 35.0 weeks (range 0.7–205.3) for 
i.v. participants (HR 0.98, 95% CI 0.77 to 1.25). DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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At the time of analysis, 13.7% and 10.6% of oral 
and i.v. topotecan participants, respectively, were 
censored for survival. The 1- and 2-year survival 
rates appeared comparable between treatment 
arms (see Table 15), but a statistical test was 
not reported. Data collected during poststudy 
monitoring showed that similar proportions of 
participants in each group had received third-
line chemotherapy (33% and 35% in oral and i.v. 
groups, respectively). It is not clear whether this 
may have had an impact on the OS rates presented.
In the study by von Pawel and colleagues (2001),58 
median survival was higher in the oral topotecan 
group (32.3 weeks, range 0.4–69.1) than in the i.v. 
topotecan group (25.1 weeks, range 0.6–65.1), but 
this difference was not statistically significant [RR 
(oral:intravenous) 0.84, 95% CI 0.53 to 1.32]. The 
study reports that regression modelling identified 
no baseline liver metastases (p = 0.001) and lower 
performance status (PS) (p = 0.025), as statistically 
significantly associated with longer survival. 
The study presents only the p-values for these 
two significant factors; no data were presented, 
neither were there any discussion of the results 
of the other possible factors tested. This hinders 
any meaningful interpretation of the results of 
the modelling and so caution is recommended. 
After accounting simultaneously for all prognostic 
factors, the RR (oral:intravenous) of survival was 
reported to be 0.90 (95% CI 0.55 to 1.47).
Response
Response rate was the primary outcome in both 
the Eckardt and colleagues study56 and the von 
Pawel and colleagues58 study, and can be seen 
in Table 16. The difference in the ORR between 
TABLE 15  Overall survival (oral topotecan versus i.v. topotecan
Study: Eckardt et al. 
200756
Treatment arms
p-value, 95% CI
Oral topotecan  
(n = 153)
Intravenous topotecan 
(n = 151)
OS (weeks), median (range), 
95% CI
33.0 (0.3 to 185.3),a 29.1 to 
42.4
35.0 (0.7 to 205.3),a 31.0 to 
37.4
HR = 0.98, 95% CI 0.77 
to 1.25, p = ns
Survival rate at year 1 (%) 33 29 Not reported
Survival rate at year 2 (%) 12 7 Not reported
von Pawel et al. 200158 Oral topotecan (n = 52) i.v. topotecan (n = 54)
OS (weeks) median (range) 32.3 (0.4–69.1) a 25.1 (0.6–65.1) a RR = 0.84, 95% CI 0.53 
to 1.32
a  Includes censored events.
those participants treated with oral topotecan and 
those treated with i.v. topotecan was reported to 
be –3.6% (95% CI –12.6% to 5.5%) in the Eckardt 
and colleagues56 study. In contrast, von Pawel 
and colleagues58 reported a difference in ORR 
of 8.3% (95% CI –6.6% to 23.1%). Although the 
overall responses in the two included studies were 
in different directions, neither was found to be 
statistically significantly different. The definition 
of response was not reported in the Eckardt and 
colleagues56 trial. However, two participants in 
the oral topotecan group were reported to have 
a CR, with the remaining 26 having a PR. In the 
i.v. treatment group, all of those responding were 
classified as a PR. Response in the von Pawel and 
colleagues58 study was classified according to the 
WHO criteria. Of the responders in this study,58 
one participant in the oral topotecan group and 
two in the i.v. topotecan group were classified as 
complete responders – the remainder were PRs.
Median time to response was the same (6.1 
weeks) for both treatment arms of the Eckardt 
and colleagues56 study. In the von Pawel and 
colleagues58 study, there was a median of 18 
weeks’ response in the orally treated participants 
compared with 14 weeks in the intravenously 
treated participants. This was not tested for 
statistical significance in the trial. In those 
responding in the Eckardt and colleagues56 study, 
the duration of response was longer in the i.v. 
topotecan arm (median 25.4 weeks) compared with 
the oral topotecan arm (median 18.3 weeks), but 
no test of statistical significance was undertaken. In 
the von Pawel and colleagues58 study, it is reported 
that regression modelling of response identified 
two factors that were statistically associated Clinical effectiveness
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TABLE 16  Response (oral topotecan versus i.v. topotecan)
Study Treatment arms p-value, 95% CI
Eckardt et al. 200756 Oral topotecan  
(n = 153)
i.v. topotecan  
(n = 151)
ORR, n (%)
95% CI
28 (18.3%)
12.2% to 24.4%
33 (21.9%)
15.3% to 28.5%
Difference (oral – i.v.) 3.6%
–12.6% to 5.5%
CR 2 (1.3%) 0
PR 26 (17.0%) 33 (21.9%)
Time to response (weeks), 
median (range)
n = 28
6.1 (4.4–17.7)
n = 33
6.1 (2.1–13.9) Not reported
Response duration (weeks),
median (range)
n = 28
18.3 (9.0–65.4)
n = 33
25.4 (8.4–132.1)a Not reported
Non-responders, n (%)a
Stable disease 27 (17.6%) 35 (23.2%) Not reported
Progressive disease 78 (51.0%) 65 (43.0%) Not reported
Not assessable 20 (13.1%) 18 (11.9%) Not reported
von Pawel et al. 200158 Oral topotecan  
(n = 52)
Intravenous topotecan 
(n = 54)
ORR, n (%)
95% CI
12 (23.1)
11.6 to 34.5
8 (14.8)
5.3 to 24.3
Difference 8.3%
–6.6% to 23.1%
CR 1 (1.9) 2 (3.7)
PR 11 (21.2) 6 (11.1)
Response duration (weeks), median n = 12, 18 n = 8, 14 Not reported
Non-responders, n (%)
Stable disease 10 (19.2) 16 (29.6) Not reported
Progressive disease 16 (30.8) 23 (42.6) Not reported
Not assessable 14 (26.9) 7 (13.0) Not reported
a  n = 38 were classed as not assessable (although n = 32 is stated in the text).
with increased probability of response – female 
gender (p = 0.021) and no previous radiotherapy 
(p = 0.015). The study only presented the p-values 
for these two significant factors, no data were 
reported. There was also no further discussion of 
the results of other possible factors, nor any data, 
so caution is required in interpreting these results 
of prognostic factors. Accounting simultaneously 
for all prognostic factors that were identified in 
the logistic regression analysis, oral topotecan 
participants were seen to be 1.6 (OR) times more 
likely to respond than i.v. topotecan participants 
(95% CI: 0.50 to 5.15).
Of those classified as non-responders in the 
Eckardt and colleagues56 study, 17.6% of the oral 
topotecan-treated participants and 23.2% of the 
i.v. topotecan-treated participants were classified 
as having stable disease. Progressive disease was 
reported in 51.0% and 43.0% of participants 
in the oral topotecan group and i.v. topotecan 
groups, respectively. The study reported that 38 
participants were not assessable for response due to 
death, withdrawal or completion of treatment after 
one or two courses (although the study also reports 
this figure as 32, it is assumed this is an error). 
Of those classified as non-responders in the von 
Pawel and colleagues58 study, 19.2% and 29.6% of 
participants in the oral- and i.v. topotecan groups, 
respectively, were classified as stable disease. 
Progressive disease was seen in 30.8% of those 
treated with oral topotecan compared with 42.6% 
of those treated with i.v. topotecan. Finally, in this 
study,58 26.9% and 13.0% of participants in the DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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oral- and i.v. topotecan groups, respectively, were 
classified as not assessable. No definitions for these 
classifications were reported in either study, and 
no statistical analyses of any differences between 
groups were undertaken.
Time to disease progression
The median TTP in the Eckardt and colleagues56 
study was reported to be 11.9 weeks in the 
oral topotecan group and 14.6 weeks in the i.v. 
topotecan group (Table 17). The trial publication 
does not report any statistical analyses of these 
data between the two groups, but it would appear 
that i.v. topotecan led to a longer duration before 
the disease progressed than oral topotecan. 
Conversely, in the von Pawel and colleagues58 
study the median TTP was reported to be 15 
weeks in the oral topotecan group and 13 weeks 
in the i.v. topotecan group. The RR was 0.90 
(95% CI 0.59 to 1.39), suggesting no differences 
between the two treatment options. von Pawel and 
colleagues58 report that regression modelling of 
TTP identified female gender (p = 0.041), no liver 
metastases at baseline (p = 0.020) and lower PS 
(p = 0.036) as associated with longer TTP. No data 
were presented for these or any other factors that 
were tested in the model and therefore caution is 
recommended when interpreting these results.
Quality of life
In the Eckardt and colleagues56 trial, HRQoL 
was assessed using the Functional Assessment 
of Cancer Therapy – Lung (FACT-L) scale. This 
is a 44-item, self-reported instrument, which is 
reported to be a validated scale and includes four 
generic dimensions and a subscale that is specific 
to lung cancer. In addition, the trial outcome 
index (TOI) was also derived from a subgroup of 
data. Very few data were presented in the study 
report, but the authors state that the mean change 
from baseline indicated no statistical difference 
between treatment groups for subscale dimension 
scores or the lung cancer scale (LCS), the TOI or 
the FACT-L total scores. The mean change from 
baseline to the last course of treatment also showed 
no statistical differences between groups (no data 
were provided). QoL was not assessed in the von 
Pawel and colleagues58 study.
Symptoms
In those reporting symptoms at baseline, von 
Pawel and colleagues58 reported the proportion 
showing an improvement, which was classed as 
sustained improvement needed until the next 
treatment cycle. Symptoms were evaluated on 
a four-point scale (1 = not at all, 2 = a little bit, 
3 = quite a bit, 4 = very much) and, although 
based on the lung cancer symptom score, it 
was reported that this was not a validated scale. 
The proportions of participants with improved 
symptoms were generally between 13% and 42% 
across all symptoms. The scores were not tested 
for statistically significant differences between the 
two groups (see Appendix 6 for full results). In the 
oral- and i.v. topotecan groups, respectively, the 
symptoms with the greatest reduction were chest 
pain (42.1% versus 31.8%), haemoptysis (33.3% 
versus 40%) and hoarseness (35.7% versus 37.5%). 
Symptoms scores were not reported by Eckardt and 
colleagues.56
Adverse events and toxicity
Eckardt and colleagues56 and von Pawel and 
colleagues58 report the rates of non-haematological 
adverse events (Table 18). Rates of grade 3 and 
grade 4 adverse events generally appeared to be 
similar across the different routes of administration 
of treatment in the Eckardt and colleagues56 study, 
TABLE 17  Time to disease progression (oral topotecan versus i.v. topotecan)
Study Treatment arms p-value, 95% CI
Eckardt et al. 200756 Oral topotecan  
(n = 153)
Intravenous topotecan 
(n = 151)
TTP (weeks), median (range)
95% CI
11.9 (0.3 to 149.0)a
9.7 to 14.1
14.6 (0.7 to 177.9)a
13.3 to 18.9
Not reported
von Pawel et al. 200158 Oral topotecan  
(n = 52)
Intravenous topotecan 
(n = 54)
TTP (weeks), median (range) 15 (0.4–69.1) 13 (0.6–65.1)a RR 0.90
95% CI 0.59 to 1.39
a  Includes censored events.Clinical effectiveness
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with the exception of grade 3 diarrhoea and 
anorexia, which were more frequently observed in 
the oral topotecan group. In the von Pawel and 
colleagues58 study, rates of non-haematological 
adverse events were also seen to be similar between 
the two treatment regimens, with perhaps the 
exception of vomiting, pneumonia and diarrhoea, 
which appeared to occur more frequently in the 
oral topotecan group, and alopecia, which occurred 
more frequently in the i.v. topotecan group. 
However, no statistical analyses of these rates 
were reported. In the Eckardt and colleagues56 
study there were six deaths in the oral topotecan 
group and four in the i.v. topotecan group. The 
study reports that participants died as a result of 
haematological toxicity, septic shock related to 
topotecan treatment or of other causes possibly 
related to topotecan treatment. In the von Pawel 
and colleagues58 study, two participants (1.9%) in 
the oral topotecan group died of sepsis and febrile 
agranulocytosis.
TABLE 18  Adverse events (oral topotecan versus i.v. topotecan)
Study Treatment arms
Eckardt et al. 200756 Oral topotecan (n = 153) Intravenous topotecan (n = 151)
Non-haematological adverse effects, 
n (%)
Grade 3 Grade 4 Grade 3 Grade 4
Diarrhoea 11 (7.2) 1 (0.7) 3 (2.0) 1 (0.7)
Fatigue 10 (6.5) 0 10 (6.6) 2 (1.3)
Dyspnoea 9 (5.9) 3 (2.0) 10 (6.6) 5 (3.3)
Anorexia 8 (5.2) 0 3 (2.0) 1 (0.7)
Nausea 6 (3.9) 0 3 (2.0) 1 (0.7)
Asthenia 4 (2.6) 3 (2.0) 7 (4.6) 3 (2.0)
Fever 3 (2.0) 3 (2.0) 4 (2.6) 6 (4.0)
von Pawel et al. 200158 Oral topotecan (n = 52) Intravenous topotecan (n = 54)
Adverse effects, n (%)a Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
Vomiting 6 (11.5) 0 0 2 (3.7) 0 0
Dyspnoea 5 (9.6) 0 0 5 (9.3) 0 1 (1.9)
Fever 2 (3.8) 1 (1.9) 1 (1.9) 1 (1.9) 0 0
Pneumonia 3 (5.8) 1 (1.9) 0 0 0 1 (1.9)
Diarrhoea 4 (7.7) 0 0 0 0 0
Pulmonary embolism 1 (1.9) 0 2 (3.8) 0 0 1 (1.9)
Asthenia 3 (5.8) 0 0 5 (9.3) 0 0
Fatigue 3 (5.8) 0 0 1 (1.9) 0 0
Alopecia 1 (1.9) 0 0 7 (13.0) 0 0
Abscess 0 0 0 2 (3.7) 1 (1.9) 0
a  Occurring in ≥ 5% participants.
Associated toxicities (grades 3 and 4) from the 
respective treatments were also reported in the 
studies by Eckardt and colleagues56 and von 
Pawel and colleagues,58 and can be seen in Table 
19. Based on observation of these data, it would 
appear that rates are similar across the treatment 
groups in the Eckardt and colleagues56 study. Grade 
4 neutropenia and grade 3 anaemia appeared to 
occur more frequently in the intravenously treated 
participants than the orally treated participants, 
while grade 4 thrombocytopenia appeared to occur 
more frequently in the orally treated participants. 
In the Eckardt and colleagues56 study the authors 
also report that fever and/or infection (≥ grade 2) 
associated with grade 4 neutropenia, together with 
sepsis, occurred in 5% of courses in both groups. 
In the von Pawel and colleagues58 study, rates of 
toxicities were also observed to be similar between 
the two treatment arms, with the exception of 
grade 4 neutropenia, which was reported to be 
statistically significantly more frequently observed DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 19  Toxicities (oral topotecan versus i.v. topotecan)
Study Treatment arms
Eckardt et al. 200756 Oral topotecan (n = 153) Intravenous topotecan (n = 151)
Toxicities, n (%)a Grade 3 Grade 4 Grade 3 Grade 4
Leucopenia 64 (42.7) 34 (22.7) 74 (49.3) 39 (26.0)
Neutropenia 39 (26.2) 70 (47.0) 35 (23.6) 95 (64.2)
Thrombocytopenia 30 (20.0) 43 (28.7) 38 (25.3) 27 (18.0)
Anaemia 26 (17.3) 8 (5.3) 42 (28.0) 4 (2.7)
von Pawel et al. 200158 Oral topotecan (n = 52) Intravenous topotecan (n = 54)
Toxicities n (%) Grade 3 Grade 4 Grade 3 Grade 4
Neutropenia 21.6 35.3 26.9 67.3
Leucopenia 27.5 17.6 45.3 28.3
Thrombocytopenia 25.5 27.5 24.5 24.5
Anaemia 27.5 3.9 26.4 3.8
a  Occurring with a frequency of ≥ 10% in either treatment group.
in the i.v. topotecan treatment group (p = 0.001). 
The trial also reports that the median duration of 
grade 4 neutropenia was similar between groups 
(oral group 7 days, i.v. group 6 days). Although 
the trial does not report a statistically significant 
difference between rates of grade 3 leucopenia, it 
can be observed that the rates are higher in the i.v. 
topotecan group than the oral topotecan group.
Summary of effectiveness of i.v. versus 
oral topotecan
There were no statistically significant differences 
in OS between treatment groups for either of 
these studies. Similarly, no statistically significant 
differences were seen in the ORR. Intravenous 
topotecan appeared to lead to a longer duration 
before disease progression than oral topotecan 
in one study,56 but this was not supported by 
the other.58 Quality of life was assessed in one of 
the included studies56 and there appeared to be 
no statistically significant differences between 
treatment groups. No statistical analyses of 
adverse event rates were reported in either study. 
Associated grade 3 and grade 4 toxicities were 
similar between i.v. topotecan and oral topotecan 
in the studies, with the exception of grade 3 or 
4 neutropenia, which appeared to occur more 
frequently in the intravenously treated participants. 
While these studies suggest that i.v. and oral 
topotecan are equivalent, it should be noted that 
neither study was powered to test for equivalence 
or non-inferiority. In addition, these studies were 
of unknown methodological quality due to the 
lack of details reported. Furthermore, it should 
be considered that there is some uncertainty over 
whether the Eckardt and colleagues56 study fully 
meets the inclusion criteria of the current review. 
For these reasons, it was deemed inappropriate to 
combine the two trials in a meta-analysis.
Intravenous amrubicin versus i.v. 
topotecan
Survival
One RCT (Inoue and colleagues63) was included, 
which compared i.v. topotecan with i.v. amrubicin. 
In this trial, median OS was not statistically 
significantly different (p = 0.17) between the 
amrubicin-treated participants (8.1 months) and 
the topotecan-treated participants (8.4 months). 
Progression-free survival between the treatment 
groups was also not statistically significant 
(p = 0.16), with a median 3.5 months for the 
amrubicin group versus 2.2 months for the 
topotecan group (Table 20). One participant in the 
amrubicin arm received no treatment due to rapid 
disease progression, and hence was not included 
in the analysis. The paper reported a subgroup 
analysis of OS and PFS according to relapse 
type. No statistical tests of the difference between 
treatment groups were presented (see Appendix 
6), although for both outcomes the trend was for 
participants with sensitive disease to do better 
than those with refractory disease. However, it is 
unclear if the study was powered for this analysis. 
Many of the participants received subsequent 
(third-line or later) chemotherapy after disease 
progression (48% and 70% in the amrubicin and Clinical effectiveness
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TABLE 20  Overall survival (i.v. amrubicin versus i.v. topotecan)
Study: Inoue et al. 200863
Treatment arms
p-value Intravenous amrubicin (n = 29) Intravenous topotecan (n = 30)
OS, median (months) 8.1 8.4 p = 0.17
Progression-free survival, median 
(months)
3.5 2.2 p = 0.16
TABLE 21  Response (i.v. amrubicin versus i.v. topotecan)
Study: Inoue et al. 200863
Treatment arms
p-value
Intravenous amrubicin 
(n = 29)
Intravenous topotecan 
(n = 30)
Overall response, n (%), 95% CI 11 (38), 21 to 58a 4 (13), 1 to 25b p = 0.039
Responses, n (%)
CR 0 (0) 0 (0)
PR 11 (38) 4 (13)
Stable disease 12 (41) 10 (33)
Progressive disease 6 (21) 16 (53)
a  In abstract, 20–56.
b  In conference presentation, 4–31.
topotecan groups, respectively) with crossover 
administration performed in 41% of participants 
(17% and 63%, respectively). In addition, the dose 
of topotecan used (1.0 mg/m2) was lower than the 
UK recommended dose (1.5 mg/m2). It is not clear 
whether these factors may have had an impact on 
the OS rates shown.
Response
Response rate was the primary outcome in this 
study and was assessed according to the RECIST 
criteria. There was a statistically significant 
difference in the ORR of 38% (95% CI 21 to 58) 
for participants who received amrubicin compared 
with 13% (95% CI 1 to 25) for participants who 
received topotecan (p = 0.039). Again, it should 
be noted that a lower dose of topotecan was used. 
In addition, there were some discrepancies in the 
reporting of CIs between the full paper, abstract 
and conference presentation (see Appendix 
6). The study reported details of participants 
with CR or PR, as well as stable or progressive 
disease in each treatment arm. No participants 
in either group showed a CR. It can be seen in 
Table 21 that a greater proportion of participants 
receiving amrubicin achieved a PR (38% versus 
13% topotecan), whereas a greater proportion 
of participants receiving topotecan were rated 
as having progressive disease (53% versus 21% 
amrubicin). Stable disease was reported in 41% 
and 33% of the amrubicin- and topotecan-treated 
groups, respectively. However, no statistical analysis 
for these data were reported.
Inoue and colleagues63 performed subgroup 
analyses examining the effects of sensitive and 
refractory relapse, and PS 0–1 versus 2 on ORRs 
between treatment groups. No statistically 
significant differences were shown (all p > 0.05, 
see Appendix 6), but it should be noted that it is 
unclear if the study was powered for these analyses. 
In addition, the trial also reports further analysis 
of three prognostic factors (age, gender and 
prior chemotherapy regimen) but no data were 
presented.
The study also reported disease control rates, but 
no definition was supplied and these are therefore 
not reported here.
Time to disease progression
Time to disease progression was not reported by 
this study.
Quality of life
Quality of life was not reported by this study.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Adverse events and toxicity
Adverse events can be seen in Table 22. Unlike the 
other included studies, febrile neutropenia was 
presented as a non-haematological toxicity in this 
study. Although rates were not tested for statistical 
significance, it can be observed that participants in 
the amrubicin treatment arm suffered much higher 
rates of adverse events of grades 3 and 4, with the 
exception of diarrhoea, which was more frequently 
observed in the topotecan group. It is not clear 
whether the lower dose of topotecan used in this 
trial affected the rates of adverse events shown.
Grades of haematological toxicity were also 
reported in the study by Inoue and colleagues63 
and can be seen in Table 23. No statistical analyses 
of grades or treatment arms were reported. Based 
on observation, it would appear that participants 
in the topotecan treatment arm suffered higher 
rates of associated toxicity of grades 3 or 4 for 
anaemia and thrombocytopenia, and lower rates 
of neutropenia, than the amrubicin group. There 
was a discrepancy between the abstract62 and full 
publication63 in the reporting of neutropenia, with 
the abstract62 reporting a higher rate (97%) in 
the amrubicin arm. One patient in the amrubicin 
treatment arm is reported to have died of 
neutropenic sepsis developing from urinary tract 
infection; no other deaths are reported in the 
study.63
Summary of effectiveness of i.v. 
amrubicin versus i.v. topotecan
In this study comparing amrubicin with topotecan, 
the primary outcome of ORR was shown to be in 
favour of the amrubicin treatment arm. OS and 
PFS were not significantly different between the two 
groups. TTP and QoL were not reported. Based on 
our observation, rates of adverse events generally 
appeared to be higher for patients in the amrubicin 
treatment arm. Rates of toxicity varied; however, 
neutropenia was higher in the amrubicin group. 
It should be noted that there is uncertainty over 
whether this study fully met the inclusion criteria 
of this review. In addition, the topotecan dose of 
1.0 mg/m2/day (the approved dose in Japan) was 
below the UK recommended dose of 1.5 mg/m2/day 
and the study is of an unknown quality due to the 
lack of details reported in the trial.
Ongoing studies
The following studies were identified in searches 
and are currently ongoing:
•  Wang XS, Hou M, Xue SL, Wu TX. Topotecan 
for small cell lung cancer. (Protocol) Cochrane 
Database of Systematic Reviews 2008, Issue 2 
(date of most recent substantive amendment 
– 26 January 2008). This systematic review 
aims to investigate the role of topotecan in 
the management of patients with SCLC by 
TABLE 22  Adverse events (i.v. amrubicin versus i.v. topotecan)
Study: Inoue et al. 2008,63 
non-haematological
toxicity, n
Treatment arms
Grade: intravenous amrubicin (n = 29) Grade: intravenous topotecan (n = 30)
2 3 4 ≥ Grade 3 (%) 2 3 4 ≥ Grade 3 (%)
Fatigue 4 5 0 17 3 2 0 7
Febrile neutropenia – 4 0 14 – 1 0 3
Infection 0 2 1 10 0 1 0 3
Anorexia 4 2 0 7 4 0 0 0
Nausea/vomiting 1 1 0 3 1 0 0 0
Stomatitis 1 1 0 3 0 0 0 0
Diarrhoea 0 0 0 0 0 1 0 3
Fever 2 0 0 0 1 0 0 0
Constipation 2 0 0 0 0 0 0 0
Pneumonitis 1 0 0 0 2 0 0 0Clinical effectiveness
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TABLE 23  Toxicities (i.v. amrubicin versus i.v. topotecan)
Study: Inoue et al. 2008,63 
haematological toxicity, n
Treatment arms
Grade: intravenous amrubicin (n = 29) Grade: intravenous topotecan (n = 30)
2 3 4 ≥ Grade 3 (%) 2 3 4 ≥ Grade 3 (%)
Neutropenia 0 5 23 93a 3 13 13 87
Thrombocytopenia 6 7 1 28 5 9 3 40
Anaemia 15 3 3 21 12 6 3 40
a  In abstract, 97.62
considering its clinical effectiveness and safety. 
(The review will include participants who were 
previously untreated, will consider topotecan 
in combination with any other chemotherapy 
agent, and will also consider topotecan used in 
first-line treatment.)
•  NCT 00319969. A phase II, randomised trial 
comparing i.v. amrubicin (40 mg/m2) versus 
i.v. topotecan (1.5 mg/m2) in adults with 
extensive-stage SCLC sensitive to first-line 
(platinum-based) chemotherapy. Study type: 
open-label, multicentre, phase II, parallel 
RCT. Sample size: 76. Start date: April 2006. 
Estimated end date: January 2009 (final data 
collection date for primary outcome measure). 
Status: the study is ongoing, but not recruiting 
participants. Funding: Calgene Corporation. 
Funding amount: not reported.
•  NCT 00547651. A phase III, randomised 
trial comparing i.v. amrubicin (40 mg/m2) 
versus i.v. topotecan (1.5 mg/m2) in adults 
with extensive-stage or limited-stage SCLC 
who are sensitive or refractory to first-line 
(platinum-based) chemotherapy. Study type: 
open-label, multicentre, phase III, parallel, 
safety/efficacy RCT. Estimated sample size: 620. 
Start date: September 2007. Estimated end 
date: March 2011 (final data collection date for 
primary outcome measure). Status: the study 
is currently recruiting participants. Funding: 
Calgene Corporation. Funding amount: not 
reported.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Methods for economic 
analysis
The aim of this section is to assess the cost-
effectiveness of topotecan compared with existing 
regimens in second-line chemotherapy for SCLC. 
The economic analysis comprises the following:
•  systematic review of the literature on the cost-
effectiveness of topotecan and a review of 
the QoL of people suffering with SCLC. An 
additional search was undertaken to inform 
different approaches to modelling disease 
progression
•  review of the MS to NICE
•  presentation of the SHTAC independent 
economic model and cost-effectiveness 
evaluation.
Systematic review of the existing 
cost-effectiveness
A systematic literature search was undertaken 
to identify economic evaluations of topotecan 
compared with other regimens as a second-line 
chemotherapy in SCLC. The details of the search 
strategy are documented in Appendix 3. The MS 
was reviewed for any additional studies that were 
missed by the searches.
Results of the systematic review
A total of 49 potentially relevant publications of 
economic evaluations relating to topotecan in 
SCLC were identified in the search. No relevant 
cost-effectiveness analyses were identified after 
screening of the titles and abstracts.
Review of research on QoL
The details of the search strategy for QoL are in 
Appendix 3. A total of 122 publications relating to 
topotecan in SCLC were identified.
The search identified one potentially relevant 
study that could be used to populate the model 
with the relevant outcome measures as specified 
in the scope. This was the RCT by O’Brien and 
colleagues,57 which used the EQ-5D to assess 
HRQoL in trial participants. A further search of 
recent abstracts was undertaken, which identified 
one additional QoL abstract based on the O’Brien 
and colleagues RCT by Chen and colleagues.64 
Both the trial report, by O’Brien and colleagues57 
and the abstract by Chen and colleagues64 have 
been data extracted and critically appraised in the 
clinical effectiveness section (see Chapter 3, Oral 
topotecan plus BSC versus BSC alone).
Review of manufacturer’s 
submission
The MS consisted of a written report and electronic 
model supporting the cost-effectiveness analyses.
A brief overview of the manufacturer’s cost-
effectiveness analysis,51 including the approach 
taken to model disease progression and the effects 
of treatment, followed by a critical appraisal of the 
cost-effectiveness analysis, is presented here.
GlaxoSmithKline submission to NICE – 
cost-effectiveness analysis
Overview
The stated aim of the analysis was to assess the cost-
effectiveness of oral topotecan plus BSC against 
BSC alone in people with relapsed SCLC in whom 
treatment with i.v. chemotherapy is not considered 
appropriate. The cost-effectiveness analysis was 
based on participant-level data from the O’Brien 
and colleagues RCT.57 BSC in the evaluation 
consisted of analgesics, antibiotics, corticosteroids, 
appetite stimulants, antidepressants, red blood 
cell (RBC) transfusions, deep relaxation therapy, 
and palliative radiotherapy or surgical procedures. 
Participants with the active treatment were also 
eligible for BSC alongside treatment with oral 
topotecan.
The base-case analysis is reported for the whole 
cohort of participants who received oral topotecan 
plus BSC compared with BSC alone after relapse 
of SCLC from the O’Brien and colleagues RCT.57 
Several subgroup analyses were also reported in 
the MS, including different times to progression, 
sex, performance status and liver metastases. The 
maximum survival in the trial was 1480 days, or 71 
21-day survival periods.
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The perspective of the economic analysis is stated 
as being that of the NHS and PSS, capturing only 
those costs and benefits that are directly relevant to 
the intervention. The submission reports lifetime 
costs and outcomes (life-years gained and QALYs) 
for each treatment arm. An incremental analysis 
of costs and outcomes of topotecan plus BSC 
compared with BSC alone was undertaken.
Model of cost-effectiveness of topotecan
The MS reports that a systematic review of 
economic evaluations for oral topotecan in SCLC 
was undertaken. The search of databases was 
limited to the NHS EED and PubMed databases. 
The search identified nine cost-effectiveness 
studies, with eight being for topotecan in ovarian 
cancer and a further study in mobilising peripheral 
blood stem cells – there were no studies identified 
for topotecan in SCLC. This is consistent with the 
SHTAC systematic literature search (see Systematic 
review of the existing cost-effectiveness, above).
The approach taken in the MS model is 
outlined below. An outline review, based on a 
checklist suggested for the critical appraisal of 
cost-effectiveness analysis by Drummond and 
colleagues,66 the requirements of NICE for the 
submission on cost-effectiveness (reference case)67 
and suggested guideline for good practice in 
decision modelling by Philips and colleagues,68 is 
given.
Modelling approach
The model developed by the manufacturer was a 
trial-based model. The multicentre trial contained 
141 participants with participant characteristics 
being evenly distributed between the two groups.57 
Median survival times were 13.9 weeks (95% CI 
11.1 to 18.6) in the BSC alone group and 25.9 
weeks (95% CI 18.3 to 31.6) in the oral topotecan 
plus BSC group. The economic model used the 
data from the trial up until the final assessment 
period, when six participants (three in the BSC 
group and three in the topotecan plus BSC group) 
were still alive. The model assumed that all 
surviving participants died the day after this final 
assessment. The participant level survival data were 
divided into 21-day periods to reflect the study 
cycles in the RCT.
Health-state utilities were collected using the EQ-
5D during the RCT. This was carried out at the 
beginning of each cycle, and up to, and including, 
cycle 12 for all participants in the topotecan plus 
BSC group and the BSC group. The quality-
adjusted survival was calculated by multiplying 
individual survival in each 21-day period by 
the corresponding EQ-5D period score for that 
participant. There were a total of 1548 21-day 
survival periods across the 141 participants in the 
RCT. Individual data, however, were available for 
only 600 periods.
The MS reports that the 948 missing EQ-5D values 
in the data were mainly due to progression of 
disease towards death. The MS used the observed 
mean EQ-5D scores for the first 12 cycles from 
both arms of the trial to take account of the missing 
data from each of the corresponding cycles. A last 
observation carried forward approach (LOCF) 
was used for the topotecan plus BSC group before 
participants entered a progressive disease state 
and after treatment had finished, and, also, in 
BSC alone group, until five periods from death. 
For all other missing EQ-5D data, the MS used 
data from the BSC group’s EQ-5D scores for the 
five 21-day cycles of disease progression before 
death, by applying this backwards from the period 
in which the participant died. This was carried 
out for both BSC and topotecan groups. If the 
participant survived more than the five periods in 
the progressive disease state, the figures for the 
fourth period before death were applied backwards 
until the start of progressive disease.
Two categories of adverse events were recorded in 
the trial and used in the model; haematological 
adverse events and non-haematological adverse 
events. The incidence of non-haematological 
adverse events was reported as a percentage for 
each grade. Haematological events were reported 
on the basis of their resource use alone in terms of 
transfusions and granulocyte colony-stimulating 
factor (GCSF) and antibiotics. No explicit reduction 
in QoL was recorded for experiencing an adverse 
event due to the ongoing recording of EQ-5D 
valuation throughout the trial.
The costs applied in the MS were split into five 
main categories:
1.  drug cost of oral topotecan
2.  oral topotecan drug administration costs
3.  drug monitoring costs
4.  cost of non-disease progression in the oral 
topotecan group
5.  adverse events associated with oral topotecan.
Not all resource use was collected in the trial and 
therefore clinical opinion was used to fill in gaps in 
the resource use.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Oral topotecan used in the trial was administered 
in 0.25- or 1.00-mg capsules and was dosed at 
2.3 mg/m2/day on days 1–5 of 21-day cycles for 
up to 12 cycles.57 The drug cost was calculated 
by multiplying the total drug use of topotecan 
per participant by the drug acquisition costs. 
The average cost of oral topotecan in the MS 
was calculated at £2500. The MS assumed that 
oral topotecan was delivered on an outpatient 
basis on days 1–5 and this was verified by clinical 
opinion. An additional small dispensing fee 
was also included. The total average cost for 
drug administration of all topotecan in the trial 
was £713. Drug monitoring costs for pathology 
monitoring, haematological toxicity monitoring 
and biochemical monitoring was taken from 
a study that included oral topotecan used as a 
chemotherapy in ovarian cancer, which had an 
average cost of £39.69
The cost of progression to death was assumed to be 
the same for both groups and was not included in 
the incremental analysis. The cost of non-disease 
progression for the topotecan plus BSC group was 
based on clinical feedback and included outpatient 
visits, GP visits, chest radiographs, and blood 
tests every 4 weeks. The total costs of non disease 
progression were £758.
Non-haematological adverse events were 
reported in terms of a percentage for grades 1 
to 4 for diarrhoea, fatigue, nausea and vomiting. 
Corresponding resource use was then applied 
to the occurrence of these events. However, 
haematological adverse events were accounted for 
in terms of transfusions, GCSF and antibiotics that 
were used in the trial. The average costs of treating 
adverse events resulting from oral topotecan in the 
MS were £1660.
The MS assumed that any PSS costs for additional 
care given outside a hospital were equally likely to 
occur in both the BSC alone and topotecan plus 
BSC groups. Unit costs from different base-years 
(from 2003 to 2007) were included in the model. 
The cost-year for the model is 2007/08. All costs 
reported in other years were inflated to 2007/08 
costs using the NHS Hospital and Community 
Health Service (HCHS) Pay and Prices Index.70 
This includes only data up to the 2006/07 year. 
An assumption was made, therefore, that the 
percentage increase in the HCHS pay and prices 
from 2006/07 to 2007/08 would be the same as that 
from 2005/06 to 2006/07.
Model/cost-effectiveness results
The MS reports only costs that were likely to be 
higher in the oral topotecan plus BSC arm of the 
trial. Outcomes were reported in terms of life-years 
and QALYs. The oral topotecan plus BSC arm 
in the base-case analysis resulted in 0.259 years 
of additional life and 0.211 QALYs over the BSC 
alone arm of the trial. The incremental cost of the 
oral topotecan plus BSC arm was £5671 compared 
with the BSC alone arm. The incremental cost-
effectiveness ratio (ICER) per life-year gained is 
£21,878 and per gained QALY is £26,833.
Drug costs were the largest single component of 
total costs (44%). The cost of treating adverse 
events was 29% of the total costs. The cost of 
non-progressive disease was 13% and monitoring 
chemotherapy was 13% of total costs. Drug 
monitoring accounted for 1% of total costs.
The MS concludes that oral topotecan plus BSC 
versus BSC alone is likely to be a cost-effective 
therapy in people with relapsed SCLC, who are not 
considered suitable for standard i.v. chemotherapy.
Outline appraisal of the manufacturer 
cost-effectiveness analysis
A summary of the MS compared with the NICE 
reference case requirements is given in Table 24. 
See Appendix 8 for a tabulation of the critical 
appraisal of the submission against Drummond 
and colleagues’ checklist.66
Outline review of the modelling 
approach
Model structure/structural assumptions
The model used the participant level survival data 
for the oral topotecan with BSC arm and the BSC 
alone arm from the O’Brien and colleagues57 trial 
to estimate survival benefit. The effect of oral 
topotecan was to increase life expectancy compared 
to BSC by extending time before the disease 
progresses. BSC is intended to reduce the impact 
of disease progression rather than affect disease 
progression itself.
The time horizon used in the economic evaluation 
is the length of the trial. No additional modelling 
was undertaken to extend survival beyond the end 
of the trial. The MS reported that there were six 
remaining participants (three in topotecan group 
and three in the BSC alone group) who were still 
alive at the end of the trial, and it was assumed that 
all of these patients died the day after the end of Economic analysis
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TABLE 24  Assessment of GlaxoSmithKline submission against NICE reference case requirements
NICE reference case requirements Included in submission
Decision problem: as per the scope developed by NICE ?a
Comparator: alternative therapies routinely used in the UK NHS ?b
Perspective on costs: NHS and Personal Social Services 
Perspective on outcomes: all health effects on individuals c
Type of economic evaluation: cost-effectiveness analysis 
Synthesis of evidence on outcomes: based on a systematic review No evidence synthesis
Measure of health benefits: QALYs 
Description of health states for QALY calculations: use of a standardised and 
validated generic instrument

Method of preference elicitation for health-state values: choice-based method  
(e.g. TTO, SG, not rating scale)

Source of preference data: representative sample of the public 
Discount rate: 3.5% p.a. for costs and health effects  
 = yes; ? = uncertain; SG, standard gamble; TTO, time trade-off.
a  Scope states that oral and i.v. topotecan be compared with each other. Also states that CAV is a comparator. The 
economic evaluation includes only oral topotecan plus BSC. CAV was excluded as topotecan (oral or i.v.) would not 
be a cost-effective alternative, therefore economic evaluation is limited to patients who are not considered to be 
suitable for CAV. Intravenous topotecan was excluded on the basis of similar efficacy, but also higher acquisition and 
administration cost, and therefore is unlikely to be a cost-effective alternative.
b  If the reasoning for exclusion of CAV is accepted then the comparator to topotecan is BSC, as in the economic 
evaluation.
c  Economic evaluation used utilities derived using EQ-5D questionnaries that were administered to participants during 
treatment with oral topotecan plus BSC and with BSC alone. It is not clear how far the EQ-5D utilities include the 
effects of treatment-related toxicity for participants treated with oral topotecan.
the study. However, from the Kaplan–Meier plot 
of OS from the O’Brien and colleagues57 trial, this 
does not appear to be the case. It appears that 
there are fewer survivors in the BSC arm than the 
three survivors reported in the MS. The reason for 
this discrepancy is unclear. Nevertheless, assuming 
that there are three survivors in each arm, based 
on the participant level data in the manufacturer’s 
model, this represents just over 4% of the 
population in each arm. There is a possibility that 
this could have underestimated the survival benefit 
for either arm of the trial.
Adverse events were incorporated into the model 
through the incidence of grades 1 to 4 non-
haematological events as they occurred in the trial. 
Haematological events were incorporated into the 
model using resource use of transfusions, the use of 
GCSF and antibiotics, rather than their incidence. 
The different methodology used to account for 
adverse events is thought not to have seriously 
impacted upon the results of the model. The large 
amount of missing EQ-5D data in the RCT means 
it is unclear whether the expected disutility from 
having an adverse event will have been adequately 
picked up. Furthermore, it is not clear if the EQ-
5D data collected at 3-week intervals captures the 
impact of the adverse events well.
An assumption was made that there would be 
a reduction in health utility once the disease 
progressed in the topotecan group. This was 
accounted for by using utility data from the BSC 
participants for the last five periods until death. 
This seems to be a fair assumption, as there is 
likely to be a reduction in utility once the disease 
progresses in the topotecan group that corresponds 
to the BSC group’s health-state valuations in the 
five periods preceding death.
Data inputs
Participant level data were taken from the O’Brien 
study,57 and this provided inputs on the survival 
length of participants in the trial, resource use 
and health utilities. Expert opinion was used to 
give additional information on resource use. The 
unit cost data were taken from national published 
sources.
Health utilities were recorded throughout the trial 
at the beginning of each cycle. However, many of 
the health-state valuations were missing due to DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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progression of the disease in participants. This 
causes great uncertainty in the model, as only 
39% of the survival periods were available. An 
average of observed cycle EQ-5D data matched 
to the corresponding cycle with missing data, and 
the LOCF technique was used to overcome this 
missing data. More rigorous modelling methods, 
for example a regression analysis, could have been 
used to take account of this missing data.
The average EQ-5D scores used for imputation are 
highly variable across cycles 1–12. The variability 
reflects the uncertainties that are involved with 
using this approach. First, the pooled data on 
average EQ-5D were used from both arms of the 
trial. No justification of pooling both groups of 
participants was given but it is likely to have been 
adopted due to the small number of observations 
that occurred as the number of cycles increased. 
This may have underestimated the health benefit in 
the topotecan arm in the first five cycles of the trial, 
as this was when the majority of BSC participants 
were experiencing disease progression towards 
death and appear to have reported lower mean 
EQ-5D scores per cycle at this time. Second, one 
would expect EQ-5D scores to decline as time goes 
on and people progress towards death. However, 
there is an upward trend in the mean EQ-5D scores 
up to cycle 7. This may reflect sicker participants 
dying first and leaving a higher proportion of 
healthier participants who will tend to report 
higher EQ-5D scores. This is likely to overestimate 
utility in the topotecan arm of the trial, as these 
participants lived longer than the BSC participants. 
Finally, the lack of observations for the last five 
cycles also causes fluctuations in the average EQ-
5D scores, with only one observation from the 
BSC group accounting for cycles 11 and 12. The 
impact on the model of using this approach to take 
account of missing data is unclear, as it is likely to 
roughly underestimate the utility in the first half of 
the cycles and roughly overestimate utility in the 
last half of the cycles.
The MS used a LOCF approach in both groups, 
prior to disease progression and once the first 12 
cycles were completed. This also only affects a very 
small number of participants in the trial and is 
unlikely to have a large effect on the model results.
The MS reported that only cost components that 
were higher in the topotecan arm were included in 
the model, suggesting that this would probably be 
most likely to overestimate the incremental costs 
associated with oral topotecan compared to BSC 
and was therefore a conservative assumption.51 This 
seems reasonable; however, it is likely that palliative 
care will be experienced at different time periods 
in both groups and discounting may underestimate 
incremental costs here in favour of topotecan.
Participant level data for resource use was reported 
for most of the categories of cost in the model. 
However, not all resource use was recorded. The 
manufacturer used expert opinion to estimate 
resource use that was not recorded in the trial, 
such as treatment of non-haematological events. 
We discussed these assumptions with clinical 
experts who concluded that they appeared to be 
reasonable.
Assessment of uncertainty
Uncertainty is addressed using both a 
deterministic and a bootstrap analysis. The 
deterministic sensitivity analysis addresses issues 
of methodological uncertainty (varying discount 
rates) and parameter uncertainty (different 
assumptions about utility weights, cost of additional 
non-progressive disease survival, cost of drug 
monitoring, cost of treating adverse events, cost of 
PSS events and assumptions about how the drug 
is administered). Only the ICER is reported in 
these analyses and so no comment can be made 
about the changes in total costs and outcomes. 
The ICERs were fairly insensitive to the changes 
made in the deterministic analysis, with a range 
from £22,512 (for halving the cost of adverse events) 
to £40,253 (for oral topotecan being administered 
during a daily outpatient visit for 5 days in each 
cycle). Other scenarios that raise the ICERs were 
doubling the cost of treating adverse events 
(£34,468), the cost of additional non-progressive 
disease survival being doubled (£30,421), and using 
the combined mean EQ-5D score at each cycle 
and LOCF approach to account for missing data 
(£33,816).
Sample uncertainty was addressed for the base-case 
analysis using a bootstrap analysis. Non-paramatic 
bootstrap methods are used to create CIs around 
a statistic of interest, which are derived from 
repeatedly drawing samples with replacement from 
the original treatment arms of the study.71 In this 
analysis, the statistic of interest was the ICER for oral 
topotecan plus BSC and BSC alone. The analysis 
used 10,000 bootstrap replications and presented 
the resulting 95% confidence ellipses for the 
ICERs. Oral topotecan plus BSC in the bootstrap 
analysis was always associated with increased costs 
(incremental costs between £4000 and £7500) and 
usually with improved QALY outcomes (incremental 
QALYs between 0 and approximately 0.6). The Economic analysis
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majority of the ICERs (98.31%) for oral topotecan 
plus BSC (compared with BSC alone) were found in 
the upper-right quadrant of the cost-effectiveness 
plane (i.e. oral topotecan plus BSC was more 
effective and more costly than BSC alone). The 
remaining 1.69% of replications are in the upper 
left quadrant, in which oral topotecan plus BSC is 
less effective and more costly than BSC alone. A 
cost-effectiveness acceptability curve was presented. 
Oral topotecan plus BSC had a probability of being 
cost-effective relative to BSC of 22% at a willingness 
to pay (WTP) threshold of £20,000 per QALY and 
60% at a WTP threshold of £30,000 per QALY.
A subgroup analysis was also presented for TTP 
that was ≤ 60 days and > 60 days, performance 
status 0/1, sex and the presence of liver metastases. 
Oral topotecan plus BSC was more cost-effective 
per QALY gained in patients for whom the TTP 
from prior therapy was ≤ 60 days (£17,946), in 
females (£11,708), and in those patients with no 
liver metastases (£21,291) and a performance status 
of 2 (£25,544). The subgroups where ICERs were 
higher than a WTP threshold of £30,000 per QALY 
were in males (£74,175) and performance status of 
zero or 1 (£30,770), liver metastases (£56,534) and 
TTP of > 60 days (£31,972).
A further analysis was undertaken in the TTP 
of > 90 days and in the no-liver-metastases 
subgroups. It is important to note the small 
sample sizes for these data with only 30 and 51 
participants, respectively. No justification was given 
for more in-depth analysis of these participant 
subgroups. However, these are the two subgroups 
that are most likely to benefit from oral topotecan 
after the ≤ 60 days TTP group. The ICERs for the 
deterministic analysis, applying the same scenarios 
as used in the base-case analysis, were in the 
range of £20,260–38,085 for TTP > 90 days and 
£17,804–32,043 for no liver metastases. The more 
conservative assumptions over the measurement of 
HRQoL, the drug administration costs and cost of 
treating adverse events, all produced ICERs over 
a WTP threshold of £30,000 per QALY in the over 
90 days to progression subgroup. The only scenario 
in the no-liver-metastases group that was above the 
WTP of £30,000 per QALY was the conservative 
assumption of drug administration cost being 
provided for 5 days of outpatient visits. A bootstrap 
analysis with 10,000 bootstrap replications was 
also undertaken in both subgroups. The bootstrap 
replications for both groups were predominantly 
in the upper-right quadrant; 95.85% for the > 90 
days to progression and 98.98% in the no-liver-
metastases group. At a WTP threshold of £20,000 
per QALY, oral topotecan plus BSC would be 
cost-effective relative to BSC alone in the > 90 
days to progression and in the no-liver-metastases 
subgroups in 33% and 44% of cases, respectively. 
If the threshold increased to £30,000 then these 
percentages would increase to 62% and 75%, 
respectively.
Summary of general concerns
•  It is unclear whether the disutility that would 
be expected from experiencing an adverse 
event in the topotecan group has been 
adequately represented due to the large 
amount of missing EQ-5D data and 3-week 
intervals between collections of EQ-5D data. 
This may be further biased due to healthier 
participants being more able and willing to 
fill in EQ-5D questionnaires than those who 
are experiencing an adverse event. If this 
is correct then utility, and therefore gain 
in QoL, compared to BSC is likely to be an 
overestimation for the topotecan group.
•  No modelling beyond the length of the trial 
was undertaken. A small, but potentially 
significant, number of participants were still 
alive at the end of the trial. However, it is not 
entirely clear how many participants in the trial 
were still alive, as the MS and Kaplan–Meier 
plot from the O’Brien and colleagues RCT57 
seem to give conflicting reports. It is assumed 
here that the MS is correct as the participant-
level data are given in the model. Therefore, 
just over 4% of each arm of the trial were still 
alive at the end of the study and there is a 
possibility this could have underestimated the 
survival benefit for either group.
•  The use of the mean observed EQ-5D scores 
from both arms of the trial to take account 
of the missing EQ-5D data raises a number 
of problems. Utility in both groups of 
participants in the trial is unlikely to be the 
same throughout the cycles. The utility for 
topotecan participants early in the treatment 
cycles is likely to have been underestimated, as 
this is when the majority of BSC participants 
were progressing towards death. In the latter 
half of the treatment cycles the mean of the 
observed EQ-5D scores appear to have been 
overestimated, due to the small number of 
observations and as the proportion of healthier 
participants increases. It is not clear what effect 
this will have had on the model results.
•  The assumptions over the costs in the model 
appear reasonable. Given that costs for the 
BSC arm of the trial were not recorded and 
that this component is common to both arms 
the conservative assumption may be justified. 
However, a small percentage of palliative care DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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costs are likely to have occurred in different 
periods for the topotecan plus BSC and BSC 
alone groups, and discounting could have been 
applied here.
•  The description of how utilities were used in 
the model, and the methods by which EQ-5D 
values were imputed to allow for missing data, 
were not entirely clear in the MS.
SHTAC independent 
economic assessment
Statement of the decision 
problem and perspective for the 
cost-effectiveness analysis
We developed a new model to estimate the 
cost-effectiveness of topotecan as a second-line 
chemotherapy compared with BSC, in a cohort of 
adults with relapsed SCLC for whom re-treatment 
with the first-line regimen was not considered 
appropriate. The perspective of the cost-
effectiveness analysis is that of the NHS and PSS. 
The type of the economic evaluation was a cost–
utility analysis. The health economic outcomes that 
are evaluated in the model are life-years gained 
(LYG) and QALYs gained. A discount rate of 3.5% 
was applied to both costs and benefits over the 
lifetime of the patients.
Strategies/comparators
The scope for the appraisal states that the 
interventions to be considered are oral and 
i.v. topotecan. The comparators for these 
interventions, including a comparison between the 
two interventions, are BSC, CAV and any other 
chemotherapy regimens.
The clinical effectiveness section above highlighted 
the different study populations that were used 
in the RCTs involving topotecan and relevant 
comparators (see Chapter 3, Quantity and quality 
of research available). It was not felt appropriate to 
pool the RCTs identified. This resulted in the base-
case analysis of our economic model being limited 
to a comparison of oral topotecan plus BSC and 
BSC alone, based on the O’Brien and colleagues 
study.57 Furthermore, as noted in the MS, CAV 
is likely to be a more cost-effective option than 
topotecan as a second-line chemotherapy for SCLC 
in patients for whom CAV is not contraindicated. 
Therefore, topotecan would be used only in a 
small subgroup of patients, for whom CAV was 
not considered to be an appropriate second-line 
chemotherapy. The base-case analysis will consist 
of a comparison between oral topotecan plus BSC 
compared to BSC alone.
A comparison of i.v. topotecan and BSC, based 
on an indirect comparison, was also attempted 
although with reservations (see Estimation of net 
benefits). This was undertaken to give a complete 
analysis of the use of topotecan (oral and i.v.) 
against BSC as a second-line chemotherapy.
Methodology
Model type and rationale for model 
structure
Figure 2 illustrates the basic survival model which, 
in its simplest form, contains three states – stable 
disease (i.e. patients’ state at entry to the trial), 
progressive disease and death. Movements 
between these states are usually only permitted 
in the progressive direction. We have adopted 
this approach to model the cost-effectiveness of 
topotecan as a second-line chemotherapy.
Patients enter the model with relapsed 
SCLC, are unable or unwilling to undergo i.v. 
chemotherapy with CAV, and receive either 
BSC alone or topotecan with BSC. Patients may 
experience disease progression or may die without 
experiencing documented disease progression.
The model uses data that are presented in the 
clinical effectiveness review (see Chapter 3, 
Results) and the MS to evaluate the most cost-
effective strategy for second-line chemotherapy 
in SCLC. The model is fully probabilistic, to take 
into account parameter imprecision. In addition, 
deterministic sensitivity analysis was used to 
explore different scenarios and assumptions in the 
model.
The base-case analysis compared the mean OS for 
oral topotecan plus BSC (meanOST) with the mean 
OS for BSC (meanOSBSC). The estimate of LYG with 
the addition of oral topotecan to BSC (LYGT), in 
the base case, was calculated as: LYGT = meanOST–
meanOSBSC.
To estimate the QALY gain associated with the 
addition of oral topotecan to BSC (QALYGT), 
treatment-specific utilities (UT and UBSC for oral 
topotecan plus BSC and for BSC, respectively) 
reported by O’Brien and colleagues57 and by 
Chen and colleagues64 were applied to the 
mean OS estimates. The quality-adjusted life 
expectancy gain was therefore calculated as: 
QALYGT = meanOST*UT – meanOSBSC*UBSC. 
This approach takes no account of the limited Economic analysis
40
Death
Progressive
disease
Relapsed
SCLC
OS-TTP TTP
OS
FIGURE 2  Survival model adopted for the cost-effectiveness model. OS, mean overall survival; OS-TTP, mean survival duration with 
progressive disease; TTP, mean time to progression.
duration of follow-up over which the utility data 
were collected. EQ-5D data were collected for 
12 follow-up assessments (up to 36 weeks from 
randomisation, as stated in the MS), although 
the abstract by Chen and colleagues64 reports 
that only data up to 12 weeks were included in 
the EQ-5D utility analyses. Therefore, the utility 
data for patients in the oral topotecan plus BSC 
arm may not reflect patients’ QoL following 
disease progression. It has been noted elsewhere 
that there is likely to be a reduction in QoL when 
patients experience disease progression. As a 
result, an additional analysis was undertaken to 
explore the impact of the difference in QoL for 
patients following the development of progressive 
disease. The estimate of the QALY gain associated 
with oral topotecan, taking into account the QoL 
impact of progressive disease, was calculated as: 
QALYGT = TTPT*UT + (meanOST – meanTTPT)*
UBSC – meanOSBSC*UBSC.
Baseline cohort
The baseline population in the economic model are 
adults with relapsed SCLC, for whom re-treatment 
with the first-line regimen is not considered 
appropriate and who are unsuitable or unwilling to 
accept i.v. chemotherapy with CAV.
Discounting of future costs and benefits
A discount rate of 3.5% was applied to future costs 
and benefits, in line with current guidance from 
NICE. Discount rates of 0% and 6% were applied in 
the sensitivity analysis.
Presentation of results of the base-case 
model
We report the results of these comparisons in terms 
of incremental gain in QALYs and the incremental 
costs.
Assessment of uncertainty in the SHTAC 
analysis (sensitivity analysis)
Parameter uncertainty is addressed using 
probabilistic sensitivity analysis. Probability 
distributions were assigned to the point estimates 
used in the base-case analysis.
Deterministic sensitivity analysis is used to address 
particular areas of uncertainty in the model 
relating to:
•  model structure
•  methodological assumptions
•  parameters around which there is considerable 
uncertainty or which may be expected, a priori, 
to have a disproportionate effect on study 
results.
The purpose of this analysis is to identify clearly 
the impact of uncertainty and to test the robustness 
of the cost-effectiveness results to variation in 
structural assumptions and parameter inputs.
Estimation of net benefits
Effectiveness data
Oral topotecan plus BSC compared 
with BSC alone
The model builds upon the Kaplan–Meier curves 
for OS from the O’Brien and colleagues57 study for 
topotecan plus BSC and BSC alone. These survival 
curves were scanned using techdig software and 
then imported into microsoft excel. In both arms, 
some of the participants remained alive at the end 
of the trial. Therefore, the final portions of the 
survival curves were extrapolated using a regression 
analysis. A range of parametric survival functions 
were fit to the observed Kaplan–Meier estimates 
(full details are included in Appendix 9). The log-
logistic survival function provided the best fit to the DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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FIGURE 3  Kaplan–Meier survival estimates from the O’Brien and colleagues trial and log-logistic fits.
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observed Kaplan–Meier estimates and was used in 
the economic model.
The extrapolated survival curves are given in Figure 
3 and compared to the Kaplan–Meier survival 
estimates (details of the regression estimates are 
found in Appendix 9). These show a good fit to the 
OS curves. The most appropriate measure of OS is 
the mean rather than the median. Therefore, the 
associated mean survival times were estimated for 
the relevant survival curves.
Mean survival (area under the survival curves) 
estimated directly from the Kaplan–Meier survival 
function (truncated at the maximum observed 
survival for each arm in the RCT by O’Brien and 
colleagues57) and from the log-logistic survival 
functions (extrapolated to a maximum duration of 
5 years) are reported in Table 25.
The mean OS figures from the Kaplan–Meier 
estimate and from the log-logistic function are very 
similar for BSC, at 0.4837 and 0.4864, respectively. 
For oral topotecan plus BSC, the mean OS from 
the log-logistic function is greater than the value 
based on the Kaplan–Meier estimate by 0.06 years, 
or approximately 3 weeks. If the modelled survival 
function is truncated at the maximum survival 
duration observed in the RCT by O’Brien and 
colleagues,57 the mean reduces to 0.7997 years. The 
difference between the modelled value and that 
estimated directly from the Kaplan–Meier curve is 
reduced to approximately 1.5 weeks.
The RCT by O’Brien and colleagues57 did not 
report Kaplan–Meier estimates for TTP, but 
reported only the median TTP for oral topotecan 
plus BSC. Moreover, no TTP data were reported 
for the BSC group (see Chapter 3, Oral topotecan 
plus BSC versus BSC alone). To estimate the 
mean TTP for oral topotecan plus BSC, the 
risk of disease progression was derived from 
the reported median TTP using an exponential 
approximation:72 λ = –ln(S)/t, where S is the 
proportion of patients surviving (or in this case 
without disease progression) at time t. For the 
median TTP the value of S in the above equation 
is set, by definition, at 0.5, whereas t = 16.3 weeks 
(as presented in this report – see Chapter 3, Oral 
topotecan plus BSC versus BSC alone). The mean 
TTP was calculated by taking the reciprocal of the 
risk of disease progression (1/λ), giving a value 
of 23.52 weeks. This approach has been used in 
previous Technology Assessment Reports (TARs) 
looking at second-line chemotherapies for ovarian 
cancer.69 The accuracy of this estimate of the mean 
TTP depends on the adequacy of the exponential 
approximation, used to convert the median TTP to 
a risk of disease progression. The appropriateness 
of this transformation cannot be assessed without 
reference to the full survival function for TTP, 
which has not been reported for the RCT by Economic analysis
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TABLE 25  Mean OS from Kaplan–Meier and log-logistic survival functions
Treatment arm
Mean OS (years)
Kaplan–Meier estimate Log-logistic function
Oral topotecan plus BSC 0.7685 0.8271
BSC 0.4837 0.4864
O’Brien and colleagues.57 This represents a 
substantial source of uncertainty in the model. See 
Appendix 9 for additional analysis on TTP, using 
data from the MS.
Intravenous topotecan versus BSC
An analysis was undertaken to assess the effect of 
i.v. topotecan on OS, relative to BSC, based on 
an adjusted indirect comparison using data from 
three RCTs included in the review. Data from 
the RCT by O’Brien and colleagues57 were used 
for the comparison of oral topotecan plus BSC 
against BSC alone, whereas the trials by Eckardt 
and colleagues56 and von Pawel and colleagues58 
provided data for the comparison of oral topotecan 
with i.v. topotecan, as discussed in Chapter 3 (see 
Oral topotecan plus BSC versus BSC alone, and 
Oral topotecan versus i.v. topotecan).
For the comparison of oral topotecan with i.v. 
topotecan, data on OS were available in the form 
of HRs (Eckardt and colleagues56) and RRs (von 
Pawel and colleagues58). The point estimates and 
their 95% CIs were entered into Review Manager 
revman 5.0 software, and combined using the 
generic inverse variance method. In a fixed-effect 
meta-analysis there was no statistically significant 
difference between treatment arms (RR 0.95, 
95% CI 0.76 to 1.17, p = 0.62) – see Figure 4. 
Study or 
subgroup log[risk ratio] SE Weight
Risk ratio
IV, ﬁxed, 95% CI
Risk ratio
IV, ﬁxed, 95% CI
Eckardt 2007
56 −0.0202 0.123599 78.0% 0.98 (0.77 to 1.25)
von Pawel 2001
58 −0.17435 0.232783 22.0% 0.84 (0.53 to 1.33)
Total (95% CI) 100.0% 0.95 (0.76 to 1.17)
Heterogeneity: χ
2 = 0.34, df = 1 (p = 0.56); I
2 = 0%
Test for overall effect: z = 0.50 (p = 0.62)
0.01 0.1 1 10 100
Favours oral topotecan Favours i.v. topotecan
FIGURE 4  Fixed-effect meta-analysis of relative risk of overall survival – oral versus intravenous topotecan.
Heterogeneity was not statistically significant 
(p = 0.56, I2 = 0%).
Combining the pooled estimate with the HR for 
oral topotecan plus BSC compared with BSC alone 
reported by O’Brien and colleagues,57 and using 
the method for indirect comparison described by 
Glenny and colleagues,73 gives a relative risk for OS 
with i.v. topotecan of 0.68 (95% CI 0.45 to 1.02) 
compared with BSC (Table 26).
This analysis is highly speculative, given the 
uncertainty whether these trials fully meet the 
inclusion criteria for this review (discussed in 
Chapter 3 under Quantity and quality of research 
available), particularly regarding the comparability 
of participant populations in the RCTs and 
therefore the suitability of pooling their results.
Health-state values/utilities
To calculate QALYs from the mean OS and mean 
TTP, derived using the methods described above, 
it was necessary to adjust the survival times for 
QoL using appropriate utility or health-state 
valuations.67 As described in the section ‘Review of 
research on quality of life’, above, we found only 
limited data sources on QoL and health-state utility 
for people with recurrent SCLC.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 26  Adjusted indirect comparison to derive the HR for OS for i.v. topotecan compared with BSC
HR ln(HR) se(ln(HR))
Oral vs i.v. topotecan 0.95 –0.0541 0.1092
Oral topotecan vs BSC 0.64 –0.4463 0.1768
Intravenous topotecan vs BSC 0.68 –0.3922 0.2078
The natural log of the HR for i.v. topotecan vs BSC is estimated by subtracting the natural log of the HR for oral vs i.v. from 
the natural log of the HR for oral vs BSC [(–0.4463) – (–0.0541) = –0.3922].
The utilities used in this analysis are based on those 
reported for the O’Brien and colleagues’ RCT,57 
which used the EQ-5D in both trial arms (see 
Chapter 3, Oral topotecan plus BSC versus BSC 
alone). Adopting these utility estimates has the 
advantage that they were derived:
•  in a relevant population – those with SCLC 
who responded to first-line treatment, for 
whom re-treatment with first-line therapy is not 
considered appropriate and for whom BSC is 
an appropriate comparator strategy
•  using a measure and methodology (EQ-
5D valued using a tariff derived from 
a representative sample of the general 
population) that is consistent with the NICE 
reference case.
In addition, it should be noted that our search for 
QoL studies and studies reporting utility estimates 
in this population failed to find any other relevant 
publications. However, there are shortcomings in 
the evidence base that need to be borne in mind:
•  The QoL assessment within the trial is 
reported only very briefly in the main RCT 
publication.57 There is very little detail on 
methods adopted for calculating utilities from 
the EQ-5D (the value set used is not reported), 
approaches to handling missing data (baseline 
data were collected for 96% of participants in 
the topotecan plus BSC arm and 93% in the 
BSC arm, whereas the proportions with at least 
one postbaseline assessment were 89% and 
70%, respectively) or methods used to estimate 
the rate of deterioration in scores over time.
•  It is not clear how far the EQ-5D data, 
collected at 3-week intervals, capture the 
impact of treatment-related toxicity for those 
receiving oral topotecan.
•  There was limited follow-up for the QoL 
assessments. The main trial publication 
does not report the duration of the QoL 
assessment. However, the abstract by Chen and 
colleagues,64 which reports the same rate of 
change from baseline to 3 months as the main 
trial publication,57 states that the data analysed 
covered a maximum of 12 weeks from baseline 
(measures were administered at baseline and 
at four subsequent visits, occurring at 3-week 
intervals). As a result, these assessments are 
unlikely to capture the full impact of disease 
progression in the oral topotecan group.
The RCT reported that the ‘rate of deterioration’ 
in EQ-5D scores over 3 months was –0.05 for oral 
topotecan plus BSC and –0.20 for BSC alone. We 
interpreted this to indicate that for each 3-month 
period, the mean utility reduces from baseline by 
5% for the oral topotecan plus BSC cohort and by 
20% for the cohort receiving BSC alone.
Baseline EQ-5D values for all participants, or 
for each trial arm separately, were not reported 
in the main publication for the RCT by O’Brien 
and colleagues.57 The abstract by Cheng and 
colleagues64 reported a mean baseline utility (for 
patients in the RCT by O’Brien and colleagues) 
of 0.72 for oral topotecan plus BSC arm and 
0.68 for BSC alone. These baseline values are 
for participants included in the pooled analysis 
(change from baseline to averaged-on-treatment 
assessments). For the cost-effectiveness model, 
we assume that the mean baseline utility for all 
participants is 0.7.
A regression analysis was used to infer the 
reduction of utility over time from the 0- and 
3-month time points, and to model utility beyond 
the last observation and beyond the trial (see 
Appendix 11). In the base case, we assumed that 
any QoL reduction due to toxicity or adverse 
events would be picked up in the EQ-5D valuations 
from trial participants.
The base-case analysis assumed that there was an 
associated loss of utility in people treated with oral 
topotecan plus BSC once disease had progressed. 
This was assumed to be the same loss of utility 
that was associated with participants receiving Economic analysis
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FIGURE 5  Impact on quality-adjusted survival of alternative assumptions regarding the utility reduction over time with topotecan.
BSC alone and was applied for survival durations 
beyond the estimated mean TTP. Quality-adjusted 
survival curves, showing the effect of assuming 
a greater reduction in utility following disease 
progression, are shown in Figure 5.
Estimation of net costs
Cost analysis
The cost data were based upon the resource use 
from the O’Brien and colleagues study.57 This was 
supplemented with data from the MS and the other 
RCTs identified in the clinical effectiveness review. 
A questionnaire was also sent out to clinical experts 
to ascertain relevant costing and resource use 
associated with oral topotecan (see Appendix 13). 
All cost data and relevant sources are given and 
discussed, in turn, below.
Base case: oral topotecan plus BSC versus 
BSC alone
The groups of health-care costs included in the 
base-case health economic model are:
•  drug costs
•  chemotherapy administration
•  on-treatment monitoring
•  cost of adverse events
•  post-treatment monitoring
•  palliative care costs.
Drug costs of oral topotecan
Oral topotecan is administered at 2.3 mg/m2/day 
on five consecutive days of each 21-day course 
of treatment.74 Table 27 reports the total dose 
per day of treatment for oral topotecan used 
in the cost-effectiveness model. This assumes 
that patients have a body surface area (BSA) of 
1.8 m2 – this assumption is based on the BSA 
adopted by the SMC for costing i.v. topotecan 
for treatment of relapsed SCLC,47 with the exact 
dosage (4.14 mg per day of treatment) rounded 
up to the nearest 0.25 mg. This allows for the fact 
that some participants in the RCT by O’Brien 
and colleagues57 experienced dose reductions 
(reported as 8% of courses) or dose escalations 
(reported as 14% of courses). Dose reductions and 
escalations occurred at increments of 0.4 mg/m2/
day to a minimum dose of 1.5 mg/m2/day and to a 
maximum dose of 3.1 mg/m2/day. We estimated the 
mean oral topotecan dosages, allowing for dose 
reductions and escalations, to be between 2.29 
and 2.38 mg/m2/day (corresponding to dosages of 
4.13–4.28 mg per day of treatment). These were 
calculated by weighting the standard dosage by 
the proportion of courses having dose reductions/
escalations and assuming that all reductions/
escalations were either one or two increments (i.e. 
either 0.4 mg/m2/day or 0.8 mg/m2/day).
Table 27 reports the unit costs – estimated cost 
per treatment day and cost per course for oral DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 27  Unit costs and cost per day of treatment with oral topotecan
Total dose per day of 
treatment Cost/mg (£)
Cost per day of 
treatment (£) Cost per course (£)
4.25 mga 30 127.50 637.50
a  Assume this is supplied by the hospital pharmacy as four 1-mg capsules and one 0.25-mg capsules for each day of 
treatment within the current treatment course.
topotecan – that were used in the cost-effectiveness 
model. Unit costs for oral topotecan were taken 
from the current British National Formulary (BNF, 
no. 57, March 2009).75 Oral topotecan is available 
on 10 capsule cards, with a unit cost of £300 per 
card of 1-mg capsules and £75 per card of 0.25-mg 
capsules.
The cost per course of oral topotecan has been 
calculated on the basis of no wastage – we assume 
that the hospital pharmacy department will supply 
patients with the exact quantity of capsules to 
deliver the required dosage over each course of 
treatment. In the case of the patient with a BSA of 
1.8 m2 this would most closely be met by supplying 
20 1-mg capsules and five 0.25-mg capsules, which 
implies that the hospital pharmacy can supply 
fractions of the 10-capsule card.
The main trial publication57 reports that a total 
of 278 treatment courses were delivered to the 71 
participants randomised to oral topotecan (with 
a median of 4 per patient, range 1–10). In the 
cost-effectiveness model we assume that people 
receive a mean of four courses of oral topotecan, 
which corresponds to a total drug cost per patient 
for oral topotecan of £2550. This is similar to the 
mean cost per patient for oral topotecan of £2500 
reported in the MS.
Administration and monitoring costs 
for oral topotecan
The summary of product characteristics (SmPC) for 
topotecan states that it should only be prescribed, 
and therapy should be supervised, by a physician 
who is experienced in the use of chemotherapeutic 
agents. We assumed that patients would attend 
the hospital once, at the beginning of each course, 
to collect the complete supply of oral topotecan 
for each course of treatment. At the same time, 
patients would also receive a supply of an oral 
antiemetic (domperidone, non-proprietary) 
and an antidiarrhoeal drug (loperamide) to use 
as required. Patients attending the hospital to 
collect oral chemotherapy agents will also have 
their condition monitored. This will include a 
consultation with their treating physician (in 
which their medical history will be assessed for 
performance status, symptoms and for side 
effects of treatment) and a series of biochemical, 
haematological and imaging tests. We have 
assumed that the medical consultation will be 
accounted for under standard resource-use 
assumptions for an outpatient attendance to 
receive oral chemotherapy. However, we have 
separately identified a set of tests that is required 
for patients undergoing chemotherapy with 
topotecan for relapsed SCLC. All patients will 
require a FBC prior to administration of the first 
course of oral topotecan to ensure they have a 
baseline neutrophil count of ≥ 1.5 × 109/l, a platelet 
count of ≥ 100 × 109/l and a haemoglobin level of 
≥ 9 g/dl (after transfusion if necessary).74 In addition 
patients require a repeat of the FBC, liver function 
tests, renal function tests (urea, creatinine and salts) 
and a chest radiograph (to assess tumour response) 
at each attendance. In addition, based on clinical 
advice, it was assumed that patients receiving 
active treatment would have a CT scan every two 
cycles. Clinical advisors confirmed that these were 
appropriate resource use assumptions for the 
management of this group of patients.
The unit cost for an outpatient attendance to 
receive oral chemotherapy has been taken from 
NHS Reference Costs.76 This does not include a 
pharmacy dispensing fee (which is included under 
‘procurement costs’ in NHS Reference Costs77). 
For the base-case analysis we adopt the same 
pharmacy cost as in the MS, based on contract 
price per prescription for community pharmacists 
(£0.90 per prescription at 2007/08 prices). Unit 
costs for routine tests undertaken to monitor 
treatment-related toxicity and disease progression 
were provided by the finance department at 
Southampton University Hospitals Trust. Table 28 
reports the unit costs that were adopted for costing 
the administration of oral topotecan and for 
patient monitoring while on treatment. Total cost 
per course is £274.14, comprising administration 
costs of £185.87 and monitoring costs of £88.28.Economic analysis
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TABLE 28  Unit costs for administration of oral topotecan and for patient monitoring while on treatment
Item Unit cost (£)a
Outpatient attendance to receive oral chemotherapy 184.97b
Pharmacy cost for dispensing oral chemotherapy 0.90c
FBC 2.90a
LFT 4.70a
U&E 4.70a
Chest radiograph 28.64b
CT scan (every two cycles) 47.34b
Total cost per course of oral topotecan 274.14
FBC, full blood count; LFT, liver function test; U&E, urea and electrolytes.
a  Finance Department, Southampton University Hospitals Trust, Southampton University.
b  NHS Reference Costs 2006/07, uprated to 2007/08 prices using HCHS Pay and Prices Index.78
c  Prescription Prescribing Authority 2007/08 dispensing fee to community pharmacists, from MS.51
TABLE 29  Proportion of participants experiencing treatment-related haematological toxicity, as reported by O’Brien and colleagues57 and 
in the clinical study report submitted as part of the MS
Toxicity Grade
Proportions of patients 
reported by O’Brien et 
al. (%)
Proportions of patients 
(from CSR) (%)
Proportions of cycles 
(from CSR) (%)
Neutropenia 3 61.2 28.4 16.4
4 32.8 11.5
Thrombocytopenia 3 37.7 30.4 11.4
4 7.2 1.8
Anaemia 3 24.6 14.5 5.1
4 10.1 9.5
CSR, clinical study report.
Notes: Figures in column 4 are taken from the CSR for the RCT by O’Brien and colleagues, submitted as appendix 5 of the 
MS, as there appears to be an error in Table 3.45 of the MS, which reports the breakdown of haematological toxicity by 
grade.
Based on the unit cost assumptions in Table 28, 
the costs of administration of oral topotecan and 
monitoring for the complete treatment duration 
of four courses of chemotherapy is £1097 (£743.47 
for administration and £353.11 for monitoring).
Adverse events costs
The RCTs included in the clinical effectiveness 
review reported that treatment with oral topotecan 
was associated with both haematological and 
non-haematological adverse events.56–58 The most 
common toxicities were haematological, with 
61%, 38% and 25% of participants experiencing 
neutropenia, thrombocytopenia or anaemia, 
respectively, at grades 3 or 4 in the oral topotecan 
arm of the RCT by O’Brien and colleagues57 (see 
Chapter 3, Oral topotecan plus BSC versus BSC 
alone). Similar proportions were reported for 
trials including oral topotecan by Eckardt and 
colleagues56 and by von Pawel and colleagues,58 (see 
Chapter 3, Oral topotecan versus i.v. topotecan). 
The proportion of participants with grade 3 and 
grade 4 non-haematological toxicities associated 
with treatment for oral topotecan was lower in the 
three trials – generally below 10% of patients.
O’Brien and colleagues57 followed the usual 
convention of only reporting toxicity at grades 3 
and 4, while the MS included non-haematological 
toxicity at all grades. Table 29 shows the proportion 
of participants, treated with oral topotecan, 
experiencing haematological toxicity, as reported 
by O’Brien and colleagues57 and also in the MS. 
Table 29 also shows the proportion of cycles in 
which participants experienced haematological 
toxicity when treated with oral topotecan.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 30  Resource use assumptions for management of haematological adverse events –unit cost assumptions and estimated cost per 
affected patient
Toxicity Grade Resource use Unit cost (£) Cost per patient (£)
Neutropenia 3 Outpatient visit 207.48a 103.74
Amoxicillin 1.37b 0.69
4 Inpatient admission (3.5 days) 249.83a 874.41
Piperacillin 22.99bc 321.86
Thrombocytopenia 3 No treatment
4 Day-case admission 367.29a 367.29
Platelet transfusion 805.67d 805.67
Type and cross 36.88d 36.88
Anaemia 3 Day-case admission 367.29a 367.29
Blood transfusion 90.05d 90.05
Type and cross 36.88d 36.88
4 Day-case admission 367.29a 367.29
Blood transfusion 535.60d 535.60
Type and cross 36.88d 36.88
Sepsis Inpatient admission (10 days):
5 days in intensive care unit 1022.86a 5114.31
5 days on ward 249.83a 1249.15
Piperacillin 22.99bc 459.80
Clarithromycin 7.47b 10.70
Fluconazole i.v. 29.28b 204.96
a  NHS Reference Costs 2006/0776 uprated to 2007/08 prices using HCHS Pay and Prices Index.78
b  BNF, September 2008.79
c  Unit cost for piperacillin includes cost of 120 ml of saline for initial dilution and for i.v. infusion.
d  Finance Department, Southampton University Hospitals Trust, Southampton University.
Note: see Appendix 12 for full details of resource use assumptions and sources.
Table 30 (and Appendix 12) report the resource 
use assumptions adopted in our cost-effectiveness 
model. Resource use assumptions adopted in a 
previous TAR for topotecan in the treatment of 
advanced ovarian cancer were updated, based on 
expert clinical opinion.
The most common grade 3/4 non-haematological 
adverse events occurring in the oral topotecan plus 
BSC arm of the RCT by O’Brien and colleagues57 
were diarrhoea, vomiting, fatigue and dyspnoea 
(Table 31). The proportion of participants with 
grade 3 or 4 fatigue was the same in both arms of 
the trial and is not included in our model. Table 
31 reports the breakdown of non-haematological 
toxicity between grades 3 and 4, taken from the 
CSR that was submitted as an appendix to the MS, 
and used in our cost-effectiveness model. This table 
includes grade 3 nausea and grade 2 diarrhoea, 
which was not reported in the publication by 
O’Brien and colleagues.57 We have included grade 
2 diarrhoea in the model, following advice from 
clinical experts that this adverse event would 
require an outpatient attendance and prescription 
of further antidiarrhoeal medication. We have 
assumed that grade 1 or 2 nausea and grade 
1 diarrhoea occurring in patients treated with 
oral topotecan will be self-managed using the 
antiemetic and antidiarrhoeal medication supplied 
at the outpatient attendance clinic, which initiates 
each course of chemotherapy.
Table 32 (and Appendix 12) present details of the 
cost per patient, as well as unit cost and resource 
estimates, for managing non-haematological 
toxicity for patients treated with oral topotecan. 
Clinical opinion was sought to validate these 
estimates, which were based on assumptions 
adopted in a previous TAR, which included 
topotecan (for advanced ovarian cancer69) and 
those developed for the MS.Economic analysis
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TABLE 31  Proportion of participants experiencing non-haematological toxicity, as reported by O’Brien and colleagues, and in the CSR 
submitted as an appendix to the MS
Toxicity Grade Proportions reported by O’Brien et al. (%) Proportions reported in CSR (%)
Diarrhoea 2 Not reported 12.9
3
6
4.3
4 1.4
Vomiting 3
3
2.9
4 0.0
Nausea 3 Not reported 1.4
4 0.0
Notes: figures in column 4 are taken from the CSR for the RCT by O’Brien and colleagues, submitted as appendix 5 of the 
MS. The main body of the MS did not report a breakdown of non-haematological toxicity by grade.
TABLE 32  Resource use assumptions for management of non-haematological adverse events in the topotecan plus BSC arm of the trial
Toxicity Grade Resource use Unit cost (£) Cost per patient (£)
Diarrhoea 2 Outpatient visit 207.48a 207.48
Loperamide 2.15b 1.40
3 Inpatient admission (5 days) 249.83a 1249.15
Loperamide 2.15b 2.01
Buscopan 2.59b 2.59
Codeine 0.97b 0.97
4 Inpatient admission (5 days) 249.83a 1249.15
Loperamide 2.15b 2.01
Buscopan 2.59b 2.59
Codeine 0.97b 0.97
Ciproflaxin i.v. 22.00b 44.00
Metronidazole i.v. 3.41b 13.64
Nausea/vomiting 3 Outpatient visit 207.48a 207.48
Dexamethasone 3.27b 13.08
Granisetron 65.49b 130.98
4 Inpatient admission (5 days)
Dexamethasone i.v.
207.48a
1.00b
1037.39
5.00
Granisetron i.v. 26.69bc 80.07
Cyclizine 1.48b 1.11
a  NHS Reference Costs 2006/0776 uprated to 2007/08 prices using HCHS Pay and Prices Index78
b  BNF, September 2008.79
c  Includes cost of 15 ml of saline for initial dilution.
Note: see Appendix 12 for full details of resource use assumptions and sources
Cost of non-progressive disease survival
In the base-case model we assumed that patients 
have a mean duration of treatment of four courses 
of oral topotecan, which corresponds to 12 weeks. 
Patients are assumed to continue to attend the 
outpatients clinic for general medical care and 
for monitoring of their condition. This continued 
monitoring is costed in the model until patients 
develop progressive disease. It is assumed that 
these patients will also have one chest radiograph 
and a CT scan to confirm disease progression.
The full package of care for patients during period 
from ceasing treatment with oral topotecan, until DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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the development of progressive disease, is listed 
in Table 33 and consists of an outpatient visit, with 
FBC every 4 weeks, and a GP consultation every 4 
weeks. These correspond to a cost of £246.38 for 
each 4-week period prior to the development of 
disease progression. We adopted these assumptions 
based on information in the MS. Clinical experts 
were asked to comment on the appropriateness 
of these assumptions and whether there were 
any additional items of resource use for patients 
following the cessation of treatment with oral 
topotecan, and prior to the development of 
progressive disease, which should be included.
Assuming that mean TTP is 23.52 weeks (derived, 
as described earlier in Methodology, from the 
median TTP reported by O’Brien and colleagues57) 
and an average treatment duration of four courses, 
we estimated that patients with SCLC, treated 
with oral topotecan, would have an average of 
11.52 weeks from treatment cessation until disease 
progression. This corresponds to an average cost 
of continued monitoring, from treatment cessation 
until disease progression, of £709.57 per patient, 
plus £123.32 for imaging to confirm disease 
progression.
Cost of palliative care
Best supportive care was available to participants 
in both arms of the RCT by O’Brien and 
colleagues,57 and involved the use of analgesics, 
antibiotics, corticosteroids, appetite stimulants, 
antidepressants, RBC transfusions, deep-relaxation 
therapy, and palliative radiotherapy or surgical 
procedures. The MS, and the main trial publication 
by O’Brien and colleagues,57 generally provide 
little detail on the BSC components of care that 
was provided to participants in the trial (either 
for participants in the BSC arm or the BSC 
component for participants receiving topotecan 
plus BSC). In particular there is no indication of 
which components of treatment participants were 
TABLE 33  Management costs for patients following cessation of treatment with oral topotecan, prior to disease progression
Resource use item Frequency of use Unit cost
Outpatient attendance
Once every 4 weeks
207.48a
FBC 2.90b
GP consultation Once every 4 weeks 36.00c
Chest radiograph
Once, to confirm disease progression
28.64a
CT scan 94.68a
a  NHS Reference Costs 2006/07, uprated to 2007/08 prices using HCHS Pay and Prices Index.78
b  Finance Department, Southampton University Hospitals Trust, Southampton University.
c  Unit costs of Health and Social Care 2008.78
receiving as palliative care. The MS and the trial 
publication57 note a greater use of medication 
and radiotherapy in the BSC arm, while there 
were more blood transfusions for participants in 
the topotecan plus BSC arm (reflecting the high 
proportion of participants in this arm experiencing 
haematological toxicity).
As BSC was common to both arms, and given 
that recording of resource use in the RCT was 
not comprehensive, the manufacturer’s economic 
model did not include palliative care costs 
(justifying this as a conservative assumption 
that is most likely to overestimate resource 
use for topotecan). However, while BSC is a 
common component in both arms, it is likely 
that participants will experience palliative care at 
different times in the two arms, given the survival 
advantage associated with topotecan. To assess the 
impact of this assumption, we include a published 
estimate of the cost of palliative care, derived in a 
retrospective analysis of case notes for 109 patients 
with SCLC conducted in the UK49 (Table 34). The 
study estimated that 28% of the total costs of care 
occur after recurrence of the disease until death, 
of which 73% are generated by palliative care. The 
average cost of palliative care, for the 71 patients 
(65%) in the study cohort who received such care, 
was £3495 at 1998 prices.
Summary of costs in SHTAC model
Table 35 reports a summary of the costs applied 
in the SHTAC base-case model, broken down by 
categories of cost, and identified separately for the 
oral topotecan plus BSC group and for the BSC 
alone group.
Subanalysis of i.v. topotecan versus BSC
Cost analysis
The categories of health care costs included in 
the model for i.v. topotecan are similar to those 
included for oral topotecan. The cost data were Economic analysis
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TABLE 34  Palliative care costs, and proportion each component contributes to total costs, inflated to 2007/08 prices
Components costed in palliative care (£)
Total Hospitalisation
Outpatient 
visits Tests and procedures Surgery/radiotherapy Other
3819 (77%) 251 (5%) 341 (7%) 245 (5%) 322 (6%) 4977 
Source: Oliver and colleagues.49
TABLE 35  Breakdown of costs used in the SHTAC base-case model for oral topotecan versus BSC
Category BSC (£) Topotecan and BSC (£)
Drug cost (per cycle) 637.50
Chemotherapy administration cost (per cycle) 185.87
Monitoring cost (per cycle) 88.28
Managing haematological adverse events (per cycle) 367.49
Managing non-haematological adverse events (per patient) 114.45
Non-progressive-disease survival (per day) 8.80a
Palliative care (per patient) 4977 4977
a  A one-off cost of £123.32 is also applied for imaging to confirm disease progression.
based upon resource use from the RCTs reported 
by Eckardt and colleagues56 and von Pawel and 
colleagues,58 supplemented by responses to the 
questionnaire that was sent to clinical experts (see 
Appendix 13).
Drug costs of i.v. topotecan
Intravenous topotecan is administered at 1.5 mg/
m2 per day on five consecutive days of each 21-
day cycle. The powder for reconstitution and i.v. 
infusion is available in 1- and 4-mg vials, at unit 
costs of £97.65 and £390.62, repectively.50 Table 
36 reports the total dose per day of treatment 
for i.v. topotecan, assuming a BSA of 1.8 m2. The 
total dosage per day cannot be delivered in exact 
multiples of 1-mg vials – in the base-case we 
assumed that all excess was wasted. The impact of 
this assumption is tested in a sensitivity analysis, 
as are the potential impact of dose escalation and 
dose reductions.
Intravenous topotecan is supplied as a powder, 
requiring reconstitution with saline (0.9% w/v 
sodium chloride i.v. infusion or 5% w/v glucose i.v. 
infusion) to a final concentration of between 25 
and 50 µg/ml. The unit cost of sodium chloride 
i.v. infusion was estimated as £0.06/ml, giving a 
total cost per day of treatment for i.v. topotecan of 
£298.95 and a cost per cycle of £1494.75.
The 54 participants in the von Pawel and 
colleagues RCT58 received a total of 213 courses 
of treatment. For the base case we assumed that 
patients would receive four cycles of treatment with 
i.v. topotecan, giving a total drug treatment cost of 
£5979 (or £5381.10, assuming reuse of excess).
Administration and monitoring costs 
for i.v. topotecan
We assumed that i.v. chemotherapy was 
administered in secondary care, on an outpatient 
basis, requiring five separate outpatient visits 
per cycle. The costs of outpatient visits for the 
administration of chemotherapy were taken from 
the NHS Reference Costs 2006/07, as detailed 
in Table 37. Pharmacy costs for chemotherapy by 
simple i.v. infusion were taken from a previous TAR 
(£23 at 2004–5 prices were uprated to £25.44 using 
the HCHS Pay and Prices Index78).
On the basis of expert clinical opinion, on-
treatment monitoring was assumed to be the 
same as for oral topotecan. The average cost per 
cycle was therefore £1027.31 for i.v. topotecan 
administration. Assuming patients receive four 
cycles of treatment with i.v. topotecan, this gives 
a total cost of £4289.26 for i.v. chemotherapy 
administration and on-treatment monitoring, 
which breaks down as £3936.15 for i.v. DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 36  Cost per day of treatment and cost per cycle with i.v. topotecan
Total dose per day of 
treatment
Intravenous topotecan cost per day of 
treatmenta Cost per cycleb
2.70 mg £298.95 £1494.75
a  Includes 100 ml of 0.9% w/v sodium chloride i.v. infusion. The cost also assumes that three 1-mg vials are used to 
deliver the required dosage, implying that 0.3 mg is wasted. Assuming that the excess can be reused, the cost per day of 
treatment for exactly 2.70 mg would be reduced to £269.06.
b  Assuming wastage. If the excess can be reused, the cost per cycle would reduce to £1345.28.
TABLE 37  Unit costs for i.v. chemotherapy administration/on-treatment monitoring and total costs per cycle for patients receiving i.v. 
topotecan
Item Unit cost (£)
Outpatient attendance to receive i.v. chemotherapy (first attendance of cycle) 175.53a
Outpatient attendance to receive i.v. chemotherapy (subsequent attendances during cycle) 195.77b
Pharmacy cost per cycle 25.44
FBC 2.90
LFT 4.70
U&E 4.70
Chest radiograph 28.64
CT scan (every two cycles) 47.34
Total cost per cycle 1027.31
a  HRG SB12Z: deliver simple parenteral chemotherapy at first attendance.
b  HRG SB15Z: deliver subsequent elements of a chemotherapy cycle.
Source: NHS Reference Costs 2006/07, uprated to 2007/08 prices using HCHS Index.78
chemotherapy administration and £353.11 for on-
treatment monitoring.
Adverse events costs for i.v. topotecan
Relative risks for the incidence of adverse events 
with i.v. topotecan compared with oral topotecan 
were estimated using data on the proportion of 
participants experiencing each adverse event 
from the RCTs by Eckardt and colleagues56 and by 
von Pawel and colleagues58 (see Tables 18 and 19, 
Chapter 3, Oral topotecan versus i.v. topotecan for 
observed proportions, and Appendix 14 for details 
of the calculation of the pooled estimates).
The proportion of patients receiving i.v. topotecan 
experiencing haematological toxicity in the 
model (reported in Table 38, below) was estimated 
by applying the pooled relative risks to the 
proportions of participants experiencing each 
grade of haematological toxicity in the O’Brien and 
colleagues RCT57 (previously reported in Table 29).
Combining the above proportions with costs in 
Table 30 gives estimate of the cost of managing 
haematological adverse events for patients treated 
with i.v. topotecan of £1105.
TABLE 38  Estimated proportion of patients treated with i.v. 
topotecan experiencing haematological toxicity
Toxicity Grade
Proportion 
experiencing 
toxicity (%)
Neutropenia 3 27.8
4 48.0
Thrombocytopenia 3 35.6
4 5.1
Anaemia 3 22.1
4 6.1
Sepsis 4.3Economic analysis
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TABLE 39  Estimated proportion of patients treated with i.v. 
topotecan experiencing non-haematological toxicity
Toxicity Grade
Proportion 
experiencing 
toxicity (%)
Diarrhoea 2 4.1
3 0.8
4 1.4
Nausea 3 1.0
4 0.0
Vomiting 3 1.4
4 0.0
A similar approach was adopted for non-
haematological adverse events – deriving relative 
risks from the RCTs comparing oral and i.v. 
topotecan and applying these to the proportions 
observed in the RCT by O’Brien and colleagues.57 
However, given the relatively lower incidence of 
non-haematological adverse events, there were 
a number of cases were no adverse events were 
reported (for example, no cases of grade 2, 3 or 4 
diarrhoea for i.v. topotecan and no cases of grade 
4 nausea for either arm were reported in the RCT 
by von Pawel and colleagues58). To take account of 
this, we increased the numerator and denominator 
by one – the grey cells in the tables for non-
haematological adverse events in Appendix 14 
indicate which calculations included zero cells. 
The estimated proportion of patients receiving 
i.v. topotecan who experience non-haematological 
toxicity, in the model, are reported in Table 39.
Combining the above proportions with the resource 
use assumptions listed in Table 32 gives an estimate 
of the cost of £45 for managing haematological 
adverse events for patients treated with i.v. 
topotecan.
Cost of non-progressive disease survival 
for i.v. topotecan
As with oral topotecan, we assume that patients 
continue to attend outpatients for general medical 
care and for monitoring of their condition after 
the completion of their course of treatment with 
i.v. topotecan. This continued monitoring is costed 
in the model until disease progression occurs. 
We assume that the components of this ongoing 
monitoring are the same as for patients receiving 
oral topotecan (see Table 33).
Estimates of the relative TTP for i.v. topotecan in 
comparison with oral topotecan were derived using 
regression analysis of the Kaplan–Meier estimates 
reported in von Pawel and colleagues58 and Eckardt 
and colleagues56 – these are reported in Appendix 
15. The estimated mean TTP using data from 
the RCT by von Pawel and colleagues,58 for which 
median TTP for i.v. topotecan was shorter than 
for oral topotecan, was 24.37 weeks. Taking into 
account the average treatment duration of four 
cycles of i.v. topotecan, patients are expected 
to remain in the non-progressive disease state 
for 12.37 weeks following the end of treatment. 
This corresponds to an average cost of continued 
monitoring, from treatment cessation until disease 
progression, of £885, including for imaging to 
confirm disease progression. Alternatively, using 
data from the RCT by Eckardt and colleagues,56 in 
which the median TTP for i.v. topotecan was longer 
than that for oral topotecan, the estimated mean 
TTP was 32.07 weeks. This means that patients 
are expected to remain in the non-progressive 
disease state for 20.07 weeks following the end of 
treatment, giving an average cost of £1360.
Cost of palliative care
Costs of palliative care were assumed to be the 
same as for BSC and oral topotecan – see Table 34.
Summary of costs in SHTAC model
Table 40 reports a summary of the cost per patient, 
applied in the SHTAC base-case model. The total 
costs are broken down by categories of cost and are 
identified separately for the oral topotecan plus 
BSC and for the BSC alone groups.
Summary of the SHTAC cost-
effectiveness model
•  The cost-effectiveness model was developed 
using a survival model methodology.
•  The model includes three states: (1) relapsed 
SCLC, (2) progressive disease and (3) death. 
No data on TTP in the BSC alone group were 
collected. TTP for oral topotecan was included 
in the model, to allow for poorer QoL with 
disease progression. QoL weights applied to 
the BSC group, were applied to oral topotecan 
patients once they had progressive disease.
•  The survival model was developed using the 
published Kaplan–Meier estimates for OS and 
TTP data included in the MS.
•  Utility values reported by O’Brien57 and 
colleagues and by Chen and colleagues64 were 
used in the model. Limited published data DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 40  Breakdown of costs used in the SHTAC base-case model for i.v. topotecan versus BSC
BSC (£)
Intravenous topotecan  
plus BSC (£)
Drug cost (per cycle) 1494.75
Chemotherapy administration cost (per cycle) 984.04
Monitoring cost (per cycle) 88.28
Managing haematological adverse events (per patient) 1104.57
Managing non-haematological adverse events (per patient) 44.62
Non-progressive disease survival (per day) 8.80a
Palliative care (per patient) 4977 4977
a  A one-off cost of £123.32 is also applied for imaging to confirm disease progression.
are available on these QoL values and full 
details of the methods used to analyse these 
data are not available in published sources. 
Limited extra detail was identified in the MS. 
QoL values were estimated by applying the 
rate of deterioration, reported by O’Brien 
and colleagues and by Chen and colleagues,64 
to the baseline EQ-5D utility value for 
participants included in the RCT by O’Brien 
and colleagues.57
•  Resource use associated with oral and i.v. 
topotecan were estimated from included RCTs, 
the MS and using advice from clinical experts. 
Where insufficient detail for estimating 
resource use or costs was available in included 
studies or the MS (particularly for palliative 
care) appropriate costs were taken from 
published sources. Where available, drug costs 
were taken from the BNF. Other unit costs were 
taken from NHS reference costs, Southampton 
University Hospitals Trust or published 
sources. The cost base for the evaluation 
was the 2007/08 financial year – where costs 
were taken from other cost years, these were 
adjusted using the HCHS Pay and Prices 
Index.
•  The base-case model has a 5-year time horizon. 
Alternative scenarios, truncating the survival 
functions at the maximum follow-up in the 
RCT (for oral topotecan) or adopting a longer 
(10 year) horizon, are included in sensitivity 
analyses to assess whether extrapolation 
using survival function is likely to introduce 
bias. Alternative forms of survival function 
were investigated to determine whether this 
introduced bias.
•  Discount rates at 3.5% for costs and outcomes 
are applied.
Estimation of cost-effectiveness
Cost-effectiveness of topotecan –  
base-case analysis
This section reports cost-effectiveness results for a 
cohort of patients with relapsed SCLC, for whom 
re-treatment with the first-line regimen is not 
considered appropriate and who are unsuitable or 
unwilling to accept i.v. chemotherapy with CAV, 
as discussed in Methodology, above. Discounted 
costs (identifying the contribution of drugs, drug 
administration and monitoring while receiving 
oral topotecan, management of adverse events, 
monitoring prior to disease progression and 
palliative care) are presented alongside the life 
expectancy and quality-adjusted life expectancy for 
patients in the cohort. The results are presented 
as incremental cost per life-year gained and 
incremental cost per QALY gained.
Costs and outcomes modelled for cohorts of 
patients receiving oral topotecan plus BSC or BSC 
alone are presented in Table 41. Costs and health 
outcomes in the table have been discounted at 
3.5%.
The estimated gain in discounted life expectancy, 
associated with the addition of oral topotecan to 
BSC is 0.3249 years (16.9 weeks). The equivalent 
undiscounted values are 0.3407 years (17.7 
weeks). The estimated gain in discounted QALYs, 
associated with the addition of oral topotecan to 
BSC, is 0.1830. The equivalent undiscounted value 
is 0.1894 QALYs.
The incremental cost associated with the addition 
of oral topotecan to BSC is £6194. Table 42 
reports a breakdown of treatment costs, by phase 
of treatment, for each cohort. Palliative care is Economic analysis
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TABLE 41  Base-case analysis
Treatment Costs (£) Life-years
Incremental cost per 
life-year gained (£) QALYs
Incremental cost per QALY 
gained (£)
BSC 4854 0.4735 0.2247
Oral 
topotecan + BSC
11,048 0.7984 19,065 0.4077 33,851
TABLE 42  Treatment costs by phase of treatment
Phase of treatment Oral topotecan (£) BSC (£)
Active treatment Drug 2550
Drug administration 743
On-treatment monitoring 353
Adverse event costs Haematological 1470
Non-haematological 114
Non-progressive disease monitoring 1082
Palliative care 4735 4854
Total 11,048 4854
the only phase of treatment that is identified for 
patients receiving BSC alone, and this represents 
100% of the treatment cost for this cohort. In 
contrast, for patients receiving treatment with oral 
topotecan in addition to BSC, while palliative care 
remains the single most costly phase these have 
reduced to 43% of total costs for this cohort. Active 
treatment with oral topotecan (including drug 
administration and on-treatment monitoring in 
addition to the costs of the drug itself) represents 
33% of total costs for this cohort, with drug costs 
constituting 70% of active treatment costs. Other 
significant contributions to total costs for the oral 
topotecan plus BSC cohort are costs of managing 
haematological toxicity (13%) and monitoring for 
disease progression in patients following cessation 
of treatment (10%).
Oral topotecan as a treatment for patients with 
relapsed SCLC, for whom re-treatment with the 
first-line regimen, is not considered appropriate 
is associated with both improved outcomes (in 
terms of life expectancy and quality-adjusted life 
expectancy) and increased costs. QALY outcomes 
have increased by approximately 80%, while costs 
have more than doubled, yielding an incremental 
cost-effectiveness ratio for the addition of oral 
topotecan to BSC of £33,851 per QALY gained.
Cost-effectiveness of topotecan – 
deterministic sensitivity analysis
We conducted a sensitivity analysis to consider the 
effect of uncertainty around the model structure 
and for variation in certain key parameters that 
were expected, a priori, to be influential on the 
cost-effectiveness results. The method adopted in 
most cases was univariate sensitivity analysis. That 
is, varying one parameter at a time, leaving all 
other variables unchanged. This is to highlight the 
impact, if any, of each selected parameter alone 
on the cost-effectiveness results. In some situations 
(such as the analysis of alternative parametric forms 
for the survival function, or the analysis using 
the upper confidence limits for all parameters in 
survival model) a set of related parameters are 
varied simultaneously. The effects of uncertainty 
in multiple parameters were addressed using 
probabilistic sensitivity analysis, which is reported 
later in the section.
Table 43 reports the results of the sensitivity 
analysis. Except for the sensitivity analysis 
with respect to time horizon, all analyses were 
conducted using a 5-year time horizon. The 
table is divided to distinguish between analyses 
undertaken due to uncertainties over structural 
assumptions in the model, methodological 
uncertainties (in this case related to the discount 
rates applied in the model) and uncertainty over 
parameter values. Where unit costs have been 
taken from NHS Reference Costs, the upper and 
lower quartiles have been used in the sensitivity 
analysis. In all other cases, unit costs have been 
varied by plus or minus 20%. To test the sensitivity 
of the cost-effectiveness results to assumptions over 
the method of estimating adverse event costs, the DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 43  Deterministic sensitivity analysis
Cost (£)
Life-years 
gained QALYs gained
ICER (£ per 
QALY gained)
Base case 6194 0.3249 0.1830 33,851
Structural assumptions
Truncate survival at maximum follow-up for 
trial
6160 0.3202 0.1806 34,114
Extrapolate OS up to 10 years 6302 0.3596 0.1871 33,681
Weibull survival and TTP model 5940 0.3144 0.1591 37,338
Methodological assumptions
Discount rates (0% for both costs and 
outcomes)
6283 0.3407 0.1894 33,177
Discount (6% for costs and 1.5% for outcomes) 6136 0.3337 0.1866 32,889
Parameter uncertainty
Lower 95% CI for treatment effect 6183 0.3514 0.1909 32,381
Upper 95% CI for treatment effect 6204 0.2991 0.1751 35,432
Lower 95% CI for all parameters in survival 
model
6144 0.4124 0.2009 30,579
Upper 95% CI for all parameters in survival 
model
6229 0.2536 0.1660 37,515
Lower 95% CI for all parameters in TTP model 6961 0.3249 0.2360 29,496
Upper 95% CI for all parameters in TTP model 5676 0.3249 0.1516 37,454
Exclude palliative care costs 6313 0.3249 0.1830 34,502
Lower limit for utility values 6194 0.3249 0.1498 41,346
Upper limit for utility values 6194 0.3249 0.2492 24,859
No adjustment to utility for oral topotecan 
cohort post progression
6194 0.3249 0.2442 25,364
Round down oral topotecan dosage 6044 0.3249 0.1830 33,031
Use proportion of patients with adverse events 5703 0.3249 0.1830 31,166
Cost of outpatient visit to administer oral 
chemotherapy: lower quartile
5714 0.3249 0.1830 31,227
Cost of outpatient visit to administer oral 
chemotherapy: upper quartile
6472 0.3249 0.1830 35,373
Cost of palliative care reduced by 20% 6313 0.3249 0.1830 34,502
Cost of palliative care increased by 20% 6313 0.3249 0.1830 34,502
Cost of outpatient visit for monitoring: lower 
quartile
5858 0.3249 0.1830 32,017
Cost of outpatient visit for monitoring: upper 
quartile
6395 0.3249 0.1830 34,949
Cost (per day) of inpatient admission: lower 
quartile
6015 0.3249 0.1830 32,871
Cost (per day) of inpatient admission: upper 
quartile
6300 0.3249 0.1830 34,432
Cost of day-case admission: lower quartile 6100 0.3249 0.1830 33,335
Cost of day-case admission: upper quartile 6294 0.3249 0.1830 34,396
Use transfusion cost from Main and 
colleagues69 for grade 4 anaemia
6025 0.3249 0.1830 32,927Economic analysis
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proportion of patients experiencing adverse events 
(rather than the proportion of cycles in which 
adverse events occurred) were used to estimate 
adverse event costs. In the assessment report by 
Main and colleagues69 the same transfusion cost 
was applied for patients experiencing grade 3 
and grade 4 anaemia. Clinical advice suggested 
that patients experiencing grade 4 anaemia would 
require four units of blood – this was costed in the 
base case. The final entry in the table shows the 
cost-effectiveness results using the transfusion cost 
from Main and colleagues.69
The cost-effectiveness results appear to be 
generally robust to variation in the parameters 
included in the deterministic sensitivity analysis, 
with ICERs varying between approximately 
£30,000 and £37,000 per QALY gained. Among 
the structural sensitivity analyses, the results 
appear to be most sensitive to assumptions over the 
functional form for the survival functions. In terms 
of parameter inputs, the results appear to be most 
sensitive to variation in utility estimates applied in 
the model, variation in values of parameters in the 
survival functions (for OS and TTP) and to the cost 
of outpatient attendance for the administration of 
oral chemotherapy.
Time horizon for the model appears to have 
a very limited impact on the cost-effectiveness 
estimates. Truncating survival at the maximum 
duration observed for each arm in the O’Brien 
and colleagues RCT57 reduces the QALY gain 
by 0.0024 and costs by £34. The proportionate 
reduction in outcome (1.3%) is greater than the 
proportionate reduction in costs (0.5%) hence 
the ICER increases, but only by a small amount. 
Increasing the maximum survival duration to 10 
years has the opposite effect – a slight increase 
in QALY gain and a slight increase in costs, with 
the proportionate change in QALYs being greater 
than the proportionate increase in costs, leading 
to a small reduction in the ICER. Adopting an 
alternative (Weibull) parametric form for the OS 
and TTP survival functions has a more dramatic 
effect, resulting in a 13% reduction in QALY gain, 
a smaller reduction in cost and an increase in the 
ICER to £37,338.
Varying the discount rates applied has 
comparatively little effect. Zero discount rates for 
costs and outcomes result in slight increases in both 
incremental cost and incremental QALYs compared 
with baseline values. Applying discount rates of 6% 
for costs and 1.5% for outcomes leads to a slight 
reduction in incremental cost and to an increase in 
incremental QALYs. The resulting ICER is slightly 
lower than in the base case.
Varying the value of the treatment effect parameter 
in the OS model, between its upper and lower 
confidence limits, has a greater effect on outcomes 
than on cost. In the model, variation in survival 
(unless it is assumed to be associated with variation 
in TTP) has an impact on only the duration of 
postprogression survival, and therefore will only 
affect the estimate of palliative care costs. A similar 
situation applies to QALY outcomes where, it is 
assumed that all gains or losses of life expectancy 
associated with variation in the treatment effect 
parameter are weighted by postprogression utility 
values. This explains why the proportionate 
variation in QALY gains in less than the variation 
in life-years gained.
The cost-effectiveness results are more variable if 
all parameters in the survival models are included 
(at the 95% confidence limits) in the sensitivity 
analysis, rather than just the treatment effect 
estimated in the OS model, with ICERs varying 
between approximately £30,000 and £37,500 per 
QALY gained. Variation in the parameters of the 
TTP survival model has a particularly large impact 
on incremental cost. This arises from the inclusion 
of a cost of approximately £9 per day (£246 every 
4 weeks) to monitor disease progression in patients 
following treatment with oral topotecan (see Table 
33 and accompanying text for assumptions).
The greatest variation in cost-effectiveness results, 
associated with parameter inputs, is related to 
the rate of deterioration in utility values over 
time. Using the lower 95% confidence limits as 
an estimate of the higher rate of deterioration 
(–0.11 for oral topotecan plus BSC, –0.27 for 
BSC alone – see Table 5) leads to a reduction of 
0.03 (18%) in the QALY gain associated with oral 
topotecan plus BSC. As a result, the ICER increases 
to £41,346 per QALY gained. In contrast, using 
the upper 95% confidence limits, giving a lower 
rate of deterioration (0.02 for oral topotecan plus 
BSC, –0.12 for BSC alone, – see Table 5) leads 
to an increase of 0.07 (36%) in the QALY gain 
associated with oral topotecan plus BSC, with the 
ICER reducing to £24,859 per QALY gained. To 
test the sensitivity of the cost-effectiveness results 
to the assumption that the QoL deterioration 
for the oral topotecan plus BSC cohort would be 
significantly greater following disease progression, 
the utility adjustment for postprogression survival 
was removed. This meant that the same rate of 
deterioration (–0.05 reported for oral topotecan DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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FIGURE 6  Cost-effectiveness plane – incremental cost and incremental quality-adjusted life-years for oral topotecan compared with best 
supportive care.
plus BSC – see Table 5) was applied for both pre- 
and postprogression survival. The increase in the 
incremental QALY gain was almost as great as 
for the sensitivity analysis using the upper 95% 
confidence limits, with the ICER reducing to 
£25,364, compared with the base case.
In terms of cost parameters, the model results 
appear to be most sensitive to variation in the cost 
of outpatient attendances for the administration 
of oral chemotherapy. This is unsurprising as 
these represent the majority of the administration 
costs for oral topotecan, and administration cost 
constitute 7% of total costs for the oral topotecan 
plus BSC cohort.
Cost-effectiveness of topotecan – 
probabilistic analysis
In a probabilistic sensitivity analysis, where the 
parameters of the survival models (both OS and 
TTP) probabilities of adverse events, proportionate 
deterioration in health-state utility values, cost of 
outpatient attendances and patient monitoring, 
as well as costs of managing adverse events and 
palliative care were sampled probabilistically, oral 
topotecan plus BSC is associated with increased 
QALYs (with a range from 0.13 to 0.31 QALYs), but 
also increased costs (from £5160 to £8040) in all 
simulations when compared with BSC alone (Figure 
6 – also shows the 95% confidence ellipse).
The distributions assigned to each variable 
included in the probabilistic sensitivity analysis and 
the parameters of the distribution are reported 
in Appendix 10. In total, 1000 simulations were 
run for this analysis. The probabilistic analysis 
generated cost and QALY estimates for each 
intervention that were similar to those for the 
base-case analysis (see Table 41 for the base-case 
analysis). Table 44 reports the mean costs and 
outcomes from the probabilistic analysis (including 
the 2.5th and 97.5th percentiles to give an 
indication of the range of the simulated values) and 
the ICER for oral topotecan plus BSC compared 
with BSC alone, based on the mean values 
generated in the probabilistic analysis.
The ICER reported in Table 44, calculated using 
the difference in mean discounted costs and mean 
discounted QALYs shown in the table, is slightly 
lower than the mean of the ICERs calculated at 
each simulation (which was £34,430).
In addition to graphing the incremental cost and 
incremental QALYs for oral topotecan plus BSC, a 
cost-effectiveness acceptability curve was derived, 
representing the proportion of simulations where 
oral topotecan treatment is cost-effective for a 
range of WTP thresholds, up to £50,000 (Figure 
7). In this analysis oral topotecan plus BSC had a 
probability of being cost-effective of 0% at a WTP Economic analysis
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TABLE 44  Costs and outcomes from probabilistic analysis for oral topotecan plus BSC
Discounted costs Discounted QALYs
ICER Mean
2.5th 
percentile
97.5th 
percentile Mean
2.5th 
percentile
97.5th 
percentile
BSC  4882 2186 8584 0.2258 0.2047 0.2522
Oral 
topotecan + BSC
11,153 8394 14,813 0.4116 0.3672 0.4732 33,753
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FIGURE 7  Cost-effectiveness acceptability curve for oral topotecan and best supportive care.
threshold of £20,000 per QALY, 20% at a WTP 
threshold of £30,000 per QALY and 100% at a 
WTP threshold of £50,000 per QALY.
Cost-effectiveness of i.v. topotecan
This section reports cost-effectiveness results 
for a cohort of patients with relapsed SCLC, for 
whom re-treatment with the first-line regimen 
is not considered appropriate and who may be 
suitable for treatment with i.v. topotecan. As for 
oral topotecan, discounted costs (identifying 
the contribution of drugs, drug administration 
and monitoring, management of adverse events, 
monitoring prior to disease progression and 
palliative care) are presented alongside the life 
expectancy and quality-adjusted life expectancy for 
patients in the cohort. The results are presented 
as incremental cost per life-year gained and 
incremental cost per QALY gained relative to BSC.
Costs and outcomes modelled for cohorts of 
patients receiving i.v. topotecan plus BSC or 
BSC alone are presented in Table 45, based on 
the indirect comparison for OS described in 
Estimation of net benefits, above, TTP as described 
in Appendix 15, and relative risks of adverse 
events (compared with oral topotecan) described 
in Appendix 14. Costs and health outcomes in the 
table have been discounted at 3.5%.
The estimated gain in discounted life expectancy, 
associated with the addition of i.v. topotecan to 
BSC, is 0.3049 years (15.9 weeks) – approximately 
1 week shorter than the life expectancy gain in 
the base-case analysis for oral topotecan, reported 
above. The equivalent undiscounted values are 
0.3196 years (16.6 weeks). As noted in Appendix 
15, the two RCTs comparing oral and i.v. topotecan 
give contradictory results on the relative TTP. This 
has no effect on the estimated life-year gain with 
i.v. topotecan. However, given the assumption of 
a higher rate of deterioration in QoL following 
disease progression (see Methodology), there 
is an effect on the QALY gain. The estimated 
gain in discounted QALYs, associated with the 
addition of i.v. topotecan to BSC is 0.1628 when DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 45  Cost-effectiveness results for i.v. topotecan compared with BSC
Treatment Costs (£) Life-years
Incremental cost per 
life-year gained (£) QALYs
Incremental cost per 
QALY gained (£)
BSC 4854 0.4735 0.2247
Intravenous 
topotecan plus BSC
16,914a 0.7784 39,552a 0.3875a 74,074a
17,369b 41,043b 0.4157b 65,507b
a  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by von Pawel and 
colleagues.58
b  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by Eckardt and 
colleagues.56
TTP is modelled using data from the RCT by von 
Pawel and colleagues,58 and 0.1910 when TTP is 
modelled using data from the RCT by Eckardt and 
colleagues.56 The equivalent undiscounted values 
are 0.1683 and 0.1981 QALYs, respectively.
The incremental cost associated with the addition 
of i.v. topotecan to BSC is substantially higher 
than for oral topotecan – £12,060, when TTP 
is modelled using data from the RCT by von 
Pawel and colleagues,58 and £12,514 when TTP 
is modelled using data from the RCT by Eckardt 
and colleagues.56 Table 46 reports a breakdown of 
treatment costs, by phase of treatment, for each 
cohort. For patients receiving treatment with i.v. 
topotecan, palliative care is no longer the most 
costly phase (reduced to 27% of total costs) for 
this cohort, while the costs of active treatment with 
topotecan constitute 58% of total costs (35% drug 
costs and 23% for chemotherapy administration).
TABLE 46  Treatment costs by phase of treatment
Phase of treatment Intravenous topotecan (£) BSC (£)
Active treatment Drug 5979
Drug administration 3936
On-treatment monitoring 353
Adverse event costs Haematological 1132
Non-haematological 45
Non-progressive disease monitoring 726a
1181b
Palliative care 4743 4854
Total 16,914a
17,369b
4854
a  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by von Pawel and 
colleagues.58
b  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by Eckardt and 
colleagues.56
Intravenous topotecan as a treatment for patients 
with relapsed SCLC, for whom re-treatment 
with the first-line regimen is not considered 
appropriate, is associated with improved outcomes 
(in terms of life expectancy and quality-adjusted 
life expectancy) over BSC and similar outcomes 
to oral topotecan. However, these outcomes are 
achieved at substantially greater cost – the ICER 
for i.v. topotecan compared with BSC is £74,074 
per QALY gained when TTP is modelled using 
data from the RCT by von Pawel and colleagues,58 
and £65,507 per QALY gained when TTP is 
modelled using data from the RCT by Eckardt 
and colleagues.56 Intravenous topotecan is strictly 
dominated by oral topotecan (poorer outcomes 
at higher cost), when TTP is modelled using 
data from the RCT by von Pawel and colleagues58 
and has an ICER of £783,734 per QALY gained 
compared with oral topotecan, when TTP is 
modelled using data from the RCT by Eckardt and 
colleagues.56Economic analysis
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TABLE 47  Deterministic sensitivity analysis
Cost (£)
Life-years 
gained QALYs gained
ICER (£ per 
QALY gained)
Base case 12,514 0.3049 0.1910 65,507
12,060 0.1628 74,074
Structural assumptions
Extrapolate OS up to 10 years 12,638 0.3371 0.1962 64,425
12,149 0.1660 73,182
Methodological assumptions
Discount rates (0% for both costs and 
outcomes)
12,611 0.3196 0.1981 63,674
12,137 0.1683 72,134
Discount (6% for costs and 1.5% for 
outcomes)
12,452 0.3131 0.1950 63,868
12,009 0.1659 72,408
Cost-effectiveness of i.v. topotecan – 
deterministic sensitivity analysis
Table 47 reports the results of a deterministic 
sensitivity analysis for i.v. topotecan. Except 
for the sensitivity analysis with respect to time 
horizon, all analyses were conducted using a 
5-year time horizon. The table is divided to 
distinguish between analyses undertaken due to 
uncertainties over structural assumptions in the 
model, methodological uncertainties (in this case 
related to the discount rates applied in the model) 
and uncertainty over parameter values. The upper 
value in each cell of Table 47 gives the incremental 
costs, life-years gained, QALYs gained and ICER 
using TTP based on data from the RCT by 
Eckardt and colleagues,56 whereas the lower value 
is based on TTP from the RCT by von Pawel and 
colleagues.58
The cost-effectiveness results appear to be 
generally robust to variation in the parameters 
included in the deterministic sensitivity analysis, 
with ICERs remaining in most cases above £60,000 
per QALY gained. As with oral topotecan, in terms 
of parameter inputs the results appear to be most 
sensitive to variation in utility estimates applied in 
the model, variation in values of parameters in the 
survival functions (for OS and TTP) and to the cost 
of outpatient attendance for the administration 
of chemotherapy. Time horizon for the model 
appears to have a very limited impact on the cost-
effectiveness estimates, as does varying the discount 
rates applied in the model.
Cost-effectiveness of i.v. topotecan – 
probabilistic analysis
In a probabilistic sensitivity analysis, where the 
parameters of the survival models (both OS and 
TTP) probabilities of adverse events, proportionate 
deterioration in health-state utility values, cost of 
outpatient attendances and patient monitoring 
as well as costs of managing adverse events and 
palliative care were sampled probabilistically, i.v. 
topotecan is associated with increased QALYs (with 
a range from 0.10 to 0.27 QALYs, when TTP is 
modelled using data from the RCT by von Pawel 
and colleagues,58 and from 0.11 to 0.33 QALYs, 
when TTP is modelled using data from the RCT 
by Eckardt and colleagues56), but also increased 
costs (from £10,091 to £14,701 and from £9669 
to £15,422, when TTP is modelled using data 
from the RCTs by von Pawel and colleagues,58 
and by Eckardt and colleagues,56 respectively) in 
all simulations, when compared with BSC alone 
[Figure 8 – also shows 95% confidence ellipses for 
when TTP is modelled using data from the RCT by 
von Pawel and colleagues58 (dashed ellipse) and by 
Eckardt and colleagues56 (solid ellipse)].
The distributions assigned to each variable 
included in the probabilistic sensitivity analysis and 
the parameters of the distribution are reported 
in Appendix 10. One thousand simulations were 
run for this analysis. The probabilistic analysis 
generated cost and QALY estimates for each 
intervention that were similar to those for the 
base-case analysis (see Table 45 for the base-case DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Cost (£)
Life-years 
gained QALYs gained
ICER (£ per 
QALY gained)
Parameter uncertainty
Lower 95% CI for treatment effect 12,504 0.3296 0.1985 62,984
12,050 0.1703 70,755
Upper 95% CI for treatment effect 12,524 0.2809 0.1836 68,200
12,069 0.1554 77,664
Lower 95% CI for all parameters in survival 
model
12,468 0.387 0.2081 59,919 
12,013 0.1799 66,796
Upper 95% CI for all parameters in survival 
model
12,547 0.2381 0.1755 71,484
12,092 0.1468 82,390
Relative treatment effect of i.v. vs oral 
(lower limit)
12,542 0.2346 0.1691 74,176
12,087 0.1408 85,831
Relative treatment effect of i.v. vs oral 
(upper limit)
12,476 0.3975 0.2186 57,063
12,021 0.1904 63,135
Lower 95% CI for all parameters in TTP 
model
13,376 0.3049 0.2815 47,514
12,725 0.2066 61,581
Upper 95% CI for all parameters in TTP 
model
11,929 0.3049 0.1539 77,487
11,614 0.1371 84,689
Exclude palliative care costs 12,626 0.3049 0.1910 66,089
12,171 0.1628 74,756
Lower limit for utility values 12,514 0.3049 0.1551 80,705
12,060 0.1343 89,767
Upper limit for utility values 12,514 0.3049 0.2643 47,347
12,060 0.2187 55,144
No adjustment to utility for oral topotecan 
cohort post progression
12,514 0.3049 0.2335 53,585
12,060 0.2335 51,638
Cost of outpatient visits to administer i.v. 
chemotherapy: lower quartile
10,522 0.3049 0.1910 55,076
10,067 0.1628 61,833
Cost of outpatient visits to administer i.v. 
chemotherapy: upper quartile
13,852 0.3049 0.1910 72,510
13,398 0.1628 82,291
Cost of palliative care (reduced by 20%) 12,542  0.3049 0.1910 65,653
12,087 0.1628 74,244
Cost of palliative care (increased by 20%) 12,487 0.3049 0.1910 65,362
12,032 0.1628 73,903
Cost of outpatient visit for monitoring: 
lower quartile
12,132 0.3049 0.1910 63,507
11,819 0.1628 72,594
Cost of outpatient visit for monitoring: 
upper quartile
12,743 0.3049 0.1910 66,705
12,204 0.1628 74,960
Use transfusion cost from Main and 
colleagues69 for grade 4 anaemia
12,487 0.3049 0.1910 65,366
12,033 0.1628 73,908
TABLE 47  Deterministic sensitivity analysis (continued)Economic analysis
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FIGURE 8  Cost-effectiveness plane – incremental cost and incremental quality-adjusted life-years for intravenous topotecan compared 
with best supportive care, with 95% confidence ellipses.
TABLE 48  Costs and outcomes from probabilistic analysis for i.v. topotecan
Discounted costs Discounted QALYs
ICER Mean
2.5th 
Percentile
97.5th 
Percentile Mean
2.5th 
Percentile
97.5th 
Percentile
BSC 4829 2305 8652 0.2260 0.2054 0.2527 73,579a
Intravenous topotecan 
plus BSC
17,000a
17,387b
14,089a
14,497b
20,752a
21,203b
0.3915a
0.4210b
0.3438a
0.3615b
0.4599a
0.4998b
64,418b
a  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by von Pawel and 
colleagues.58
b  Costs and outcomes calculated using TTP for i.v. topotecan (relative to oral topotecan) from the RCT by Eckardt and 
colleagues.56
analysis). Table 48 reports the mean costs and 
outcomes from the probabilistic analysis (including 
the 2.5th and 97.5th percentiles to give an 
indication of the range of the simulated values) and 
the ICER for i.v. topotecan plus BSC compared 
with BSC alone, based on the mean values 
generated in the probabilistic analysis.
The ICERs reported in Table 48, calculated using 
the difference in mean discounted costs and mean 
discounted QALYs shown in the table, are slightly 
lower than the mean of the ICERs calculated at 
each simulation (which were £75,325 and £66,444, 
when TTP is modelled using data from the RCTs 
by von Pawel and colleagues58 and by Eckardt and 
colleagues,56 respectively).
In addition to providing a graph of the incremental 
cost and incremental QALYs for i.v. topotecan 
and BSC, cost-effectiveness acceptability curves 
were derived for each analysis, representing the 
proportion of simulations where i.v. topotecan 
treatment is cost-effective for a range of WTP 
thresholds, up to £100,000 (Figure 9). In this 
analysis i.v. topotecan plus BSC had a probability 
of being cost-effective of 0% at WTP threshold 
of £20,000 and £30,000 per QALY, and 1% at a 
WTP threshold of £50,000 per QALY, when TTP 
is modelled using data from the RCT by von Pawel 
and colleagues.58 When TTP is modelled using 
data from the RCT by Eckardt and colleagues,56 the 
probability of being cost-effective remained at 0% 
at the lower WTP thresholds but increased slightly 
(to 7.6%) at a WTP threshold of £50,000 per QALY.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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FIGURE 9  Cost-effectiveness acceptability curve for intravenous topotecan and best supportive care.
Summary of cost-effectiveness
•  A systematic search of the literature found no 
fully published economic evaluations of oral 
or i.v. topotecan as a treatment for patients 
with relapsed SCLC, for whom re-treatment 
with the first-line regimen is not considered 
appropriate.
•  A systematic search for published studies of 
QoL for patients with relapsed SCLC found 
no fully published studies other than the main 
RCT publication by O’Brien and colleagues.57 
There is very little detail on the methods 
used to analyse the utility data presented in 
the main trial report. The searches identified 
an additional publication, available only in 
abstract form,64 which provided more details 
(including baseline utility scores for the trial 
arms). Further methodological detail was 
extracted from the CSR (submitted as an 
appendix to the MS to NICE).
•  The manufacturer submitted a dossier in 
support of oral topotecan, including an 
economic evaluation based on individual 
participant data from the RCT reported by 
O’Brien and colleagues.57 This compares oral 
topotecan plus BSC with BSC alone. CAV was 
excluded from the manufacturer’s analysis 
on the a priori basis that topotecan (oral or 
i.v.) would be unlikely to be a cost-effective 
alternative, given its higher acquisition cost.
•  Mean survival, in the manufacturer’s model, 
was estimated directly from the survival 
durations for patients in the O’Brien and 
colleagues RCT.57 Censored cases were assumed 
to have died on the day following censoring 
– the manufacturer conducted no sensitivity 
analysis in respect of this assumption.
•  Health-related QoL was recorded using the 
EQ-5D, for up to 12 cycles (36 weeks), and 
valued using a general population tariff.80 
Missing values were imputed using data 
from the trial, using the mean utility score 
(across both trial arms) for missing values up 
to cycle 12. Where oral topotecan plus BSC 
patients survived with non-progressive disease 
beyond the 36-week data collection, the last 
observation was carried forward until disease 
progression occurred. Once these patients 
developed progressive disease, values for BSC 
patients were applied.
•  Oral topotecan was costed at the observed 
total dose for each participant in the topotecan 
plus BSC arm of the RCT by O’Brien and 
colleagues57 (with dosage rounded up 
to the nearest 0.25 mg). Chemotherapy 
administration was costed for the observed 
number of cycles for each patient, assuming 
one attendance per cycle to collect oral 
chemotherapy and assumed monitoring costs 
of £10 per cycle (using monitoring costs from 
a previous TAR,69 which included topotecan, 
inflated to 2007/08 costs). Haematological 
adverse events were costed on the basis 
of the observed prescribing of GCSF and Economic analysis
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antibiotics, as well as blood products (RBC 
units and platelet units) delivered to patients 
in the RCT by O’Brien and colleagues,57 
with additional assumptions regarding costs 
of administration. All blood transfusions 
were assumed to be provided on a day-case 
basis. Patients were assumed to be managed 
as day cases where drugs were administered 
intravenously, whereas patients receiving oral 
drugs were assumed to have their adverse 
events managed in outpatients. Resource 
use for management of non-haematological 
adverse events was based on expert opinion 
and costed according to the proportion of 
non-haematological adverse events which were 
deemed to be treatment-related in the RCT 
by O’Brien and colleagues.57 Resource use for 
monitoring patients following the cessation of 
treatment with topotecan, and prior to disease 
progression, was also based on expert opinion.
•  In the manufacturer’s base case, the QALY 
gain for the cohort of patients receiving oral 
topotecan plus BSC was estimated at 0.211. 
The cost difference was £5671, giving an ICER 
of £26,833 per QALY gained.
•  Deterministic sensitivity analysis showed 
that the results were sensitive to methods of 
estimating QoL (methods of carrying forward 
utility scores when patients had missing data), 
drug administration cost (significantly higher 
costs if patient attend on 5 days of the cycle to 
receive chemotherapy) and adverse event costs 
(halving or doubling adverse event costs).
•  In a bootstrap analysis, treatment with oral 
topotecan plus BSC was always associated with 
increased costs (incremental costs between 
£4000 and £7500) and with improved QALY 
outcomes (incremental QALYs between 0 and 
approximately 0.6) in the majority (98%) of 
replications. Cost effectiveness acceptability 
curves reported in the MS estimate a 
probability of oral topotecan plus BSC being 
cost-effective at 22% at a WTP threshold 
of £20,000 per QALY and 60% at a WTP 
threshold of £30,000 per QALY.
•  Subgroup analyses showed that oral topotecan 
was more likely to be cost-effective in patients 
whose TTP from prior therapy was less than or 
equal to 60 days (ICER = £17,946 per QALY 
gained), in women (ICER = £11,708 per QALY 
gained) and in those patients without liver 
metastases (ICER = £21,291 per QALY gained). 
Treatment with oral topotecan plus BSC also 
appeared to be more cost-effective for patients 
with a PS of 2 (ICER = £25,544 per QALY 
gained) as opposed to those with a PS of 0 or 1 
(ICER = £30,770 per QALY gained).
•  We developed an independent model that 
adopted a survival model methodology, using 
the published Kaplan–Meier estimates for 
OS and TTP data included in the MS. The 
model includes three states – relapsed SCLC, 
progressive disease and death.
•  Utility values reported for participants in 
the RCT by O’Brien and colleagues57 were 
used in the model. QoL data for the trial 
were reported as a rate of deterioration per 
3-month interval for participants in each arm 
in the trial, controlling for baseline utility. 
The reported reductions over 3 months were 
converted to daily utility reductions for use in 
our model and applied to the baseline utility 
values for participants in the RCT by O’Brien 
and colleagues.57 The rate of deterioration 
reported for oral topotecan plus BSC was used 
for participants prior to disease progression. To 
allow for poorer QoL in participants following 
disease progression the rate of deterioration 
reported for BSC alone was applied to oral 
topotecan patients who had experienced 
disease progression.
•  Resource use associated with oral and i.v. 
topotecan were estimated from the included 
RCTs, the MS and using advice from clinical 
experts. Where insufficient detail was available 
(such as for palliative care), appropriate costs 
were taken from published sources. Drug 
costs were taken from the BNF.79 Other unit 
costs were taken from NHS reference costs, 
Southampton University Hospitals Trust or 
published sources. Cost base for evaluation was 
2007/08 financial year – where costs were taken 
from other cost years, these were adjusted 
using the HCHS Pay and Prices Index.
•  The base-case model has approximate lifetime 
horizon, with extrapolation of the survival 
functions up to 5 years in the base case. 
Alternative scenarios using a longer time 
horizon or limited to the maximum follow 
up in the RCT by O’Brien and colleagues57 
are reported in the deterministic sensitivity 
analysis to ascertain whether extrapolation 
using survival function introduces bias. 
Alternative forms of survival function were also 
investigated to assess the sensitivity of the cost-
effectiveness to structural assumptions.
•  The gain in discounted life expectancy 
associated with the addition of oral topotecan 
to BSC, for patients with relapsed SCLC for 
whom re-treatment with the first-line regimen 
is not considered appropriate, is 0.33 years in DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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our model (approximately 16.9 weeks). The 
discounted QALY gain is 0.1830 QALYs. The 
incremental cost associated with the addition of 
oral topotecan to BSC is approximately £6200, 
resulting in an ICER of £33,851 per QALY 
gained. Approximately 40% of the incremental 
cost of the addition of oral topotecan to BSC 
is associated with drug acquisition costs, 
while approximately 26% is accounted for by 
management of adverse events, the majority of 
which are non-haematological toxicities.
•  The cost-effectiveness results for oral topotecan 
plus BSC are generally robust to variation in 
the parameters included in the deterministic 
sensitivity analysis, with ICERs varying between 
£30,000 and £37,000 per QALY gained. 
Among the structural sensitivity analyses, 
the results are most sensitive to assumptions 
over the functional form for the survival 
functions. In terms of parameter inputs, the 
results are most sensitive to variation in utility 
estimates applied in the model, variation in 
values of parameters in the survival functions 
(for OS and TTP) and the cost of outpatient 
attendance for the administration of oral 
chemotherapy.
•  Probabilistic sensitivity analysis shows a 0% 
probability of oral topotecan plus BSC being 
cost-effective, compared with BSC alone, at 
a WTP threshold of £20,000. The equivalent 
figure for a WTP threshold of £30,000 is 20%.
•  The gain in discounted life expectancy 
associated with i.v. topotecan, for patients 
with relapsed SCLC for whom re-treatment 
with the first-line regimen is not considered 
appropriate, in our model is 0.30 years 
(approximately 15.9 weeks) – approximately 
1 week shorter than the base-case analysis 
for oral topotecan. The discounted QALY 
gain is 0.1628 QALYs when TTP is modelled 
using data from the RCT by von Pawel and 
colleagues,58 and 0.1910,when TTP is modelled 
using data from the RCT by Eckardt and 
colleagues.56 The incremental cost associated 
with i.v. topotecan is approximately £12,000 
(£12,060 and £12,514 when TTP is modelled 
using data from the RCTs by von Pawel and 
colleagues58 and by Eckardt and colleagues,56 
respectively). For patients receiving treatment 
with i.v. topotecan, palliative care constitutes 
27% of total costs for this cohort, while 
the cost of active treatment with topotecan 
constitutes 58% of total costs (35% drug costs 
and 23% for chemotherapy administration). 
The resulting cost for i.v. topotecan compared 
with BSC is between £74,074 and £65,507 
per QALY gained, depending on assumptions 
regarding TTP. Compared with oral topotecan, 
i.v. topotecan is strictly dominated (poorer 
outcomes at higher cost) when TTP is 
modelled using data from the RCT by von 
Pawel and colleagues,58 while the ICER is 
approximately £783,734 per QALY gained 
when TTP is modelled using data from the 
RCT by Eckardt and colleagues.56
•  In a probabilistic sensitivity analysis, i.v. 
topotecan had a zero probability of being cost-
effective compared with BSC alone at WTP 
thresholds of £20,000 and £30,000 per QALY. 
For a WTP threshold of £50,000 the equivalent 
figure was between 1% and 7.6%, depending 
on assumptions regarding TTP.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Chapter 5  
Implications for other parties
T
opotecan (oral or i.v.) appears to provide 
gains in life expectancy over BSC alone, 
for people with relapsed SCLC. Recent debates 
over the assessment of technologies for peoples 
with short life expectancies have argued that a 
person’s family and carers may place a high value 
on relatively small extensions of life expectancy. 
Such potential benefits need to be weighed against 
the impact of patients taking up treatment. 
Attendance at hospital on five consecutive days of 
each chemotherapy cycle, as would be the case with 
i.v. topotecan, may be an unacceptable burden for 
carers. While oral topotecan offers advantages in 
terms of frequency of attendance for chemotherapy 
administration, both forms of topotecan are 
associated with high incidences of grade 3 and 
grade 4 haematological toxicities, which may 
have a substantial impact on patients’ carers and 
families.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Chapter 6  
Factors relevant to the NHS
O
ral topotecan offers an active treatment option 
to peoples who were previously deemed only 
suitable for palliative care, with potential gains in 
life expectancy over BSC alone. Adoption of oral 
topotecan as an addition to BSC for people with 
relapsed SCLC, in whom re-treatment with first-
line therapy is not considered appropriate, is likely 
to require some additional treatment capacity. 
People undergoing chemotherapy with oral 
topotecan will be required to attend outpatients 
once every 3 weeks to collect their medication, to 
undergo monitoring for treatment-related toxicity 
and assessment of disease progression as well as for 
general medical assessment. Additional capacity 
will be required for management of serious adverse 
events, when they occur – the RCTs by O’Brien 
and colleagues57, von Pawel and colleagues58 and 
Eckardt and colleagues56 suggest that grade 3 or 4 
neutropenia will occur in 60–75% of people who 
are treated with oral topotecan, while 22–32% 
of people will experience grade 3 or 4 anaemia. 
Treatment with i.v. topotecan would have similar 
requirements in terms of managing adverse 
events, but substantially higher requirements for 
chemotherapy administration – these are reflected 
in the treatment cost estimates developed for 
the independent model. As a consequence, i.v. 
topotecan appears unlikely to be a treatment of 
choice in normal NHS practice.
The SmPC for topotecan74 makes clear that the 
supervision of people receiving treatment requires 
specialist knowledge and experience of the use 
of chemotherapeutic agents. On this basis, it 
seems most likely that the active care component 
of management will be based in secondary care, 
under management of clinical oncology, although 
this may also require co-ordination with primary 
care. Given the poor prognosis and relatively short 
life expectancy for those with relapsed SCLC, even 
those initially responding topotecan, management 
will also require co-ordination with palliative care 
services.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Statement of principal 
findings
Clinical effectiveness
The results from five RCTs were included in 
this systematic review. One RCT compared 
oral topotecan plus BSC with BSC alone,57 one 
compared i.v. topotecan with CAV combination 
therapy,59 two compared oral topotecan with 
i.v. topotecan,56,58 and one other compared i.v. 
topotecan with amrubicin.63 In one of the included 
studies of oral versus i.v. topotecan56 and the 
study comparing topotecan with amrubicin,63 
we could not ascertain with any certainty if the 
population in the trials exactly matched those of 
the marketing authorisation for topotecan, i.e. 
participants were inappropriate for re-treatment 
with their first-line therapy. Therefore, is not clear 
how generalisable these studies are to the likely 
eligible participants in a UK setting. In terms of 
demographic characteristics, these studies, where 
reported, had similar population groups; the age 
ranges in each study were similar, with a higher 
proportion of males and a higher proportion 
having had extensive SCLC. No studies provided 
details of the ethnicity of participants, although 
it may be assumed that a high proportion of the 
participants in the study by Inoue and colleagues63 
were of Asian origin. Assessment of methodological 
reporting and quality varied between the included 
studies. There was a risk of selection bias in three 
studies56,58,63 and a risk of detection bias in all of the 
studies. Three studies were assessed as having an 
adequate ITT analysis, however.57–59
The primary outcome measure in most studies 
was response rate. For this measure, the evidence 
showed that there was no difference between i.v. 
topotecan and i.v. CAV, and no difference between 
topotecan that was administered orally compared 
with topotecan administered intravenously. 
Response rate was seen to be better in those treated 
with amrubicin, although it is worth noting the 
lower dose of topotecan in this study. In the trial of 
oral topotecan compared with BSC, measurement 
of response rates were appropriate only in the 
treatment group and hence no comparison on this 
outcome can be made.
Other outcome measures included duration 
of response, TTP, OS, symptoms, HRQoL and 
toxicities/adverse events. The evidence showed that 
OS was better in those treated with oral topotecan 
compared to BSC (the primary outcome in this 
study). There were no differences in OS between 
i.v. topotecan and CAV therapy, i.v. topotecan and 
amrubicin, or oral topotecan compared with i.v. 
topotecan. Health related QoL was seen to favour 
topotecan in the oral topotecan versus BSC study, 
although results may need to be viewed critically 
due to a number of issues (noted above). In one 
of the studies comparing i.v. topotecan with oral 
topotecan there were reportedly no differences in 
QoL between study arms; however no data were 
reported. Where reported, it would appear that 
symptoms were favourable to topotecan therapy, 
although care is required as some scales may not 
have been validated measures. Toxicities were 
reported across treatment groups in all studies, 
except in the O’Brien and colleagues57 study where 
no treatment was given to those in the BSC group. 
There were some grades of toxicities that showed 
higher rates in the topotecan arms of studies, 
however there were also some grades of toxicities 
that showed lower rates. This, together with the 
small sample sizes of the studies and the different 
comparators evaluated, mean that it is difficult to 
establish with any degree of certainty if topotecan 
is more or less toxic in those with SCLC than 
comparator interventions.
Cost-effectiveness
Systematic searches identified no fully published 
economic evaluations of oral or i.v. topotecan for 
the treatment of relapsed SCLC, in patients who 
were not considered appropriate for re-treatment 
with their first-line regimen and only limited 
information on QoL in patients with relapsed 
SCLC.
The MS included an economic evaluation that 
compared oral topotecan plus BSC with BSC alone, 
based on individual participant data from the 
RCT reported by O’Brien and colleagues.57 CAV 
was excluded from the manufacturer’s analysis 
on the basis that topotecan (oral or i.v.) would be 
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unlikely to be a cost-effective alternative, given its 
higher acquisition cost. The QALY gain with oral 
topotecan plus BSC, compared with BSC alone, 
was estimated at 0.211 in the manufacturer’s 
base-case analysis. The cost difference was £5671, 
giving an ICER of £26,833 per QALY gained. 
Deterministic sensitivity analysis showed that the 
results were sensitive to methods of estimating 
QoL, drug administration cost and adverse 
event costs, although the scenarios examined for 
costs were extreme. Parametric cost-effectiveness 
acceptability curves were used in the MS to estimate 
the probability of oral topotecan plus BSC being 
cost-effective, compared with BSC alone. The MS 
reported a probability of being cost-effective of 
22% at a WTP threshold of £20,000 per QALY, and 
60% at a WTP threshold of £30,000 per QALY.
Subgroup analyses undertaken with the 
manufacturer’s model showed that oral topotecan 
was more likely to be cost-effective in patients 
whose TTP from prior therapy was less than or 
equal to 60 days (ICER = £17,946 per QALY 
gained), in women (ICER = £11,708 per QALY 
gained) and in those patients without liver 
metastases (ICER = £21,291 per QALY gained). 
Treatment with oral topotecan plus BSC also 
appeared to be more cost-effective for patients 
with a PS of 2 (ICER = £25,544 per QALY 
gained) as apposed to those with a PS of 0 or 1 
(ICER = £30,770 per QALY gained).
The manufacturer’s approach to estimating 
the cost-effectiveness of oral topotecan appears 
generally reasonable. However, specific concerns 
were raised regarding the extent to which the 
within-trial QoL assessments captured the impact 
of adverse events for patients in the oral topotecan 
arm, the adequacy of approaches to imputing 
values where QoL data were missing and the lack 
of survival modelling for patients whose data were 
censored (although the proportion of censored 
cases is comparatively low).
We developed an independent model to assess 
the cost-effectiveness of topotecan (oral or i.v.) 
compared with BSC, using survival analysis. The 
model consists of three states – relapsed SCLC, 
progressive disease and death – and includes the 
utility estimates reported for patients in the RCT 
by O’Brien and colleagues.57 In the base case we 
extrapolate survival up to 5 years.
Resource use associated with oral and i.v. topotecan 
was estimated from included RCTs, the MS, advice 
from clinical experts and published sources. Unit 
costs were taken from the BNF,79 NHS Reference 
Costs and other published sources. Where 
published estimates were inadequate we used costs 
supplied by the Southampton University Hospitals 
Trust. The cost base for the evaluation was 2007/08 
financial year.
The gain in discounted life expectancy associated 
with the addition of oral topotecan to BSC in our 
model is 0.33 years (approximately 16.9 weeks). 
The discounted QALY gain is 0.1830 QALYs. The 
incremental cost associated with the addition of 
oral topotecan to BSC is approximately £6200, 
resulting in an ICER of £33,851 per QALY gained. 
The cost-effectiveness results for oral topotecan 
plus BSC are generally robust to variation in 
the parameters included in the deterministic 
sensitivity analysis. The results were most sensitive 
to assumptions over the form of survival functions 
adopted and variation in values of parameters in 
the survival functions, variation in utility estimates 
applied in the model and the cost of outpatient 
attendance for the administration of oral 
chemotherapy. In a probabilistic sensitivity analysis 
we estimated a 0% probability of oral topotecan 
plus BSC being cost-effective, compared with BSC 
alone, at a WTP threshold of £20,000 and a 20% 
probability at a WTP threshold of £30,000 per 
QALY.
The gain in discounted life expectancy associated 
with i.v. topotecan, compared with BSC, in our 
model is 0.30 years (approximately 15.9 weeks) – 
approximately one week shorter than the base-case 
analysis for oral topotecan. The discounted QALY 
gain is between 0.1628 QALYs and 0.1910 QALYs 
depending on assumptions regarding TTP and the 
incremental cost is approximately £12,000. The 
resulting ICER for i.v. topotecan compared with 
BSC is between £74,074 and £65,507 per QALY 
gained, depending on assumptions regarding TTP. 
Compared with oral topotecan, i.v. topotecan is 
strictly dominated or is associated with a very high 
ICER. A probabilistic sensitivity analysis for i.v. 
topotecan showed zero or very low probability of 
being cost-effective, compared with BSC alone, at 
WTP thresholds of up to £50,000.
Strengths, limitations and 
uncertainties
This evidence synthesis has the following strengths:
•  It is independent of any vested interest.
•  It has been undertaken following the principles 
for conducting a systematic review. The 
methods were set out in a research protocol DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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(Appendix 2) that defined the research 
question, inclusion criteria, quality criteria, 
data extraction process and methods to be used 
at different stages of the review.
•  An advisory group has informed the review 
from its initiation. The research protocol was 
informed by comments received from the 
advisory group and the advisory group has 
reviewed and commented on the final report.
•  The review brings together the evidence for 
the clinical and cost-effectiveness of topotecan 
for SCLC. This evidence has been critically 
appraised and presented in a consistent and 
transparent manner.
•  An economic model has been developed 
following recognised guidelines and systematic 
searches have been conducted to identify data 
for the economic model. The main results have 
been summarised and presented.
•  Clinical evidence to populate the model has 
been extracted from reasonable quality RCTs 
included in the systematic review. The effect 
of treatment was assessed using appropriate 
measures (survival and quality-adjusted 
survival) to model cost and outcome differences 
over the model time horizons. Additional 
relevant data on TTP were included to take 
account of expected differences in QoL 
following disease progression.
In contrast, this review also has certain limitations 
and uncertainties, which include:
•  Where possible, the data included in the model 
are in the public domain. However, additional 
data inputs, such as TTP and adverse event 
data, were extracted from the MS where 
these were not reported in sufficient detail in 
published sources. The model structure and 
data inputs are clearly presented in this report. 
This should facilitate replication and testing of 
our model assumptions.
•  The resource use assumptions were developed 
with advice from clinical experts who advised 
on the development of this review. Our 
resource-use assumptions and unit cost 
estimates were compared with those included 
in the MS to assess their comprehensiveness.
•  There is substantial uncertainty over the QoL 
data included in the model. However, these 
are key to assessing the cost-effectiveness of 
chemotherapeutic interventions for cancer 
patients. Adverse events associated with highly 
toxic agents may entirely offset life expectancy 
or QoL gains for responding patients. To 
address this uncertainty we have tested the 
impact of assumptions regarding QoL in 
the model and attempted to identify which 
assumptions have greatest impact on the cost-
effectiveness results.
•  The validity of applying the survival model 
approach has been examined by comparing 
the results from our model with those from the 
manufacturer’s analysis. The survival model 
gives a higher estimate of mean survival than 
the manufacturer’s model using individual 
participant data. This difference largely results 
from the assumption, in the manufacturer’s 
model, that censored patients day on the day 
following censoring – this appears to have a 
disproportionately large effect for the oral 
topotecan plus BSC cohort where one patient 
is censored after a relatively short period of 
follow-up, but also involves truncation of the 
maximum survival duration where up to 5% of 
patients in the oral topotecan plus BSC arm of 
the trial were still alive.
Other relevant factors
A number of other issues that need to be taken into 
account when considering the results of the present 
review are noted below.
•  Authors of trials were contacted to try to 
establish with certainty that the participant 
populations in the included trials met the 
marketing authorisation. Responses were 
received from three of these authors (relating 
to four studies). However, it remains uncertain 
whether the participant groups in these 
trials fully meet the licensed indication for 
topotecan.
•  Only two RCTs reported any assessment of 
QoL issues; one of these reported no baseline 
data and reported only minimal information 
on participants included in the analysis and 
the other provided no data at all. It is therefore 
difficult to make any judgement about the 
impact of topotecan on a person’s QoL.
•  Dose escalations and reductions were permitted 
in the protocols of each of the included trials. 
However, full details of these changes are not 
always presented and it is therefore unknown 
if these dose changes would have a significant 
effect on the outcomes.
•  The duration of many of the trials was unclear, 
but in many was likely to be less than 12 
months, in part likely owing to the nature of 
SCLC, which deteriorates rapidly. However, 
this does mean that long-term evidence on Discussion
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outcomes and adverse events are limited for 
those eligible for treatment with topotecan. 
This may mean that the impact of adverse 
events are underestimated.
•  All but one of the included trials were 
multicentre studies and it is unclear whether 
intercentre variability is an issue within these 
trials, particularly on measurement of self-
report outcomes such as QoL. In addition, all 
the studies included in this review included 
participants from countries other than the UK. 
It is difficult to determine how generalisable 
the results of the included studies are to the 
population within the UK.
•  Four of the five included trials were sponsored 
evaluations by the manufacturer of topotecan.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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O
ral topotecan appears to improve survival 
in people with SCLC when compared with 
BSC alone. On measures of response there is no 
evidence that i.v. topotecan is better or worse than 
treatment with CAV, but i.v. topotecan appears 
to be less effective than amrubicin. Treatment 
toxicities and adverse events with i.v. topotecan 
are comparable to those with CAV or amrubicin, 
based on the data available. Oral and i.v. topotecan 
were not seen to be different from one another on 
survival or measures of response.
In the cost-effectiveness analysis, topotecan (oral or 
i.v.) for patients with relapsed SCLC was associated 
with improved health outcomes compared with 
BSC. However, these improved outcomes were 
achieved at increased cost. Costs for i.v. topotecan 
were substantially higher than for oral topotecan, 
while the health benefits are roughly equivalent 
(or possibly poorer). ICERs for i.v. topotecan, 
compared with BSC, were high, and suggest that 
it is unlikely to be a cost-effective option for this 
group of patients. The ICER for oral topotecan 
compared with BSC was lower than for i.v. 
topotecan, but is at the upper extreme of the range 
conventionally regarded as cost-effective from 
an NHS decision-making perspective. Sensitivity 
analyses suggest that the exact value of the ICER is 
highly dependent on assumptions regarding QoL 
for patients with relapsed SCLC who are receiving 
oral topotecan.
Need for further research
•  While it is desirable for further good-
quality RCT evidence on the effectiveness of 
topotecan, it is neither likely that any further 
RCTs of topotecan compared to BSC will be 
ethically acceptable, nor likely for there to 
be a need to undertake a further comparison 
with CAV therapy, and there is little to be 
gained from undertaking further evidence of 
the effectiveness of i.v. versus oral topotecan. 
However, given the ongoing RCTs of topotecan 
versus amrubicin, it would be desirable to 
update the current review when these report.
•  Further research into the QoL of patients with 
relapsed SCLC would be beneficial, to identify 
the impact of disease progression on QoL. In 
the case of patients receiving active treatment 
further research is needed on the impact 
of response (CR or PR) and the impact of 
treatment-related adverse events on QoL.
•  Further research on the impact of active 
treatment on resource use for palliative care 
would improve cost-effectiveness models for 
topotecan. The data collection on resource 
use in the RCT by O’Brien and colleagues 
was not comprehensive. It is difficult to 
determine whether the lower proportion of 
patients receiving radiotherapy and palliative 
medication (in the topotecan plus BSC arm) 
indicates a genuine reduction in palliative care 
interventions or a postponement until disease 
progression occurs.
Chapter 8  
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S
ubsequent to the NICE appraisal committee 
meeting, SHTAC were requested to provide 
additional information to their original assessment 
of topotecan for SCLC. This addendum therefore 
sets out to answer the following questions:
•  Please could you provide further details of why 
the comparison of oral topotecan with CAV was 
not undertaken, highlighting more clearly the 
various areas of uncertainty?
•  Please could you provide a detailed cost 
comparison for oral topotecan compared with 
CAV per cycle and total?
•  Please could you provide a threshold analysis 
that shows what magnitude of QALY gain 
would need to be achieved with oral topotecan 
to make it a cost-effective alternative to CAV?
The rationale for not 
conducting a formal 
comparison of oral 
topotecan with CAV, 
highlighting the various 
areas of uncertainty
The rationale for not conducting a formal 
comparison of oral topotecan with CAV derived 
from three broad considerations:
•  the lack of any direct comparison of oral 
topotecan and CAV
•  uncertainties over the comparability of patient 
populations in included trials (undermining 
the robustness of formal indirect comparisons)
•  limitations in the available data to support 
robust economic modelling.
While these considerations are clearly linked 
– the absence of direct evidence comparing 
oral topotecan and CAV lead directly to our 
consideration of the feasibility of conducting a 
robust indirect comparison using data from the 
RCTs comparing oral and i.v. topotecan – they are 
considered here in turn. The inadequacy of the 
evidence base in relation to each of these points led 
to our decision not to conduct a formal comparison 
(for clinical or cost-effectiveness) of oral topotecan 
with CAV.
Lack of any direct comparison of 
oral topotecan and CAV
While one RCT of i.v. topotecan versus CAV1 was 
identified and included in the systematic review, 
no comparisons of oral topotecan versus CAV were 
identified. Two trials were identified comparing 
i.v. topotecan with oral topotecan,2,3 and one 
comparing oral topotecan plus BSC to BSC alone.4
Uncertainties over the 
comparability of patient 
populations in included trials 
(undermining the robustness of 
formal indirect comparisons)
In the absence of direct evidence, comparing oral 
topotecan and CAV, we considered undertaking 
an indirect comparison. CAV could be compared 
with oral topotecan using the RCT of i.v. topotecan 
versus CAV1 and the two RCTs of i.v. topotecan 
versus oral topotecan.2,3 By including the RCT by 
O’Brien and colleagues4 the set of comparators 
could be extended to include BSC, thereby 
covering all standard comparators listed in the 
scope. This is illustrated in Figure 10.
Addendum
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oral topotecan vs BSC
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CAV vs i.v. topotecan
von Pawel and colleagues1
and Eckardt and colleagues3
oral vs i.v. topotecan
FIGURE 10  Potential evidence network for comparing cyclophosphamide, adriamycin (doxorubicin) and vincristine, oral topotecan and 
best supportive care.Addendum
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To determine the comparability of the patient 
populations in these four RCTs we contacted the 
lead authors to confirm that participants met 
our inclusion criteria [since, as stated on p. 24 
of the assessment report, only one (O’Brien and 
colleagues4) appeared to fully meet the criteria 
on inspection of the published article]. We 
received confirmation that three of the included 
trials1,2,4 met the criterion that participants were 
inappropriate for re-treatment with their original 
first-line chemotherapy, as per the licensed 
indication for topotecan. No reply was received 
from the author of the remaining study3 – this 
is the phase III study comparing oral and i.v. 
topotecan, with 155 and 154 participants receiving 
oral and i.v. topotecan, respectively, and represents 
the best evidence in the hierarchy of clinical trials 
for this comparison.
In the included trial participants who were 
ineligible for CAV were excluded from the RCT 
comparing i.v. topotecan and CAV.1 It was not 
clear to the assessment group whether this study 
represented the patient group who would be 
appropriate for topotecan in clinical practice, 
since patients most appropriate for treatment with 
topotecan may be those for whom CAV therapy is 
contraindicated.
Inclusion of patients in RCT comparing oral 
topotecan and CAV1 specified relapse 60 days after 
completion of first-line therapy. In the O’Brien and 
colleagues study4 the relapse time was required to 
be at least 45 days, and in the two trials comparing 
i.v. topotecan with oral topotecan2,3 the relapse 
time was specified as 90 days after completion of 
first-line therapy.
Performance status of the participants across 
these included trials also varied, for example 
the proportions with a performance status of 2 
were between 27% and 33% in the O’Brien and 
colleagues study,4 19–23% in the i.v. topotecan 
versus CAV study,1 and 12–13% in one of the i.v. 
versus oral topotecan studies3 and 15–30% in the 
other.2
Owing to the heterogeneous nature of these trials, 
at best, this would have been illustrative only.
Limitations in the available data 
to support robust economic 
modelling
We constructed an economic model that would be 
able to include all relevant comparators, where 
suitable data on disease progression, survival and 
QoL were available. Key data for the economic 
model are missing from published articles and 
from the clinical trial reports included in the 
submission to NICE. In some cases these data were 
not collected in the relevant trials and in others 
they are not reported in sufficient detail. Examples 
of such missing data would be survival curves for 
TTP (not reported), and utility data for CAV/IV 
topotecan (not collected). In our model (as with 
most economic models of cancer treatment) disease 
progression is a key event with respect both to costs 
and QoL. However, only summary data (median 
TTP) were reported for TTP. Inadequate estimates 
of the form of the survival curve derived from 
summary measures such as the median TTP would 
undermine the robustness of the economic analysis. 
As stated in the assessment report, no quality-of-
life data were collected in the RCT comparing 
CAV and i.v. topotecan, although some data on 
symptoms were recorded (using an unvalidated 
symptom-specific SCLC questionnaire). No QoL 
or utility data for CAV treatment in this patient 
population were found in our searches substantially 
undermining our ability to derive reliable QALY 
estimates for CAV.
We concluded that, although an adjusted 
indirect comparison of oral topotecan and CAV 
was technically feasible, uncertainties over the 
comparability of patient populations (in particular 
the exclusion of CAV ineligible patients from the 
RCT comparing oral topotecan and CAV1) meant 
that such a comparison would be unreliable. In 
addition, the absence of key data required to model 
both costs and outcomes for CAV in our economic 
model meant that a robust economic evaluation of 
oral topotecan and CAV could not be conducted.
To summarise, these three considerations were 
discussed in detail within the assessment group. 
At this stage no consideration of the possible cost 
difference between oral topotecan and CAV had 
been given. The assessment group discussed this 
with the NICE technical team at a project meeting, 
and it was agreed that the most appropriate 
population would be those not eligible for CAV 
and these (at least in part) will be the population in 
the O’Brien RCT4 comparing oral topotecan plus 
BSC with BSC alone (which both SHTAC and the 
manufacturer modelled).
However, our qualitative assessment of the lack 
of evidence of significant survival benefits for 
topotecan (i.v.) over CAV from the von Pawel RCT1 
and the lack of evidence of significant survival DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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benefits for oral topotecan over i.v. topotecan, 
taken together with our assessment of a large cost 
difference between CAV and oral topotecan, led us 
to suggest that oral topotecan was unlikely to be a 
cost-effective option when compared with CAV.
Detailed cost comparison 
for oral topotecan 
compared with CAV per 
cycle and total (drug, 
administration, pharmacy 
and monitoring costs, etc.)
Table 49 reports the estimated cost per cycle for 
CAV, i.v. topotecan and oral topotecan. Oral 
and i.v. topotecan costs are estimated as in the 
assessment report (see Appendix 1 for drug 
costs, chemotherapy administration and patient 
monitoring costs for oral and i.v. topotecan). CAV 
has been costed at the dosage used in the RCT 
by von Pawel and colleagues1 (cyclophosphamide 
1000 mg/m2, doxorubicin 45 mg/m2 and vincristine 
2 mg), assuming a mean BSA of 1.8 m2 (as for 
topotecan). It was assumed that patients attend 
respiratory medicine outpatients (for medical 
assessment) once per cycle in addition to their 
chemotherapy administration. NHS Reference 
Costs5 make a distinction between the cost for 
a first attendance and follow-up attendances 
at outpatients. In this case a first attendance is 
estimated at £182.65 and a follow-up attendance at 
£111.77 – hence the cost per cycle is higher for the 
first cycle of CAV. Full details of the resource use 
and unit cost assumptions underlying these cost 
estimates for CAV are presented in Appendix 2.
Under these assumptions oral topotecan is 
estimated to cost between £171 and £242 more per 
cycle than CAV. This takes no account of possible 
differences in incidence of adverse events between 
topotecan and CAV. Table 50 presents estimates of 
the incidence of haematological adverse events for 
patients treated with CAV or oral topotecan, along 
with the estimated costs of managing those adverse 
events (see Appendix 3 for full details of derivation 
of adverse events for CAV and oral topotecan, and 
see Table 30 in the assessment report for details of 
costs of managing adverse events).
This suggests that the costs of managing 
haematological adverse events may be higher 
for oral topotecan than for CAV, although there 
are large differences in the estimated incidences 
and costs for individual toxicities. Oral topotecan 
appears to be associated with a lower proportion 
of grade 4 neutropenia than is the case for 
CAV, while the situation is reversed for grade 4 
thrombocytopenia. These estimates are subject to 
a large degree of uncertainty, in being derived via 
an adjusted indirect comparison and due to the 
questionable comparability of patient populations 
in the studies included in the indirect comparison.
NHS Reference Costs for 2007/08 have 
been published since the assessment 
report was completed (www.dh.gov.uk/
en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH_098945). 
Updated cost estimates for CAV and oral 
topotecan, using the 2007/08 NHS Reference 
Costs,6 rather than 2006/07 costs uprated to 
2007/08 (as used in the assessment report), are 
presented in Table 51. These indicate no substantial 
differences between estimates based on assessment 
report and those using updated costs.
Compared with the costs shown in Table 49 
[estimated using 2006/07 NHS Reference Costs 
(uprated to 2007/08 costs)], cost per cycle for 
CAV is approximately £30 higher (predominantly 
due to a higher reference cost for administration 
of i.v. chemotherapy), while the cost per cycle 
for oral topotecan is approximately £17 lower 
(predominantly due to a lower reference cost for 
administration of oral chemotherapy).
TABLE 49  Chemotherapy costs, per cycle
Costs (£)
Drugs Administration Monitoring Total
CAV First cycle 208.43 443.58 88.28 740.29
Subsequent cycles 208.43 372.70 88.28 669.41
Intravenous 
topotecan
All cycles 1494.75 984.04 88.28 2567.06
Oral topotecan All cycles 637.50 185.87 88.28 911.64Addendum
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TABLE 50  Incidence of adverse events (per patient) for CAV and oral topotecan and estimated management costs, by indirect comparison
Toxicity Grade
Adverse events (%)
Cost per 
adverse event
Cost of adverse events (£)
CAV Oral topotecan CAV Oral topotecan
Neutropenia Grade 3 15.2 18.7 104 16 19
Grade 4 71.7 48.1 1196 858 575
Thrombocytopenia Grade 3 9.9 24.6 0 0 0
Grade 4 5.0 41.3 1210 60 500
Anaemia Grade 3 17.8 28.8 494 88 142
Grade 4 2.0 4.8 940 19 45
TOTAL 1040 1282
TABLE 51  Chemotherapy costs, per cycle (using 2007/08 Reference Costs)
Drugs Administration Monitoring Total
CAV First cycle 208.43 470.41 89.44 768.28
Subsequent cycles 208.43 402.23 89.44 700.10
Oral topotecan All cycles 637.50 167.53 89.44 894.47
Threshold analysis – what 
magnitude of QALY gain 
would be needed with oral 
topotecan to make it a cost-
effective alternative to CAV
Section 2 of this addendum indicates that oral 
topotecan is likely to be between £171 and £242 
more expensive than CAV, per cycle. In the absence 
of robust data that directly compares oral topotecan 
with CAV, we have used indirect comparison 
methods to estimate the relative costs of managing 
adverse events with oral topotecan and with CAV, 
which indicate that these may be around £240 
higher with oral topotecan than with CAV. This 
section presents a threshold analysis exploring the 
magnitude of QALY gain that would be required 
to make oral topotecan a cost-effective alternative 
to CAV. The cost-effectiveness thresholds adopted 
here (£20,000 and £30,000) are those indicated in 
the current NICE methods guidance.7
Table 52 reports the estimated costs of 
chemotherapy for relapsed SCLC based on the 
costs reported in section 2 of this addendum. The 
total chemotherapy cost for oral topotecan is based 
on four treatment cycles, as in the assessment 
report. Chemotherapy costs for CAV are calculated 
for three cycles (the median number of cycles in 
the RCT by von Pawel and colleagues1) and for four 
cycles (assuming the same treatment duration as 
for oral topotecan).
In the scenario where three cycles of CAV are 
provided, chemotherapy costs for CAV are 57% 
those of oral topotecan (with a cost difference of 
approximately £1600, which rises to £1800 if the 
costs of managing adverse events are included). 
If four cycles of CAV are provided, costs are 75% 
those of oral topotecan (with a cost difference of 
approximately £900, rising to £1100 if the costs of 
managing adverse events are included).
Given that the ICER is defined as the change 
in costs divided by change in outcomes, we can 
estimate the minimum QALY gain required to 
meet a cost-effectiveness threshold given a change 
in costs. For example, in the scenario where three 
cycles of CAV are provided, the change in costs 
is £1567, therefore the minimum QALY gain 
required to meet a cost-effectiveness threshold 
of £30,000 per QALY gained is 0.05. Table 53 
reports the results of this calculation for treatment 
scenarios where patients receive three or four cycles 
of CAV, and the impact of including adverse event 
costs, using cost-effectiveness thresholds of £20,000 
and £30,000 per QALY gained.
The RCT comparing CAV with i.v. topotecan 
reported no statistically significant differences in 
survival – median survival was 25.0 weeks (95% DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 52  Total chemotherapy cost and estimated difference in cost between CAV and oral topotecan
Chemotherapy regimen Total chemotherapy cost (£)
Cost difference (£)
Chemotherapy only
Including adverse event 
costs
CAV for three cycles 2079 1567 1809
CAV for four cycles 2749 898 1140
Oral topotecan 3647
TABLE 53  Minimum QALY gain (for oral topotecan compared with CAV) required for cost-effectiveness thresholds
Chemotherapy regimen
Chemotherapy costs only (£) Including adverse event costs (£)
20,000 30,000 20,000 30,000
CAV for three cycles 0.08 0.05 0.09 0.06
CAV for four cycles 0.04 0.03 0.06 0.04
Oral topotecan
CI 20.6 to 29.6) and 24.7 weeks (95% CI 21.7 to 
30.3) for patients treated with topotecan and CAV, 
respectively (RR = 1.039, p = 0.795). Similarly, non-
significant survival differences were reported for 
the RCTs comparing oral and i.v. topotecan [HR of 
0.98, 95% CI 0.77 to 1.253 and RR (oral–i.v.) 0.84, 
95% CI 0.53 to 1.322]. In the absence of evidence 
of a survival benefit for topotecan over CAV, it 
may be argued that the QALY gains indicated in 
Table 53 would need to arise through quality-of-
life improvements associated with treatment with 
topotecan. These may arise from a preference for 
oral over i.v. chemotherapy [which will be realised 
only while patients in both cohorts (oral topotecan 
and CAV treated) are under treatment] or may 
arise from differences in symptom relief between 
the topotecan- and CAV-treated cohorts.
We developed a number of scenarios, based 
on possible durations of utility gain with oral 
topotecan, to estimate the utility difference 
required to achieve the minimum QALY gains 
reported in Table 53. For example, if patients 
experience a utility gain by receiving oral, rather 
than i.v. chemotherapy, we assumed that patients 
would accrue that utility gain for the expected 
duration of treatment with i.v. chemotherapy (in 
the scenario where three cycles of CAV are provided 
this is 9 weeks, and, when four cycles of CAV are 
provided, this is 12 weeks). If the minimum QALY 
gain required to be cost-effective is 0.078 QALYs 
(at a threshold of £20,000 per QALY gained) and 
the duration of utility gain is 9 weeks (0.173 years) 
then we estimate the utility difference would need 
to be 0.45 (0.078/0.173). Table 54 reports estimated 
utility differences required to achieve the minimum 
QALY gains reported in Table 53, by a range 
of possible durations of utility gain, assuming 
that three cycles of CAV and four cycles of oral 
topotecan are provided (Table 55 reports the results 
of similar calculations assuming four cycles of CAV 
and four cycles of oral topotecan are provided).
The four scenarios considered in Table 54 are that 
patients receiving oral topotecan rather than CAV 
experience utility gains by:
•  receiving oral rather than i.v. chemotherapy 
(duration three cycles)
•  symptom improvements (for example, 
improvements over baseline assessment for 
dyspnoea as noted in the RCT by von Pawel 
and colleagues1); however, as noted in the 
assessment report, the symptom-specific 
questionnaire used in this study was not a 
validated instrument and it is unclear how 
reliable the results are, and as the duration 
of symptom improvement was not reported 
in the RCT by von Pawel and colleagues,1 a 
range of possible durations for the symptom 
improvement were considered:
  – symptom improvement assumed to be 
maintained until disease progression;
  – duration based on time to symptom 
worsening as reported in the clinical study 
report, submitted to NICE as part of the 
MS.Addendum
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TABLE 54  Utility difference required to achieve minimum QALY gains, by possible sources of utility difference (assuming three cycles of 
CAV and four cycles of oral topotecan)
Duration of utility gain with oral 
topotecan
Utility difference required to achieve the minimum QALY gain at the 
given cost-effectiveness thresholds
Chemotherapy costs only (£) Including adverse event costs (£)
20,000 30,000 20,000 30,000
Utility gain from receiving oral rather than i.v. chemotherapy
9 weeks (three  cycles of CAV) 0.45 0.30 0.52 0.35
Utility gain from symptom improvements or increased time to worsening of symptoms
20 weeks (mean TTP based on the von 
Pawel RCT)
0.20 0.14 0.23 0.16
28 weeks (mean TTP based on the  
O’Brien RCT)
0.15 0.10 0.17 0.11
9.4 weeks (difference in mean time to 
worsening of dyspnoea, estimated from 
data in CSR)
0.43 0.29 0.50 0.33
TABLE 55  Utility difference required to achieve minimum QALY gains, by possible sources of utility difference (assuming four cycles of CAV 
and four cycles of oral topotecan)
Duration of utility gain with oral 
topotecan
Utility difference required to achieve the minimum QALY gain at 
the given cost-effectiveness thresholds
Chemotherapy costs only (£) Including adverse event costs (£)
20,000 30,000 20,000 30,000
Utility gain from receiving oral rather than i.v. chemotherapy
12 weeks (four cycles of CAV) 0.20 0.13 0.24 0.16
Utility gain from symptom improvements or increased time to worsening of symptoms
20 weeks (mean TTP based on the von Pawel 
RCT)
0.12 0.08 0.15 0.10
28 weeks (mean TTP based on the O’Brien 
RCT)
0.08 0.06 0.10 0.07
9.4 weeks (difference in mean time to 
worsening of dyspnoea, estimated from data 
in CSR)
0.25 0.17 0.31 0.21
Table 54 suggests that large utility differences 
(0.30 to 0.52 depending on the cost-effectiveness 
threshold and whether adverse event costs are 
included) would need to be associated with 
receiving oral, rather than i.v. chemotherapy, 
in order to achieve the minimum QALY gains 
required for oral topotecan to be cost-effective 
relative to CAV. With respect to symptom 
improvement, lower differences (0.10 to 0.23) 
would be required – if the symptom improvement 
is assumed to be maintained until disease 
progression. However, if the duration of symptom 
improvement is based on the estimated difference 
in time to symptom worsening for dyspnoea, then 
the required utility differences are much greater 
(0.29 to 0.50).
The scenarios considered in Table 55 are identical 
to those in Table 54, except that the duration of 
utility gain associated with receiving oral rather 
than i.v. chemotherapy is increased to four cycles 
(since the estimates in Table 55 are based on all 
patients receiving four cycles of chemotherapy).
The pattern of results in Table 55 is similar to that 
in Table 54. Comparatively large utility differences DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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(0.13–0.20) would need to be associated with 
receiving oral, rather than i.v. chemotherapy, in 
order to achieve the minimum QALY gains for 
oral topotecan to be cost-effective relative to CAV. 
Lower differences (0.06–0.15) would be required 
– if symptom improvement is assumed to be 
maintained until disease progression. However, if 
the duration of symptom improvement is based 
on the estimated difference in time to symptom 
worsening for dyspnoea then the required utility 
differences are much greater (0.17–0.31).
Summary
Oral topotecan is likely to be between 23% and 36% 
more expensive than CAV, per cycle, and may be 
associated with higher costs of managing adverse 
events. Total costs of chemotherapy for relapsed 
SCLC are likely to be between £900 and £1800 
higher for oral topotecan than CAV (depending on 
the number of cycles of CAV provided and whether 
costs of managing adverse events are included). 
In a threshold analysis, QALY gains of between 
0.03 and 0.09 (depending on the number of cycles 
of CAV provided and whether costs of managing 
adverse events are included) were required for 
oral topotecan to be cost-effective relative to CAV. 
It is unlikely that utility differences associated 
with receiving oral rather than i.v. chemotherapy, 
symptom improvements or increased time to 
worsening of symptoms, such as dyspnoea, would 
be high enough to realise these QALY gains.
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Appendix I – details of cost calculations for topotecan  
(oral and i.v.)
TABLE 56  Resource use assumptions, unit costs and cost per cycle for oral topotecan (drug costs)
Drug
Dosage: Cost (£)
mg/m2
mg/day of 
treatment
Unit cost per 
mg 
Drug cost per 
day of treatment
Cost per cycle (5 
treatment days)
Oral topotecan 2.3 4.14 30.00 127.50 637.50
TABLE 57  Resource use assumptions, unit costs and cost per cycle for oral topotecan (chemotherapy administration costs)
Resource item
Resource use 
per cycle
Reference cost 
2006/07 (£)
Uprated to 
2007/08 (£)
Reference cost 
2007/08 (£)
Chemotherapy administrationa 1 178.99 184.97 166.63
Pharmacy preparation cost 1 0.90 0.90
Total cost per cycle 185.87 167.53
a  Code SB11Z (Deliver exclusively Oral Chemotherapy) on worksheet named TCHEMTHPYOP (Chemotherapy: 
Outpatients) in 2006/07 NHS Reference Costs;5 Code SB11Z (Deliver exclusively Oral Chemotherapy) on worksheet 
named TPCTCHEMTHPY_DEL_OP (Chemotherapy Delivery: Outpatients) in 2007/08 NHS Reference Costs.7
TABLE 58  Resource use assumptions, unit costs and cost per cycle for i.v. topotecan (drug costs)
Drug
Dosage: Cost (£)
mg/m2
mg/day of 
treatment Saline (ml)
Unit cost 
per mg
Drug cost per 
day of treatment
Total (including 
saline) per cycle
Intravenous 
topotecan
1.5 2.7 100 97.65 292.95 1494.75
Final concentration of i.v. topotecan = 27 μg/ml.
TABLE 59  Resource use assumptions, unit costs and cost per cycle for i.v. topotecan (chemotherapy administration costs)
Resource item
Resource use 
per cycle
Reference cost 
2006/07 (£)
Uprated to 
2007/08 (£)
Reference cost 
2007/08 (£)
First chemotherapy administration in cyclea 1 169.85 175.53  153.40
Subsequent chemotherapy administration 
in cycleb
4 189.44 195.77  154.18
Pharmacy preparation cost 1 25.44  25.44
Total cost per cycle 984.04 795.56
a  Code SB12Z (Deliver simple Parenteral Chemotherapy at first attendance) on worksheet named TCHEMTHPYOP 
(Chemotherapy: Outpatients) in 2006/07 NHS Reference Costs;5 Code SB12Z (Deliver simple Parenteral Chemotherapy 
at first attendance) on worksheet named TPCTCHEMTHPY_DEL_OP (Chemotherapy Delivery: Outpatients) in 2007/08 
NHS Reference Costs.7
b  Code SB12Z (Deliver subsequent elements of a chemotherapy cycle) on worksheet named TCHEMTHPYOP 
(Chemotherapy: Outpatients) in 2006/07 NHS Reference Costs;5 Code SB12Z (Deliver subsequent elements of a 
chemotherapy cycle) on worksheet named TPCTCHEMTHPY_DEL_OP (Chemotherapy Delivery: Outpatients) in 
2007/08 NHS Reference Costs.7DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 60  Resource-use assumptions, unit costs and cost per cycle for i.v. and oral topotecan (on-treatment monitoring costs)
Resource item
Resource use per 
cycle
Reference cost 
2006/07 (£)
Uprated to 
2007/08 (£)
Reference cost 
2007/08 (£)
FBC 1 2.90  2.90
LFT 1 4.70 4.70
U&E 1 4.70 4.70
Chest radiograph 1 27.71 28.64 ?
CT scan (every two cycles) 0.5 91.62  94.68 97.00
Total cost per cycle 88.28
Appendix II – details of cost calculations for CAV
TABLE 61  Resource use assumptions, unit costs and cost per cycle for CAV (drug costs)
Drug
Dosage Cost
mg
mg per 
cycle
Saline (ml) for 
reconstitution
Unit cost 
(£)
Cost 
per mg 
(£)
Drug 
cost per 
cycle
Total cost 
(including saline) 
per cycle (£)
Cyclophosphamide 1000/m2 1800 100 5.04  0.01 10.08 16.08
Doxorubicin 45/m2 81 45 18.72 1.87 168.48 171.18
Vincristine 2 2 21.17 10.59 21.17 21.17
Total 199.73 208.43
Dose per cycle has been estimated on the basis of an average BSA of 1.8m2.
Cyclophosphamide unit cost is for a (non-proprietary) 1-g vial of powder for reconstitution (BNF no. 578). Costing assumes 
that two 1-g vials are used, diluted with 100 ml of saline to a final concentration 20 mg/ml. Assume wastage of unused 
solution.
Doxorubicin unit cost is for a (non-proprietary) 10-mg vial of powder for reconstitution (BNF no. 578). Costing assumes 
that nine 10-mg vials are used, diluted with 45 ml of saline to a final concentration 2 mg/ml. Assume wastage of unused 
solution. Alternatively, could use one 50-mg vial (unit cost £96.86, BNF no. 578) and four 10-mg vials, giving a drug cost per 
cycle for doxorubicin of £171.74 and total cost (including saline) of £174.44.
Vincristine unit cost is for a (non-proprietary) 2-mg vial for injection (BNF no 578).
Saline costed at £0.06 per ml.Addendum
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TABLE 62  Resource use assumptions, unit costs and cost per cycle for CAV (chemotherapy administration costs)
Resource use 
per cycle
Reference cost 
2006/07 (£)
Uprated to 
2007/08 (£)
Reference cost 
2007/08 (£)
Outpatient first attendancea 1 176.75 182.65 185.80
Outpatient follow-up attendanceb 1 108.16  111.77  117.62
Chemotherapy administrationc 1 178.66  184.62 208.29
Pharmacy preparation cost 3 25.44  25.44
Total cost first cycle 443.58 470.41
Total cost subsequent cycle 372.70 402.23
a  Code 340 (Thoracic Medicine) on worksheet named TCLFASFF (Consultant Led First Attendance Outpatient Face 
to Face) in 2006/07 NHS Reference Costs;5 Code 340 (Respiratory Medicine) on worksheet named TPCTCLFASFF 
(Consultant Led: First Attendance Non-Admitted Face to Face) in 2007/08 NHS Reference Costs.7
b  Code 340 (Thoracic Medicine) on worksheet named TCLFUSFF (Consultant Led Follow up Attendance Outpatient Face 
to Face) in 2006/07 NHS Reference Costs;5 Code 340 (Respiratory Medicine) on worksheet named TPCTCLFUSFF 
(Consultant Led: Follow up Attendance Non-Admitted Face to Face) in 2007/08 NHS Reference Costs.7
c  Code SB14Z (Deliver complex chemotherapy, including prolonged infusional treatment at first attendance) on worksheet 
named TCHEMTHPYOP (Chemotherapy: Outpatients) in 2006/07 Reference costs;5 Code SB14Z (Deliver complex 
chemotherapy, including prolonged infusional treatment at first attendance) on worksheet named TPCTCHEMTHPY_
DEL_OP (Chemotherapy Delivery: Outpatient) in 2007/08 Reference costs.7
On-treatment monitoring per cycle, as for topotecan (see Table 60).
Appendix III – adverse events (haematological toxicity only)
TABLE 63  Proportion of patients experiencing haematological adverse events and relative risks (CAV versus i.v. topotecan) from RCT by 
von Pawel and colleagues
Toxicity Grade
CAV
Intravenous 
top Per cent events
RR SE LCI UCI Event n Event n CAV
Intravenous 
top
Neutropenia Grade 3 15 99 19 104 15.2 18.3 0.829 0.316 0.447 1.539
Grade 4 71 99 73 104 71.7 70.2 1.022 0.090 0.857 1.218
Thrombocytopenia Grade 3 10 101 30 104 9.9 28.8 0.343 0.337 0.177 0.665
Grade 4 5 101 30 104 5.0 28.8 0.172 0.462 0.069 0.425
Anaemia Grade 3 18 101 41 104 17.8 39.4 0.452 0.246 0.279 0.732
Grade 4 2 101 3 104 2.0 2.9 0.686 0.902 0.117 4.023
LCI, lower confidence interval; UCI, upper confidence interval.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 65  Relative risk of adverse events (per patient) (CAV versus oral topotecan) by indirect comparison
Toxicity Grade
CAV vs i.v. 
topotecan
Oral vs i.v. 
topotecan
CAV vs oral 
topotecan
LCI UCI RR SE RR SE RR SE
Neutropenia Grade 3 0.829 0.316 1.022 0.175 1.232 0.361 0.607 2.498
Grade 4 1.022 0.090 0.685 0.095 0.670 0.131 0.518 0.866
Thrombocytopenia Grade 3 0.343 0.337 0.854 0.182 2.489 0.383 1.174 5.274
Grade 4 0.172 0.462 1.433 0.181 8.350 0.497 3.154 22.104
Anaemia Grade 3 0.452 0.246 0.730 0.183 1.616 0.306 0.887 2.944
Grade 4 0.686 0.902 1.672 0.513 2.436 1.038 0.319 18.617
TABLE 66  Incidence of adverse events (per patient) for CAV and oral topotecan and estimated management costs, by indirect comparison
Toxicity Grade
Adverse events (%)
Cost per 
adverse event
Cost adverse events (£)
CAV Oral topotecan CAV Oral topotecan
Neutropenia Grade 3 15.2 18.7 104 16 19
Grade 4 71.7 48.1 1196 858 575
Thrombocytopenia Grade 3 9.9 24.6 0 0 0
Grade 4 5.0 41.3 1210 60 500
Anaemia Grade 3 17.8 25.9 494 88 142
Grade 4 2.0 4.8 940 19 45
Total 1040 1282DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Appendix 1  
Performance scales and 
response criteria in SCLC
Performance scales
Eastern Cooperative Oncology Group (ECOG) performance status
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature, e.g. light housework, office work
2 Ambulatory and capable of all self-care but unable to carry out any work activities; up and about for more than 
50% of waking hours
3 Capable of only limited self-care; confined to bed or chair for more than 50% of waking hours
4 Completely disabled; cannot carry on any self-care; totally confined to bed or chair
5 Dead
Source: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of The 
Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.18
Karnofsky performance index
Definition
Able to carry on normal activity and to 
work
100 Normal; no complaints; no evidence of disease
90 Able to carry on normal activity; minor signs or symptoms of disease
80 Normal activity with effort; some signs or symptoms of disease
Unable to work; able to live at home, care 
for most personal needs; a varying amount 
of assistance is needed
70 Cares for self; unable to carry on normal activity or to do active work
60 Requires occasional assistance but is able to care for most needs
50 Requires considerable assistance and frequent medical care
Unable to care for self; requires equivalent 
of institutional or hospital care; disease 
may be progressing rapidly
40 Disabled; requires special care and assistance
30 Severely disabled; hospitalisation is indicated, although death is not 
imminent
20 Very sick; hospitalisation necessary; active supportive treatment 
necessary
10 Moribund; fatal processes progressing rapidly
0 Dead
Source: Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of 
carcinoma. Cancer 1948;1:634–56.19Appendix 1
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Treatment response criteria
WHO criteria treatment response (summarised from Miller et al.54)
Characteristic Criteria
Measurability of lesions at baseline 1.  Measurable, bidimensional (product of LD and greatest perpendicular diameter)a
2.  Non-measurable/evaluable (e.g. lymphangitic pulmonary metastases, abdominal 
masses)
Objective response 1.  Measurable disease (change in sum of products of LDs and greatest perpendicular 
diameters, no maximum number of lesions specified)
CR: disappearance of all known disease, confirmed at ≥ 4 weeks
PR: ≥ 50% decrease from baseline, confirmed at ≥ 4 weeks
PD: ≥ 25% increase of one or more lesions, or appearance of new lesions
NC: neither PR or PD criteria met
2.  Non-measurable disease
CR: disappearance of all known disease, confirmed at ≥ 4 weeks
PR: estimated decrease of ≥ 50%, confirmed at ≥ 4 weeks
PD: estimated increase of ≥ 25% in existent lesions or appearance of new lesions
NC: neither PR or PD criteria met
Overall response  1.  Best response recorded in measurable disease
2.  NC in non-measurable lesions will reduce a CR in measurable lesions to an overall 
PR
3.  NC in non-measurable lesions will not reduce a PR in measurable lesions
Duration of response 1.  CR
From: date CR criteria first met
To: date PD first noted
2.  Overall response
From: date of treatment start
To: date PD first noted
3.  In patients who only achieve a PR, only the period of overall response should be 
recorded
LD, longest diameter; NC, no change; PD, progressive disease.
a  Lesions that can only be measured unidimensionally are considered to be measurable (e.g. mediastinal adenopathy, 
malignant hepatomegaly).DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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RECIST criteria treatment response (summarised from Therasse et al.55)
Characteristic Criteria
Measurability of lesions at baseline 1.  Measurable, unidimensional (LD only, size with conventional techniques > 20 mm; 
spiral CT > 10 mm)
2.  Non-measurable: all other lesions, including small lesions. ‘Evaluable’ is not 
recommended.
Objective response 1.  Target lesions [change in sum of LDs, maximum of five per organ up to 10 total 
(more than one organ)]
CR: disappearance of all target lesions, confirmed at ≥ 4 weeks
PR: ≥ 30% decrease from baseline, confirmed at 4 weeks
PD: ≥ 20% increase over smallest sum observed, or appearance of new lesions
SD: neither PR or PD criteria met
2.  Non-target lesions
CR: disappearance of all target lesions and normalization of tumour markers, 
confirmed at ≥ 4 weeks
PD: unequivocal progression of non-target lesions, or appearance of new lesions
Non-PD: persistence of one or more non-target lesions and/or tumour markers 
above normal limits
Overall response 1.  Best response recorded in measurable disease from treatment start to disease 
progression or recurrence
2.  Non-PD in non-target lesion(s) will reduce a CR in target lesion(s) to an overall PR
3.  Non-PD in non-target lesion(s) will not reduce a PR in target lesion(s)
Duration of response 1.  Overall CR
From: date CR criteria first met
To: date recurrent disease first noted
2.  Overall response
From: date CR or PR criteria first met (whichever status came first)
To: date recurrent disease or PD first noted
3.  SD
From: date of treatment start
To: date PD first noted
CT, computerised tomography; LD, longest diameter; PD, progressive disease; NC, no change; SD, stable disease.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Title of the project
Topotecan for the second-line treatment of small 
cell lung cancer (SCLC).
Report methods for synthesis of 
evidence of clinical effectiveness 
and cost-effectiveness
A review of the evidence for clinical effectiveness 
and cost-effectiveness will be undertaken 
systematically following the general principles 
outlined in CRD Report Number 4 (2nd edn) 
Undertaking Systematic Reviews of Research on 
Effectiveness.53
Search strategy
A search strategy will be developed and tested by 
an experienced information scientist. The strategy 
will be designed to identify: (1) clinical effectiveness 
studies reporting on comparisons between 
topotecan (oral or i.v., but not combined) and best 
supportive care (BSC) or other chemotherapy 
regimens (as described in the economic modelling 
section) and (2) studies reporting on the cost-
effectiveness of topotecan and different second-
line treatments, and the relative comparisons. The 
search strategy will also identify studies reporting 
resource use and costs, epidemiology and natural 
history.
The following electronic databases will be searched: 
The Cochrane library, including the Cochrane 
Database of Systematic Reviews (CDSR), the 
Cochrane Central Register of Controlled Trials, 
CRD (University of York) Database of Abstracts 
of Reviews of Effectiveness (DARE), the NHS 
Economic Evaluation Database (NHS EED) 
and the Health Technology Assessment (HTA) 
database; MEDLINE (OVID); EMBASE (OVID); 
PREMEDLINE In-Process and Other Non-Indexed 
Citations; Web of Knowledge Science Citation 
Index (SCI); Web of Knowledge ISI Proceedings; 
PsycInfo; Biosis; UKCRN Study Portfolio and 
Current Controlled Trials. Key cancer resources 
(such as the American Society of Clinical Oncology 
(ASCO), European CanCer Organisation (ECCO), 
etc.) and relevant cancer symposia will also be 
searched. The search strategy for MEDLINE will be 
adapted for other databases.
Bibliographies of related papers will be assessed for 
relevant studies where possible. The manufacturer’s 
submission to the National Institute for Health and 
Clinical Excellence (NICE) will be assessed for any 
additional studies that meet the inclusion criteria. 
Experts will be contacted to identify additional 
published and unpublished evidence.
Searches will be carried out from 1990 and will 
be limited to the English language. For the cost-
effectiveness section, searches for other evidence 
to inform cost-effectiveness modelling will be 
conducted as required and may include a wider 
range of study types (including non-randomised 
studies). All searches will be updated when the 
draft report is under review, prior to submission of 
the final report.
Inclusion and exclusion criteria
Population
•  Adults (≥ 18 years) with relapsed SCLC who 
responded to first-line treatment and for 
whom re-treatment with first-line therapy 
is not considered appropriate (due to 
contraindications, adverse effects).
•  Patients may have limited-stage disease or 
extensive-stage disease.
•  Response to initial treatment may be either 
complete response or partial response.
•  Patients who did not respond to first-line 
therapy (including patients whose tumours did 
not respond, or who progressed, during first-
line treatment) will not be included.
•  Studies with a mix of untreated and previously 
treated patients (or responders and non-
responders), will not be included unless the 
groups are reported separately.
Intervention
•  Intravenous topotecan (administered as 
second-line treatment).
•  Oral topotecan (administered as second-line 
treatment).
•  Studies with a focus on first-line treatment will 
not be included.
•  Effectiveness data for oral and i.v. topotecan 
will not be combined.
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Comparators
•  Intravenous and oral topotecan will be 
compared with each other.
•  BSC (including radiotherapy).
•  CAV (cyclophosphamide, doxorubicin, 
vincristine).
•  Other chemotherapy regimens.
Outcomes
Studies reporting one or more of the following 
outcomes will be included:
•  time to disease progression (TTP)
•  progression-free survival (PFS)
•  response rate
•  response duration
•  overall survival (OS)
•  symptom control
•  health-related quality of life (using a validated 
measure)
•  cost-effectiveness (incremental cost per life-year 
gained) or cost–utility [incremental cost per 
quality-adjusted life-year (QALY) gained].
Adverse effects of treatments will be reported if 
available within trials that meet the other inclusion 
criteria.
Types of studies
•  Fully published randomised controlled trials 
(RCTs) will be included. If no RCTs are found, 
controlled clinical trials and prospective cohort 
studies (with a concurrent control) will be 
eligible for inclusion.
•  Studies published as abstracts or conference 
presentations will only be included if sufficient 
details are presented to allow an appraisal of 
the methodology and the assessment of results 
to be undertaken.
•  For the systematic review of cost-effectiveness, 
studies will only be included if they report 
the results of full economic evaluations [cost-
effectiveness analyses (reporting cost per 
life-year gained), cost–utility analyses or cost–
benefit analyses].
•  Systematic reviews will be used as a source of 
references.
•  Case series, case studies, narrative reviews, 
editorials and opinions will not be included.
•  Non-English language studies will be excluded.
Screening and data extraction process
Reference screening
The titles and abstracts of studies identified by 
the search strategy will be assessed for potential 
eligibility using the inclusion/exclusion criteria 
detailed above. This will be performed by two 
reviewers. Full papers of studies which appear 
potentially relevant will be requested for further 
assessment. These will be screened by two reviewers 
and a final decision regarding inclusion will be 
agreed. At each stage, any disagreements will be 
resolved by discussion, with involvement of a third 
reviewer where necessary.
Data extraction
Data will be extracted by one reviewer using a 
standardised data extraction form. Extracted data 
will be checked by a second reviewer. Discrepancies 
will be resolved by discussion, with recourse to a 
third reviewer when necessary.
Quality assessment strategy
The quality of the clinical effectiveness studies will 
be assessed according to criteria based on Centre 
for Reviews and Dissemination (CRD) (University 
of York) criteria.53 Economic evaluations will 
be assessed using criteria recommended by 
Drummond and colleagues,66 and/or the format 
recommended and applied in the CRD NHS 
Economic Evaluation Database (using principles 
outlined in the NHS EED Handbook81). For any 
studies based on decision models we will also 
make use of the checklist for assessing good 
practice in decision-analytic modelling (Philips 
and colleagues68). Published studies carried out 
from the UK National Health Service (NHS) and 
Personal Social Services (PSS) perspective will be 
examined in more detail.
The quality of the individual studies will be 
assessed by one reviewer, and independently 
checked for agreement by a second reviewer. Any 
disagreements will be resolved by consensus, and, if 
necessary, a third reviewer will be consulted.
Methods of data analysis/synthesis of 
clinical effectiveness data
Clinical effectiveness data will be synthesised 
through a narrative review with tabulation of 
the results of included studies. Where data are 
of sufficient quality and homogeneity, a meta-
analysis of the clinical-effectiveness studies will 
be performed to estimate a summary measure of 
effect on relevant outcomes. If a meta-analysis is 
appropriate, it will be performed using Review 
Manager (revman) software.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Methods of data analysis/
synthesis of cost-effectiveness 
data
Published and submitted economic 
evaluations
Narrative synthesis, supported by the data 
extraction tables, will be used to summarise 
the evidence base from published economic 
evaluations. Any economic evaluation included in 
sponsor submissions to NICE will be assessed using 
the same quality criteria as for published economic 
evaluations, but will be reported separately.
Economic modelling
Where appropriate, an economic model will 
be constructed by adapting an existing model 
or developing a new one using best available 
evidence. The perspective will be that of the NHS 
and PSS. The incremental cost-effectiveness of the 
interventions will be estimated in terms of cost 
per QALY gained, as well as the cost per life-year 
gained if data permit. Both cost and outcomes will 
be discounted at 3.5%.
Model structure will be determined on the basis of 
research evidence and clinical expert opinion of:
•  the biological disease process (i.e. knowledge of 
the natural history of the disease)
•  the main diagnostic and care pathways for 
patients in the UK NHS context [both with and 
without the intervention(s) of interest]
•  the disease states or events which are 
most important in determining patients’ 
clinical outcomes, quality of life (QoL) and 
consumption of NHS or PSS resources.
For patients receiving topotecan, or comparator 
treatments, for relapsed SCLC following first-line 
treatment, TTP will be a major factor in defining 
costs of second-line treatment and is also likely 
to be a significant determinant of QoL. Any 
improvements in OS or impacts on QoL that may 
be associated with changes in PFS will need to 
be offset by consideration of the toxicity profile 
of alternative therapies. There is likely to be 
considerable uncertainty surrounding modes of 
treatment following disease progression on second-
line treatment, which may have an influence on 
costs and QoL. Clinical guidance will be sought 
to define appropriate protocols for patient 
management following disease progression on 
second-line treatment.
Parameter values will be obtained from relevant 
research literature, including our own systematic 
review of clinical effectiveness. Where required 
parameters are not available from good-quality 
published studies in the relevant patient group, we 
may use data from sponsor submissions to NICE or 
experts’ clinical opinions. Searches for additional 
information regarding model parameters, patient 
preferences and other topics will be conducted 
as required. Sources for parameters will be stated 
clearly.
Resource use will be specified and valued from 
the perspective of the NHS and PSS. Cost data 
will be derived from local sources, extracted from 
published sources or from sponsor submissions to 
NICE, as appropriate.
The simulated population will be defined on the 
basis of both the published evidence about the 
characteristics of the UK population with SCLC 
relevant to the licensed indication for topotecan, 
and the populations for which good-quality clinical 
effectiveness is available. The base-case results will 
be presented for the population of UK patients 
undergoing second-line treatment of SCLC. The 
time horizon for our analysis will initially be 
governed by follow-up data available from included 
clinical trials – we will investigate the feasibility of 
extrapolating treatment effects beyond the clinical 
trials.
Methods for estimating QoL
The primary aim of treatment for SCLC is to 
palliate symptoms, prolong survival and maintain 
a good QoL with minimal adverse events from 
treatment. This assessment will aim to identify 
adverse effects of treatment that are likely to have a 
substantial impact on patients’ QoL, and to include 
these in estimates of health-state utility while on 
treatment. Where presented, QoL information, as 
well as incidence of adverse events and side effects 
of treatment, will be extracted from included RCTs. 
Where QoL data are insufficient to calculate utility 
estimates, data will be derived from the broader 
literature or estimated from other sources. Ideally, 
utility values will be taken from studies that have 
been based on ‘public’ (as opposed to patient or 
clinician) preferences elicited using a choice-based 
method (in accordance with NICE methodological 
guidance).67
Analysis of uncertainty
Analysis of uncertainty will focus on cost–utility, 
assuming that the cost per QALY can be estimated. 
Uncertainty will be explored through one-way 
sensitivity analysis and, if the data and modelling 
approach permit, probabilistic sensitivity analysis Appendix 2
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(PSA). The outputs of PSA will be presented both 
using plots on the cost-effectiveness plane and cost-
effectiveness acceptability curves.
Handling the company 
submission(s)
All data submitted by the manufacturers will 
be considered if received by the Technology 
Assessment Report (TAR) team no later than 12 
December 2008. Data arriving after this date will 
not be considered. If the data meet the inclusion 
criteria for the review, they will be extracted and 
quality assessed in accordance with the procedures 
outlined in this protocol. Any economic evaluations 
included in the company submission, provided it 
complies with NICE’s guidance on presentation,67 
will be assessed for clinical validity, reasonableness 
of assumptions and appropriateness of the data 
used in the economic model.
Methods adopted, and incremental cost-
effectiveness ratios (ICERs) estimated from 
consultee models will be compared with published 
economic evaluations of topotecan included in the 
assessment report and with the results from the 
Assessment Group’s analysis. Reasons for large 
discrepancies in estimated ICERs will be explored 
and, where possible, explained.
Any ‘academic in confidence’ data or ‘commercial 
in confidence’ data taken from a company 
submission will be underlined and highlighted in 
the assessment report.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
103
T
he following databases were searched for 
published studies and recently completed 
and ongoing research. All searches were limited to 
English language only. Searches were updated in 
February 2009.
•  Cochrane Library – Cochrane Database of 
Systematic Reviews (CDSR)
•  Cochrane Library – Central Register of 
Controlled Trials (Clinical Trials)
•  MEDLINE (OVID)
•  PREMEDLINE In-Process & Other Non-
Indexed citations (OVID)
•  EMBASE (OVID)
•  Web of Knowledge Science Citation Index 
(SCI)
•  Web of Knowledge ISI Proceedings
•  BIOSIS
•  PsycInfo (EBSCO)
•  CINAHL (EBSCO)
•  DARE (CRD)
•  HTA (CRD)
•  NHS Economic Evaluation Database (CRD)
•  Health Technology Assessment (HTA) database
•  Current Controlled Trials
•  ClinicalTrials.gov
•  Cancer Research UK trials
•  NIHR-Clinical Research Network Portfolio
•  American Society of Clinical Oncology (ASCO)
•  12th World Lung Cancer Conference
Clinical effectiveness searches
The following strategies were used to search 
MEDLINE (OVID) 1990–2008 and EMBASE 
(OVID) 1990–2008. These were translated to search 
the other databases listed above.
MEDLINE
1.  Randomized Controlled Trials as Topic/(56584)
2.  randomized controlled trial.pt. (263468)
3.  controlled clinical trial.pt. (79901)
4.  Controlled Clinical Trial/(79901)
5.  placebos/(28018)
6.  random allocation/(62530)
7.  Double-Blind Method/(99912)
8.  Single-Blind Method/(12433)
9.  (random* adj2 allocat*).tw. (13703)
10. placebo*.tw. (113108)
11. ((singl* or doubl* or trebl* or tripl*) adj 
(blind* or mask*)).tw. (96640)
12. crossover studies/(22777)
13. (crossover* or (cross adj over*)).tw. (42546)
14. Research Design/(54086)
15. ((random* or control*) adj5 (trial* or stud*)).
tw. (332493)
16. clinical trials.sh. (0)
17. Clinical Trials as Topic/(142719)
18. trial.ti. (76577)
19. randomly.ab. (124831)
20. (randomized or randomised).ab. (205326)
21. Drug Evaluation/(41604)
22. Follow-Up Studies/(377946)
23. prospective studies/(251441)
24. Comparative Study/(1425847)
25. Evaluation Studies as Topic/(120471)
26. or/1–25 (2586344)
27. limit 26 to (english language and humans and 
yr = “1990 – 2008”) (1257730)
28. Topotecan/(1346)
29. (topotecan or hycamtin).ti,ab. (1661)
30. or/28–29 (1860)
31. 27 and 30 (561)
32. SCLC.ti,ab. (3693)
33. Carcinoma, Small Cell/(15715)
34. Lung Neoplasms/(123052)
35. 33 and 34 (13271)
36. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(28814)
37. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(82293)
38. 32 or 33 or 35 or 36 or 37 (88051)
39. 31 and 38 (165)
40. from 39 keep 1–165 (165)
EMBASE (Ovid)
1.  Randomized Controlled Trial/(161361)
2.  RANDOMIZATION/(26101)
3.  PLACEBO/(116829)
4.  placebo*.tw. (106937)
5.  random*.tw. (377424)
6.  Randomization/(26101)
7.  Double Blind Procedure/(70149)
8.  single blind procedure/(7734)
9.  Crossover Procedure/(20539)
10. (crossover* or (cross adj over*)).tw. (38438)
11. Controlled Clinical Trial/(49917)
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12. ((random* or control* or clinical*) adj5 (trial* 
or stud*)).tw. (500666)
13. (random adj5 allocat*).tw. (1308)
14. ((singl* or doubl* or trebl* or tripl*) adj 
(blind* or mask*)).tw. (91281)
15. exp clinical trials/(522756)
16. Prospective Study/(76363)
17. Comparative Study/(110563)
18. Evaluation/(52829)
19. or/1–18 (1211004)
20. animal/(18250)
21. human/(6212410)
22. 20 not (20 and 21) (14472)
23. 19 not 22 (1210216)
24. limit 23 to (english language and yr = “1990 – 
2008”) (977835)
25. *topotecan/(1200)
26. hycamtin.ti,ab. (59)
27. topotecan.ti,ab. (1688)
28. or/25–27 (1856)
29. Lung Small Cell Cancer/(9125)
30. SCLC.ti,ab. (3511)
31. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(27336)
32. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(68834)
33. or/29–32 (72839)
34. 24 and 28 and 33 (257)
35. from 34 keep 1–257 (257)
Cost-effectiveness searches
The clinical effectiveness strategies above were 
combined with the following cost-effectiveness 
filters and run in MEDLINE (OVID) and EMBASE 
(OVID). The strategies were translated and run in 
the other databases noted above.
MEDLINE (Ovid)
1.  exp economics/(401622)
2.  exp economics hospital/(15764)
3.  exp economics pharmaceutical/(1958)
4.  exp economics nursing/(3849)
5.  exp economics dental/(3737)
6.  exp economics medical/(12120)
7.  exp “Costs and Cost Analysis”/(140560)
8.  Cost Benefit Analysis/(44369)
9.  value of life/(5057)
10. exp models economic/(6055)
11. exp fees/and charges/(7457)
12. exp budgets/(9937)
13. (economic$or price$or pricing or financ$or 
fee$or pharmacoeconomic$or pharma 
economic$).tw. (364284)
14. (cost$or costly or costing$or costed).tw. 
(215271)
15. (cost$adj2 (benefit$or utilit$or minim$or 
effective$)).tw. (55616)
16. (expenditure$not energy).tw. (11749)
17. (value adj2 (money or monetary)).tw. (716)
18. budget$.tw. (11787)
19. (economic adj2 burden).tw. (1798)
20. “resource use”.ti,ab. (2425)
21. or/1–20 (831568)
22. (news or letter or editorial or comment).pt. 
(1037052)
23. 21 not 22 (769363)
24. topotecan/(1348)
25. (topotecan or hycamtin).ti,ab. (1664)
26. 24 or 25 (1863)
27. SCLC.ti,ab. (3694)
28. Carcinoma, Small Cell/(15724)
29. Lung Neoplasms/(123253)
30. 28 and 29 (13275)
31. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(28891)
32. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(82493)
33. 26 and (27 or 30 or 31 or 32) (377)
34. 23 and 33 (12)
35. 26 and 28 (171)
36. 23 and 35 (5)
37. 34 or 36 (12)
38. from 37 keep 1–12 (12)
EMBASE
1.  cost$.ti. (38273)
2.  (cost$adj2 (effective$or utilit$or benefit$or 
minimi$)).ab. (45245)
3.  (economic$or pharmacoeconomic$or 
pharmaco economic$).ti. (14978)
4.  (price$or pricing$).ti,ab. (11266)
5.  (financial or finance or finances or financed).
ti,ab. (23140)
6.  (fee or fees).ti,ab. (5171)
7.  cost/(20116)
8.  cost minimization analysis/(1383)
9.  cost of illness/(4659)
10. cost utility analysis/(2350)
11. drug cost/(33975)
12. health care cost/(60374)
13. health economics/(10179)
14. economic evaluation/(4274)
15. economics/(5647)
16. pharmacoeconomics/(91517 budget/(7640)
17. “resource use”.ti,ab. (2184)
18. economic burden.ti,ab. (1743)
19. or/1–19 (207147)
20. (editorial or letter).pt. (638905)DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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21. 20 not 21 (186062)
22. topotecan/(4883)
23. (topotecan or hycamtin).ti,ab. (1695)
24. 23 or 24 (4966)
25. Lung Small Cell Cancer/(9151)
26. SCLC.ti,ab. (3517)
27. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(27408)
28. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(69004)
29. or/26–29 (73028)
30. 22 and 25 and 30 (33)
31. from 31 keep 1–33 (33)
Quality-of-life searches
The following strategy was used to search 
MEDLINE (OVID) and EMBASE (OVID) and the 
strategies were translated and run in the other 
databases noted above.
MEDLINE
1.  “Quality of Life”/(70898)
2.  (hql or hqol or “h qol” or hrqol or “hr qol”).
ti,ab. (3046)
3.  (“hye” or “hyes”).ti,ab. (47)
4.  (euroqol or “euro qol” or “eq5d” or “eq 5d”).
ti,ab. (1330)
5.  Quality-Adjusted Life Year/(3593)
6.  “quality adjusted life”.ti,ab. (2709)
7.  (qaly$or qald$or qale$or qtime$).ti,ab. (2200)
8.  “disability adjusted life”.ti,ab. (475)
9.  “quality of wellbeing”.ti,ab. (1)
10. “quality of well being”.ti,ab. (221)
11. daly$.ti,ab. (552)
12. (sf36 or sf 36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform 
thirtysix or shortform thirty six or short form 
thirty six or short form thirtysix or short form 
thirty six).ti,ab. (7995)
13. health$year$equivalent$.tw. (31)
14. disutil*.ti,ab. (87)
15. “Value of Life”/(5057)
16. rosser.ti,ab. (63)
17. willingness to pay.tw. (1010)
18. standard gamble$.tw. (493)
19. time trade off.tw. (414)
20. time tradeoff.tw. (160)
21. health utilit*.ab. (493)
22. or/1–21 (83056)
23. topotecan/(1348)
24. (topotecan or hycamtin).ti,ab. (58)
25. 23 or 24 (1358)
26. SCLC.ti,ab. (3694)
27. “small cell lung cancer”.ti,ab. (19336)
28. Carcinoma, Small Cell/(15724)
29. Lung Neoplasms/(123253)
30. 28 and 29 (13275)
31. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(28891)
32. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(82493)
33. 25 and (26 or 27 or 30 or 31 or 32) (271)
34. 22 and 33 (10)
35. (quality adj5 topotecan).ti,ab. (9)
36. (qol adj5 topotecan).ti,ab. (3)
37. (quality adj5 hycamtin).ti,ab. (1)
38. (qol adj5 hycamtin).ti,ab. (0)
39. or/35–37 (12)
40. 22 and 39 (9)
41. 34 or 40 (16)
42. from 41 keep 1–16 (16)
43. Survival Analysis/(69669)
44. “symptom palliation”.mp. (141)
45. 43 or 44 (69782)
46. 33 and 45 (39)
47. 46 not 42 (36)
48. from 47 keep 1–36 (36)
49. from 41 keep 1–16 (16)
EMBASE
1.  exp quality of life/(94730)
2.  quality adjusted life year/(3820)
3.  quality adjusted life.ti,ab. (2591)
4.  (qaly$or qald$or qale$or qtime$).ti,ab. (2096)
5.  disability adjusted life.ti,ab. (428)
6.  daly*.ti,ab. (465)
7.  (sf36 or sf 36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform 
thirtysix or shortform thirty six or short form 
thirty six or short form thirtysix or short form 
thirty six).ti,ab. (7682)
8.  (sf6 or sf 6 or short form 6 or shortform 6 or sf 
six or sfsix or shortform six or short form six).
ti,ab. (845)
9.  (sf12 or sf 12 or short form 12 or shortform 12 
or sf twelve or sftwelve or shortform twelve or 
short form twelve).ti,ab. (953)
10. (sf16 or sf 16 or short form 16 or shortform 16 
or sf sixteen or sfsixteen or shortform sixteen 
or short form sixteen).ti,ab. (11)
11. (sf20 or sf 20 or short form 20 or shortform 20 
or sf twenty or sftwenty or shortform twenty or 
short form twenty).ti,ab. (193)
12. (euroqol or “euro qol” or “eq5d” or “eq 5d”).
ti,ab. (1315)
13. (hql or hqol or “h qol” or hrqol or “hr qol”).
ti,ab. (2915)
14. (“hye” or “hyes”).ti,ab. (28)
15. health* year* equivalent*.ti,ab. (24)Appendix 3
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16. ((health or cost) adj5 util*).ti,ab. (10006)
17. (hui or hui1 or hui2 or hui3).ti,ab. (399)
18. disutil*.ti,ab. (88)
19. rosser.ti,ab. (51)
20. quality of well being.ti,ab. (197)
21. quality of wellbeing.ti,ab. (5)
22. qwb.ti,ab. (114)
23. willingness to pay.ti,ab. (972)
24. standard gamble*.ti,ab. (447)
25. time trade off.ti,ab. (392)
26. time tradeoff.ti,ab. (144)
27. tto.ti,ab. (307)
28. (index adj2 well being).mp. (277)
29. (quality adj2 well being).mp. (511)
30. (health adj3 util* adj ind*).mp. (372)
31. ((multiattribute* or multi attribute) adj3 
(health ind* or theor* or health state* or util* 
or analys*)).mp. (152)
32. quality adjusted life year*.mp. (4639)
33. (EORTC adj2 “LC-13”).mp. [mp = title, 
abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, 
drug manufacturer name] (2)
34. FACT-L.mp. (37)
35. LCSS.mp. (35)
36. or/1–35 (108127)
37. topotecan/(4904)
38. topotecan.mp. (4988)
39. hycamtin.mp. (447)
40. or/37–39 (4988)
41. Lung Small Cell Cancer/(9172)
42. SCLC.ti,ab. (3524)
43. (small cell* adj3 (cancer* or carcinoma*)).ti,ab. 
(27478)
44. (lung* adj3 (cancer* or carcinoma* or 
neoplasm* or tumor* or tumour*)).ti,ab. 
(69221)
45. or/41–44 (73251)
46. 36 and 40 and 45 (94)
47. (letter or editorial or comment).pt. (641036)
48. 46 not 47 (90)
Epidemiology searches
The following strategies were used to search 
MEDLINE (OVID) and EMBASE (OVID):
1.  *carcinoma small cell/ep (161)
2.  *lung neoplasms/(94669)
3.  1 and 2 (124)
4.  *lung small cell cancer/ep (162)
5.  ((“small cell lung cancer” or SCLC) adj3 
(incidence or prevalence or epidemiolog* 
or mortality or morbidity or aetiology or 
etiology)).ti,ab. (128)
6.  “non small cell lung cancer”.ti. (18884)
7.  5 not 6 (80)
8.  5 not 7 (48)
9.  *carcinoma small cell/et (247)
10. *lung cancer/et (7046)
11. 9 and 10 (74)
12. (SCLC and aetiology).ti,ab. (9)
13. (SCLC and etiolog*).ti,ab. (35)
14. (“small cell lung cancer” and etiolog*).ti. (1)
15. (“small cell lung cancer” and aetiolog*).ti. (0)
16. lung cancer trend*.ti,ab. (55)
17. lung cancer pattern*.ti,ab. (24)
18. lung cancer epidemiolog*.ti,ab. (80)
19. 3 or 4 or 7 or 11 or 12 or 13 or 14 or 16 or 17 
or 18 (624)
20. limit 19 to english language (529)
21. NSCLC.ti. (1555)
22. “non small cell lung cancer”.ti. (18884)
23. 21 or 22 (19767)
24. 20 not 23 (516)
25. remove duplicates from 24 (395)
26. from 25 keep 1–251 (251) – note this is the 
medline set downloaded separately for import 
purposes)
27. from 25 keep 252–395 – note this is the embase 
record set downloaded separately for import 
purposes)
Additional searching
Bibliographies: all references of articles for which 
full papers were retrieved were checked to ensure 
that no eligible studies had been missed.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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O
ther consultee submissions were checked and 
there was nothing to add.
Comprehensiveness of 
ascertainment of published 
studies
Clinical effectiveness
•  Databases and dates of searches were specified 
in an appendix ‘full systematic review’ (no full 
check of this was made).
•  Search strategies in annex of appendix (not 
fully checked).
•  Enough detail provided to be reproducible.
•  Searched for ongoing studies.
•  No direct searching of conference proceedings, 
although searched using Google.
Cost-effectiveness
•  Search terms specified (although minimal).
•  Only searched NHS EED.
•  However, unlikely that anything was missed.
Searches identified
•  Four clinical trials (oral topotecan versus BSC, 
i.v. topotecan versus CAV, oral topotecan versus 
i.v. topotecan × 2).
•  Did not identify our fifth study (i.v. topotecan 
versus i.v. amrubicin) – possibly as no 
conferences were directly searched and owing 
to date of their searches.
•  No cost-effectiveness studies identified.
•  Also searched for indirect comparisons but 
found no studies of value.
Clinical analysis
•  Evidence reported is similar to ours, with the 
exception of the amrubicin study, although 
they do not appear to report the new QOL 
data from the O’Brien study.
•  Their conclusions are similar to ours.
•  They indirectly compared oral topotecan 
versus CAV (no real rationale given but see 
below). They observed the survival data and 
statistically compared the ORR data only.
•  Adverse event reporting is similar to ours. 
They undertook a meta-analysis of some data 
(not checked to see if data are consistent with a 
meta-analysis).
Interpretation
•  Their interpretation of the clinical data 
matches their analyses.
Questions
The clinical effectiveness review ran an indirect 
comparison of oral topotecan versus CAV. Although 
no justification for this was given directly, it is 
assumed that this is because CAV is the most 
likely comparator in this population, and, that 
although i.v. treatment has been compared to 
CAV in a trial, a proportion of patients would 
prefer oral topotecan. In the economic evaluation, 
however, CAV is not considered as it is reported 
that this would not be a cost-effective option due 
to the higher cost of topotecan. So, although on 
paper the comparator would be CAV, assume 
the manufacturer’s view is that the comparator 
should be those who are ineligible for CAV (this 
population would be a part of those in the O’Brien 
trial as they were ‘not appropriate’ for further i.v. 
treatment). In addition, the population in the CAV 
trial were excluded if they were ineligible for CAV 
so will not be those ‘eligible’ for topotecan in this 
sense.
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Quality criteria for assessment of experimental studies53
1. Was the assignment to the treatment groups really random?
2. Was the treatment allocation concealed?
3. Were the groups similar at baseline in terms of prognostic factors?
4. Were the eligibility criteria specified?
5. Were outcome assessors blinded to the treatment allocation?
6. Was the care provider blinded?
7. Was the patient blinded?
8. Were the point estimates and measure of variability presented for the primary outcome measure?
9. Did the analyses include an ITT analysis?
10. Were withdrawals and dropouts completely described?
Some instructions for using a checklist for RCTs
Quality item  Coding Explanation
Was the assignment to the treatment groups really random?
Random sequence generation Adequate
Partial
Inadequate
Unknown
Adequate: random numbers table or computer and 
central office or coded packages
Partial: (sealed) envelopes without further description or 
serially numbered opaque, sealed envelopes
Inadequate: alternation, case record number, birth date, or 
similar procedures
Unknown: just the term ‘randomised’ or ‘randomly 
allocated’, etc.
Was the treatment allocation concealed?
Concealment of randomisation
The person(s) who decide on eligibility should 
not be able to know or be able to predict 
with reasonable accuracy to which treatment 
group a patient will be allocated. In trials that 
use good placebos this should normally be 
the case; however, different modes or timing 
of drug administration in combination with 
the use of small block sizes of known size may 
present opportunities for clinicians who are 
also involved in the inclusion procedure to 
make accurate guesses and selectively exclude 
eligible patients in the light of their most likely 
treatment allocation; in centres with very low 
inclusion frequencies combined with very brief 
follow-up times this may also present a potential 
problem because the outcome of the previous 
patient may serve as a predictor of the next 
likely allocation
Adequate
Inadequate
Unknown
Adequate: when a paper convinces you that allocation 
cannot be predicted [separate persons, placebo really 
indistinguishable, clever use of block sizes (large or 
variable)]; adequate approaches might include centralised 
or pharmacy-controlled randomisation, serially numbered 
identical containers, on-site computer-based system 
with a randomisation sequence that is not readable until 
allocation, and other approaches with robust methods 
to prevent foreknowledge of the allocation sequence to 
clinicians and patients
Inadequate: this option is often difficult – you have to 
visualise the procedure and think how people might 
be able to circumvent it; inadequate approaches might 
include use of alternation, case record numbers, birth 
dates or week days, open random numbers lists, serially 
numbered envelopes (even sealed opaque envelopes can 
be subject to manipulation) and any other measures that 
cannot prevent foreknowledge of group allocation
Unknown: no details in text; disagreements or lack of 
clarity should be discussed in the review team
Appendix 5  
Quality assessment criteriaAppendix 5
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Quality item  Coding Explanation
Were the groups similar at baseline regarding the prognostic factors?
Baseline characteristics
Main aim is to enable the reviewer to see which 
patients were actually recruited. It enables one 
to get a rough idea on prognostic comparability. 
A real check on comparability requires 
multivariable stratification (seldom shown)
Reported
Unknown
Consult the list of prognostic factors or baseline 
characteristics (not included in this appendix); reviewer 
decides
Were the eligibility criteria specified?
Prestratification
Consult the list of prognostic factors or baseline 
characteristics (not included in this appendix).
Adequate
Partial
Inadequate
Unknown
Single-centre study:
Adequate: prestratification on at least one factor from 
the list or no prestratification if the number of patients 
exceeds a prespecified number
Partial: leave judgement to reviewer
Inadequate: stratification on a factor(s) not on our list or 
no stratification, whereas the number of patients is less 
than the prespecified number
Unknown: no details in text and no way to deduce the 
procedure from the tables
Multicentre study:
Adequate: must prestratify on centre; within each centre 
the criteria for single-centre studies also apply
Partial: impossible option
Inadequate: no prestratification on centre or violating the 
criteria for single-centre studies (see above)
Unknown: no details in text and no way to deduce the 
procedure from the tables
Were outcome assessors blinded to the treatment allocation?
Blinding of assessors
The assessor may be the patient (self report), 
the clinician (clinical scale, blood pressure…) or, 
ideally, a third person or a panel; very important 
in judgement of cause of death but unimportant 
in judgement of death
Adequate
Inadequate
Unknown
Adequate: independent person or panel or (self) 
assessments in watertight double-blind conditions
Inadequate: clinician is assessor in trial on drugs with 
clear side effects or a different influence on lab results, 
ECGs, etc.
Unknown: no statements on procedures and not 
deducible
Was the care provider blinded?
Blinding of caregivers
Look out for good placebos (see, hear, taste, 
feel, smell), tricky unmasking side effects 
accounting for the subjectivity of the outcome 
measurements and the accessibility of 
cointerventions by the caregivers
Adequate
Partial
Inadequate
Unknown
Adequate: placebo described as ‘indistinguishable’ and 
procedures watertight (use your imagination with the 
‘cheat’ in mind, e.g. statement that sensitive/unmasking 
lab results were kept separate from ward personnel)
Partial: just ‘double blind’ in text and no further 
description of procedures or nature of the placebo
Inadequate: wrong placebo (e.g. fructose in trial on 
ascorbic acid)
Unknown: no details in textDOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Quality item  Coding Explanation
Cointerventions
Register when they may have an impact on any 
of the outcome phenomena; consult the list of 
cointerventions (not included in this appendix)
Adequate
Partial
Inadequate
Unknown
Adequate: percentages of all relevant interventions in all 
groups
Partial: one or more interventions omitted or omission of 
percentages in each group
Inadequate: not deducible
Unknown: no statements
Was the patient blinded?
Blinding of patients: this item is hard to 
define; just the statement ‘double blind’ in the 
paper is really insufficient if the procedure to 
accomplish this is not described or reasonably 
deducible by the reviewer; good placebos (see, 
hear, taste, feel, smell), tricky unmasking side 
effects accounting for the subjectivity of the 
outcome measurements and the accessibility of 
cointerventions by the patient are required
Adequate
Partial
Inadequate
Unknown
Adequate: placebo described as ‘indistinguishable’ and 
procedures watertight
Partial: just ‘double blind’ in text and no further 
description of procedures or nature of the placebo
Inadequate: wrong placebo
Unknown: no details in text
Compliance
Dosing errors and timing errors
Adequate
Partial
Inadequate
Unknown
Adequate: Medication Event Monitoring System (MEMS or 
eDEM)
Partial: blood samples, urine samples (use of indicator 
substances)
Inadequate: pill count or self report
Unknown: not mentioned
Check on blinding: questionnaire for patients, 
caregivers, assessors and analysis of the 
results; the (early) timing is critical because the 
treatment effect may be the cause of unblinding, 
in which case it may be used as an outcome 
measure
Reported
Unknown
Reviewer decides
Were the point estimates and measure of variability presented for the primary outcome measure?
Results for the primary outcome measure Adequate
Partial
Inadequate
Unknown
Adequate: mean outcome in each group together with 
mean difference and its standard error (SE) or standard 
deviation (SD) or any CI around it or the possibility to 
calculate those from the paper; survival curve with log-
rank test and patient numbers at later time points
Partial: partially reported
Inadequate: no SE or SD, or SD without N (SE = SD/N)
Unknown: very unlikely
Did the analysis include an intention to treat analysis?
ITT analysis
Early dropout can make this very difficult; 
strictest requirement is sensitivity analysis 
including early dropouts
Adequate
Inadequate
Reviewers should not just look for the term ITT but 
assure themselves that the calculations were according 
to the ITT principleAppendix 5
112
Quality item  Coding Explanation
Dealing with missing values
The percentage of missing values on potential 
confounders and outcome measurements 
(seldom given) is a rough estimate of a trial’s 
quality; one can carry them forward, perform 
sensitivity analysis assuming the worst and 
best-case scenarios, use statistical imputation 
techniques, etc.; note that the default option 
(deletion) assumes that the value is randomly 
missing, which seems seldom justified
Adequate
Partial
Inadequate
Unknown
Adequate: percentage of missing values and distribution 
over the groups and procedure of handling this stated
Partial: some statement on numbers or percentages
Inadequate: wrong procedure (a matter of great debate)
Unknown: no mentioning at all of missing and not 
deducible from tables
Loss to follow-up
This item examines both numbers and reasons 
– typically an item that needs checking in the 
methods section and the marginal totals in 
the tables; note that it may differ for different 
outcome phenomena or time points; some 
reasons may be reasons given by the patient 
when asked and may not be the true reason; 
there is no satisfactory solution for this
Adequate
Partial
Inadequate
Unknown
Adequate: number randomised must be stated. Number(s) 
lost to follow-up (dropped out) stated or deducible 
(from tables) for each group and reasons summarised for 
each group
Partial: numbers, but not the reasons (or vice versa)
Inadequate: numbers randomised not stated or not 
specified for each group
Unknown: no details in textDOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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T
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
 
(
w
e
e
k
s
)
,
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
n
 
=
 
2
8
n
 
=
 
3
3
6
.
1
 
(
4
.
4
–
1
7
.
7
)
6
.
1
 
(
2
.
1
–
1
3
.
9
)
R
e
s
p
o
n
s
e
 
d
u
r
a
t
i
o
n
 
(
w
e
e
k
s
)
,
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
n
 
=
 
2
8
n
 
=
 
3
3
1
8
.
3
 
(
9
.
0
–
6
5
.
4
)
2
5
.
4
 
(
8
.
4
–
1
3
2
.
1
)
h
h
 
I
n
c
l
u
d
e
s
 
c
e
n
s
o
r
e
d
 
e
v
e
n
t
s
.
N
o
n
-
r
e
s
p
o
n
d
e
r
s
,
 
n
 
(
%
)
i
S
t
a
b
l
e
 
d
i
s
e
a
s
e
2
7
 
(
1
7
.
6
)
3
5
 
(
2
3
.
2
)
P
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
7
8
 
(
5
1
.
0
)
6
5
 
(
4
3
.
0
)
N
o
t
 
a
s
s
e
s
s
a
b
l
e
2
0
 
(
1
3
.
1
)
1
8
 
(
1
1
.
9
)
i
 
S
t
a
t
e
s
 
t
h
a
t
 
3
2
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
n
o
t
 
a
s
s
e
s
s
a
b
l
e
 
f
o
r
 
r
e
s
p
o
n
s
e
 
d
u
e
 
t
o
 
d
e
a
t
h
,
 
w
i
t
h
d
r
a
w
a
l
 
o
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
f
t
e
r
 
o
n
e
 
o
r
 
t
w
o
 
c
o
u
r
s
e
s
.
 
T
h
e
s
e
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
i
n
s
u
f
fi
c
i
e
n
t
 
t
r
e
a
t
m
e
n
t
 
t
o
 
a
s
s
i
g
n
 
a
 
r
e
s
p
o
n
s
e
,
 
b
u
t
 
n
 
=
 
3
8
 
w
e
r
e
 
c
l
a
s
s
e
d
 
a
s
 
n
o
t
 
a
s
s
e
s
s
a
b
l
e
 
(
t
a
b
l
e
 
2
)
.
H
R
Q
o
L
N
o
 
d
a
t
a
 
r
e
p
o
r
t
e
d
T
h
e
 
H
R
Q
o
L
 
q
u
e
s
t
i
o
n
n
a
i
r
e
 
r
e
s
p
o
n
s
e
 
w
a
s
 
7
5
%
 
a
n
d
 
7
8
%
 
f
o
r
 
o
r
a
l
 
a
n
d
 
i
.
v
.
 
g
r
o
u
p
s
,
 
r
e
s
p
e
c
t
i
v
e
l
y
,
 
a
f
t
e
r
 
t
w
o
 
c
o
u
r
s
e
s
 
o
f
 
t
h
e
r
a
p
y
.
 
R
a
t
e
s
 
a
t
 
w
h
i
c
h
 
p
a
t
i
e
n
t
s
 
f
a
i
l
e
d
 
t
o
 
c
o
m
p
l
e
t
e
 
Q
o
L
 
a
s
s
e
s
s
m
e
n
t
 
a
t
 
o
n
e
 
o
r
 
m
o
r
e
 
c
o
u
r
s
e
s
 
w
e
r
e
 
s
i
m
i
l
a
r
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
(
n
o
 
d
a
t
a
 
p
r
o
v
i
d
e
d
)
.
L
e
a
s
t
 
s
q
u
a
r
e
s
 
e
s
t
i
m
a
t
e
s
 
f
o
r
 
m
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
d
i
c
a
t
e
d
 
n
o
 
s
t
a
t
i
s
t
i
c
a
l
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
f
o
r
 
s
u
b
s
c
a
l
e
 
d
i
m
e
n
s
i
o
n
 
s
c
o
r
e
s
 
a
n
d
 
l
u
n
g
 
c
a
n
c
e
r
 
s
c
a
l
e
,
 
T
O
I
 
a
n
d
 
F
A
C
T
-
L
 
t
o
t
a
l
 
s
c
o
r
e
s
.
O
n
l
y
 
a
 
s
m
a
l
l
 
d
e
c
l
i
n
e
 
i
n
 
H
R
Q
o
L
 
w
a
s
 
n
o
t
e
d
 
f
o
r
 
e
a
c
h
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
d
e
c
l
i
n
e
s
 
t
h
a
t
 
m
a
y
 
b
e
 
e
x
p
e
c
t
e
d
 
i
n
 
a
n
 
u
n
t
r
e
a
t
e
d
 
l
u
n
g
 
c
a
n
c
e
r
 
p
o
p
u
l
a
t
i
o
n
 
(
i
.
e
.
 
b
e
s
t
 
s
u
p
p
o
r
t
i
v
e
 
c
a
r
e
)
.
 
M
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
t
o
 
l
a
s
t
 
c
o
u
r
s
e
 
a
l
s
o
 
s
h
o
w
e
d
 
n
o
 
s
t
a
t
i
s
t
i
c
a
l
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
(
n
o
 
d
a
t
a
 
p
r
o
v
i
d
e
d
)
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O
r
a
l
 
t
o
p
o
t
e
c
a
n
I
n
t
r
a
v
e
n
o
u
s
 
t
o
p
o
t
e
c
a
n
D
i
f
f
e
r
e
n
c
e
A
d
v
e
r
s
e
 
e
f
f
e
c
t
s
,
 
n
 
(
%
)
j
G
r
a
d
e
 
3
G
r
a
d
e
 
4
G
r
a
d
e
 
3
G
r
a
d
e
 
4
N
o
t
 
t
e
s
t
e
d
L
e
u
c
o
p
e
n
i
a
6
4
 
(
4
2
.
7
)
3
4
 
(
2
2
.
7
)
7
4
 
(
4
9
.
3
)
3
9
 
(
2
6
.
0
)
N
e
u
t
r
o
p
e
n
i
a
3
9
 
(
2
6
.
2
)
7
0
 
(
4
7
.
0
)
3
5
 
(
2
3
.
6
)
9
5
 
(
6
4
.
2
)
T
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
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0
 
(
2
0
.
0
)
4
3
 
(
2
8
.
7
)
3
8
 
(
2
5
.
3
)
2
7
 
(
1
8
.
0
)
A
n
a
e
m
i
a
2
6
 
(
1
7
.
3
)
8
 
(
5
.
3
)
4
2
 
(
2
8
.
0
)
4
 
(
2
.
7
)
N
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
a
d
v
e
r
s
e
 
e
f
f
e
c
t
s
,
 
n
 
(
%
)
G
r
a
d
e
 
3
G
r
a
d
e
 
4
G
r
a
d
e
 
3
G
r
a
d
e
 
4
N
o
t
 
t
e
s
t
e
d
D
i
a
r
r
h
o
e
a
1
1
 
(
7
.
2
)
1
 
(
0
.
7
)
3
 
(
2
.
0
)
1
 
(
0
.
7
)
F
a
t
i
g
u
e
1
0
 
(
6
.
5
)
0
1
0
 
(
6
.
6
)
2
 
(
1
.
3
)
D
y
s
p
n
o
e
a
9
 
(
5
.
9
)
3
 
(
2
.
0
)
1
0
 
(
6
.
6
)
5
 
(
3
.
3
)
A
n
o
r
e
x
i
a
8
 
(
5
.
2
)
0
3
 
(
2
.
0
)
1
 
(
0
.
7
)
N
a
u
s
e
a
6
 
(
3
.
9
)
0
3
 
(
2
.
0
)
1
 
(
0
.
7
)
A
s
t
h
e
n
i
a
4
 
(
2
.
6
)
3
 
(
2
.
0
)
7
 
(
4
.
6
)
3
 
(
2
.
0
)
F
e
v
e
r
3
 
(
2
.
0
)
3
 
(
2
.
0
)
4
 
(
2
.
6
)
6
 
(
4
.
0
)
R
e
c
e
i
v
e
d
 
s
y
s
t
e
m
i
c
 
a
n
t
i
b
i
o
t
i
c
 
(
%
)
4
1
5
6
R
e
c
e
i
v
e
d
 
i
.
v
.
 
a
n
t
i
b
i
o
t
i
c
 
(
%
)
1
4
2
3
D
e
a
t
h
,
 
n
k
6
4
j
 
O
c
c
u
r
r
i
n
g
 
w
i
t
h
 
a
 
f
r
e
q
u
e
n
c
y
 
o
f
 
≥
 
1
0
%
 
i
n
 
e
i
t
h
e
r
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
.
k
 
D
i
e
d
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
,
 
s
e
p
t
i
c
 
s
h
o
c
k
 
r
e
l
a
t
e
d
 
t
o
 
t
o
p
o
t
e
c
a
n
 
t
r
e
a
t
m
e
n
t
 
o
r
 
o
f
 
o
t
h
e
r
 
c
a
u
s
e
s
 
p
o
s
s
i
b
l
y
 
r
e
l
a
t
e
d
 
t
o
 
t
o
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o
t
e
c
a
n
 
t
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n
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F
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e
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l
)
 
v
s
 
1
6
%
 
(
i
.
v
.
)
 
o
f
 
p
a
t
i
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p
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i
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p
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c
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.
 
W
i
t
h
 
t
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p
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o
l
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p
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c
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d
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s
e
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d
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s
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n
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r
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c
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r
o
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A
d
d
i
t
i
o
n
a
l
 
c
o
m
m
e
n
t
s
D
a
t
a
 
c
o
l
l
e
c
t
e
d
 
d
u
r
i
n
g
 
p
o
s
t
s
t
u
d
y
 
m
o
n
i
t
o
r
i
n
g
 
s
h
o
w
e
d
 
t
h
a
t
 
s
i
m
i
l
a
r
 
p
r
o
p
o
r
t
i
o
n
s
 
o
f
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
g
r
o
u
p
 
h
a
d
 
r
e
c
e
i
v
e
d
 
t
h
i
r
d
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
 
–
 
3
3
%
 
i
n
 
t
h
e
 
o
r
a
l
 
g
r
o
u
p
 
a
n
d
 
3
5
%
 
i
n
 
t
h
e
 
i
.
v
.
 
g
r
o
u
p
.
M
e
d
i
a
n
 
d
o
s
e
 
i
n
t
e
n
s
i
t
y
 
w
a
s
 
3
.
7
4
 
m
g
/
m
2
 
(
o
r
a
l
)
 
a
n
d
 
2
.
3
1
 
m
g
/
m
2
 
(
i
.
v
.
)
,
 
r
a
t
i
o
 
=
 
1
.
6
1
,
 
w
h
i
c
h
 
r
e
fl
e
c
t
s
 
t
h
e
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
o
r
a
l
 
a
n
d
 
i
.
v
.
 
d
o
s
e
s
 
(
r
a
t
i
o
 
=
 
1
.
5
3
)
.
 
D
o
s
e
 
r
e
d
u
c
t
i
o
n
s
 
w
e
r
e
 
m
a
d
e
 
f
o
r
 
3
1
%
 
(
o
r
a
l
)
 
a
n
d
 
3
5
%
 
(
i
.
v
.
)
 
o
f
 
p
a
t
i
e
n
t
s
 
p
r
i
m
a
r
i
l
y
 
a
t
 
t
h
e
 
e
n
d
 
o
f
 
c
o
u
r
s
e
 
1
 
d
u
e
 
t
o
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
.
 
I
n
 
t
o
t
a
l
,
 
3
6
%
 
(
o
r
a
l
)
 
a
n
d
 
1
9
%
 
(
i
.
v
.
)
 
h
a
d
 
a
 
d
o
s
e
 
e
s
c
a
l
a
t
i
o
n
.
N
o
t
e
:
 
I
f
 
r
e
v
i
e
w
e
r
 
c
a
l
c
u
l
a
t
e
s
 
a
 
s
u
m
m
a
r
y
 
m
e
a
s
u
r
e
 
o
r
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
 
P
L
E
A
S
E
 
I
N
D
I
C
A
T
E
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
r
a
n
d
o
m
i
s
e
d
 
1
:
1
.
 
N
o
 
d
e
t
a
i
l
s
 
o
n
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
m
e
t
h
o
d
.
 
G
r
o
u
p
s
 
w
e
r
e
 
s
t
r
a
t
i
fi
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
d
u
r
a
t
i
o
n
 
o
f
 
r
e
s
p
o
n
s
e
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
 
(
p
r
o
g
r
e
s
s
i
o
n
 
≤
 
6
 
m
o
n
t
h
s
 
o
r
 
>
 
6
 
m
o
n
t
h
s
)
,
 
g
e
n
d
e
r
 
a
n
d
 
p
r
e
s
e
n
c
e
 
o
r
 
a
b
s
e
n
c
e
 
o
f
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
.
B
l
i
n
d
i
n
g
:
 
o
p
e
n
-
l
a
b
e
l
 
s
t
u
d
y
.
 
A
n
 
i
n
d
e
p
e
n
d
e
n
t
 
c
e
n
t
r
a
l
 
r
a
d
i
o
l
o
g
i
s
t
 
w
h
o
 
w
a
s
 
b
l
i
n
d
e
d
 
t
o
 
s
t
u
d
y
 
t
r
e
a
t
m
e
n
t
 
v
e
r
i
fi
e
d
 
a
l
l
 
r
e
s
p
o
n
s
e
s
,
 
a
l
t
h
o
u
g
h
 
i
t
 
i
s
 
n
o
t
 
c
l
e
a
r
 
w
h
e
t
h
e
r
 
t
h
i
s
 
w
a
s
 
t
h
e
 
c
a
s
e
 
f
o
r
 
a
l
l
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
.
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
s
t
a
t
e
s
 
t
h
a
t
 
d
e
m
o
g
r
a
p
h
i
c
s
 
a
n
d
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
w
e
r
e
 
w
e
l
l
-
m
a
t
c
h
e
d
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
–
 
n
o
t
 
s
u
p
p
o
r
t
e
d
 
s
t
a
t
i
s
t
i
c
a
l
l
y
,
 
b
u
t
 
g
r
o
u
p
s
 
d
o
 
a
p
p
e
a
r
 
c
o
m
p
a
r
a
b
l
e
 
(
b
a
s
e
d
 
o
n
 
t
h
o
s
e
 
w
h
o
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
c
o
u
r
s
e
 
o
f
 
t
r
e
a
t
m
e
n
t
)
.
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
I
T
T
 
p
o
p
u
l
a
t
i
o
n
 
i
n
c
l
u
d
e
d
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
c
e
i
v
e
d
 
t
r
e
a
t
m
e
n
t
 
(
n
o
t
 
a
l
l
 
r
a
n
d
o
m
i
s
e
d
 
p
a
t
i
e
n
t
s
)
.
 
T
i
m
e
 
t
o
 
e
v
e
n
t
 
d
a
t
a
 
w
e
r
e
 
s
u
m
m
a
r
i
s
e
d
 
u
s
i
n
g
 
K
a
p
l
a
n
–
M
e
i
e
r
 
s
u
r
v
i
v
a
l
 
m
e
t
h
o
d
s
.
 
A
 
H
R
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
i
n
 
t
h
e
 
p
r
e
s
e
n
c
e
 
o
f
 
c
o
v
a
r
i
a
t
e
s
 
(
i
.
e
.
 
d
u
r
a
t
i
o
n
 
o
f
 
p
r
i
o
r
 
r
e
s
p
o
n
s
e
,
 
s
e
x
 
a
n
d
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
)
 
u
s
i
n
g
 
t
h
e
 
C
o
x
 
p
r
o
p
o
r
t
i
o
n
a
l
 
h
a
z
a
r
d
s
 
m
o
d
e
l
 
w
a
s
 
g
e
n
e
r
a
t
e
d
 
f
o
r
 
t
h
e
 
s
u
r
v
i
v
a
l
 
e
n
d
 
p
o
i
n
t
.
 
Q
o
L
 
d
a
t
a
 
w
e
r
e
 
e
v
a
l
u
a
t
e
d
 
b
y
 
c
a
l
c
u
l
a
t
i
n
g
 
t
h
e
 
t
o
t
a
l
 
F
A
C
T
-
L
 
s
c
o
r
e
 
a
n
d
 
t
h
e
 
2
1
-
i
t
e
m
 
T
O
I
.
 
S
c
o
r
e
s
 
r
e
c
o
r
d
e
d
 
b
e
f
o
r
e
 
e
a
c
h
 
c
o
u
r
s
e
 
o
f
 
t
r
e
a
t
m
e
n
t
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
b
a
s
e
l
i
n
e
 
s
c
o
r
e
s
.
 
A
 
r
e
p
e
a
t
e
d
 
m
e
a
s
u
r
e
s
 
a
n
a
l
y
s
i
s
 
w
a
s
 
p
e
r
f
o
r
m
e
d
 
t
o
 
c
o
m
p
a
r
e
 
t
h
e
 
r
a
t
e
 
o
f
 
c
h
a
n
g
e
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
f
o
r
 
e
a
c
h
 
d
i
m
e
n
s
i
o
n
 
o
r
 
s
u
b
s
c
a
l
e
.
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
b
a
s
e
d
 
o
n
 
t
h
e
 
f
e
a
s
i
b
i
l
i
t
y
 
o
f
 
p
a
t
i
e
n
t
 
a
c
c
r
u
a
l
 
a
n
d
 
s
t
u
d
y
 
c
o
m
p
l
e
t
i
o
n
 
r
a
t
h
e
r
 
t
h
a
n
 
o
n
 
f
o
r
m
a
l
 
s
t
a
t
i
s
t
i
c
a
l
 
c
r
i
t
e
r
i
a
.
 
A
 
s
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
 
o
f
 
1
5
0
 
p
a
t
i
e
n
t
s
 
p
e
r
 
t
r
e
a
t
m
e
n
t
 
a
r
m
 
p
r
o
v
i
d
e
d
 
7
1
%
 
p
o
w
e
r
 
t
h
a
t
 
t
h
e
 
9
5
%
 
C
I
 
w
o
u
l
d
 
e
x
c
l
u
d
e
 
m
o
r
e
 
t
h
a
n
 
1
0
%
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
f
a
v
o
u
r
 
o
f
 
i
.
v
.
 
t
r
e
a
t
m
e
n
t
.
A
t
t
r
i
t
i
o
n
/
d
r
o
p
o
u
t
:
 
n
u
m
b
e
r
s
 
a
n
d
 
r
e
a
s
o
n
s
 
r
e
p
o
r
t
e
d
.
 
H
o
w
e
v
e
r
,
 
d
i
s
c
r
e
p
a
n
c
y
 
b
e
t
w
e
e
n
 
fi
g
u
r
e
 
1
 
a
n
d
 
t
e
x
t
 
r
e
g
a
r
d
i
n
g
 
n
u
m
b
e
r
 
o
f
 
d
r
o
p
o
u
t
s
 
f
o
r
 
o
r
a
l
 
t
h
e
r
a
p
y
 
(
3
0
 
v
s
 
3
1
,
 
r
e
s
p
e
c
t
i
v
e
l
y
)
.
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
l
i
m
i
t
e
d
 
o
r
 
e
x
t
e
n
s
i
v
e
-
s
t
a
g
e
 
S
C
L
C
 
w
h
o
 
h
a
d
 
d
o
c
u
m
e
n
t
e
d
 
C
R
 
o
r
 
P
R
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
 
w
i
t
h
 
d
i
s
e
a
s
e
 
r
e
c
u
r
r
e
n
c
e
 
a
f
t
e
r
 
≥
 
9
0
 
d
a
y
s
.
 
L
i
k
e
l
y
 
t
o
 
b
e
 
a
 
m
i
x
t
u
r
e
 
o
f
 
p
a
t
i
e
n
t
s
 
g
r
o
u
p
s
 
a
c
r
o
s
s
 
a
 
v
a
r
i
e
t
y
 
o
f
 
c
o
u
n
t
r
i
e
s
 
b
u
t
 
n
o
 
d
e
t
a
i
l
s
 
o
n
 
e
t
h
n
i
c
i
t
y
 
o
r
 
d
e
m
o
g
r
a
p
h
i
c
s
 
w
e
r
e
 
g
i
v
e
n
.
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
:
 
o
u
t
c
o
m
e
s
 
a
r
e
 
a
p
p
r
o
p
r
i
a
t
e
 
b
u
t
 
u
n
c
e
r
t
a
i
n
 
o
f
 
t
h
e
 
r
e
l
i
a
b
i
l
i
t
y
 
o
f
 
s
o
m
e
 
r
e
s
u
l
t
s
 
t
h
a
t
 
d
o
 
n
o
t
 
h
a
v
e
 
9
5
%
 
C
I
 
o
r
 
h
a
v
e
 
w
i
d
e
 
r
a
n
g
e
s
;
 
a
l
s
o
 
n
o
 
p
-
v
a
l
u
e
s
 
o
r
 
s
t
a
t
i
s
t
i
c
a
l
 
t
e
s
t
s
 
w
e
r
e
 
c
a
l
c
u
l
a
t
e
d
 
t
o
 
c
o
m
p
a
r
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
f
o
r
 
a
l
l
 
b
u
t
 
t
w
o
 
o
u
t
c
o
m
e
s
.
I
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
:
 
n
o
t
 
r
e
p
o
r
t
e
d
.
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
s
u
p
p
o
r
t
e
d
 
b
y
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
,
 
U
K
.
 
M
a
n
y
 
a
u
t
h
o
r
s
 
a
r
e
 
e
i
t
h
e
r
 
G
S
K
 
e
m
p
l
o
y
e
e
s
 
o
r
 
a
r
e
 
c
o
n
s
u
l
t
a
n
t
s
 
t
o
 
G
S
K
.
 
G
S
K
 
e
m
p
l
o
y
e
e
s
 
w
e
r
e
 
i
n
v
o
l
v
e
d
 
i
n
 
a
l
l
 
a
s
p
e
c
t
s
 
o
f
 
t
h
e
 
t
r
i
a
l
,
 
i
n
c
l
u
d
i
n
g
 
s
t
u
d
y
 
d
e
s
i
g
n
 
a
n
d
 
d
a
t
a
 
a
n
a
l
y
s
i
s
.
 
M
a
n
y
 
t
r
i
a
l
 
a
u
t
h
o
r
s
 
h
a
d
 
p
o
t
e
n
t
i
a
l
 
c
o
n
fl
i
c
t
s
 
o
f
 
i
n
t
e
r
e
s
t
 
n
o
t
e
d
 
i
n
 
t
h
e
 
r
e
p
o
r
t
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Q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
f
o
r
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
R
C
T
s
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
U
n
k
n
o
w
n
2
.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
U
n
k
n
o
w
n
3
.
 
W
e
r
e
 
t
h
e
 
g
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
R
e
p
o
r
t
e
d
4
.
 
W
e
r
e
 
t
h
e
 
e
l
i
g
i
b
i
l
i
t
y
 
c
r
i
t
e
r
i
a
 
s
p
e
c
i
fi
e
d
?
A
d
e
q
u
a
t
e
5
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
P
a
r
t
i
a
l
6
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
7
.
 
W
a
s
 
t
h
e
 
p
a
t
i
e
n
t
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
8
.
 
W
e
r
e
 
t
h
e
 
p
o
i
n
t
 
e
s
t
i
m
a
t
e
s
 
a
n
d
 
m
e
a
s
u
r
e
 
o
f
 
v
a
r
i
a
b
i
l
i
t
y
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
?
A
d
e
q
u
a
t
e
9
.
 
D
i
d
 
t
h
e
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
 
a
n
 
I
T
T
 
a
n
a
l
y
s
i
s
?
I
n
a
d
e
q
u
a
t
e
1
0
.
 
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
a
n
d
 
d
r
o
p
o
u
t
s
 
c
o
m
p
l
e
t
e
l
y
 
d
e
s
c
r
i
b
e
d
?
A
d
e
q
u
a
t
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
A
u
t
h
o
r
:
 
I
n
o
u
e
 
e
t
 
a
l
.
6
3
 
a
n
d
 
S
u
g
a
w
a
r
a
 
e
t
 
a
l
.
 
(
a
b
s
t
r
a
c
t
)
6
2
Y
e
a
r
:
 
2
0
0
8
C
o
u
n
t
r
y
:
 
J
a
p
a
n
S
t
u
d
y
 
d
e
s
i
g
n
:
 
R
C
T
 
(
p
h
a
s
e
 
I
I
)
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
1
2
F
u
n
d
i
n
g
:
 
s
t
a
t
e
s
 
t
w
o
 
a
u
t
h
o
r
s
 
p
r
o
v
i
d
e
d
 
fi
n
a
n
c
i
a
l
 
s
u
p
p
o
r
t
G
r
o
u
p
 
A
:
 
I
n
t
r
a
v
e
n
o
u
s
 
a
m
r
u
b
i
c
i
n
D
o
s
e
:
 
4
0
 
m
g
/
m
2
/
d
a
y
D
u
r
a
t
i
o
n
:
 
5
-
m
i
n
 
i
n
f
u
s
i
o
n
 
o
n
 
d
a
y
s
 
1
–
3
 
e
v
e
r
y
 
3
 
w
e
e
k
s
G
r
o
u
p
 
B
:
 
I
n
t
r
a
v
e
n
o
u
s
 
t
o
p
o
t
e
c
a
n
D
o
s
e
:
 
1
.
0
 
m
g
/
m
2
/
d
a
y
D
u
r
a
t
i
o
n
:
 
3
0
-
m
i
n
u
t
e
 
i
n
f
u
s
i
o
n
 
o
n
 
d
a
y
s
 
1
–
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
t
h
r
e
e
 
c
y
c
l
e
s
 
(
a
m
r
u
b
i
c
i
n
:
 
m
e
d
i
a
n
 
3
,
 
r
a
n
g
e
 
1
–
7
;
 
t
o
p
o
t
e
c
a
n
:
 
m
e
d
i
a
n
 
2
,
 
r
a
n
g
e
 
1
–
4
)
 
u
n
l
e
s
s
 
o
b
v
i
o
u
s
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
,
 
p
a
t
i
e
n
t
 
r
e
f
u
s
a
l
 
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
t
o
x
i
c
i
t
y
O
t
h
e
r
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
u
s
e
d
:
 
G
C
S
F
 
p
e
r
m
i
t
t
e
d
 
a
s
 
a
 
t
h
e
r
a
p
e
u
t
i
c
 
i
n
t
e
r
v
e
n
t
i
o
n
 
f
o
r
 
n
e
u
t
r
o
p
e
n
i
a
 
(
b
u
t
 
n
o
t
 
f
o
r
 
u
s
e
 
a
s
 
a
 
p
r
o
p
h
y
l
a
c
t
i
c
)
S
u
b
s
e
q
u
e
n
t
 
d
o
s
e
s
 
o
f
 
a
m
r
u
b
i
c
i
n
 
a
n
d
 
t
o
p
o
t
e
c
a
n
 
w
e
r
e
 
r
e
d
u
c
e
d
 
t
o
 
3
5
 
m
g
/
m
2
/
d
a
y
 
o
r
 
0
.
8
 
m
g
/
m
2
/
d
a
y
,
 
r
e
s
p
e
c
t
i
v
e
l
y
,
 
i
f
 
t
o
x
i
c
i
t
i
e
s
 
w
e
r
e
 
o
b
s
e
r
v
e
d
 
(
g
r
a
d
e
 
4
 
n
e
u
t
r
o
p
e
n
i
a
 
f
o
r
 
≥
 
4
 
d
a
y
s
,
 
g
r
a
d
e
 
3
 
f
e
b
r
i
l
e
 
n
e
u
t
r
o
p
e
n
i
a
,
 
g
r
a
d
e
 
4
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
 
o
r
 
g
r
a
d
e
 
≥
 
3
 
n
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
)
S
u
b
s
e
q
u
e
n
t
 
c
h
e
m
o
t
h
e
r
a
p
y
 
a
f
t
e
r
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
n
o
t
 
l
i
m
i
t
e
d
;
 
1
4
 
a
m
r
u
b
i
c
i
n
 
p
a
t
i
e
n
t
s
 
a
n
d
 
2
1
 
t
o
p
o
t
e
c
a
n
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
s
u
b
s
e
q
u
e
n
t
 
c
h
e
m
o
t
h
e
r
a
p
y
N
u
m
b
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
 
6
0
A
m
r
u
b
i
c
i
n
 
=
 
2
9
,
 
t
o
p
o
t
e
c
a
n
 
=
 
3
0
S
a
m
p
l
e
 
a
t
t
r
i
t
i
o
n
/
d
r
o
p
o
u
t
:
O
n
e
 
r
a
n
d
o
m
i
s
e
d
 
a
m
r
u
b
i
c
i
n
 
p
a
t
i
e
n
t
 
w
a
s
 
n
o
t
 
t
r
e
a
t
e
d
 
d
u
e
 
t
o
 
r
a
p
i
d
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
;
 
1
 
t
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
 
d
e
a
t
h
 
(
a
m
r
u
b
i
c
i
n
 
g
r
o
u
p
)
S
a
m
p
l
e
 
c
r
o
s
s
o
v
e
r
s
:
 
c
r
o
s
s
o
v
e
r
 
f
o
r
 
t
h
i
r
d
-
l
i
n
e
 
(
o
r
 
l
a
t
e
r
)
 
c
h
e
m
o
t
h
e
r
a
p
y
 
p
e
r
f
o
r
m
e
d
 
i
n
 
4
1
%
 
o
f
 
p
a
t
i
e
n
t
s
 
(
a
m
r
u
b
i
c
i
n
 
=
 
5
,
 
t
o
p
o
t
e
c
a
n
 
=
 
1
9
)
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
P
a
t
i
e
n
t
s
 
≥
 
2
0
 
y
e
a
r
s
,
 
h
i
s
t
o
l
o
g
i
c
a
l
l
y
 
o
r
 
c
y
t
o
l
o
g
i
c
a
l
l
y
 
c
o
n
fi
r
m
e
d
 
d
i
a
g
n
o
s
i
s
 
o
f
 
S
C
L
C
,
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
w
i
t
h
 
p
l
a
t
i
n
u
m
-
b
a
s
e
d
 
c
h
e
m
o
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
,
 
E
C
O
G
 
P
S
 
o
f
 
≥
 
2
,
 
a
d
e
q
u
a
t
e
 
b
o
n
e
 
m
a
r
r
o
w
 
f
u
n
c
t
i
o
n
 
(
a
b
s
o
l
u
t
e
 
n
e
u
t
r
o
p
h
i
l
 
c
o
u
n
t
 
≥
 
1
5
0
0
/
m
m
3
,
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
 
≥
 
1
0
0
,
0
0
0
 
m
l
,
 
H
b
 
≥
 
9
 
m
g
/
d
l
,
 
A
S
T
 
a
n
d
 
A
L
T
 
≤
 
1
0
0
 
I
U
/
l
,
 
t
o
t
a
l
 
b
i
l
i
r
u
b
i
n
 
l
e
v
e
l
 
≤
 
2
.
0
 
m
g
/
d
L
,
 
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
 
≤
 
1
.
5
 
m
g
/
d
l
,
 
a
r
t
e
r
i
a
l
 
o
x
y
g
e
n
 
p
r
e
s
s
u
r
e
 
≥
 
6
0
 
m
m
H
g
,
 
E
C
G
 
fi
n
d
i
n
g
s
 
w
i
t
h
i
n
 
n
o
r
m
a
l
 
r
a
n
g
e
,
 
l
e
f
t
 
v
e
n
t
r
i
c
u
l
a
r
 
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
≥
 
6
0
%
)
,
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
o
r
 
p
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
 
a
f
t
e
r
 
fi
r
s
t
-
l
i
n
e
 
t
r
e
a
t
m
e
n
t
,
 
m
e
a
s
u
r
a
b
l
e
 
d
i
s
e
a
s
e
 
w
i
t
h
 
R
E
C
I
S
T
 
c
r
i
t
e
r
i
a
,
 
n
o
 
c
h
e
m
o
t
h
e
r
a
p
y
 
o
r
 
c
h
e
s
t
 
r
a
d
i
o
t
h
e
r
a
p
y
 
w
i
t
h
i
n
 
4
 
w
e
e
k
s
 
p
r
i
o
r
 
t
o
 
e
n
r
o
l
m
e
n
t
E
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
P
a
t
i
e
n
t
s
 
w
i
t
h
 
s
y
m
p
t
o
m
a
t
i
c
 
b
r
a
i
n
 
m
e
t
a
s
t
a
s
e
s
,
 
m
a
s
s
i
v
e
 
p
l
e
u
r
a
l
 
o
r
 
p
e
r
i
c
a
r
d
i
a
l
 
e
f
f
u
s
i
o
n
 
r
e
q
u
i
r
i
n
g
 
d
r
a
i
n
a
g
e
,
 
s
e
v
e
r
e
 
c
o
m
o
r
b
i
d
i
t
i
e
s
 
s
u
c
h
 
a
s
 
u
n
c
o
n
t
r
o
l
l
e
d
 
d
i
a
b
e
t
e
s
,
 
h
e
a
r
t
 
d
i
s
e
a
s
e
,
 
i
n
f
e
c
t
i
o
u
s
 
d
i
s
e
a
s
e
,
 
o
r
 
p
u
l
m
o
n
a
r
y
 
fi
b
r
o
s
i
s
,
 
n
o
 
p
r
i
o
r
 
A
 
o
r
 
T
 
c
h
e
m
o
t
h
e
r
a
p
y
,
 
s
y
m
p
t
o
m
a
t
i
c
 
i
n
t
e
r
s
t
i
t
i
a
l
 
p
n
e
u
m
o
n
i
t
i
s
 
o
r
 
p
u
l
m
o
n
a
r
y
 
fi
b
r
o
s
i
s
 
a
p
p
a
r
e
n
t
 
o
n
 
c
h
e
s
t
 
X
-
r
a
y
,
 
h
i
s
t
o
r
y
 
o
f
 
d
r
u
g
 
a
l
l
e
r
g
y
,
 
l
a
c
t
a
t
i
n
g
 
o
r
 
p
r
e
g
n
a
n
t
 
o
r
 
p
o
s
s
i
b
l
y
 
p
r
e
g
n
a
n
t
 
w
o
m
e
n
,
 
o
r
 
t
h
o
s
e
 
w
i
l
l
i
n
g
 
t
o
 
b
e
 
p
r
e
g
n
a
n
t
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
G
e
n
d
e
r
 
(
M
/
F
)
,
 
n
 
(
%
)
:
•
 
a
m
r
u
b
i
c
i
n
:
 
2
4
 
(
8
3
)
/
5
 
(
1
7
)
,
 
t
o
p
o
t
e
c
a
n
 
2
5
 
(
8
3
)
/
5
 
(
1
7
)
,
 
p
 
=
 
1
.
0
0
0
A
g
e
 
(
y
e
a
r
s
)
,
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
:
•
 
a
m
r
u
b
i
c
i
n
 
7
0
 
(
5
4
–
7
7
)
,
 
t
o
p
o
t
e
c
a
n
 
6
4
 
(
3
2
–
7
8
)
,
 
p
 
=
 
0
.
1
9
5
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
:
 
O
R
R
S
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
:
 
P
F
S
,
 
O
S
 
a
n
d
 
t
o
x
i
c
i
t
y
 
p
r
o
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l
e
.
 
A
l
s
o
 
r
e
p
o
r
t
s
 
d
i
s
e
a
s
e
 
c
o
n
t
r
o
l
 
r
a
t
e
s
 
b
u
t
 
d
a
t
a
 
n
o
t
 
e
x
t
r
a
c
t
e
d
 
h
e
r
e
M
e
t
h
o
d
s
 
o
f
 
a
s
s
e
s
s
i
n
g
 
o
u
t
c
o
m
e
s
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C
T
 
s
c
a
n
 
u
s
e
d
 
t
o
 
a
s
s
e
s
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O
R
R
 
a
c
c
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r
d
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n
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h
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R
e
s
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n
s
e
 
E
v
a
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C
r
i
t
e
r
i
a
 
i
n
 
S
o
l
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T
u
m
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R
E
C
I
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c
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o
x
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c
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n
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N
a
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n
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C
a
n
c
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r
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n
s
t
i
t
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t
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C
o
m
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T
o
x
i
c
i
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C
r
i
t
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r
i
a
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v
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L
e
n
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t
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o
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f
o
l
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R
e
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c
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r
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c
i
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u
t
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o
m
e
 
m
e
a
s
u
r
e
s
P
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
,
 
n
 
(
%
)
:
•
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:
 
a
m
r
u
b
i
c
i
n
 
1
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(
4
8
)
,
 
t
o
p
o
t
e
c
a
n
 
1
7
 
(
5
7
)
•
 
1
:
 
a
m
r
u
b
i
c
i
n
 
1
0
 
(
3
4
)
,
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o
p
o
t
e
c
a
n
 
9
 
(
3
0
)
•
 
2
:
 
a
m
r
u
b
i
c
i
n
 
5
 
(
1
7
)
,
 
t
o
p
o
t
e
c
a
n
 
4
 
(
1
3
)
,
 
p
 
=
 
0
.
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3
1
P
r
e
v
i
o
u
s
 
t
r
e
a
t
m
e
n
t
:
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R
a
d
i
o
t
h
e
r
a
p
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:
 
a
m
r
u
b
i
c
i
n
 
1
5
 
(
5
2
)
,
 
t
o
p
o
t
e
c
a
n
 
1
6
 
(
5
3
)
•
 
P
l
a
t
i
n
u
m
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e
t
o
p
o
s
i
d
e
:
 
a
m
r
u
b
i
c
i
n
 
2
2
 
(
7
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)
,
 
t
o
p
o
t
e
c
a
n
 
2
0
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(
6
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)
•
 
P
l
a
t
i
n
u
m
 
+
 
i
r
i
n
o
t
e
c
a
n
:
 
a
m
r
u
b
i
c
i
n
 
7
 
(
2
4
)
;
 
t
o
p
o
t
e
c
a
n
 
1
1
a
 
(
3
7
)
R
e
s
p
o
n
s
e
 
t
y
p
e
,
 
n
 
(
%
)
:
•
 
S
e
n
s
i
t
i
v
e
:
 
a
m
r
u
b
i
c
i
n
 
1
7
 
(
5
9
)
;
 
t
o
p
o
t
e
c
a
n
 
1
9
 
(
6
3
)
•
 
R
e
f
r
a
c
t
o
r
y
:
 
a
m
r
u
b
i
c
i
n
 
1
2
 
(
4
1
)
,
 
t
o
p
o
t
e
c
a
n
 
1
1
 
(
3
7
)
,
 
p
 
=
 
0
.
7
9
3
a
 
O
n
e
 
p
a
t
i
e
n
t
 
r
e
c
e
i
v
e
d
 
fi
r
s
t
-
l
i
n
e
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
p
l
a
t
i
n
u
m
 
+
 
e
t
o
p
o
s
i
d
e
 
+
 
i
r
i
n
o
t
e
c
a
n
.
C
o
m
m
e
n
t
s
:
 
R
e
f
r
a
c
t
o
r
y
 
r
e
l
a
p
s
e
 
d
e
fi
n
e
d
 
a
s
 
n
o
 
r
e
s
p
o
n
s
e
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
 
o
r
 
r
e
l
a
p
s
e
 
w
i
t
h
i
n
 
9
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
;
 
s
e
n
s
i
t
i
v
e
 
r
e
l
a
p
s
e
 
d
e
fi
n
e
d
 
a
s
 
r
e
l
a
p
s
e
 
a
t
 
a
n
 
i
n
t
e
r
v
a
l
 
o
f
 
≥
 
9
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
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R
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S
U
L
T
S
O
u
t
c
o
m
e
s
A
m
r
u
b
i
c
i
n
 
(
n
 
=
 
2
9
)
T
o
p
o
t
e
c
a
n
 
(
n
 
=
 
3
0
)
p
-
v
a
l
u
e
,
 
9
5
%
 
C
I
O
S
,
 
m
e
d
i
a
n
 
(
m
o
n
t
h
s
)
8
.
1
8
.
4
p
 
=
 
0
.
1
7
O
S
 
b
y
 
r
e
l
a
p
s
e
 
t
y
p
e
,
 
m
e
d
i
a
n
 
(
m
o
n
t
h
s
)
 
S
e
n
s
i
t
i
v
e
9
.
9
1
1
.
7
N
o
t
 
r
e
p
o
r
t
e
d
 
R
e
f
r
a
c
t
o
r
y
5
.
3
5
.
4
N
o
t
 
r
e
p
o
r
t
e
d
C
o
m
m
e
n
t
s
:
 
T
h
e
 
O
S
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
c
e
i
v
e
d
 
s
u
b
s
e
q
u
e
n
t
 
c
h
e
m
o
 
(
s
e
c
o
n
d
-
l
i
n
e
,
 
t
h
i
r
d
-
l
i
n
e
 
o
r
 
l
a
t
e
r
)
 
a
f
t
e
r
 
t
h
e
 
e
n
r
o
l
m
e
n
t
 
o
f
 
t
h
i
s
 
s
t
u
d
y
 
w
a
s
 
p
r
e
s
e
n
t
e
d
 
a
s
 
s
u
r
v
i
v
a
l
 
c
u
r
v
e
s
.
 
A
d
d
i
t
i
o
n
a
l
l
y
,
 
r
e
p
o
r
t
s
 
t
h
a
t
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
t
o
 
e
x
a
m
i
n
e
 
t
h
e
 
e
f
f
e
c
t
 
o
f
 
a
g
e
,
 
g
e
n
d
e
r
,
 
i
n
i
t
i
a
l
 
c
l
i
n
i
c
a
l
 
s
t
a
g
e
,
 
P
S
,
 
r
e
l
a
p
s
e
 
t
y
p
e
,
 
a
n
d
 
s
u
b
s
e
q
u
e
n
t
 
c
h
e
m
o
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
s
 
o
n
 
O
S
 
w
e
r
e
 
p
r
e
s
e
n
t
e
d
 
i
n
 
a
n
 
a
p
p
e
n
d
i
x
 
o
n
l
i
n
e
 
–
 
d
a
t
a
 
n
o
t
 
e
x
t
r
a
c
t
e
d
 
h
e
r
e
.
T
i
m
e
 
t
o
 
p
r
o
g
r
e
s
s
i
o
n
N
o
t
 
r
e
p
o
r
t
e
d
N
o
t
 
r
e
p
o
r
t
e
d
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
,
 
m
e
d
i
a
n
 
(
m
o
n
t
h
s
)
3
.
5
2
.
2
p
 
=
 
0
.
1
6
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
b
y
 
r
e
l
a
p
s
e
 
t
y
p
e
,
 
m
e
d
i
a
n
 
(
m
o
n
t
h
s
)
:
S
e
n
s
i
t
i
v
e
3
.
9
3
.
0
N
o
t
 
r
e
p
o
r
t
e
d
R
e
f
r
a
c
t
o
r
y
2
.
6
1
.
5
N
o
t
 
r
e
p
o
r
t
e
d
O
v
e
r
a
l
l
 
r
e
s
p
o
n
s
e
,
 
%
 
(
n
/
N
)
,
 
9
5
%
 
C
I
3
8
 
(
1
1
/
2
9
)
,
 
2
1
–
5
8
b
1
3
 
(
4
/
3
0
)
,
 
1
–
2
5
c
p
 
=
 
0
.
0
3
9
R
e
s
p
o
n
s
e
,
 
n
 
(
%
)
C
R
0
 
(
0
)
0
 
(
0
)
N
o
t
 
r
e
p
o
r
t
e
d
P
R
1
1
 
(
3
8
)
4
 
(
1
3
)
N
o
t
 
r
e
p
o
r
t
e
d
S
t
a
b
l
e
 
d
i
s
e
a
s
e
1
2
 
(
4
1
)
1
0
 
(
3
3
)
N
o
t
 
r
e
p
o
r
t
e
d
P
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
6
 
(
2
1
)
1
6
 
(
5
3
)
N
o
t
 
r
e
p
o
r
t
e
d
R
e
s
p
o
n
s
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
r
e
l
a
p
s
e
-
t
y
p
e
,
%
 
(
n
/
N
)
 
(
9
5
%
 
C
I
)
:
S
e
n
s
i
t
i
v
e
5
3
 
(
9
/
1
7
)
 
(
2
8
 
t
o
 
7
7
)
2
1
 
(
4
/
1
9
)
 
(
6
 
t
o
 
4
6
)
p
 
=
 
0
.
0
8
2
R
e
f
r
a
c
t
o
r
y
1
7
 
(
2
/
1
2
)
 
(
2
 
t
o
 
4
8
)
0
 
(
0
/
1
1
)
 
(
–
2
8
)
p
 
=
 
0
.
4
7
8
R
e
s
p
o
n
s
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
P
S
 
(
E
C
O
G
)
,
 
%
 
(
n
/
N
)
 
(
9
5
%
 
C
I
)
:
0
–
1
4
2
 
(
1
0
/
2
4
)
,
 
(
2
2
 
t
o
 
6
3
)
1
5
 
(
4
/
2
6
)
;
 
(
4
 
t
o
 
3
5
)
p
 
=
 
0
.
0
5
9
2
2
0
 
(
1
/
5
)
;
 
(
1
 
t
o
 
7
2
)
0
 
(
0
/
4
)
;
 
(
–
6
0
)
p
 
=
 
1
.
0
0
0
b
 
D
i
f
f
e
r
e
n
t
 
f
r
o
m
 
C
I
s
 
r
e
p
o
r
t
e
d
 
i
n
 
S
u
g
a
w
a
r
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a
b
s
t
r
a
c
t
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%
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I
 
2
0
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o
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)
.
c
 
D
i
f
f
e
r
e
n
t
 
f
r
o
m
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I
s
 
r
e
p
o
r
t
e
d
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n
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n
f
e
r
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n
c
e
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r
e
s
e
n
t
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t
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I
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t
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o
m
m
e
n
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e
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r
t
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h
a
t
 
b
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t
e
r
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w
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c
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p
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c
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i
m
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t
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a
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n
o
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h
o
w
n
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R
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r
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2
8
2
1
3
5
1
2
1
3
9
6
1
3
3
3
8
7
4
0
3
0
N
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
F
a
t
i
g
u
e
4
5
0
1
7
3
2
0
7
F
e
b
r
i
l
e
 
n
e
u
t
r
o
p
e
n
i
a
–
4
0
1
4
–
1
0
3
I
n
f
e
c
t
i
o
n
0
2
1
e
1
0
0
1
0
3
A
n
o
r
e
x
i
a
4
2
0
7
4
0
0
0
N
a
u
s
e
a
/
v
o
m
i
t
i
n
g
1
1
0
3
1
0
0
0
S
t
o
m
a
t
i
t
i
s
1
1
0
3
0
0
0
0
D
i
a
r
r
h
o
e
a
0
0
0
0
0
1
0
3
F
e
v
e
r
2
0
0
0
1
0
0
0
C
o
n
s
t
i
p
a
t
i
o
n
2
0
0
0
0
0
0
0
P
n
e
u
m
o
n
i
t
i
s
1
0
0
0
2
0
0
0
d
 
T
o
t
a
l
 
o
f
 
9
7
 
i
n
 
S
u
g
a
w
a
r
a
 
a
b
s
t
r
a
c
t
.
e
 
O
n
e
 
t
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
 
d
e
a
t
h
 
(
g
r
a
d
e
 
5
)
 
–
 
p
a
t
i
e
n
t
 
d
i
e
d
 
o
f
 
n
e
u
t
r
o
p
e
n
i
c
 
s
e
p
s
i
s
 
d
e
v
e
l
o
p
i
n
g
 
f
r
o
m
 
a
 
u
r
i
n
a
r
y
 
t
r
a
c
t
 
i
n
f
e
c
t
i
o
n
.
N
o
t
e
:
 
I
f
 
r
e
v
i
e
w
e
r
 
c
a
l
c
u
l
a
t
e
s
 
a
 
s
u
m
m
a
r
y
 
m
e
a
s
u
r
e
 
o
r
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
 
P
L
E
A
S
E
 
I
N
D
I
C
A
T
E
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
R
a
n
d
o
m
i
s
a
t
i
o
n
 
a
c
c
o
r
d
i
n
g
 
t
o
 
s
t
r
a
t
i
fi
e
d
 
f
a
c
t
o
r
 
(
P
S
 
0
 
o
r
 
1
 
v
s
 
2
;
 
r
e
l
a
p
s
e
 
t
y
p
e
,
 
s
e
n
s
i
t
i
v
e
 
v
s
 
r
e
f
r
a
c
t
o
r
y
)
.
 
N
o
 
o
t
h
e
r
 
d
e
t
a
i
l
s
 
r
e
p
o
r
t
e
d
.
B
l
i
n
d
i
n
g
:
 
M
a
y
 
h
a
v
e
 
b
e
e
n
 
p
o
s
s
i
b
l
e
 
d
u
e
 
t
o
 
b
o
t
h
 
t
r
e
a
t
m
e
n
t
s
 
b
e
i
n
g
 
i
n
t
r
a
v
e
n
o
u
s
.
 
R
e
p
o
r
t
s
 
t
h
a
t
 
e
x
t
r
a
m
u
r
a
l
 
r
e
v
i
e
w
e
r
s
 
a
s
s
e
s
s
e
d
 
t
h
e
 
e
l
i
g
i
b
i
l
i
t
y
,
 
a
s
s
e
s
s
a
b
i
l
i
t
y
 
a
n
d
 
r
e
s
p
o
n
s
e
 
o
f
 
e
a
c
h
 
p
a
t
i
e
n
t
.
 
N
o
 
o
t
h
e
r
 
d
e
t
a
i
l
s
 
r
e
p
o
r
t
e
d
.
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
G
r
o
u
p
s
 
a
p
p
e
a
r
 
c
o
m
p
a
r
a
b
l
e
.
 
P
a
p
e
r
 
r
e
p
o
r
t
s
 
t
h
e
r
e
 
w
e
r
e
 
n
o
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
f
o
r
 
d
e
m
o
g
r
a
p
h
i
c
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
(
p
-
v
a
l
u
e
s
 
p
r
e
s
e
n
t
e
d
 
i
n
 
S
u
g
a
w
a
r
a
 
a
b
s
t
r
a
c
t
)
.
 
P
a
t
i
e
n
t
s
 
i
n
 
t
o
p
o
t
e
c
a
n
 
a
r
m
 
w
e
r
e
 
s
l
i
g
h
t
l
y
 
y
o
u
n
g
e
r
 
t
h
a
n
 
t
h
o
s
e
 
i
n
 
a
m
r
u
b
i
c
i
n
 
a
r
m
,
 
b
u
t
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
 
(
p
 
=
 
0
.
1
9
5
)
.
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
I
f
 
r
e
s
p
o
n
s
e
 
r
a
t
e
s
 
o
f
 
s
u
b
g
r
o
u
p
s
 
d
e
fi
n
e
d
 
i
n
 
p
a
t
i
e
n
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
w
e
r
e
 
u
n
u
s
u
a
l
l
y
 
l
a
r
g
e
 
o
r
 
s
m
a
l
l
,
 
a
d
d
i
t
i
o
n
a
l
 
a
n
a
l
y
s
e
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
f
o
r
 
t
h
e
s
e
 
s
u
b
g
r
o
u
p
s
.
 
T
h
e
 
9
5
%
 
C
I
 
w
a
s
 
c
a
l
c
u
l
a
t
e
d
 
u
s
i
n
g
 
a
 
b
i
n
o
m
i
n
a
l
 
d
i
s
t
r
i
b
u
t
i
o
n
.
 
F
i
s
h
e
r
’
s
 
e
x
a
c
t
 
t
e
s
t
 
w
a
s
 
u
s
e
d
 
t
o
 
e
s
t
i
m
a
t
e
 
t
h
e
 
c
o
r
r
e
l
a
t
i
o
n
 
a
m
o
n
g
 
d
i
f
f
e
r
e
n
t
 
v
a
r
i
a
b
l
e
s
 
b
e
t
w
e
e
n
 
a
r
m
s
.
 
S
u
r
v
i
v
a
l
 
e
s
t
i
m
a
t
i
o
n
 
w
a
s
 
p
e
r
f
o
r
m
e
d
 
u
s
i
n
g
 
t
h
e
 
K
a
p
l
a
n
–
M
e
i
e
r
 
m
e
t
h
o
d
 
a
n
d
 
l
o
g
-
r
a
n
k
 
t
e
s
t
.
 
S
t
e
p
w
i
s
e
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
w
a
s
 
u
s
e
d
 
t
o
 
a
s
s
e
s
s
 
t
h
e
 
p
r
o
g
n
o
s
t
i
c
 
s
i
g
n
i
fi
c
a
n
c
e
 
o
f
 
s
e
v
e
r
a
l
 
v
a
r
i
a
b
l
e
s
.
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
I
t
 
i
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
a
n
 
O
R
R
 
o
f
 
4
0
%
 
i
n
 
e
l
i
g
i
b
l
e
 
p
a
t
i
e
n
t
s
 
i
n
d
i
c
a
t
e
s
 
p
o
t
e
n
t
i
a
l
 
u
s
e
f
u
l
n
e
s
s
,
 
w
h
i
l
e
 
a
n
 
O
R
R
 
o
f
 
1
5
%
 
i
s
 
t
h
e
 
l
o
w
e
r
 
l
i
m
i
t
 
o
f
 
i
n
t
e
r
e
s
t
,
 
w
i
t
h
 
a
l
p
h
a
 
=
 
0
.
0
5
 
a
n
d
 
b
e
t
a
 
=
 
0
.
1
0
,
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
a
c
c
r
u
a
l
 
w
a
s
 
2
7
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
a
r
m
.
 
A
c
c
r
u
a
l
 
i
n
 
b
o
t
h
 
g
r
o
u
p
s
 
w
a
s
 
c
o
n
t
i
n
u
e
d
 
i
f
 
a
t
 
l
e
a
s
t
 
t
h
r
e
e
 
r
e
s
p
o
n
s
e
s
 
w
e
r
e
 
d
o
c
u
m
e
n
t
e
d
 
i
n
 
t
h
e
 
fi
r
s
t
 
1
6
 
a
s
s
e
s
s
a
b
l
e
 
p
a
t
i
e
n
t
s
.
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
d
e
t
a
i
l
s
 
r
e
p
o
r
t
e
d
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G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
P
o
p
u
l
a
t
i
o
n
 
o
f
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
s
e
n
s
i
t
i
v
e
 
(
r
e
l
a
p
s
e
 
≥
 
9
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
)
 
a
n
d
 
r
e
f
r
a
c
t
o
r
y
 
(
n
o
 
r
e
s
p
o
n
s
e
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
 
o
r
 
r
e
l
a
p
s
e
 
w
i
t
h
i
n
 
9
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
t
h
e
r
a
p
y
)
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
S
C
L
C
.
 
S
e
n
s
i
t
i
v
e
 
r
e
l
a
p
s
e
,
 
n
 
=
 
3
6
/
5
9
 
(
6
1
%
)
;
 
r
e
f
r
a
c
t
o
r
y
 
r
e
l
a
p
s
e
,
 
n
 
=
 
2
3
/
5
9
 
(
3
9
%
)
.
 
T
h
e
r
e
f
o
r
e
,
 
a
 
p
r
o
p
o
r
t
i
o
n
 
w
e
r
e
 
n
o
t
 
r
e
s
p
o
n
d
e
r
s
,
 
b
u
t
 
t
h
i
s
 
n
u
m
b
e
r
 
i
s
 
u
n
k
n
o
w
n
.
 
A
l
s
o
,
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
d
o
s
e
 
i
s
 
l
o
w
e
r
 
t
h
a
n
 
t
h
a
t
 
u
s
e
d
 
i
n
 
t
h
e
 
U
K
 
(
a
p
p
r
o
v
e
d
 
d
o
s
e
 
i
n
 
J
a
p
a
n
 
i
s
 
1
.
0
 
m
g
/
m
2
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
1
.
5
 
m
g
/
m
2
 
i
n
 
U
K
)
.
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
:
 
A
p
p
r
o
p
r
i
a
t
e
.
 
H
o
w
e
v
e
r
,
 
m
e
d
i
a
n
 
i
n
s
t
e
a
d
 
o
f
 
m
e
a
n
 
r
e
p
o
r
t
e
d
 
a
n
d
 
n
o
 
S
D
 
p
r
o
v
i
d
e
d
.
I
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
:
 
N
o
t
 
r
e
p
o
r
t
e
d
.
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
R
e
p
o
r
t
 
n
o
 
c
o
n
fl
i
c
t
s
 
o
f
 
i
n
t
e
r
e
s
t
.
Q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
f
o
r
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
R
C
T
s
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
U
n
k
n
o
w
n
2
.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
U
n
k
n
o
w
n
3
.
 
W
e
r
e
 
t
h
e
 
g
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
R
e
p
o
r
t
e
d
4
.
 
W
e
r
e
 
t
h
e
 
e
l
i
g
i
b
i
l
i
t
y
 
c
r
i
t
e
r
i
a
 
s
p
e
c
i
fi
e
d
?
A
d
e
q
u
a
t
e
5
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
U
n
k
n
o
w
n
6
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
7
.
 
W
a
s
 
t
h
e
 
p
a
t
i
e
n
t
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
8
.
 
W
e
r
e
 
t
h
e
 
p
o
i
n
t
 
e
s
t
i
m
a
t
e
s
 
a
n
d
 
m
e
a
s
u
r
e
 
o
f
 
v
a
r
i
a
b
i
l
i
t
y
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
?
P
a
r
t
i
a
l
9
.
 
D
i
d
 
t
h
e
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
 
a
n
 
I
T
T
 
a
n
a
l
y
s
i
s
?
I
n
a
d
e
q
u
a
t
e
1
0
.
 
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
a
n
d
 
d
r
o
p
o
u
t
s
 
c
o
m
p
l
e
t
e
l
y
 
d
e
s
c
r
i
b
e
d
?
A
d
e
q
u
a
t
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
A
u
t
h
o
r
s
:
 
O
’
B
r
i
e
n
 
e
t
 
a
l
.
5
7
;
 
C
h
e
n
 
e
t
 
a
l
.
 
(
a
b
s
t
r
a
c
t
)
6
4
,
 
O
’
B
r
i
e
n
 
e
t
 
a
l
.
 
(
a
b
s
t
r
a
c
t
)
6
5
Y
e
a
r
s
:
 
2
0
0
6
 
a
n
d
 
2
0
0
7
 
(
a
b
s
t
r
a
c
t
s
)
C
o
u
n
t
r
i
e
s
:
 
E
u
r
o
p
e
,
 
C
a
n
a
d
a
,
 
R
u
s
s
i
a
S
t
u
d
y
 
d
e
s
i
g
n
:
 
R
C
T
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
4
0
F
u
n
d
i
n
g
:
 
s
p
o
n
s
o
r
e
d
 
b
y
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
 
(
m
a
n
u
f
a
c
t
u
r
e
r
)
G
r
o
u
p
 
A
:
 
O
r
a
l
 
t
o
p
o
t
e
c
a
n
 
h
y
d
r
o
c
h
l
o
r
i
d
e
 
+
 
B
S
C
D
o
s
e
:
 
2
.
3
 
m
g
/
m
2
/
d
a
y
D
u
r
a
t
i
o
n
:
 
D
a
y
s
 
1
–
5
 
e
v
e
r
y
 
2
1
 
d
a
y
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
b
o
n
e
 
m
a
r
r
o
w
 
r
e
c
o
v
e
r
y
.
 
A
t
 
l
e
a
s
t
 
f
o
u
r
 
t
r
e
a
t
m
e
n
t
 
c
y
c
l
e
s
 
w
e
r
e
 
r
e
c
o
m
m
e
n
d
e
d
,
 
d
e
p
e
n
d
i
n
g
 
o
n
 
t
o
l
e
r
a
b
i
l
i
t
y
 
a
n
d
 
r
e
s
p
o
n
s
e
.
 
D
e
l
a
y
s
 
a
n
d
 
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
s
 
w
e
r
e
 
p
r
e
s
c
r
i
b
e
d
 
i
n
 
t
h
e
 
p
r
o
t
o
c
o
l
 
i
f
 
a
 
n
u
m
b
e
r
 
o
f
 
p
a
r
a
m
e
t
e
r
s
 
w
e
r
e
 
n
o
t
 
m
e
t
 
(
n
o
t
 
r
e
p
r
o
d
u
c
e
d
 
h
e
r
e
)
.
 
P
a
r
t
i
c
i
p
a
n
t
 
w
i
t
h
d
r
a
w
n
 
i
f
 
d
e
l
a
y
s
 
o
f
 
m
o
r
e
 
t
h
a
n
 
2
 
w
e
e
k
s
 
a
t
 
m
i
n
i
m
u
m
 
d
o
s
e
 
o
f
 
1
.
5
 
m
g
/
m
2
/
d
a
y
G
r
o
u
p
 
B
:
 
B
S
C
 
a
l
o
n
e
O
t
h
e
r
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
u
s
e
d
:
 
a
l
l
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
e
q
u
a
l
 
a
c
c
e
s
s
 
t
o
 
s
u
p
p
o
r
t
i
v
e
 
c
a
r
e
 
m
e
a
s
u
r
e
s
 
(
a
n
a
l
g
e
s
i
c
s
,
 
a
n
t
i
b
i
o
t
i
c
s
,
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
,
 
a
p
p
e
t
i
t
e
 
s
t
i
m
u
l
a
n
t
s
,
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
,
 
R
B
C
 
t
r
a
n
s
f
u
s
i
o
n
s
,
 
d
e
e
p
-
r
e
l
a
x
a
t
i
o
n
 
t
h
e
r
a
p
y
,
 
p
a
l
l
i
a
t
i
v
e
 
r
a
d
i
o
t
h
e
r
a
p
y
 
o
r
 
s
u
r
g
i
c
a
l
 
p
r
o
c
e
d
u
r
e
s
)
.
 
A
l
l
 
t
h
e
r
a
p
i
e
s
 
w
i
t
h
 
p
o
t
e
n
t
i
a
l
 
s
y
s
t
e
m
i
c
 
a
n
t
i
t
u
m
o
u
r
 
e
f
f
e
c
t
 
w
e
r
e
 
e
x
c
l
u
d
e
d
N
u
m
b
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
 
1
4
1
:
 
t
o
p
o
t
e
c
a
n
 
7
1
,
 
B
S
C
 
7
0
S
a
m
p
l
e
 
a
t
t
r
i
t
i
o
n
/
d
r
o
p
o
u
t
:
 
T
o
p
o
t
e
c
a
n
 
2
1
 
(
3
0
%
)
,
 
B
S
C
 
3
3
 
(
4
7
%
)
.
 
R
e
a
s
o
n
s
 
f
o
r
 
w
i
t
h
d
r
a
w
a
l
 
w
e
r
e
:
 
a
d
v
e
r
s
e
 
e
v
e
n
t
 
[
t
o
p
o
t
e
c
a
n
 
1
3
 
(
1
8
%
(
;
 
B
S
C
 
9
 
(
1
3
%
)
]
;
 
p
r
o
t
o
c
o
l
 
v
i
o
l
a
t
i
o
n
 
[
t
o
p
o
t
e
c
a
n
 
0
,
 
B
S
C
 
7
 
(
1
0
%
)
]
;
 
l
o
s
t
 
t
o
 
f
o
l
l
o
w
-
u
p
 
[
t
o
p
o
t
e
c
a
n
 
2
 
(
3
%
)
;
 
B
S
C
 
4
 
(
6
%
)
]
;
 
o
t
h
e
r
 
[
t
o
p
o
t
e
c
a
n
 
5
 
(
7
%
,
 
p
a
t
i
e
n
t
 
c
h
o
i
c
e
 
4
,
 
l
a
c
k
 
o
f
 
c
o
m
p
l
i
a
n
c
e
 
1
]
;
 
B
S
C
 
1
3
 
(
1
9
%
,
 
p
a
t
i
e
n
t
 
c
h
o
i
c
e
 
6
,
 
d
e
a
t
h
 
2
,
 
p
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
 
2
,
 
p
a
t
i
e
n
t
 
m
o
v
e
d
 
1
,
 
p
a
t
i
e
n
t
 
r
e
c
e
i
v
e
d
 
t
e
r
m
i
n
a
l
 
c
a
r
e
 
a
t
 
h
o
m
e
 
1
,
 
p
a
t
i
e
n
t
 
s
t
a
r
t
e
d
 
s
e
c
o
n
d
-
l
i
n
e
 
t
h
e
r
a
p
y
 
1
)
;
 
o
n
g
o
i
n
g
 
[
t
o
p
o
t
e
c
a
n
 
1
 
(
1
%
)
;
 
B
S
C
 
0
]
S
a
m
p
l
e
 
c
r
o
s
s
o
v
e
r
s
:
 
N
o
n
e
.
 
H
o
w
e
v
e
r
,
 
1
3
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
e
a
c
h
 
a
r
m
 
(
1
8
.
3
%
 
B
S
C
,
 
1
8
.
6
%
 
t
o
p
o
t
e
c
a
n
)
 
r
e
c
e
i
v
e
d
 
p
o
s
t
s
t
u
d
y
 
c
h
e
m
o
t
h
e
r
a
p
y
 
e
i
t
h
e
r
 
a
l
o
n
e
 
o
r
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
o
t
h
e
r
 
t
h
e
r
a
p
y
,
 
s
u
c
h
 
a
s
 
r
a
d
i
o
t
h
e
r
a
p
y
 
a
n
d
 
s
u
r
g
e
r
y
.
 
I
n
 
a
d
d
i
t
i
o
n
,
 
p
o
s
t
s
t
u
d
y
 
r
a
d
i
o
t
h
e
r
a
p
y
 
a
l
o
n
e
 
w
a
s
 
r
e
c
e
i
v
e
d
 
b
y
 
7
 
(
1
0
%
)
 
t
o
p
o
t
e
c
a
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
a
n
d
 
1
 
(
1
%
)
 
B
S
C
 
p
a
r
t
i
c
i
p
a
n
t
I
n
c
l
u
s
i
o
n
/
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
O
n
l
y
 
t
h
o
s
e
 
c
o
n
s
i
d
e
r
e
d
 
u
n
s
u
i
t
a
b
l
e
 
f
o
r
 
f
u
r
t
h
e
r
 
i
.
v
.
 
c
h
e
m
o
t
h
e
r
a
p
y
 
w
e
r
e
 
r
e
c
r
u
i
t
e
d
.
 
U
n
s
u
i
t
a
b
i
l
i
t
y
 
w
a
s
 
b
a
s
e
d
 
o
n
 
l
o
c
a
l
 
p
o
l
i
c
y
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
r
e
s
i
s
t
a
n
t
 
(
s
h
o
r
t
 
T
F
I
)
 
S
C
L
C
 
a
n
d
 
a
s
s
e
s
s
e
d
 
o
n
 
a
n
 
i
n
d
i
v
i
d
u
a
l
 
b
a
s
i
s
 
b
y
 
t
h
e
 
o
n
c
o
l
o
g
i
s
t
I
n
i
t
i
a
l
l
y
 
e
x
c
l
u
d
e
d
 
w
e
r
e
 
t
h
o
s
e
 
w
i
t
h
 
a
 
T
F
I
 
o
f
 
>
 
9
0
 
d
a
y
s
 
f
o
r
 
w
h
o
m
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
B
S
C
 
w
a
s
 
n
o
t
 
a
c
c
e
p
t
a
b
l
e
;
 
h
o
w
e
v
e
r
,
 
d
u
r
i
n
g
 
t
h
e
 
t
r
i
a
l
,
 
s
o
m
e
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
i
t
h
 
s
e
n
s
i
t
i
v
e
 
S
C
L
C
 
w
h
o
 
w
e
r
e
 
u
n
s
u
i
t
a
b
l
e
 
f
o
r
 
s
t
a
n
d
a
r
d
 
c
h
e
m
o
t
h
e
r
a
p
y
 
d
u
e
 
t
o
 
c
o
m
o
r
b
i
d
i
t
i
e
s
 
o
r
 
w
h
o
 
h
a
d
 
r
e
f
u
s
e
d
 
c
h
e
m
o
t
h
e
r
a
p
y
 
d
u
e
 
t
o
 
t
h
e
 
r
i
s
k
 
o
f
 
t
o
x
i
c
i
t
y
 
w
e
r
e
 
e
l
i
g
i
b
l
e
E
l
i
g
i
b
i
l
i
t
y
 
c
r
i
t
e
r
i
a
 
a
l
s
o
 
i
n
c
l
u
d
e
d
 
e
x
t
e
n
s
i
v
e
 
o
r
 
l
i
m
i
t
e
d
 
S
C
L
C
,
 
o
n
e
 
p
r
i
o
r
 
c
h
e
m
o
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
,
 
a
g
e
 
≥
 
1
8
 
y
e
a
r
s
,
 
P
S
 
o
f
 
0
,
 
1
 
o
r
 
2
 
(
E
C
O
G
 
s
c
a
l
e
 
u
s
e
d
)
,
 
h
a
e
m
o
g
l
o
b
i
n
 
≥
 
9
.
0
g
/
d
l
,
 
w
h
i
t
e
 
b
l
o
o
d
 
c
e
l
l
 
c
o
u
n
t
 
≥
 
3
5
0
0
/
m
m
,
3
 
p
l
a
t
e
l
e
t
s
 
≥
 
1
0
0
,
0
0
0
/
m
m
,
3
 
n
e
u
t
r
o
p
h
i
l
s
 
≥
 
1
5
0
0
/
m
m
3
,
 
c
a
l
c
u
l
a
t
e
d
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
≥
 
6
0
 
m
l
/
m
i
n
,
 
s
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
≤
 
2
.
0
 
m
g
/
d
l
,
 
A
S
T
,
 
A
L
T
 
a
n
d
 
a
l
k
a
l
i
n
e
 
p
h
o
s
p
h
a
t
i
s
e
 
≤
 
5
 
×
 
U
L
N
 
w
i
t
h
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
 
o
r
 
≤
 
2
 
×
 
w
i
t
h
o
u
t
,
 
a
t
 
l
e
a
s
t
 
2
4
 
h
o
u
r
s
 
s
i
n
c
e
 
l
a
s
t
 
r
a
d
i
o
t
h
e
r
a
p
y
,
 
a
t
 
l
e
a
s
t
 
3
 
m
o
n
t
h
s
 
s
i
n
c
e
 
l
a
s
t
 
i
m
m
u
n
o
t
h
e
r
a
p
y
E
x
c
l
u
s
i
o
n
s
 
–
 
s
y
m
p
t
o
m
a
t
i
c
 
C
N
S
 
m
e
t
a
s
t
a
s
e
s
,
 
c
o
n
c
o
m
i
t
a
n
t
 
o
r
 
p
r
e
v
i
o
u
s
 
m
a
l
i
g
n
a
n
c
i
e
s
 
w
i
t
h
i
n
 
t
h
e
 
l
a
s
t
 
5
 
y
e
a
r
s
 
(
e
x
c
e
p
t
 
S
C
L
C
 
a
n
d
 
a
d
e
q
u
a
t
e
l
y
 
t
r
e
a
t
e
d
 
n
o
n
-
m
e
l
a
n
o
m
a
 
s
k
i
n
 
c
a
n
c
e
r
,
 
c
e
r
v
i
c
a
l
 
c
a
r
c
i
n
o
m
a
 
i
n
 
s
i
t
u
,
 
o
r
 
l
o
c
a
l
i
s
e
d
 
l
o
w
-
g
r
a
d
e
 
p
r
o
s
t
a
t
e
 
c
a
n
c
e
r
)
,
 
i
n
f
e
c
t
i
o
n
,
 
s
e
v
e
r
e
 
c
o
m
o
r
b
i
d
i
t
i
e
s
,
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
 
c
o
n
d
i
t
i
o
n
s
 
o
r
 
d
r
u
g
s
 
a
f
f
e
c
t
i
n
g
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
 
a
b
s
o
r
p
t
i
o
n
,
 
p
r
i
o
r
 
t
o
p
o
t
e
c
a
n
 
t
h
e
r
a
p
y
,
 
h
y
p
e
r
s
e
n
s
i
t
i
v
i
t
y
 
o
r
 
o
t
h
e
r
 
c
o
n
t
r
a
i
n
d
i
c
a
t
i
o
n
 
t
o
 
t
h
e
 
s
t
u
d
y
 
d
r
u
g
s
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
G
e
n
d
e
r
 
(
M
/
F
)
,
 
n
 
(
%
)
:
•
 
T
o
p
o
t
e
c
a
n
 
5
2
/
1
9
 
(
7
3
/
2
7
)
,
 
B
S
C
 
5
1
/
1
9
 
(
7
3
/
2
7
)
A
g
e
 
(
y
e
a
r
s
)
,
 
m
e
a
n
 
(
S
D
)
 
r
a
n
g
e
:
•
 
T
o
p
o
t
e
c
a
n
 
5
9
.
8
 
(
9
.
0
)
,
 
3
7
–
7
6
;
 
B
S
C
 
5
8
.
6
 
(
8
.
2
)
,
 
4
3
–
7
9
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
:
 
O
S
 
(
a
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
)
S
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
:
 
R
e
s
p
o
n
s
e
 
r
a
t
e
 
(
W
H
O
 
c
r
i
t
e
r
i
a
)
,
 
T
T
P
,
 
P
a
t
i
e
n
t
 
S
y
m
p
t
o
m
 
A
s
s
e
s
s
m
e
n
t
 
(
P
S
A
)
,
 
Q
O
L
,
 
s
a
f
e
t
y
M
e
t
h
o
d
s
 
o
f
 
a
s
s
e
s
s
i
n
g
 
o
u
t
c
o
m
e
s
:
S
t
a
t
e
s
 
i
n
d
e
p
e
n
d
e
n
t
 
r
e
v
i
e
w
 
o
f
 
r
e
s
p
o
n
s
e
s
 
w
a
s
 
n
o
t
 
c
o
n
d
u
c
t
e
d
P
S
A
:
 
E
v
a
l
u
a
t
e
d
 
t
h
e
 
d
e
g
r
e
e
 
t
o
 
w
h
i
c
h
 
p
a
r
t
i
c
i
p
a
n
t
s
 
e
x
p
e
r
i
e
n
c
e
d
 
n
i
n
e
 
c
o
m
m
o
n
 
a
n
d
 
c
l
i
n
i
c
a
l
l
y
 
r
e
l
e
v
a
n
t
 
s
y
m
p
t
o
m
s
 
u
s
i
n
g
 
a
 
L
i
k
e
r
t
 
s
c
a
l
e
 
f
o
r
 
s
e
v
e
r
i
t
y
 
[
f
r
o
m
 
1
 
(
n
o
t
 
a
t
 
a
l
l
)
 
t
o
 
4
 
(
v
e
r
y
 
m
u
c
h
)
]
Q
O
L
 
b
y
 
p
a
t
i
e
n
t
 
s
e
l
f
-
r
e
p
o
r
t
 
u
s
i
n
g
 
t
h
e
 
E
u
r
o
Q
o
l
-
5
D
 
i
n
d
e
x
 
a
n
d
 
E
Q
-
5
D
 
V
A
S
 
–
 
e
v
a
l
u
a
t
i
n
g
 
fi
v
e
 
h
e
a
l
t
h
 
s
t
a
t
u
s
 
d
i
m
e
n
s
i
o
n
s
:
 
m
o
b
i
l
i
t
y
,
 
s
e
l
f
-
c
a
r
e
,
 
u
s
u
a
l
 
a
c
t
i
v
i
t
i
e
s
,
 
p
a
i
n
/
d
i
s
c
o
m
f
o
r
t
,
 
a
n
d
 
a
n
x
i
e
t
y
/
d
e
p
r
e
s
s
i
o
n
.
 
R
a
t
i
n
g
 
o
f
 
1
 
(
n
o
 
p
r
o
b
l
e
m
)
 
t
o
 
3
 
(
e
x
t
r
e
m
e
 
p
r
o
b
l
e
m
)
.
 
E
Q
-
5
D
 
i
n
d
e
x
 
s
c
o
r
e
d
 
o
n
 
a
 
s
c
a
l
e
 
f
r
o
m
 
0
 
(
d
e
a
d
)
 
t
o
 
1
 
(
p
e
r
f
e
c
t
 
h
e
a
l
t
h
)
;
 
V
A
S
 
s
c
o
r
e
d
 
f
r
o
m
 
0
 
(
w
o
r
s
e
 
i
m
a
g
i
n
a
b
l
e
)
 
t
o
 
1
0
0
 
(
b
e
s
t
 
i
m
a
g
i
n
a
b
l
e
)
 
h
e
a
l
t
h
 
s
t
a
t
e
P
a
t
i
e
n
t
 
s
e
l
f
-
r
e
p
o
r
t
e
d
 
l
u
n
g
 
s
y
m
p
t
o
m
s
 
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
P
S
A
L
C
 
i
n
s
t
r
u
m
e
n
t
 
(
b
u
t
 
d
a
t
a
 
n
o
t
 
e
x
t
r
a
c
t
e
d
 
h
e
r
e
)
L
e
n
g
t
h
 
o
f
 
f
o
l
l
o
w
-
u
p
:
 
E
v
e
r
y
 
2
 
m
o
n
t
h
s
 
f
o
r
 
t
h
e
 
f
u
l
l
 
d
u
r
a
t
i
o
n
 
o
f
 
s
u
r
v
i
v
a
l
.
 
M
e
d
i
a
n
 
t
i
m
e
 
o
n
 
s
t
u
d
y
 
7
.
8
 
w
e
e
k
s
 
i
n
 
t
h
e
 
B
S
C
 
g
r
o
u
p
 
a
n
d
 
1
2
.
3
 
w
e
e
k
s
 
i
n
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
g
r
o
u
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
D
i
s
e
a
s
e
 
s
t
a
g
e
,
 
n
 
(
%
)
:
•
 
L
i
m
i
t
e
d
:
 
t
o
p
o
t
e
c
a
n
 
2
3
 
(
3
2
)
,
 
B
S
C
 
2
7
 
(
3
9
)
•
 
E
x
t
e
n
s
i
v
e
:
 
t
o
p
o
t
e
c
a
n
 
4
8
 
(
6
8
)
,
 
B
S
C
 
4
3
 
(
6
1
)
P
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
,
 
n
 
(
%
)
:
•
 
0
:
 
t
o
p
o
t
e
c
a
n
 
8
 
(
1
1
)
,
 
B
S
C
 
6
 
(
9
)
•
 
1
:
 
t
o
p
o
t
e
c
a
n
 
4
4
 
(
6
2
)
,
 
B
S
C
 
4
1
 
(
5
9
)
•
 
2
:
 
t
o
p
o
t
e
c
a
n
 
1
9
 
(
2
7
)
,
 
B
S
C
 
2
3
 
(
3
3
)
M
a
x
i
m
u
m
 
l
e
s
i
o
n
 
d
i
a
m
e
t
e
r
 
(
c
m
)
,
 
n
 
(
%
)
:
•
 
<
 
2
:
 
t
o
p
o
t
e
c
a
n
 
7
 
(
1
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1
.
8
4
1
.
1
5
 
t
o
 
4
.
0
6
0
.
6
3
 
t
o
 
2
.
8
7
1
.
2
5
 
t
o
 
4
.
1
9
0
.
9
5
 
t
o
 
3
.
0
3
p
 
<
 
0
.
0
5
N
S
N
S
N
S
N
S
p
<
0
.
0
5
N
S
p
<
0
.
0
5
N
S
C
o
m
m
e
n
t
s
:
 
B
a
s
e
l
i
n
e
 
q
u
e
s
t
i
o
n
n
a
i
r
e
s
 
w
e
r
e
 
c
o
m
p
l
e
t
e
d
 
b
y
 
7
0
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
g
r
o
u
p
 
a
n
d
 
6
7
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
B
S
C
 
g
r
o
u
p
.
 
T
h
e
 
n
u
m
b
e
r
s
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
i
t
h
 
s
u
f
fi
c
i
e
n
t
 
d
a
t
a
 
t
o
 
b
e
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
a
n
a
l
y
s
e
s
 
v
a
r
i
e
d
 
f
o
r
 
t
h
e
 
s
y
m
p
t
o
m
 
s
c
o
r
e
s
 
b
e
t
w
e
e
n
 
4
7
 
a
n
d
 
4
8
 
f
o
r
 
t
h
e
 
B
S
C
 
g
r
o
u
p
,
 
a
n
d
 
b
e
t
w
e
e
n
 
6
0
 
a
n
d
 
6
1
 
f
o
r
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
g
r
o
u
p
.
 
O
R
 
>
 
1
 
i
n
d
i
c
a
t
e
s
 
g
r
e
a
t
e
r
 
l
i
k
e
l
i
h
o
o
d
 
o
f
 
s
y
m
p
t
o
m
 
i
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
o
p
o
t
e
c
a
n
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A
d
v
e
r
s
e
 
e
f
f
e
c
t
s
T
o
p
o
t
e
c
a
n
 
(
n
 
=
 
7
1
)
B
S
C
 
(
n
 
=
 
7
0
)
p
-
v
a
l
u
e
,
 
9
5
%
 
C
I
T
o
x
i
c
i
t
y
:
 
g
r
a
d
e
 
3
/
4
 
n
e
u
t
r
o
p
e
n
i
a
6
1
%
T
o
x
i
c
i
t
y
:
 
g
r
a
d
e
 
3
/
4
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
3
8
%
T
o
x
i
c
i
t
y
:
 
g
r
a
d
e
 
3
/
4
 
a
n
a
e
m
i
a
2
5
%
F
e
b
r
i
l
e
 
n
e
u
t
r
o
p
e
n
i
a
3
%
N
o
n
-
s
e
p
s
i
s
 
i
n
f
e
c
t
i
o
n
 
≥
 
g
r
a
d
e
 
2
1
0
 
(
1
4
%
)
8
 
(
1
2
%
)
S
e
p
s
i
s
3
 
(
4
%
)
1
 
(
1
%
)
D
i
a
r
r
h
o
e
a
6
%
0
F
a
t
i
g
u
e
4
%
4
%
V
o
m
i
t
i
n
g
3
%
0
D
y
s
p
n
o
e
a
3
%
9
%
C
o
u
g
h
0
2
%
T
o
x
i
c
 
d
e
a
t
h
s
4
 
(
6
%
)
,
 
3
 
d
u
e
 
t
o
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
A
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
 
w
i
t
h
i
n
 
3
0
 
d
a
y
s
 
o
f
 
r
a
n
d
o
m
i
s
a
t
i
o
n
5
 
(
7
%
)
9
 
(
1
3
%
)
C
o
m
m
e
n
t
:
 
T
w
o
 
p
a
r
t
i
c
i
p
a
n
t
s
 
(
3
%
)
 
i
n
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
a
r
m
 
r
e
c
e
i
v
e
d
 
G
S
C
F
 
o
r
 
g
r
a
n
u
l
o
c
y
t
e
–
m
a
c
r
o
p
h
a
g
e
 
c
o
l
o
n
y
-
s
t
i
m
u
l
a
t
i
n
g
 
f
a
c
t
o
r
 
a
n
d
 
t
w
o
 
(
3
%
)
 
r
e
c
e
i
v
e
d
 
e
r
y
t
h
r
o
p
o
i
e
t
i
n
.
N
o
t
e
:
 
I
f
 
r
e
v
i
e
w
e
r
 
c
a
l
c
u
l
a
t
e
s
 
a
 
s
u
m
m
a
r
y
 
m
e
a
s
u
r
e
 
o
r
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
 
P
L
E
A
S
E
 
I
N
D
I
C
A
T
E
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
a
r
t
i
c
i
p
a
n
t
s
 
r
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
1
 
:
 
1
 
u
s
i
n
g
 
a
 
c
e
n
t
r
a
l
i
s
e
d
 
a
u
t
o
m
a
t
e
d
 
r
e
g
i
s
t
r
a
t
i
o
n
 
a
n
d
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
s
y
s
t
e
m
,
 
s
t
r
a
t
i
fi
e
d
 
b
y
 
g
e
n
d
e
r
,
 
p
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
,
 
T
F
I
 
a
n
d
 
p
r
e
s
e
n
c
e
 
o
f
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
.
B
l
i
n
d
i
n
g
:
 
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
n
o
t
 
r
e
p
o
r
t
e
d
.
 
B
l
i
n
d
i
n
g
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
o
r
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
u
n
l
i
k
e
l
y
 
t
o
 
b
e
 
a
p
p
r
o
p
r
i
a
t
e
 
w
i
t
h
 
t
h
e
s
e
 
i
n
t
e
r
v
e
n
t
i
o
n
s
.
 
H
o
w
e
v
e
r
,
 
n
o
 
d
i
s
c
u
s
s
i
o
n
 
o
f
 
w
h
y
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
d
o
u
b
l
e
-
b
l
i
n
d
 
s
t
u
d
y
 
n
o
t
 
p
e
r
f
o
r
m
e
d
.
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
a
p
e
r
 
s
t
a
t
e
s
 
p
a
r
t
i
c
i
p
a
n
t
 
d
e
m
o
g
r
a
p
h
i
c
s
 
w
e
r
e
 
w
e
l
l
 
m
a
t
c
h
e
d
 
b
e
t
w
e
e
n
 
a
r
m
s
,
 
p
a
r
t
i
c
u
l
a
r
l
y
 
w
i
t
h
 
r
e
s
p
e
c
t
 
t
o
 
t
h
e
 
m
a
j
o
r
 
p
r
o
g
n
o
s
t
i
c
 
v
a
r
i
a
b
l
e
s
 
o
f
 
P
S
 
a
n
d
 
s
e
x
.
 
H
o
w
e
v
e
r
,
 
p
-
v
a
l
u
e
s
 
n
o
t
 
r
e
p
o
r
t
e
d
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M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
S
t
a
t
e
s
 
e
f
fi
c
a
c
y
 
a
s
s
e
s
s
m
e
n
t
s
 
b
a
s
e
d
 
o
n
 
a
l
l
 
r
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
p
a
r
t
i
c
i
p
a
n
t
s
 
u
s
i
n
g
 
a
n
 
I
T
T
 
p
o
p
u
l
a
t
i
o
n
.
 
S
a
f
e
t
y
 
a
n
d
 
Q
O
L
 
w
e
r
e
 
b
a
s
e
d
 
o
n
 
a
l
l
 
w
h
o
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
p
o
s
t
r
a
n
d
o
m
 
a
s
s
i
g
n
m
e
n
t
 
e
v
a
l
u
a
t
i
o
n
 
o
n
 
t
h
e
 
B
S
C
 
a
r
m
 
o
r
 
o
n
e
 
d
o
s
e
 
o
f
 
t
o
p
o
t
e
c
a
n
 
(
7
0
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
o
p
o
t
e
c
a
n
 
a
r
m
,
 
6
7
 
i
n
 
B
S
C
 
a
r
m
 
e
v
a
l
u
a
t
e
d
)
.
 
O
S
 
w
a
s
 
a
n
a
l
y
s
e
d
 
u
s
i
n
g
 
t
h
e
 
K
a
p
l
a
n
–
M
e
i
e
r
 
m
e
t
h
o
d
 
a
n
d
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
l
o
g
-
r
a
n
k
 
t
e
s
t
.
 
A
n
a
l
y
s
i
s
 
o
f
 
s
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
 
w
e
r
e
 
d
e
s
c
r
i
p
t
i
v
e
 
w
i
t
h
 
n
o
 
a
d
j
u
s
t
m
e
n
t
s
 
m
a
d
e
 
f
o
r
 
m
u
l
t
i
p
l
i
c
i
t
y
.
 
R
e
s
p
o
n
s
e
 
r
a
t
e
s
 
w
e
r
e
 
s
u
m
m
a
r
i
s
e
d
 
a
l
o
n
g
 
w
i
t
h
 
a
 
9
5
%
 
C
I
 
a
n
d
 
T
T
P
 
w
a
s
 
s
u
m
m
a
r
i
s
e
d
 
b
y
 
K
a
p
l
a
n
–
M
e
i
e
r
.
 
A
l
l
 
p
-
v
a
l
u
e
s
 
w
e
r
e
 
t
w
o
-
s
i
d
e
d
.
 
F
o
r
 
P
S
A
 
a
 
g
e
n
e
r
a
l
i
s
e
d
 
e
s
t
i
m
a
t
i
n
g
 
e
q
u
a
t
i
o
n
s
 
m
o
d
e
l
 
w
a
s
 
fi
t
t
e
d
 
t
o
 
l
o
n
g
i
t
u
d
i
n
a
l
 
s
y
m
p
t
o
m
 
d
a
t
a
 
t
o
 
e
s
t
i
m
a
t
e
 
t
r
e
a
t
m
e
n
t
 
e
f
f
e
c
t
 
o
n
 
e
a
c
h
 
s
y
m
p
t
o
m
 
(
r
e
s
p
o
n
s
e
 
w
a
s
 
c
a
t
e
g
o
r
i
s
e
d
 
a
s
 
f
a
v
o
u
r
a
b
l
e
 
o
r
 
u
n
f
a
v
o
u
r
a
b
l
e
)
.
 
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
E
Q
-
5
D
 
i
n
d
e
x
 
a
n
d
 
E
Q
-
5
D
 
V
A
S
 
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
a
 
p
o
o
l
e
d
 
a
n
a
l
y
s
i
s
 
(
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
t
o
 
a
v
e
r
a
g
e
d
 
o
n
-
t
r
e
a
t
m
e
n
t
 
a
s
s
e
s
s
m
e
n
t
s
)
 
a
n
d
 
a
l
s
o
 
c
o
n
s
i
d
e
r
i
n
g
 
o
n
l
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
t
o
 
l
a
s
t
 
e
v
a
l
u
a
t
i
o
n
.
 
T
h
e
 
r
a
t
e
 
o
f
 
c
h
a
n
g
e
 
i
n
 
E
Q
-
5
D
 
i
n
d
e
x
 
s
c
o
r
e
 
(
r
a
t
e
 
a
t
 
w
h
i
c
h
 
s
y
m
p
t
o
m
s
 
i
m
p
r
o
v
e
d
 
o
r
 
d
e
t
e
r
i
o
r
a
t
e
d
)
 
a
c
r
o
s
s
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
w
a
s
 
e
v
a
l
u
a
t
e
d
 
w
i
t
h
 
a
 
l
o
n
g
i
t
u
d
i
n
a
l
 
a
n
a
l
y
s
i
s
 
u
s
i
n
g
 
a
 
m
i
x
e
d
 
m
o
d
e
l
 
(
t
o
 
a
c
c
o
u
n
t
 
f
o
r
 
r
e
p
e
a
t
e
d
 
m
e
a
s
u
r
e
m
e
n
t
s
 
o
v
e
r
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
c
o
u
r
s
e
)
 
w
i
t
h
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
s
c
o
r
e
 
a
s
 
r
e
s
p
o
n
s
e
.
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
D
e
s
i
g
n
e
d
 
t
o
 
d
e
t
e
c
t
 
a
 
6
6
.
7
%
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
m
e
d
i
a
n
 
s
u
r
v
i
v
a
l
.
 
T
h
e
 
e
x
p
e
c
t
e
d
 
s
u
r
v
i
v
a
l
 
i
n
 
t
h
e
 
B
S
C
 
a
r
m
 
w
a
s
 
1
2
 
w
e
e
k
s
,
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
m
e
d
i
a
n
 
s
u
r
v
i
v
a
l
 
i
n
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
a
r
m
 
w
a
s
 
2
0
 
w
e
e
k
s
.
 
I
n
i
t
i
a
l
 
s
a
m
p
l
e
 
s
i
z
e
 
c
a
l
c
u
l
a
t
i
o
n
s
 
d
e
t
e
r
m
i
n
e
d
 
t
h
a
t
 
2
2
0
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
e
r
e
 
r
e
q
u
i
r
e
d
 
t
o
 
a
s
s
e
s
s
 
a
 
s
u
r
v
i
v
a
l
 
b
e
n
e
fi
t
 
w
i
t
h
 
t
o
p
o
t
e
c
a
n
 
w
i
t
h
 
9
0
%
 
p
o
w
e
r
 
a
n
d
 
a
 
s
i
g
n
i
fi
c
a
n
c
e
 
l
e
v
e
l
 
o
f
 
0
.
0
5
.
 
H
o
w
e
v
e
r
,
 
r
e
c
r
u
i
t
m
e
n
t
 
w
a
s
 
s
l
o
w
e
r
 
t
h
a
n
 
a
n
t
i
c
i
p
a
t
e
d
,
 
a
n
d
 
a
 
f
o
r
m
a
l
 
p
r
o
t
o
c
o
l
 
a
m
e
n
d
m
e
n
t
 
w
a
s
 
i
m
p
l
e
m
e
n
t
e
d
 
t
o
 
t
e
r
m
i
n
a
t
e
 
t
h
e
 
s
t
u
d
y
 
o
n
c
e
 
1
2
5
 
d
e
a
t
h
s
 
h
a
d
 
b
e
e
n
 
r
e
p
o
r
t
e
d
.
 
T
h
i
s
 
p
r
o
v
i
d
e
d
 
a
n
 
8
0
%
 
p
o
w
e
r
 
t
o
 
a
s
s
e
s
s
 
a
 
s
u
r
v
i
v
a
l
 
b
e
n
e
fi
t
 
f
o
r
 
t
o
p
o
t
e
c
a
n
 
a
t
 
a
 
0
.
0
5
 
s
i
g
n
i
fi
c
a
n
c
e
 
l
e
v
e
l
.
 
T
h
i
s
 
p
o
i
n
t
 
w
a
s
 
r
e
a
c
h
e
d
 
w
h
e
n
 
1
4
1
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
b
e
e
n
 
r
e
c
r
u
i
t
e
d
.
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
N
u
m
b
e
r
s
 
a
n
d
 
r
e
a
s
o
n
s
 
p
r
o
v
i
d
e
d
 
(
a
b
o
v
e
)
.
O
t
h
e
r
 
c
o
m
m
e
n
t
s
:
 
O
v
e
r
a
l
l
,
 
6
9
 
(
9
9
%
)
 
t
o
p
o
t
e
c
a
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
t
o
o
k
 
≥
 
9
0
%
 
o
f
 
t
h
e
i
r
 
p
r
e
s
c
r
i
b
e
d
 
c
a
p
s
u
l
e
s
.
 
A
 
m
e
d
i
a
n
 
o
f
 
f
o
u
r
 
c
o
u
r
s
e
s
 
(
r
a
n
g
e
 
1
–
1
0
)
 
o
f
 
t
o
p
o
t
e
c
a
n
 
w
e
r
e
 
a
d
m
i
n
i
s
t
e
r
e
d
.
 
D
o
s
e
 
r
e
d
u
c
t
i
o
n
s
 
o
c
c
u
r
r
e
d
 
i
n
 
1
6
 
c
o
u
r
s
e
s
 
(
8
%
)
 
p
r
i
m
a
r
i
l
y
 
f
o
r
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
(
1
3
 
c
o
u
r
s
e
s
,
 
6
%
)
.
 
D
o
s
e
 
d
e
l
a
y
s
 
o
c
c
u
r
r
e
d
 
i
n
 
4
1
 
c
o
u
r
s
e
s
 
(
2
0
%
)
,
 
m
o
s
t
 
c
o
m
m
o
n
l
y
 
f
o
r
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
(
2
5
 
c
o
u
r
s
e
s
,
 
1
2
%
)
.
 
D
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
o
c
c
u
r
r
e
d
 
i
n
 
3
9
 
c
o
u
r
s
e
s
 
(
1
4
%
)
.
 
T
h
e
 
m
e
d
i
a
n
 
t
o
p
o
t
e
c
a
n
 
d
o
s
e
 
i
n
t
e
n
s
i
t
y
 
a
c
h
i
e
v
e
d
 
w
a
s
 
3
.
7
7
 
m
g
/
m
2
/
w
e
e
k
,
 
r
e
p
r
e
s
e
n
t
i
n
g
 
9
8
%
 
o
f
 
t
h
e
 
s
c
h
e
d
u
l
e
d
 
d
o
s
e
.
 
B
S
C
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
e
r
e
 
o
b
s
e
r
v
e
d
 
f
o
r
 
t
h
e
 
e
q
u
i
v
a
l
e
n
t
 
o
f
 
a
 
m
e
d
i
a
n
 
o
f
 
t
h
r
e
e
 
c
o
u
r
s
e
s
 
(
r
a
n
g
e
 
1
–
1
3
)
.
 
P
a
l
l
i
a
t
i
v
e
 
m
e
d
i
c
a
t
i
o
n
s
 
a
n
d
 
r
a
d
i
o
t
h
e
r
a
p
y
 
w
e
r
e
 
u
s
e
d
 
m
o
r
e
 
f
r
e
q
u
e
n
t
l
y
 
i
n
 
t
h
e
 
B
S
C
 
g
r
o
u
p
,
 
w
h
i
l
e
 
t
r
a
n
s
f
u
s
i
o
n
s
 
w
e
r
e
 
u
s
e
d
 
m
o
r
e
 
f
r
e
q
u
e
n
t
l
y
 
i
n
 
t
h
e
 
t
o
p
o
t
e
c
a
n
 
g
r
o
u
p
 
(
d
a
t
a
 
n
o
t
 
e
x
t
r
a
c
t
e
d
 
a
s
 
n
o
t
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
a
n
a
l
y
s
e
d
)
.
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
O
n
l
y
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
r
e
s
i
s
t
a
n
t
 
d
i
s
e
a
s
e
 
(
r
e
l
a
p
s
e
 
w
i
t
h
i
n
 
9
0
 
d
a
y
s
)
 
i
n
c
l
u
d
e
d
 
i
n
i
t
i
a
l
l
y
,
 
b
u
t
 
t
h
i
s
 
w
a
s
 
w
i
d
e
n
e
d
 
t
o
 
i
n
c
l
u
d
e
 
t
h
o
s
e
 
w
i
t
h
 
s
e
n
s
i
t
i
v
e
 
d
i
s
e
a
s
e
 
(
g
r
e
a
t
e
r
 
t
h
a
n
 
9
0
 
d
a
y
s
’
 
r
e
s
p
o
n
s
e
)
.
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
:
 
U
n
c
l
e
a
r
 
h
o
w
 
v
a
l
i
d
 
a
n
d
 
r
e
l
i
a
b
l
e
I
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
:
 
N
o
t
 
r
e
p
o
r
t
e
d
 
w
h
e
t
h
e
r
 
p
o
t
e
n
t
i
a
l
 
i
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
 
w
a
s
 
a
n
 
i
s
s
u
e
 
o
r
 
h
o
w
 
t
h
i
s
 
w
a
s
 
h
a
n
d
l
e
d
.
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
S
u
p
p
o
r
t
e
d
 
b
y
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
 
U
K
,
 
t
r
i
a
l
 
d
e
s
i
g
n
e
d
 
b
y
 
G
S
K
,
 
d
a
t
a
 
a
n
a
l
y
s
e
d
 
b
y
 
G
S
K
.
 
M
a
n
y
 
t
r
i
a
l
 
a
u
t
h
o
r
s
 
h
a
d
 
p
o
t
e
n
t
i
a
l
 
c
o
n
fl
i
c
t
s
 
o
f
 
i
n
t
e
r
e
s
t
 
n
o
t
e
d
 
i
n
 
t
h
e
 
r
e
p
o
r
t
.
Q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
f
o
r
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
R
C
T
s
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
A
d
e
q
u
a
t
e
2
.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
A
d
e
q
u
a
t
e
3
.
 
W
e
r
e
 
t
h
e
 
g
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
R
e
p
o
r
t
e
d
4
.
 
W
e
r
e
 
t
h
e
 
e
l
i
g
i
b
i
l
i
t
y
 
c
r
i
t
e
r
i
a
 
s
p
e
c
i
fi
e
d
?
A
d
e
q
u
a
t
e
5
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
I
n
a
d
e
q
u
a
t
e
6
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
7
.
 
W
a
s
 
t
h
e
 
p
a
t
i
e
n
t
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
8
.
 
W
e
r
e
 
t
h
e
 
p
o
i
n
t
 
e
s
t
i
m
a
t
e
s
 
a
n
d
 
m
e
a
s
u
r
e
 
o
f
 
v
a
r
i
a
b
i
l
i
t
y
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
?
A
d
e
q
u
a
t
e
9
.
 
D
i
d
 
t
h
e
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
 
a
n
 
I
T
T
 
a
n
a
l
y
s
i
s
?
A
d
e
q
u
a
t
e
1
0
.
 
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
a
n
d
 
d
r
o
p
o
u
t
s
 
c
o
m
p
l
e
t
e
l
y
 
d
e
s
c
r
i
b
e
d
?
A
d
e
q
u
a
t
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
A
u
t
h
o
r
:
 
v
o
n
 
P
a
w
e
l
 
e
t
 
a
l
.
5
8
Y
e
a
r
:
 
2
0
0
1
C
o
u
n
t
r
i
e
s
:
 
E
u
r
o
p
e
,
 
S
o
u
t
h
 
A
f
r
i
c
a
,
 
A
u
s
t
r
a
l
i
a
S
t
u
d
y
 
d
e
s
i
g
n
:
 
R
C
T
 
(
p
h
a
s
e
 
I
I
)
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
3
1
F
u
n
d
i
n
g
:
 
S
m
i
t
h
K
l
i
n
e
 
B
e
e
c
h
a
m
G
r
o
u
p
 
A
:
 
o
r
a
l
 
t
o
p
o
t
e
c
a
n
D
o
s
e
:
 
2
.
3
 
m
g
/
m
2
/
d
a
y
 
f
o
r
 
5
 
d
a
y
s
 
e
v
e
r
y
 
2
1
 
d
a
y
s
D
u
r
a
t
i
o
n
:
 
d
e
p
e
n
d
e
d
 
o
n
 
r
e
s
p
o
n
s
e
 
b
u
t
 
t
h
o
s
e
 
w
i
t
h
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
 
r
e
c
o
m
m
e
n
d
e
d
 
t
o
 
h
a
v
e
 
a
t
 
l
e
a
s
t
 
f
o
u
r
 
c
y
c
l
e
s
G
r
o
u
p
 
B
:
 
i
n
t
r
a
v
e
n
o
u
s
 
t
o
p
o
t
e
c
a
n
D
o
s
e
:
 
1
.
5
 
m
g
/
m
2
/
d
a
y
,
 
3
0
-
m
i
n
u
t
e
 
i
n
f
u
s
i
o
n
 
f
o
r
 
5
 
d
a
y
s
 
e
v
e
r
y
 
2
1
 
d
a
y
s
D
u
r
a
t
i
o
n
:
 
d
e
p
e
n
d
e
d
 
o
n
 
r
e
s
p
o
n
s
e
 
b
u
t
 
t
h
o
s
e
 
w
i
t
h
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
 
r
e
c
o
m
m
e
n
d
e
d
 
t
o
 
h
a
v
e
 
a
t
 
l
e
a
s
t
 
f
o
u
r
 
c
y
c
l
e
s
O
t
h
e
r
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
u
s
e
d
:
 
D
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
p
e
r
m
i
t
t
e
d
 
i
f
 
n
o
 
t
o
x
i
c
i
t
y
 
g
r
e
a
t
e
r
 
t
h
a
n
 
g
r
a
d
e
 
2
,
 
a
s
s
e
s
s
e
d
 
b
y
 
N
a
t
i
o
n
a
l
 
C
a
n
c
e
r
 
I
n
s
t
i
t
u
t
e
 
o
f
 
C
a
n
a
d
a
 
C
o
m
m
o
n
 
T
o
x
i
c
i
t
y
 
C
r
i
t
e
r
i
a
,
 
w
a
s
 
s
e
e
n
 
i
n
 
t
h
e
 
p
r
e
c
e
d
i
n
g
 
c
o
u
r
s
e
.
 
F
o
r
 
t
h
o
s
e
 
i
n
 
t
h
e
 
o
r
a
l
 
g
r
o
u
p
,
 
d
a
i
l
y
 
d
o
s
e
 
i
n
c
r
e
a
s
e
d
 
b
y
 
0
.
4
 
m
g
/
m
2
/
d
a
y
 
(
u
p
 
t
o
 
a
 
m
a
x
i
m
u
m
 
d
o
s
e
 
o
f
 
3
.
1
 
m
g
/
m
2
/
d
a
y
)
.
 
F
o
r
 
t
h
o
s
e
 
i
n
 
t
h
e
 
i
.
v
.
 
g
r
o
u
p
,
 
d
a
i
l
y
 
d
o
s
e
 
i
n
c
r
e
a
s
e
d
 
b
y
 
0
.
2
5
 
m
g
/
m
2
/
d
a
y
 
(
u
p
 
t
o
 
a
 
m
a
x
i
m
u
m
 
d
o
s
e
 
o
f
 
2
.
0
 
m
g
/
m
2
/
d
a
y
)
.
 
F
o
r
 
o
r
a
l
 
t
o
p
o
t
e
c
a
n
,
 
d
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
w
a
s
 
m
a
d
e
 
i
n
 
1
7
.
2
%
 
o
f
 
c
o
u
r
s
e
s
,
 
f
o
r
 
i
.
v
.
 
t
o
p
o
t
e
c
a
n
 
d
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
o
c
c
u
r
r
e
d
 
i
n
 
6
.
3
%
 
o
f
 
c
o
u
r
s
e
s
G
C
S
F
 
f
o
r
 
t
h
e
r
a
p
e
u
t
i
c
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
t
 
m
a
n
d
a
t
o
r
y
 
f
o
r
 
p
r
o
p
h
y
l
a
x
i
s
 
a
g
a
i
n
s
t
 
n
e
u
t
r
o
p
e
n
i
a
 
f
o
r
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
.
 
S
e
v
e
r
e
 
o
r
 
p
r
o
l
o
n
g
e
d
 
n
e
u
t
r
o
p
e
n
i
a
 
m
a
n
a
g
e
d
 
t
h
r
o
u
g
h
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
d
u
r
i
n
g
 
n
e
x
t
 
c
o
u
r
s
e
.
 
R
e
d
u
c
t
i
o
n
 
i
n
 
o
r
a
l
 
g
r
o
u
p
 
b
y
 
0
.
4
 
m
g
/
m
2
/
d
a
y
,
 
i
n
 
i
.
v
.
 
g
r
o
u
p
 
b
y
 
0
.
2
5
 
m
g
/
m
2
/
d
a
y
.
 
I
f
 
g
r
a
d
e
 
3
/
4
 
t
o
x
i
c
i
t
y
 
(
e
x
c
l
u
d
i
n
g
 
n
a
u
s
e
a
 
o
r
 
v
o
m
i
t
i
n
g
)
 
d
o
s
e
 
r
e
d
u
c
e
d
 
a
s
 
a
b
o
v
e
,
 
i
f
 
d
i
s
e
a
s
e
 
d
i
d
 
n
o
t
 
r
e
s
p
o
n
d
 
t
h
e
n
 
p
a
t
i
e
n
t
 
w
i
t
h
d
r
a
w
n
F
o
r
 
o
r
a
l
 
t
o
p
o
t
e
c
a
n
,
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
w
a
s
 
m
a
d
e
 
i
n
 
6
.
7
%
 
o
f
 
c
o
u
r
s
e
s
,
 
f
o
r
 
i
.
v
.
 
t
o
p
o
t
e
c
a
n
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
c
c
u
r
r
e
d
 
i
n
 
1
6
.
4
%
 
o
f
 
c
o
u
r
s
e
s
.
 
H
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
l
e
a
d
 
t
o
 
d
o
s
e
 
d
e
l
a
y
s
 
o
f
 
≥
 
7
 
d
a
y
s
 
i
n
 
o
n
l
y
 
2
.
5
%
 
o
f
 
c
o
u
r
s
e
s
 
w
i
t
h
 
e
i
t
h
e
r
 
r
e
g
i
m
e
n
T
r
e
a
t
m
e
n
t
 
a
l
s
o
 
d
e
l
a
y
e
d
 
i
f
 
b
o
n
e
 
m
a
r
r
o
w
 
h
a
d
 
n
o
t
 
r
e
c
o
v
e
r
e
d
 
a
n
d
 
w
a
s
 
a
 
c
l
i
n
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
n
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
t
o
 
s
t
u
d
y
 
d
r
u
g
N
u
m
b
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
 
1
0
6
 
(
o
r
a
l
 
5
2
,
 
i
.
v
.
 
5
4
)
S
a
m
p
l
e
 
a
t
t
r
i
t
i
o
n
/
d
r
o
p
o
u
t
:
 
n
o
t
 
r
e
p
o
r
t
e
d
S
a
m
p
l
e
 
c
r
o
s
s
o
v
e
r
s
:
 
n
o
n
e
I
n
c
l
u
s
i
o
n
/
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
P
a
t
i
e
n
t
s
 
o
f
 
e
i
t
h
e
r
 
s
e
x
,
 
a
g
e
d
 
≥
 
1
8
 
y
e
a
r
s
,
 
w
i
t
h
 
l
i
m
i
t
e
d
 
o
r
 
e
x
t
e
n
s
i
v
e
 
S
C
L
C
 
t
h
a
t
 
h
a
d
 
r
e
c
u
r
r
e
d
 
≥
 
3
 
m
o
n
t
h
s
 
a
f
t
e
r
 
t
h
e
 
e
n
d
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
,
 
p
r
o
v
i
d
e
d
 
o
n
l
y
 
o
n
e
 
p
r
i
o
r
 
c
h
e
m
o
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
.
 
A
l
l
 
h
a
d
 
P
R
 
o
r
 
C
R
.
 
M
e
a
s
u
r
a
b
l
e
 
d
i
s
e
a
s
e
 
o
f
 
a
t
 
l
e
a
s
t
 
2
 
c
m
 
i
n
 
d
i
a
m
e
t
e
r
,
 
W
H
O
 
p
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
 
o
f
 
n
o
 
m
o
r
e
 
t
h
a
n
 
2
,
 
l
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 
o
f
 
a
t
 
l
e
a
s
t
 
2
 
m
o
n
t
h
s
,
 
a
d
e
q
u
a
t
e
 
b
o
n
e
 
m
a
r
r
o
w
 
f
u
n
c
t
i
o
n
 
(
W
B
C
 
c
o
u
n
t
 
≥
 
3
.
5
 
×
 
1
0
9
/
l
,
 
n
e
u
t
r
o
p
h
i
l
s
 
≥
 
1
.
5
 
×
 
1
0
9
/
l
,
 
p
l
a
t
e
l
e
t
s
 
≥
 
1
0
0
 
×
 
1
0
9
/
l
,
 
h
a
e
m
o
g
l
o
b
i
n
 
≥
 
9
 
g
/
d
l
)
 
a
n
d
 
a
d
e
q
u
a
t
e
 
r
e
n
a
l
 
a
n
d
 
h
e
p
a
t
i
c
 
f
u
n
c
t
i
o
n
 
(
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
 
≤
 
1
.
5
 
m
g
/
d
l
;
 
b
i
l
i
r
u
b
i
n
 
≤
 
2
.
0
 
m
g
/
d
l
;
 
a
l
k
a
l
i
n
e
 
p
h
o
s
p
h
a
t
a
s
e
,
 
A
S
T
 
a
n
d
 
A
L
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h
e
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L
N
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h
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L
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l
i
v
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r
 
m
e
t
a
s
t
a
s
e
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w
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r
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p
r
e
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c
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p
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c
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.
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p
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b
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p
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i
c
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n
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b
e
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i
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t
 
t
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t
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s
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t
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c
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v
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g
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r
t
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d
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r
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c
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n
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y
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p
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x
c
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u
d
e
d
:
 
t
h
o
s
e
 
w
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t
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p
r
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v
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o
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s
 
o
r
 
c
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r
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t
 
m
a
l
i
g
n
a
n
c
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t
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x
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e
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t
e
l
y
 
t
r
e
a
t
e
d
 
c
a
r
c
i
n
o
m
a
 
o
f
 
t
h
e
 
c
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c
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r
c
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c
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a
r
a
c
t
e
r
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t
i
c
s
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
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e
n
d
e
r
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M
/
F
)
,
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(
%
)
:
•
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r
a
l
 
3
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(
7
5
/
2
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)
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i
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v
.
 
4
3
/
1
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(
7
9
.
6
/
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A
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s
)
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n
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)
:
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r
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.
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.
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3
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:
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.
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.
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r
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y
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t
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m
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:
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e
s
p
o
n
s
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,
 
r
e
s
p
o
n
s
e
 
d
u
r
a
t
i
o
n
,
 
T
T
P
S
e
c
o
n
d
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r
y
 
o
u
t
c
o
m
e
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:
 
t
i
m
e
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o
 
r
e
s
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n
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,
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r
v
i
v
a
l
,
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y
m
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t
o
m
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,
 
t
o
x
i
c
i
t
y
M
e
t
h
o
d
s
 
o
f
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s
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e
s
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i
n
g
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t
c
o
m
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R
e
s
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n
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v
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l
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a
t
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g
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c
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r
a
b
l
e
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t
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n
g
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w
e
e
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s
 
w
i
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h
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o
 
a
p
p
e
a
r
a
n
c
e
 
o
f
 
n
e
w
 
l
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s
i
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c
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l
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h
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c
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w
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e
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m
 
fi
r
s
t
 
d
o
s
e
 
o
f
 
t
o
p
o
t
e
c
a
n
 
t
o
 
fi
r
s
t
 
d
o
c
u
m
e
n
t
e
d
 
r
e
s
p
o
n
s
e
.
 
D
u
r
a
t
i
o
n
 
o
f
 
r
e
s
p
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e
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p
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.
 
T
T
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r
v
i
v
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l
 
w
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u
r
e
d
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o
m
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t
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n
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n
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f
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e
c
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o
 
p
r
o
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r
e
s
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n
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r
 
d
e
a
t
h
,
 
r
e
s
p
e
c
t
i
v
e
l
y
S
y
m
p
t
o
m
s
 
w
e
r
e
 
e
v
a
l
u
a
t
e
d
 
o
n
 
a
 
4
-
p
o
i
n
t
 
s
y
m
p
t
o
m
s
 
o
f
 
d
i
s
e
a
s
e
 
s
c
a
l
e
 
(
1
 
=
 
n
o
t
 
a
t
 
a
l
l
,
 
2
 
=
 
a
 
l
i
t
t
l
e
 
b
i
t
,
 
3
 
=
 
q
u
i
t
e
 
a
 
b
i
t
,
 
4
 
=
 
v
e
r
y
 
m
u
c
h
)
.
 
N
o
t
 
a
 
v
a
l
i
d
a
t
e
d
 
s
c
a
l
e
 
a
l
t
h
o
u
g
h
 
b
a
s
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d
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e
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A
 
s
y
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p
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b
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b
e
 
r
e
p
o
r
t
e
d
 
a
s
 
a
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e
A
l
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g
i
c
a
l
 
r
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s
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r
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p
e
n
d
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e
w
 
b
y
 
a
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t
 
r
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.
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h
e
 
r
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w
a
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b
l
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n
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e
d
 
a
s
 
t
o
 
w
h
e
t
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e
r
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a
r
t
i
c
i
p
a
n
t
s
 
r
e
c
e
i
v
e
d
 
o
r
a
l
 
o
r
 
i
.
v
.
 
t
o
p
o
t
e
c
a
n
L
e
n
g
t
h
 
o
f
 
f
o
l
l
o
w
-
u
p
:
 
u
n
c
l
e
a
r
,
 
a
l
t
h
o
u
g
h
 
p
r
o
g
r
e
s
s
i
o
n
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a
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s
s
e
s
s
e
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5
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e
e
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u
r
v
i
v
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
P
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
,
 
n
 
(
%
)
:
•
 
0
:
 
o
r
a
l
 
1
0
 
(
1
9
.
2
)
,
 
i
.
v
.
 
1
8
 
(
3
3
.
3
)
•
 
1
:
 
o
r
a
l
 
3
4
 
(
6
5
.
4
)
,
 
i
.
v
.
 
2
1
 
(
3
8
.
9
)
•
 
2
:
 
o
r
a
l
 
8
 
(
1
5
.
4
)
,
 
i
.
v
.
 
1
5
 
(
2
7
.
8
)
M
a
x
i
m
u
m
 
l
e
s
i
o
n
 
d
i
a
m
e
t
e
r
 
(
c
m
)
,
 
n
 
(
%
)
:
•
 
<
 
2
:
 
o
r
a
l
 
0
,
 
i
.
v
.
 
1
 
(
1
.
9
)
•
 
2
–
 
<
 
5
:
 
o
r
a
l
 
2
6
 
(
5
0
)
,
 
i
.
v
.
 
2
1
 
(
3
8
.
9
)
•
 
5
–
1
0
:
 
o
r
a
l
 
2
5
 
(
4
8
.
1
)
,
 
i
.
v
.
 
3
0
 
(
5
5
.
6
)
•
 
>
 
1
0
:
 
o
r
a
l
 
1
 
(
1
.
9
)
,
 
i
.
v
.
 
2
 
(
3
.
7
)
P
r
e
v
i
o
u
s
 
t
r
e
a
t
m
e
n
t
:
•
 
R
e
s
p
o
n
s
e
:
 
n
o
t
 
r
e
p
o
r
t
e
d
•
 
R
e
s
p
o
n
s
e
 
t
y
p
e
:
 
n
o
t
 
r
e
p
o
r
t
e
d
T
T
P
 
a
f
t
e
r
 
e
n
d
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
,
 
n
 
(
%
)
 
m
o
n
t
h
s
:
•
 
<
 
3
 
m
o
n
t
h
s
b
:
 
o
r
a
l
 
1
 
(
1
.
9
)
,
 
i
.
v
.
 
1
 
(
1
.
8
)
•
 
3
–
6
 
m
o
n
t
h
s
:
 
o
r
a
l
 
1
9
 
(
3
6
.
5
)
,
 
i
.
v
.
 
1
9
 
(
3
5
.
2
)
•
 
>
 
6
 
m
o
n
t
h
s
:
 
o
r
a
l
 
3
2
 
(
6
1
.
5
)
,
 
i
.
v
.
 
3
4
 
(
6
3
.
0
)
L
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
,
 
n
 
(
%
)
:
•
 
P
r
e
s
e
n
t
:
 
o
r
a
l
 
1
6
 
(
3
0
.
8
)
,
 
1
7
 
(
3
1
.
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)
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A
b
s
e
n
t
:
 
o
r
a
l
 
3
6
 
(
6
9
.
2
)
,
 
i
.
v
.
 
3
7
 
(
6
8
.
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)
P
r
e
v
i
o
u
s
 
r
a
d
i
o
t
h
e
r
a
p
y
 
(
%
)
:
 
o
r
a
l
 
7
1
.
2
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i
.
v
.
 
7
2
.
2
%
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M
i
s
s
i
n
g
 
d
a
t
a
 
f
o
r
 
o
n
e
 
p
a
r
t
i
c
i
p
a
n
t
 
i
n
 
e
a
c
h
 
g
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o
u
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.
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T
F
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o
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1
1
 
w
e
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1
1
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R
E
S
U
L
T
S
O
u
t
c
o
m
e
s
O
r
a
l
 
t
o
p
o
t
e
c
a
n
 
(
n
 
=
 
5
2
)
I
n
t
r
a
v
e
n
o
u
s
 
t
o
p
o
t
e
c
a
n
 
(
n
 
=
 
5
4
)
p
-
v
a
l
u
e
,
 
9
5
%
 
C
I
O
S
,
 
m
e
d
i
a
n
3
2
 
w
e
e
k
s
2
5
 
w
e
e
k
s
R
R
 
=
 
0
.
8
4
 
(
9
5
%
 
C
I
 
0
.
5
3
 
t
o
 
1
.
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2
)
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2
.
3
 
w
e
e
k
s
 
(
0
.
4
 
t
o
 
6
9
.
1
)
c
2
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.
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(
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.
6
 
t
o
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.
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)
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c
 
R
e
p
o
r
t
 
i
n
 
t
a
b
l
e
 
w
h
i
c
h
 
i
n
c
l
u
d
e
s
 
c
e
n
s
o
r
e
d
 
e
v
e
n
t
s
.
C
o
m
m
e
n
t
s
:
 
S
t
a
t
e
s
 
t
h
a
t
 
a
c
c
o
u
n
t
i
n
g
 
s
i
m
u
l
t
a
n
e
o
u
s
l
y
 
f
o
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a
l
l
 
p
r
o
g
n
o
s
t
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f
a
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o
r
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R
R
 
o
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s
u
r
v
i
v
a
l
 
w
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s
 
0
.
9
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(
9
5
%
 
C
I
 
0
.
5
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t
o
 
1
.
4
7
)
.
S
t
a
t
e
s
 
t
h
a
t
 
t
w
o
 
f
a
c
t
o
r
s
 
(
n
o
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
 
a
n
d
 
l
o
w
e
r
 
P
S
)
 
w
e
r
e
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
l
o
n
g
e
r
 
s
u
r
v
i
v
a
l
 
(
p
 
=
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.
0
0
1
 
a
n
d
 
p
 
=
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.
0
2
5
,
 
r
e
s
p
e
c
t
i
v
e
l
y
)
 
b
u
t
 
n
o
 
d
a
t
a
 
r
e
p
o
r
t
e
d
,
 
n
o
r
 
a
n
y
 
d
a
t
a
 
f
o
r
 
o
t
h
e
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f
a
c
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o
r
s
 
t
e
s
t
e
d
.
R
e
s
p
o
n
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e
 
r
a
t
e
,
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(
%
)
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i
f
f
e
r
e
n
c
e
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O
R
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)
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3
%
 
(
9
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%
 
C
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.
6
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o
 
2
3
.
1
%
)
O
v
e
r
a
l
l
 
r
e
s
p
o
n
s
e
1
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(
2
3
.
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)
 
9
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I
 
1
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.
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t
o
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.
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.
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t
o
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.
3
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R
1
 
(
1
.
9
)
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(
3
.
7
)
P
R
1
1
 
(
2
1
.
2
)
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(
1
1
.
1
)
N
o
n
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r
e
s
p
o
n
d
e
r
s
,
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(
%
)
:
S
t
a
b
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d
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s
e
a
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e
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(
1
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.
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)
1
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(
2
9
.
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)
N
o
t
 
r
e
p
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r
t
e
d
P
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
1
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(
3
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.
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)
2
3
 
(
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2
.
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N
o
t
 
r
e
p
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e
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N
o
t
 
a
s
s
e
s
s
a
b
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2
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.
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1
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.
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)
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o
t
 
r
e
p
o
r
t
e
d
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o
m
m
e
n
t
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S
t
a
t
e
s
 
t
r
u
e
 
u
n
d
e
r
l
y
i
n
g
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
w
i
t
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o
r
a
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o
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o
t
e
c
a
n
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a
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w
o
r
s
t
 
6
.
6
%
 
l
o
w
e
r
 
t
h
a
n
 
t
h
a
t
 
o
f
 
t
h
e
 
i
.
v
.
 
t
o
p
o
t
e
c
a
n
,
 
w
h
i
c
h
 
i
s
 
n
o
t
 
a
 
c
l
i
n
i
c
a
l
l
y
 
m
e
a
n
i
n
g
f
u
l
 
d
i
f
f
e
r
e
n
c
e
.
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t
a
t
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f
a
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f
e
m
a
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e
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e
n
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e
r
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d
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p
r
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s
 
r
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d
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o
t
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w
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i
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t
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a
l
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o
c
i
a
t
e
d
 
w
i
t
h
 
i
n
c
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.
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.
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o
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r
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c
a
n
 
p
a
r
t
i
c
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r
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c
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r
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w
e
e
k
s
T
T
P
,
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
n
 
=
 
5
2
n
 
=
 
5
4
R
R
 
=
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.
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w
e
e
k
s
1
3
 
(
0
.
6
–
6
5
.
1
)
d
 
w
e
e
k
s
d
 
I
n
c
l
u
d
e
s
 
c
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d
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.
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.
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.
 
N
o
 
d
a
t
a
 
w
e
r
e
 
r
e
p
o
r
t
e
d
 
f
o
r
 
t
h
e
s
e
 
o
r
 
a
n
y
 
o
t
h
e
r
 
f
a
c
t
o
r
s
 
t
e
s
t
e
d
 
i
n
 
t
h
e
 
m
o
d
e
l
.
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p
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c
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p
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.
9
8
 
(
9
5
%
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p
t
o
m
s
 
a
t
 
b
a
s
e
l
i
n
e
)
n
/
N
 
(
%
)
n
/
N
 
(
%
)
N
o
t
 
r
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r
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p
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b
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c
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b
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p
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e
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e
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.
 
I
m
p
r
o
v
e
m
e
n
t
 
r
e
p
r
e
s
e
n
t
s
 
i
m
p
r
o
v
e
m
e
n
t
 
f
o
r
 
t
w
o
 
c
o
n
s
e
c
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c
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c
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c
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c
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p
e
n
i
a
2
1
.
6
3
5
.
3
2
6
.
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p
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.
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c
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c
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p
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p
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.
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c
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b
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c
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c
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c
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c
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.
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c
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p
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.
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c
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n
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c
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c
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c
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b
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c
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r
e
l
a
t
e
s
 
j
u
s
t
 
t
o
 
t
h
e
 
r
a
d
i
o
l
o
g
i
c
a
l
 
o
u
t
c
o
m
e
s
 
o
r
 
a
l
l
 
o
u
t
c
o
m
e
s
.
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
S
t
a
t
e
s
 
d
e
m
o
g
r
a
p
h
i
c
 
i
m
b
a
l
a
n
c
e
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
w
a
s
 
g
e
n
e
r
a
l
l
y
 
n
e
g
l
i
g
i
b
l
e
 
a
n
d
 
w
a
s
 
a
c
c
o
u
n
t
e
d
 
f
o
r
 
i
n
 
t
h
e
 
m
u
l
t
i
v
a
r
i
a
t
e
 
c
o
m
p
a
r
i
s
o
n
s
 
o
f
 
t
r
e
a
t
m
e
n
t
 
r
e
g
i
m
e
n
s
.
 
B
a
s
e
l
i
n
e
 
c
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c
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t
e
r
 
≤
 
5
 
c
m
 
v
s
 
>
 
5
 
c
m
)
 
o
n
 
r
e
s
p
o
n
s
e
 
a
n
d
 
t
i
m
e
 
t
o
 
e
v
e
n
t
 
v
a
r
i
a
b
l
e
s
,
 
r
e
s
p
e
c
t
i
v
e
l
y
 
(
d
a
t
a
 
n
o
t
 
r
e
p
o
r
t
e
d
)
.
 
S
t
a
t
e
s
 
a
l
l
 
t
h
o
s
e
 
e
n
t
e
r
i
n
g
 
t
h
e
 
s
t
u
d
y
 
w
e
r
e
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
I
T
T
 
a
n
a
l
y
s
i
s
.
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
S
t
u
d
y
 
w
a
s
 
d
e
s
i
g
n
e
d
 
t
o
 
g
i
v
e
 
a
n
 
i
n
d
i
c
a
t
i
o
n
 
a
s
 
t
o
 
t
h
e
 
n
u
m
b
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
r
e
q
u
i
r
e
d
 
i
n
 
a
 
p
h
a
s
e
 
I
I
I
 
s
t
u
d
y
 
o
f
 
a
 
s
i
m
i
l
a
r
 
d
e
s
i
g
n
.
 
T
o
 
i
n
d
i
c
a
t
e
 
b
o
t
h
 
r
i
s
k
 
a
n
d
 
b
e
n
e
fi
t
 
a
 
s
t
u
d
y
 
o
f
 
1
0
0
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
t
h
e
 
m
o
s
t
 
a
p
p
r
o
p
r
i
a
t
e
,
 
b
u
t
 
n
o
 
o
f
fi
c
i
a
l
 
s
a
m
p
l
e
 
s
i
z
e
 
c
a
l
c
u
l
a
t
i
o
n
 
w
a
s
 
p
r
o
v
i
d
e
d
.
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
N
o
 
fl
o
w
 
c
h
a
r
t
 
p
r
o
v
i
d
e
d
,
 
n
o
 
d
i
s
c
u
s
s
i
o
n
 
o
f
 
n
u
m
b
e
r
s
 
o
r
 
r
e
a
s
o
n
s
 
f
o
r
 
a
t
t
r
i
t
i
o
n
.
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
P
o
p
u
l
a
t
i
o
n
 
o
f
 
r
e
l
a
p
s
e
d
 
S
C
L
C
,
 
m
i
n
i
m
a
l
 
d
e
m
o
g
r
a
p
h
i
c
 
d
e
t
a
i
l
 
r
e
p
o
r
t
e
d
.
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
:
 
A
p
p
r
o
p
r
i
a
t
e
,
 
a
l
t
h
o
u
g
h
 
s
y
m
p
t
o
m
 
s
c
o
r
e
 
n
o
t
 
v
a
l
i
d
a
t
e
d
.
I
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
:
 
N
o
t
 
r
e
p
o
r
t
e
d
.
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
S
p
o
n
s
o
r
e
d
 
b
y
 
a
 
g
r
a
n
t
 
f
r
o
m
 
S
m
i
t
h
K
l
i
n
e
 
B
e
e
c
h
a
m
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
.
 
T
h
r
e
e
 
a
u
t
h
o
r
s
 
a
r
e
 
e
m
p
l
o
y
e
e
s
 
o
f
 
S
K
B
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Q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
f
o
r
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
R
C
T
s
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
I
n
a
d
e
q
u
a
t
e
2
.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
U
n
k
n
o
w
n
3
.
 
W
e
r
e
 
t
h
e
 
g
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
R
e
p
o
r
t
e
d
4
.
 
W
e
r
e
 
t
h
e
 
e
l
i
g
i
b
i
l
i
t
y
 
c
r
i
t
e
r
i
a
 
s
p
e
c
i
fi
e
d
?
A
d
e
q
u
a
t
e
5
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
P
a
r
t
i
a
l
6
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
7
.
 
W
a
s
 
t
h
e
 
p
a
t
i
e
n
t
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
8
.
 
W
e
r
e
 
t
h
e
 
p
o
i
n
t
 
e
s
t
i
m
a
t
e
s
 
a
n
d
 
m
e
a
s
u
r
e
 
o
f
 
v
a
r
i
a
b
i
l
i
t
y
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
?
A
d
e
q
u
a
t
e
9
.
 
D
i
d
 
t
h
e
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
 
a
n
 
I
T
T
 
a
n
a
l
y
s
i
s
?
A
d
e
q
u
a
t
e
1
0
.
 
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
a
n
d
 
d
r
o
p
o
u
t
s
 
c
o
m
p
l
e
t
e
l
y
 
d
e
s
c
r
i
b
e
d
?
I
n
a
d
e
q
u
a
t
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
D
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
A
u
t
h
o
r
s
:
 
v
o
n
 
P
a
w
e
l
 
e
t
 
a
l
.
5
9
 
a
n
d
 
S
c
h
i
l
l
e
r
 
e
t
 
a
l
.
 
(
a
b
s
t
r
a
c
t
)
6
1
Y
e
a
r
s
:
 
1
9
9
9
 
a
n
d
 
1
9
9
8
 
(
a
b
s
t
r
a
c
t
)
C
o
u
n
t
r
i
e
s
:
 
G
e
r
m
a
n
y
,
 
C
a
n
a
d
a
,
 
F
r
a
n
c
e
,
 
U
K
,
 
U
S
A
S
t
u
d
y
 
d
e
s
i
g
n
:
 
R
C
T
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
u
n
k
n
o
w
n
F
u
n
d
i
n
g
:
 
S
m
i
t
h
K
l
i
n
e
 
B
e
e
c
h
a
m
G
r
o
u
p
 
A
:
 
t
o
p
o
t
e
c
a
n
D
o
s
e
:
 
1
.
5
 
m
g
/
m
2
/
d
a
y
 
a
s
 
3
0
-
m
i
n
u
t
e
 
i
n
f
u
s
i
o
n
.
 
D
u
r
a
t
i
o
n
:
 
fi
v
e
 
c
o
n
s
e
c
u
t
i
v
e
 
d
a
y
s
 
e
v
e
r
y
 
2
1
 
d
a
y
s
G
r
o
u
p
 
B
:
 
c
y
c
l
o
p
h
o
s
p
h
a
m
i
d
e
 
(
C
)
,
 
d
o
x
o
r
u
b
i
c
i
n
 
(
D
)
 
a
n
d
 
v
i
n
c
r
i
s
t
i
n
e
 
(
V
)
 
(
C
A
V
)
D
o
s
e
:
 
C
 
1
0
0
0
 
m
g
/
m
2
 
(
m
a
x
i
m
u
m
 
2
0
0
0
 
m
g
)
 
+
 
D
 
4
5
 
m
g
/
m
2
 
(
m
a
x
i
m
u
m
 
1
0
0
 
m
g
)
 
+
 
V
 
2
-
m
g
 
i
n
f
u
s
i
o
n
D
u
r
a
t
i
o
n
:
 
d
a
y
 
1
 
o
f
 
e
a
c
h
 
2
1
-
d
a
y
 
c
o
u
r
s
e
F
u
l
l
 
d
o
s
e
 
i
f
 
o
n
 
t
r
e
a
t
m
e
n
t
 
d
a
y
 
n
e
u
t
r
o
p
h
i
l
 
c
o
u
n
t
 
≥
 
1
.
0
 
×
 
1
0
9
/
l
,
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
 
≥
 
1
0
0
 
x
 
1
0
9
/
l
 
+
 
H
b
 
c
o
u
n
t
 
≥
 
9
.
0
 
g
/
d
L
.
 
T
o
p
o
t
e
c
a
n
 
c
o
u
l
d
 
b
e
 
e
s
c
a
l
a
t
e
d
 
t
o
 
m
a
x
i
m
u
m
 
d
o
s
e
 
2
.
0
 
m
g
/
m
2
 
i
n
 
a
b
s
e
n
c
e
 
o
f
 
g
r
a
d
e
 
≥
 
2
 
t
o
x
i
c
i
t
y
P
a
t
i
e
n
t
s
 
w
h
o
s
e
 
b
e
s
t
 
r
e
s
p
o
n
s
e
 
w
a
s
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
 
a
f
t
e
r
 
f
o
u
r
 
c
o
u
r
s
e
s
 
c
o
u
l
d
 
b
e
 
r
e
m
o
v
e
d
 
f
r
o
m
 
s
t
u
d
y
 
o
r
 
c
o
n
t
i
n
u
e
 
a
t
 
i
n
v
e
s
t
i
g
a
t
o
r
’
s
 
d
i
s
c
r
e
t
i
o
n
;
 
p
a
t
i
e
n
t
s
 
w
h
o
s
e
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
e
d
 
w
e
r
e
 
r
e
m
o
v
e
d
 
f
r
o
m
 
s
t
u
d
y
P
a
t
i
e
n
t
s
 
i
n
 
b
o
t
h
 
g
r
o
u
p
s
 
w
e
r
e
 
w
i
t
h
d
r
a
w
n
 
i
f
 
d
e
l
a
y
 
>
 
2
 
w
e
e
k
s
 
c
a
u
s
e
d
 
b
y
 
p
e
r
s
i
s
t
e
n
t
 
t
o
x
i
c
i
t
y
 
a
t
 
m
i
n
.
 
d
o
s
e
s
;
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
C
R
 
P
R
 
t
o
 
t
h
e
r
a
p
y
 
c
o
n
t
i
n
u
e
d
 
t
r
e
a
t
m
e
n
t
 
u
n
t
i
l
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
o
r
 
u
n
a
c
c
e
p
t
a
b
l
e
 
t
o
x
i
c
i
t
y
 
o
c
c
u
r
r
e
d
,
 
o
r
 
f
o
r
 
a
t
 
l
e
a
s
t
 
s
i
x
 
c
o
u
r
s
e
s
 
p
a
s
t
 
t
h
e
 
m
a
x
i
m
a
l
 
r
e
s
p
o
n
s
e
T
o
p
o
t
e
c
a
n
 
r
e
d
u
c
e
d
 
b
y
 
0
.
2
5
 
m
g
/
m
2
/
d
a
y
 
a
n
d
 
C
/
D
 
r
e
d
u
c
e
d
 
b
y
 
2
5
%
 
f
o
r
:
 
g
r
a
d
e
 
4
 
n
e
u
t
r
o
p
e
n
i
a
 
c
o
m
p
l
i
c
a
t
e
d
 
b
y
 
f
e
v
e
r
 
o
r
 
i
n
f
e
c
t
i
o
n
 
o
r
 
l
a
s
t
i
n
g
 
≥
 
7
 
d
a
y
s
,
 
g
r
a
d
e
 
3
 
n
e
u
t
r
o
p
e
n
i
a
 
l
a
s
t
i
n
g
 
>
 
2
1
 
d
a
y
s
 
o
f
 
t
r
e
a
t
m
e
n
t
 
c
y
c
l
e
 
o
r
 
g
r
a
d
e
 
4
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
.
 
S
a
m
e
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
f
o
r
 
g
r
a
d
e
 
3
 
o
r
 
4
 
n
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
(
e
x
c
l
u
d
i
n
g
 
g
r
a
d
e
 
3
 
n
a
u
s
e
a
)
 
o
r
 
p
a
t
i
e
n
t
 
c
o
u
l
d
 
b
e
 
w
i
t
h
d
r
a
w
n
 
f
r
o
m
 
s
t
u
d
y
.
 
M
i
n
i
m
u
m
 
d
o
s
e
 
o
f
 
t
o
p
o
t
e
c
a
n
 
w
a
s
 
1
.
0
 
m
g
/
m
2
/
d
a
y
D
 
d
i
s
c
o
n
t
i
n
u
e
d
 
o
r
 
p
a
t
i
e
n
t
 
w
i
t
h
d
r
a
w
n
 
f
r
o
m
 
s
t
u
d
y
 
o
n
c
e
 
l
i
f
e
t
i
m
e
 
m
a
x
i
m
u
m
-
t
o
l
e
r
a
t
e
d
 
d
o
s
e
 
o
f
 
D
 
(
4
5
0
 
m
g
/
m
2
)
 
o
r
 
c
o
m
p
a
r
a
b
l
e
 
d
o
s
e
 
o
f
 
e
p
i
r
u
b
i
c
i
n
 
(
9
0
0
 
m
g
/
m
2
)
 
r
e
a
c
h
e
d
 
o
r
 
s
i
g
n
s
 
o
f
 
c
a
r
d
i
o
m
y
o
p
a
t
h
y
 
e
v
i
d
e
n
t
.
 
D
 
+
 
V
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
s
 
w
e
r
e
 
r
e
q
u
i
r
e
d
 
f
o
r
 
b
i
l
i
r
u
b
i
n
 
o
r
 
s
e
r
u
m
 
t
r
a
n
s
a
m
i
n
a
s
e
 
e
l
e
v
a
t
i
o
n
s
.
 
V
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
f
 
2
5
%
 
r
e
q
u
i
r
e
d
 
f
o
r
 
g
r
a
d
e
 
2
 
n
e
u
r
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
:
 
V
 
e
l
i
m
i
n
a
t
e
d
 
f
o
r
 
g
r
a
d
e
 
3
–
4
 
n
e
u
r
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
u
n
t
i
l
 
t
o
x
i
c
i
t
y
 
r
e
s
o
l
v
e
d
N
u
m
b
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
 
2
1
1
T
o
p
o
t
e
c
a
n
:
 
n
 
=
 
1
0
7
,
 
C
A
V
 
n
 
=
 
1
0
4
S
a
m
p
l
e
 
a
t
t
r
i
t
i
o
n
/
d
r
o
p
o
u
t
:
 
T
o
t
a
l
 
n
u
m
b
e
r
 
o
f
 
d
r
o
p
o
u
t
s
 
n
o
t
 
r
e
p
o
r
t
e
d
 
a
n
d
 
u
n
c
l
e
a
r
 
f
r
o
m
 
t
e
x
t
 
(
p
.
 
6
6
4
 
r
e
p
o
r
t
s
 
2
0
 
w
i
t
h
d
r
a
w
a
l
,
 
p
.
 
6
6
1
 
r
e
p
o
r
t
s
 
1
6
)
I
n
 
t
o
t
a
l
 
t
h
e
r
e
 
w
e
r
e
 
2
0
 
w
i
t
h
d
r
a
w
a
l
s
 
d
u
e
 
t
o
 
t
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
 
t
o
x
i
c
i
t
y
:
 
1
0
 
t
o
p
o
t
e
c
a
n
 
(
9
.
3
%
)
 
a
n
d
 
1
0
 
C
A
V
 
(
9
.
6
%
)
;
 
1
6
 
p
a
t
i
e
n
t
s
 
(
7
 
t
o
p
o
t
e
c
a
n
 
a
n
d
 
9
 
C
A
V
)
 
w
e
r
e
 
w
i
t
h
d
r
a
w
n
 
f
r
o
m
 
s
t
u
d
y
,
 
e
i
t
h
e
r
 
a
t
 
p
a
t
i
e
n
t
’
s
 
o
r
 
i
n
v
e
s
t
i
g
a
t
o
r
’
s
 
r
e
q
u
e
s
t
,
 
b
e
c
a
u
s
e
 
o
f
 
t
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
 
t
o
x
i
c
i
t
y
 
(
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
a
n
d
 
a
s
s
o
c
i
a
t
e
d
 
s
e
q
u
e
l
a
e
)
.
 
N
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
r
e
a
s
o
n
s
:
 
o
n
e
 
t
o
p
o
t
e
c
a
n
 
p
a
t
i
e
n
t
 
h
a
d
 
t
u
m
o
u
r
 
l
y
s
i
s
 
s
y
n
d
r
o
m
e
 
a
n
d
 
r
e
q
u
e
s
t
e
d
 
w
i
t
h
d
r
a
w
a
l
 
a
n
d
 
t
w
o
 
C
A
V
 
p
a
t
i
e
n
t
s
 
w
i
t
h
d
r
e
w
 
d
u
e
 
t
o
 
a
 
d
e
c
l
i
n
e
 
i
n
 
c
a
r
d
i
a
c
 
s
t
a
t
u
s
S
t
u
d
y
 
a
l
s
o
 
r
e
p
o
r
t
s
 
t
h
a
t
 
o
n
e
 
t
o
p
o
t
e
c
a
n
 
a
n
d
 
t
w
o
 
C
A
V
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
e
m
o
v
e
d
 
f
o
r
 
l
a
c
k
 
o
f
 
c
l
i
n
i
c
a
l
 
b
e
n
e
fi
t
,
 
b
u
t
 
d
i
d
 
n
o
t
 
h
a
v
e
 
r
a
d
i
o
l
o
g
i
c
a
l
 
e
v
i
d
e
n
c
e
 
o
f
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
S
a
m
p
l
e
 
c
r
o
s
s
o
v
e
r
s
:
 
N
/
A
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
D
o
c
u
m
e
n
t
e
d
 
p
r
o
g
r
e
s
s
i
v
e
,
 
l
i
m
i
t
e
d
 
o
r
 
e
x
t
e
n
s
i
v
e
 
S
C
L
C
 
w
i
t
h
 
d
a
t
e
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
 
a
t
 
l
e
a
s
t
 
6
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
;
 
a
t
 
l
e
a
s
t
 
o
n
e
 
l
e
s
i
o
n
,
 
b
i
d
i
m
e
n
s
i
o
n
a
l
l
y
 
m
e
a
s
u
r
a
b
l
e
 
b
y
 
C
T
,
 
M
R
I
,
 
u
l
t
r
a
s
o
u
n
d
,
 
r
a
d
i
o
g
r
a
p
h
,
 
p
h
o
t
o
g
r
a
p
h
 
o
r
 
p
h
y
s
i
c
a
l
 
e
x
a
m
i
n
a
t
i
o
n
;
 
m
i
n
i
m
u
m
 
o
f
 
4
 
w
e
e
k
s
 
b
e
t
w
e
e
n
 
p
r
i
o
r
 
s
u
r
g
e
r
y
 
o
r
 
i
m
m
u
n
o
t
h
e
r
a
p
y
 
a
n
d
 
s
t
u
d
y
 
e
n
t
r
y
;
 
m
i
n
i
m
u
m
 
o
f
 
2
4
 
h
o
u
r
s
 
b
e
t
w
e
e
n
 
r
a
d
i
o
t
h
e
r
a
p
y
 
a
n
d
 
i
n
i
t
i
a
t
i
o
n
 
o
f
 
s
t
u
d
y
 
d
r
u
g
s
;
 
E
C
O
G
 
p
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
 
(
P
S
)
 
≤
 
2
,
 
H
b
 
≥
 
9
.
0
 
g
/
d
l
,
 
W
B
C
 
c
o
u
n
t
 
≥
 
3
.
5
 
×
 
1
0
9
/
l
,
 
n
e
u
t
r
o
p
h
i
l
s
 
≥
 
1
.
5
 
×
 
1
0
9
/
l
,
 
p
l
a
t
e
l
e
t
s
 
≥
 
1
0
0
 
×
 
1
0
9
/
l
,
 
b
i
l
i
r
u
b
i
n
 
≤
 
2
.
0
 
m
g
/
d
l
,
 
t
r
a
n
s
a
m
i
n
a
s
e
 
a
n
d
 
a
l
k
a
l
i
n
e
 
p
h
o
s
p
h
a
t
a
s
e
 
v
a
l
u
e
s
 
≤
 
2
 
×
 
U
L
N
 
(
o
r
 
i
f
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
 
p
r
e
s
e
n
t
 
≤
 
3
 
U
L
N
)
,
 
c
r
e
a
t
i
n
e
 
≤
 
1
.
5
 
m
g
/
d
l
 
o
r
 
c
r
e
a
t
i
n
e
 
c
l
e
a
r
a
n
c
e
 
≥
 
6
0
 
m
l
/
m
i
n
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
:
 
R
R
 
a
n
d
 
d
u
r
a
t
i
o
n
 
o
f
 
r
e
s
p
o
n
s
e
S
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
:
 
T
T
P
,
 
t
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
,
 
s
u
r
v
i
v
a
l
 
a
n
d
 
i
m
p
r
o
v
e
m
e
n
t
 
o
f
 
d
i
s
e
a
s
e
-
r
e
l
a
t
e
d
 
s
y
m
p
t
o
m
s
M
e
t
h
o
d
s
 
o
f
 
a
s
s
e
s
s
i
n
g
 
o
u
t
c
o
m
e
s
:
R
e
s
p
o
n
s
e
s
 
w
e
r
e
 
d
e
t
e
r
m
i
n
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
W
H
O
 
c
r
i
t
e
r
i
a
.
 
S
t
a
n
d
a
r
d
 
r
e
s
p
o
n
s
e
 
c
r
i
t
e
r
i
a
 
w
e
r
e
 
u
s
e
d
,
 
d
u
r
a
t
i
o
n
 
o
f
 
r
e
s
p
o
n
s
e
 
m
e
a
s
u
r
e
d
 
f
r
o
m
 
t
i
m
e
 
o
f
 
i
n
i
t
i
a
l
 
d
o
c
u
m
e
n
t
e
d
 
r
e
s
p
o
n
s
e
 
t
o
 
fi
r
s
t
 
s
i
g
n
 
o
f
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
T
T
P
 
w
a
s
 
m
e
a
s
u
r
e
d
 
f
r
o
m
 
t
i
m
e
 
o
f
 
fi
r
s
t
 
s
t
u
d
y
 
d
r
u
g
 
t
o
 
d
o
c
u
m
e
n
t
e
d
 
p
r
o
g
r
e
s
s
i
v
e
 
d
i
s
e
a
s
e
 
(
o
r
 
i
n
i
t
i
a
t
i
o
n
 
o
f
 
s
u
b
s
e
q
u
e
n
t
 
c
h
e
m
o
t
h
e
r
a
p
y
)
T
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
 
a
n
d
 
s
u
r
v
i
v
a
l
 
m
e
a
s
u
r
e
d
 
f
r
o
m
 
t
i
m
e
 
o
f
 
fi
r
s
t
 
s
t
u
d
y
 
d
r
u
g
 
t
o
 
i
n
i
t
i
a
l
 
r
e
s
p
o
n
s
e
 
a
n
d
 
d
e
a
t
h
,
 
r
e
s
p
e
c
t
i
v
e
l
y
S
y
m
p
t
o
m
 
s
c
o
r
e
s
 
e
v
a
l
u
a
t
e
d
 
f
o
r
 
d
y
s
p
n
o
e
a
,
 
c
o
u
g
h
,
 
c
h
e
s
t
 
p
a
i
n
,
 
h
a
e
m
o
p
t
y
s
i
s
,
 
a
n
o
r
e
x
i
a
,
 
i
n
s
o
m
n
i
a
,
 
h
o
a
r
s
e
n
e
s
s
,
 
f
a
t
i
g
u
e
 
a
n
d
 
i
n
t
e
r
f
e
r
e
n
c
e
 
w
i
t
h
 
d
a
i
l
y
 
a
c
t
i
v
i
t
y
;
 
i
m
p
r
o
v
e
m
e
n
t
 
h
a
d
 
t
o
 
b
e
 
s
u
s
t
a
i
n
e
d
 
f
o
r
 
t
w
o
 
c
o
n
s
e
c
u
t
i
v
e
 
c
o
u
r
s
e
s
.
 
S
y
m
p
t
o
m
 
e
v
a
l
u
a
t
i
o
n
 
i
n
c
l
u
d
e
d
 
t
i
m
e
 
t
o
 
s
y
m
p
t
o
m
 
w
o
r
s
e
n
i
n
g
 
a
s
 
d
e
fi
n
e
d
 
b
y
 
i
n
t
e
r
v
a
l
 
f
r
o
m
 
fi
r
s
t
 
d
o
s
e
 
o
f
 
m
e
d
i
c
a
t
i
o
n
 
u
n
t
i
l
 
fi
r
s
t
 
e
v
i
d
e
n
c
e
 
o
f
 
w
o
r
s
e
n
i
n
g
 
i
n
 
p
o
s
t
b
a
s
e
l
i
n
e
 
a
s
s
e
s
s
m
e
n
t
N
o
n
-
v
a
l
i
d
a
t
e
d
,
 
s
y
m
p
t
o
m
 
s
p
e
c
i
fi
c
 
‘
s
y
m
p
t
o
m
s
 
o
f
 
d
i
s
e
a
s
e
’
 
S
C
L
C
 
q
u
e
s
t
i
o
n
n
a
i
r
e
 
u
s
e
d
 
a
t
 
s
c
r
e
e
n
i
n
g
 
a
n
d
 
b
e
f
o
r
e
 
e
a
c
h
 
c
o
u
r
s
e
 
o
f
 
t
r
e
a
t
m
e
n
t
,
 
s
c
o
r
e
d
 
o
n
 
4
-
p
o
i
n
t
 
s
c
a
l
e
 
(
1
 
=
 
n
o
t
 
a
t
 
a
l
l
,
 
2
 
=
 
a
 
l
i
t
t
l
e
 
b
i
t
,
 
3
 
=
 
q
u
i
t
e
 
a
 
b
i
t
,
 
4
 
=
 
v
e
r
y
 
m
u
c
h
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
D
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
M
i
n
i
m
u
m
 
d
o
s
e
 
C
,
 
D
 
+
 
V
 
s
e
t
 
b
y
 
a
d
m
i
n
i
s
t
e
r
i
n
g
 
p
h
y
s
i
c
i
a
n
O
t
h
e
r
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
u
s
e
d
:
 
G
C
S
F
 
a
t
 
d
i
s
c
r
e
t
i
o
n
 
o
f
 
i
n
v
e
s
t
i
g
a
t
o
r
E
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
S
y
m
p
t
o
m
a
t
i
c
 
b
r
a
i
n
 
m
e
t
a
s
t
a
s
e
s
 
r
e
q
u
i
r
i
n
g
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
o
r
 
p
r
e
-
e
x
i
s
t
i
n
g
 
c
a
r
d
i
a
c
 
d
i
s
e
a
s
e
 
(
i
n
c
l
u
d
i
n
g
 
c
l
i
n
i
c
a
l
 
c
o
n
g
e
s
t
i
v
e
 
h
e
a
r
t
 
f
a
i
l
u
r
e
,
 
a
r
r
h
y
t
h
m
i
a
s
 
r
e
q
u
i
r
i
n
g
 
t
r
e
a
t
m
e
n
t
 
o
r
 
a
 
m
y
o
c
a
r
d
i
a
l
 
i
n
f
r
a
c
t
i
o
n
 
w
i
t
h
i
n
 
p
r
e
c
e
d
i
n
g
 
3
 
m
o
n
t
h
s
)
;
 
c
o
n
t
r
a
i
n
d
i
c
a
t
e
d
 
C
A
V
 
(
i
n
c
l
u
d
i
n
g
 
h
i
s
t
o
r
y
 
o
f
 
d
e
m
y
e
l
i
n
a
t
i
n
g
 
p
o
l
y
n
e
u
r
o
p
a
t
h
y
 
o
r
 
p
o
l
i
o
m
y
e
l
i
t
i
s
)
;
 
l
i
f
e
t
i
m
e
 
c
u
m
u
l
a
t
i
v
e
 
d
o
s
e
 
o
f
 
d
o
x
o
r
u
b
i
c
i
n
 
>
 
2
7
0
 
m
g
/
m
2
 
o
r
 
c
u
m
u
l
a
t
i
v
e
 
d
o
s
e
 
o
f
 
e
p
i
r
u
b
i
c
i
n
 
>
 
5
4
0
 
m
g
/
m
2
;
 
p
r
i
o
r
 
t
o
p
o
t
e
c
a
n
 
t
h
e
r
a
p
y
 
o
r
 
>
 
1
 
p
r
e
v
i
o
u
s
 
c
h
e
m
o
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
:
A
g
e
:
 
N
o
t
 
r
e
p
o
r
t
e
d
•
 
G
e
n
d
e
r
 
(
%
 
m
a
l
e
)
:
 
t
o
p
o
t
e
c
a
n
 
5
7
%
,
 
C
A
V
 
6
8
%
D
i
s
e
a
s
e
 
s
t
a
g
e
,
 
n
 
(
%
)
:
•
 
L
i
m
i
t
e
d
:
 
t
o
p
o
t
e
c
a
n
 
1
8
 
(
1
6
.
8
)
,
 
C
A
V
 
1
6
 
(
1
5
.
4
)
•
 
E
x
t
e
n
s
i
v
e
:
 
t
o
p
o
t
e
c
a
n
 
8
9
 
(
8
3
.
2
)
,
 
C
A
V
 
8
8
 
(
8
4
.
6
)
P
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
,
 
n
 
(
%
)
:
•
 
0
:
 
t
o
p
o
t
e
c
a
n
 
1
8
 
(
1
6
.
8
)
,
 
C
A
V
 
2
0
 
(
1
9
.
2
)
•
 
1
:
 
t
o
p
o
t
e
c
a
n
 
6
4
 
(
5
9
.
8
)
,
 
C
A
V
 
6
4
 
(
6
1
.
5
)
•
 
2
:
 
t
o
p
o
t
e
c
a
n
 
2
5
 
(
2
3
.
4
)
,
 
C
A
V
 
2
0
 
(
1
9
.
2
)
M
a
x
i
m
u
m
 
l
e
s
i
o
n
 
d
i
a
m
e
t
e
r
 
(
c
m
)
,
 
n
 
(
%
)
:
•
 
<
 
2
:
 
t
o
p
o
t
e
c
a
n
 
2
 
(
1
.
9
)
,
 
C
A
V
 
1
 
(
1
)
•
 
2
–
 
<
5
:
 
t
o
p
o
t
e
c
a
n
 
5
3
 
(
4
9
.
5
)
,
 
C
A
V
 
4
9
 
(
4
7
.
1
)
•
 
5
–
1
0
:
 
t
o
p
o
t
e
c
a
n
 
4
6
 
(
4
3
)
,
 
C
A
V
 
4
7
 
(
4
5
.
2
)
•
 
>
 
1
0
:
 
t
o
p
o
t
e
c
a
n
 
4
 
(
3
.
7
)
,
 
C
A
V
 
4
 
(
3
.
8
)
M
i
s
s
i
n
g
:
 
t
o
p
o
t
e
c
a
n
 
2
 
(
1
.
9
)
,
 
C
A
V
 
3
 
(
2
.
9
)
P
r
e
v
i
o
u
s
 
t
r
e
a
t
m
e
n
t
,
 
n
 
(
%
)
:
R
a
d
i
o
t
h
e
r
a
p
y
:
 
t
o
p
o
t
e
c
a
n
 
6
6
 
(
6
1
.
7
)
,
 
C
A
V
 
5
8
 
(
5
5
.
8
)
I
m
m
u
n
o
t
h
e
r
a
p
y
:
 
t
o
p
o
t
e
c
a
n
 
0
,
 
C
A
V
 
2
 
(
1
.
9
)
S
u
r
g
e
r
y
:
 
t
o
p
o
t
e
c
a
n
 
1
5
 
(
1
4
)
,
 
C
A
V
 
2
9
 
(
2
7
.
9
)
B
r
a
i
n
 
i
r
r
a
d
i
a
t
i
o
n
:
•
 
Y
e
s
:
 
t
o
p
o
t
e
c
a
n
 
2
7
 
(
2
5
.
2
)
,
 
C
A
V
 
2
4
 
(
2
3
.
1
)
•
 
N
o
:
 
t
o
p
o
t
e
c
a
n
 
8
0
 
(
7
4
.
8
)
,
 
C
A
V
 
8
0
 
(
7
6
.
9
)
S
a
f
e
t
y
 
a
s
s
e
s
s
m
e
n
t
:
 
M
i
n
i
m
u
m
 
w
e
e
k
l
y
 
c
o
m
p
l
e
t
e
 
b
l
o
o
d
 
c
e
l
l
 
c
o
u
n
t
s
,
 
b
l
o
o
d
 
c
h
e
m
i
s
t
r
i
e
s
 
o
n
 
d
a
y
 
1
5
 
o
f
 
e
a
c
h
 
c
o
u
r
s
e
 
a
n
d
 
u
r
i
n
a
l
y
s
i
s
 
e
a
c
h
 
c
y
c
l
e
.
 
E
l
e
c
t
r
o
c
a
r
d
i
o
g
r
a
m
 
a
n
d
 
m
u
l
t
i
p
l
e
-
g
a
t
e
d
 
a
c
q
u
i
s
i
t
i
o
n
 
o
r
 
e
c
h
o
c
a
r
d
i
o
g
r
a
m
 
p
e
r
f
o
r
m
e
d
 
p
r
i
o
r
 
a
n
d
 
a
t
 
e
n
d
 
o
f
 
t
r
e
a
t
m
e
n
t
.
 
Q
u
a
n
t
i
t
a
t
i
v
e
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
n
o
n
-
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
i
e
s
 
w
e
r
e
 
a
s
s
e
s
s
e
d
 
p
r
i
o
r
 
t
o
 
e
a
c
h
 
c
y
c
l
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
N
a
t
i
o
n
a
l
 
C
a
n
c
e
r
 
I
n
s
t
i
t
u
t
e
 
C
o
m
m
o
n
 
T
o
x
i
c
i
t
y
 
C
r
i
t
e
r
i
a
L
e
n
g
t
h
 
o
f
 
f
o
l
l
o
w
-
u
p
:
 
m
i
n
i
m
u
m
 
o
f
 
f
o
u
r
 
c
o
u
r
s
e
s
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
,
 
≥
 
6
 
c
o
u
r
s
e
s
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
C
R
 
o
r
 
P
RAppendix 6
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
D
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
P
l
a
t
i
n
u
m
 
(
c
i
s
 
o
r
 
c
a
r
b
o
)
/
e
t
o
p
o
s
i
d
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t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
 
o
c
c
u
r
r
e
d
 
i
n
 
o
n
e
 
t
o
p
o
t
e
c
a
n
 
p
a
t
i
e
n
t
 
(
0
.
9
%
)
 
d
u
e
 
t
o
 
g
r
a
d
e
 
3
 
f
a
t
i
g
u
e
 
a
n
d
 
i
n
 
1
1
 
C
A
V
 
p
a
t
i
e
n
t
s
 
(
1
0
.
6
%
)
,
 
n
i
n
e
 
d
u
e
 
t
o
 
n
e
u
r
o
t
o
x
i
c
i
t
y
 
(
p
 
=
 
0
.
0
0
3
)
.
 
I
n
c
i
d
e
n
c
e
 
o
f
 
w
o
r
s
e
n
i
n
g
 
o
f
 
l
e
f
t
 
v
e
n
t
r
i
c
u
l
a
r
 
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
[
w
a
s
 
b
a
s
e
d
 
o
n
 
e
c
h
o
c
a
r
d
i
o
g
r
a
m
 
o
r
 
m
u
l
t
i
p
l
e
-
g
a
t
e
d
 
a
c
q
u
i
s
i
t
i
o
n
 
r
e
s
u
l
t
s
 
a
n
d
 
c
a
n
 
b
e
 
s
e
e
n
 
f
r
o
m
 
d
a
t
a
 
i
n
 
t
a
b
l
e
 
(
1
0
0
 
t
o
p
o
t
e
c
a
n
 
a
n
d
 
9
7
 
C
A
V
 
b
a
s
e
l
i
n
e
 
a
s
s
e
s
s
m
e
n
t
s
)
]
.
N
o
t
e
:
 
I
f
 
r
e
v
i
e
w
e
r
 
c
a
l
c
u
l
a
t
e
s
 
a
 
s
u
m
m
a
r
y
 
m
e
a
s
u
r
e
 
o
r
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
 
P
L
E
A
S
E
 
I
N
D
I
C
A
T
EAppendix 6
144
DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
145
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
a
t
i
e
n
t
s
 
s
t
r
a
t
i
fi
e
d
 
b
y
 
e
x
t
e
n
t
 
o
f
 
d
i
s
e
a
s
e
 
a
n
d
 
P
S
 
a
t
 
b
a
s
e
l
i
n
e
 
a
n
d
 
r
a
n
d
o
m
i
s
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
b
y
 
a
 
t
e
l
e
p
h
o
n
e
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
s
y
s
t
e
m
.
B
l
i
n
d
i
n
g
:
 
A
l
l
 
c
l
a
i
m
e
d
 
r
e
s
p
o
n
s
e
s
 
w
e
r
e
 
r
e
v
i
e
w
e
d
 
b
y
 
a
n
 
i
n
d
e
p
e
n
d
e
n
t
 
r
a
d
i
o
l
o
g
i
s
t
 
b
l
i
n
d
e
d
 
t
o
 
a
l
l
 
c
l
a
i
m
e
d
 
r
e
s
p
o
n
s
e
s
,
 
b
u
t
 
i
t
 
i
s
 
u
n
c
l
e
a
r
 
w
h
e
t
h
e
r
 
t
h
i
s
 
w
a
s
 
t
h
e
 
c
a
s
e
 
f
o
r
 
a
l
l
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
.
 
B
l
i
n
d
i
n
g
 
o
f
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
o
r
 
p
a
t
i
e
n
t
s
 
w
a
s
 
n
o
t
 
r
e
p
o
r
t
e
d
.
 
N
o
 
d
i
s
c
u
s
s
i
o
n
 
o
f
 
w
h
y
 
a
 
d
o
u
b
l
e
-
b
l
i
n
d
 
s
t
u
d
y
 
w
a
s
 
n
o
t
 
p
e
r
f
o
r
m
e
d
.
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
a
p
e
r
 
s
t
a
t
e
s
 
t
h
a
t
 
s
t
r
a
t
i
fi
e
d
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
e
n
s
u
r
e
d
 
t
h
a
t
 
t
h
e
 
d
i
s
t
r
i
b
u
t
i
o
n
 
o
f
 
t
w
o
 
p
r
o
g
n
o
s
t
i
c
 
v
a
r
i
a
b
l
e
s
,
 
b
a
s
e
l
i
n
e
 
P
S
 
a
n
d
 
e
x
t
e
n
t
 
o
f
 
d
i
s
e
a
s
e
 
w
e
r
e
 
c
o
m
p
a
r
a
b
l
e
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
.
 
P
a
p
e
r
 
s
t
a
t
e
s
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
w
e
r
e
 
c
o
m
p
a
r
a
b
l
e
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
–
 
n
o
t
 
s
u
p
p
o
r
t
e
d
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
(
n
o
 
p
-
v
a
l
u
e
s
)
,
 
b
u
t
 
g
r
o
u
p
s
 
d
o
 
a
p
p
e
a
r
 
c
o
m
p
a
r
a
b
l
e
 
f
o
r
 
m
o
s
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
,
 
e
x
c
e
p
t
 
i
n
c
i
d
e
n
c
e
 
o
f
 
p
r
i
o
r
 
s
u
r
g
e
r
y
 
(
1
4
%
 
t
o
p
o
t
e
c
a
n
 
v
s
 
2
8
%
 
C
A
V
)
.
 
G
e
n
d
e
r
 
(
t
o
p
o
t
e
c
a
n
 
4
3
%
 
w
o
m
e
n
 
v
s
 
C
A
V
 
3
2
%
,
 
p
 
=
 
0
.
0
9
1
)
 
a
n
d
 
d
o
c
u
m
e
n
t
e
d
 
b
r
a
i
n
 
m
e
t
a
s
t
a
s
e
s
 
(
t
o
p
o
t
e
c
a
n
 
1
1
.
2
%
 
v
s
 
C
A
V
 
2
4
.
0
%
,
 
p
 
=
 
0
.
0
4
4
)
 
w
e
r
e
 
n
o
t
 
c
o
m
p
a
r
a
b
l
e
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
.
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
P
a
p
e
r
 
s
t
a
t
e
s
 
t
h
a
t
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
c
e
i
v
e
d
 
a
 
d
o
s
e
 
o
f
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
 
w
e
r
e
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
e
f
fi
c
a
c
y
 
e
v
a
l
u
a
t
i
o
n
s
.
 
T
w
o
 
p
r
o
g
n
o
s
t
i
c
 
v
a
r
i
a
b
l
e
s
,
 
b
a
s
e
l
i
n
e
 
P
S
 
a
n
d
 
e
x
t
e
n
t
 
o
f
 
d
i
s
e
a
s
e
 
i
n
c
l
u
d
e
d
 
i
n
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
t
i
c
a
l
 
m
o
d
e
l
s
 
f
o
r
 
t
i
m
e
-
t
o
-
e
v
e
n
t
 
o
u
t
c
o
m
e
s
.
 
S
u
b
g
r
o
u
p
 
a
n
a
l
y
s
i
s
 
i
n
c
l
u
d
e
d
 
r
e
s
p
o
n
s
e
 
b
y
 
g
e
n
d
e
r
 
a
n
d
 
T
T
P
 
r
e
l
a
t
i
v
e
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
;
 
9
5
%
 
C
I
 
f
o
r
 
r
e
s
p
o
n
s
e
 
r
a
t
e
s
 
a
n
d
 
e
s
t
i
m
a
t
e
d
 
p
e
r
c
e
n
t
a
g
e
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
r
e
s
p
o
n
s
e
 
r
a
t
e
s
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
w
e
r
e
 
c
a
l
c
u
l
a
t
e
d
.
 
K
a
p
l
a
n
–
M
e
i
e
r
 
s
u
r
v
i
v
a
l
 
e
s
t
i
m
a
t
e
s
 
u
s
e
d
 
f
o
r
 
t
i
m
e
-
t
o
-
e
v
e
n
t
 
v
a
r
i
a
b
l
e
s
,
 
i
n
c
l
u
d
i
n
g
 
t
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
,
 
r
e
s
p
o
n
s
e
 
d
u
r
a
t
i
o
n
,
 
T
T
P
 
a
n
d
 
s
u
r
v
i
v
a
l
.
 
T
i
m
e
-
t
o
-
e
v
e
n
t
 
o
u
t
c
o
m
e
s
 
w
e
r
e
 
a
l
s
o
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
t
h
e
 
C
o
x
 
r
e
g
r
e
s
s
i
o
n
 
m
o
d
e
l
.
 
M
u
l
t
i
v
a
r
i
a
t
e
 
s
t
a
t
i
s
t
i
c
a
l
 
m
e
t
h
o
d
s
 
w
e
r
e
 
a
p
p
l
i
e
d
 
t
o
 
s
u
r
v
i
v
a
l
 
a
n
d
 
r
e
s
p
o
n
s
e
 
t
o
 
d
e
t
e
r
m
i
n
e
 
o
t
h
e
r
 
p
o
s
s
i
b
l
e
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
 
s
u
c
h
 
a
s
 
g
e
n
d
e
r
,
 
P
S
 
e
x
t
e
n
t
 
o
f
 
d
i
s
e
a
s
e
,
 
a
g
e
,
 
p
r
e
s
e
n
c
e
 
o
f
 
b
a
s
e
l
i
n
e
 
b
r
a
i
n
 
a
n
d
/
o
r
 
l
i
v
e
r
 
m
e
t
a
s
t
a
s
e
s
,
 
r
e
s
p
o
n
s
e
 
t
o
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
 
(
C
R
 
o
r
 
P
R
)
,
 
r
e
s
p
o
n
s
e
 
d
u
r
a
t
i
o
n
 
a
n
d
 
T
T
P
 
f
r
o
m
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
.
 
A
s
 
b
a
s
e
l
i
n
e
 
g
r
o
u
p
s
 
w
e
r
e
 
n
o
t
 
b
a
l
a
n
c
e
d
 
w
i
t
h
 
r
e
s
p
e
c
t
 
t
o
 
t
h
e
 
a
d
d
i
t
i
o
n
a
l
 
c
o
v
a
r
i
a
t
e
,
 
r
e
s
u
l
t
s
 
w
e
r
e
 
a
d
j
u
s
t
e
d
 
f
o
r
 
o
n
l
y
 
t
h
e
 
s
t
r
a
t
i
fi
c
a
t
i
o
n
 
v
a
r
i
a
b
l
e
s
.
 
F
o
r
 
e
a
c
h
 
o
f
 
t
h
e
 
s
y
m
p
t
o
m
s
 
o
f
 
d
i
s
e
a
s
e
,
 
P
e
a
r
s
o
n
’
s
 
u
n
c
o
r
r
e
c
t
e
d
 
c
h
i
-
s
q
u
a
r
e
d
 
s
t
a
t
i
s
t
i
c
 
w
a
s
 
u
s
e
d
 
t
o
 
c
o
m
p
a
r
e
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
 
w
h
o
 
w
e
r
e
 
e
x
p
e
r
i
e
n
c
i
n
g
 
s
u
s
t
a
i
n
e
d
 
i
m
p
r
o
v
e
m
e
n
t
 
o
v
e
r
 
b
a
s
e
l
i
n
e
 
(
p
a
t
i
e
n
t
s
 
h
a
d
 
t
o
 
h
a
v
e
 
b
o
t
h
 
b
a
s
e
l
i
n
e
 
a
n
d
 
p
o
s
t
 
b
a
s
e
l
i
n
e
)
.
 
F
o
r
 
m
i
s
s
i
n
g
 
b
a
s
e
l
i
n
e
 
m
e
a
s
u
r
e
m
e
n
t
s
 
a
n
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
n
o
n
-
m
i
s
s
i
n
g
 
p
o
s
t
b
a
s
e
l
i
n
e
 
m
e
a
s
u
r
e
 
o
f
 
‘
a
 
l
i
t
t
l
e
 
b
i
t
’
 
o
r
 
w
o
r
s
e
,
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
 
w
a
s
 
i
m
p
u
t
e
d
 
a
s
 
‘
n
o
t
 
a
t
 
a
l
l
’
 
a
n
d
 
t
h
e
 
p
a
t
i
e
n
t
 
w
a
s
 
i
n
c
l
u
d
e
d
 
i
n
 
a
n
a
l
y
s
i
s
 
o
f
 
t
h
a
t
 
s
y
m
p
t
o
m
.
 
I
f
 
s
y
m
p
t
o
m
 
a
s
s
e
s
s
m
e
n
t
s
 
n
o
t
 
r
e
c
o
r
d
e
d
,
 
a
l
g
o
r
i
t
h
m
s
 
w
e
r
e
 
u
s
e
d
 
t
o
 
i
m
p
u
t
e
 
s
c
o
r
e
s
 
f
o
r
 
t
h
e
 
c
o
u
r
s
e
 
w
i
t
h
 
m
i
s
s
i
n
g
 
a
s
s
e
s
s
m
e
n
t
s
.
 
K
a
p
l
a
n
–
M
e
i
e
r
 
e
s
t
i
m
a
t
e
s
 
w
e
r
e
 
o
b
t
a
i
n
e
d
 
a
n
d
 
t
e
s
t
e
d
 
u
s
i
n
g
 
l
o
g
-
r
a
n
k
 
t
e
s
t
 
f
o
r
 
t
h
e
 
t
i
m
e
 
t
o
 
w
o
r
s
e
n
i
n
g
 
f
o
r
 
e
a
c
h
 
s
y
m
p
t
o
m
.
 
T
i
m
e
 
t
o
 
s
y
m
p
t
o
m
 
w
o
r
s
e
n
i
n
g
 
d
e
fi
n
e
d
 
a
s
 
t
h
e
 
i
n
t
e
r
v
a
l
 
f
r
o
m
 
fi
r
s
t
 
d
o
s
e
 
o
f
 
s
t
u
d
y
 
d
r
u
g
 
u
n
t
i
l
 
i
n
c
r
e
a
s
e
 
i
n
 
p
o
s
t
b
a
s
e
l
i
n
e
 
a
s
s
e
s
s
m
e
n
t
 
s
c
o
r
e
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
o
u
t
 
w
o
r
s
e
n
i
n
g
 
o
f
 
t
h
a
t
 
s
y
m
p
t
o
m
 
w
e
r
e
 
c
e
n
s
o
r
e
d
 
a
t
 
t
h
e
i
r
 
l
a
s
t
 
s
y
m
p
t
o
m
 
a
s
s
e
s
s
m
e
n
t
.
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
N
o
t
 
r
e
p
o
r
t
e
d
.
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
R
e
p
o
r
t
e
d
 
n
u
m
b
e
r
s
 
d
o
 
n
o
t
 
a
d
d
 
u
p
 
o
r
 
i
s
 
u
n
c
l
e
a
r
 
(
s
e
e
 
c
o
l
u
m
n
 
3
,
 
p
.
 
1
)
.
 
B
r
e
a
k
d
o
w
n
 
o
f
 
n
u
m
b
e
r
s
 
a
n
d
 
r
e
a
s
o
n
s
 
n
o
t
 
g
i
v
e
n
.
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
p
r
o
g
r
e
s
s
i
v
e
,
 
l
i
m
i
t
e
d
 
o
r
 
e
x
t
e
n
s
i
v
e
 
S
C
L
C
.
 
P
a
p
e
r
 
r
e
p
o
r
t
s
 
t
h
a
t
 
s
t
u
d
y
 
w
a
s
 
t
o
 
f
o
c
u
s
 
o
n
 
t
h
e
 
s
e
n
s
i
t
i
v
e
 
p
o
p
u
l
a
t
i
o
n
 
(
r
e
l
a
p
s
e
 
>
 
9
0
 
d
a
y
s
 
a
f
t
e
r
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
,
 
b
u
t
 
i
n
c
l
u
d
e
d
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
d
a
t
e
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
 
≥
 
6
0
 
d
a
y
s
 
a
f
t
e
r
 
c
o
m
p
l
e
t
i
o
n
 
o
f
 
fi
r
s
t
-
l
i
n
e
 
c
h
e
m
o
t
h
e
r
a
p
y
)
.
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
:
 
P
r
i
m
a
r
y
 
a
n
d
 
s
e
c
o
n
d
a
r
y
 
m
e
a
s
u
r
e
s
 
a
r
e
 
a
p
p
r
o
p
r
i
a
t
e
,
 
b
u
t
 
i
t
 
i
s
 
u
n
c
l
e
a
r
 
h
o
w
 
v
a
l
i
d
 
a
n
d
 
r
e
l
i
a
b
l
e
 
o
t
h
e
r
 
m
e
a
s
u
r
e
s
 
a
r
e
.
 
N
o
 
m
e
a
n
 
o
r
 
S
D
 
r
e
p
o
r
t
e
d
.
I
n
t
e
r
c
e
n
t
r
e
 
v
a
r
i
a
b
i
l
i
t
y
:
 
N
u
m
b
e
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Appendix 7  
List of excluded studies
Excluded trials Reason for exclusion
Chen L, Antras L, Neary M, Dharan B, O’Brien ME. Symptom assessment in small cell 
lung cancer (SCLC) in a randomized trial: a psychometric analysis of Patient Symptom 
Assessment in Lung Cancer (PSALC). J Clin Oncol 2007;25(Suppl.):18101.
Not an RCT
Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M et al. Topotecan and 
paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial 
of the North Central Cancer Treatment Group. J Thoracic Oncol 2006;1:211–17.
Did not include the right 
intervention
Eckardt JR, Ramlau R, Gervais R, Shepherd F, O’Brien M, Ciuleanu T, et al. Compliance with 
oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC). J Clin Oncol 2006;24(Suppl.):7092.
Not an RCT
Gormley N, Edelman MJ, Smith R, Hausner PF, Bedor M, Bisaccia S. Phase II trial of 
docetaxel and topotecan in recurrent and extensive small cell lung cancer. Lung Cancer 
2004;46:S42–3.
Not an RCT
Jotte RM, Reynolds CH, Conkling P, Oliver JW, Allen A. A randomized phase 2 trial of 
amrubicin compared to topotecan as second-line treatments in extensive disease small 
cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol 
2007;25(Suppl.):18064. 
Abstract – not enough 
information on methodology
Jotte RM, Conkling PR, Reynolds C, Allen AR, Oliver JW. A randomized phase II trial of 
amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell 
lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. Journal of Clinical 
Oncology 2008;26(Suppl.):8040.
Abstract – not enough 
information on methodology
Jotte RM, Reynolds C, Conkling PR, Jungnelius U, Oliver J. Amrubicin (Amr) vs topotecan 
as second-line treatment of extensive-disease small cell lung cancer (SCLC) sensitive 
to platinum-based first-line chemotherapy: a randomized phase 2 trial. Ann Oncol 
2008;19:116.
Abstract – not enough 
information on methodology
O’Brien ME, Duh M, Chen L, Antras L, Neary M, Dharan B, et al. Is symptom improvement 
in patients with small cell lung cancer (SCLC) associated with clinical response? 
An analysis using the Patient Symptom Assessment Lung Cancer (PSALC) scale in a 
randomized trial comparing oral topotecan (OT) with best supportive care (BSC). J Clin 
Oncol 2007;25(Suppl.):7725.
Not an RCT
Peacock NW, Hainsworth JD, Switzer AB, Burris HA, Barrett C, Nicolau MF, et al. Weekly 
bolus topotecan as secondary therapy in extensive stage small cell lung cancer: A Minnie 
Pearl Cancer Research Network phase II trial. J Clin Oncol 2004;22(Suppl.):7278.
Not an RCT
Ruotsalainen, Mattson K. Topotecan (T) as second-line therapy following ifosfamide-
carboplatin-etoposide (ICE) and maintenance for small cell lung cancer (SCLC). Lung 
Cancer 2000;29(Suppl.1):217.
Not an RCTDOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Appendix 8  
Tabulation of the critical appraisal of the MS 
against Drummond and colleagues’ checklist
TABLE 67  Critical appraisal checklist66 of economic evaluation
Item
Critical 
appraisal Reviewer comment
Is there a well-defined 
question?
Yes Cost effectiveness of oral topotecan plus BSC compared with BSC alone for 
people with relapsed SCLC, for whom re-treatment with first-line regimen 
is not considered appropriate, and who are unable or unwilling to receive i.v. 
chemotherapy
Is there a clear description of 
alternatives?
Yes (see 
Rationale 
section at 
beginning of 
chapter 4 
of MS)
CAV excluded as ‘topotecan (i.v. and oral) would not provide a cost-effective 
alternative to CAV in the majority of patients given its relatively higher 
acquisition cost’
‘compared with oral topotecan the i.v. formulation has a similar efficacy profile 
but a higher acquisition and administration costs associated. Thus, it is unlikely to 
be a cost-effective alternative to oral topotecan’
The economic evaluation therefore focuses only on the use of oral topotecan in 
relapsed patients with SCLC who are not considered as candidates for standard 
i.v. therapy with CAV, and for whom BSC represents the main option in the 
absence of suitable alternative therapies
Has the correct patient group/
population of interest been 
clearly stated?
? Scope states population as ‘adults with relapsed SCLC, for whom re-treatment 
with first-line regimen is not considered appropriate’. Does not make 
reference to those unable or unwilling to receive i.v. chemotherapy – however, 
this was part of inclusion criteria for O’Brien and colleagues RCT57
Is the correct comparator 
used?
? BSC would be appropriate comparator for patients identified as unsuitable or 
unwilling to receive standard chemotherapy, having progressed following first-
line treatment (and unsuitable for re-treatment with first-line). Appropriate 
given the inclusion criteria for O’Brien and colleagues RCT,57 but at variance 
with scope
Is the study type reasonable? Yes Cost–utility analysis suitable – takes into account life expectancy differences 
(e.g. median OS of 13.9 and 25.9 weeks for BSC and topotecan, respectively) 
and QoL differences (deterioration of 0.20 vs 0.05 over 3-month interval for 
BSC and topotecan respectively) documented in main trial publication
Is the perspective of the 
analysis clearly stated?
Yes NHS and PSS for costs (although PSS costs not explicitly included other than 
in sensitivity analysis)
Patient perspective for outcomes – OS weighted for QoL
Is the perspective employed 
appropriate?
Yes Costs
Only NHS costs included, no PSS costs included. As major difference between 
groups expected to relate to monitoring and administration costs incurred in 
NHS setting, then focus on NHS rather than PSS seems appropriate. However, 
some discussion in sensitivity analysis on inclusion of PSS costs for palliative 
care
Outcomes
Patient perspective adopted; OS, QoL weights based on patient responses to 
EQ-5D (over 12 3-week periods, i.e. maximum follow-up of 36 weeks) with 
values from population survey (Dolan and colleagues80)
continuedAppendix 8
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Item
Critical 
appraisal Reviewer comment
Is effectiveness of the 
intervention established?
Yes Effectiveness data are taken directly from O’Brien trial. Patient level data, 
recording:
• survival [days from randomisation till death, unclear on censoring, other than 
those still alive at final follow-up (reported as six, three in each arm) who 
were assumed to die the following day]
• QoL is measured using EQ-5D. Questions raised during review of MS on 
imputation for missing utility values and effects of LOCF
Has a lifetime horizon 
been used for analysis (has 
a shorter horizon been 
justified)?
Yes The model has used survival as observed in the study – patients who were 
still alive at last follow-up were assumed to die the following day. May 
underestimate life expectancy – may have greater effect on oral topotecan 
plus BSC group. Unlikely to bias in favour of BSC
Are the costs and 
consequences consistent with 
the perspective employed? 
Covered in detail in questions 
below
Yes Costs reported as using NHS and PSS perspective. All included costs are NHS 
– application of an uplift for PSS costs used in sensitivity analysis
Approach to costing is to only include treatment costs for patients receiving 
topotecan, on the assumption that costs of supportive care/symptom control 
are the same for both arms. Referred to in text as ‘a conservative approach’ 
(MS, p. 90). O’Brien and colleagues trial report stated that ‘palliative care 
and radiotherapy were used more frequently in BSC’ (p. 5444 of journal 
publication) – see also table 3 of journal publication. Suggests that excluding 
BSC is unlikely to bias results in favour of BSC
Categories of included cost are:
• Drug acquisition costs of £2500 (using total dose per in mg per m2 BSA and 
patient BSA from trial data set to get total mg per patient). Drug costs £30 
per mg (sourced from November MIMS, BNF price not available when MS 
submitted)
• Drug administration costs of £713 (assuming patients attend secondary care 
to receive drugs once per cycle and unit costs of £180.43 for delivery of 
exclusively oral chemotherapy from “TCHEMTHPYOP” worksheet on NHS 
Reference Costs 2006/07 plus £0.90 dispensing fee, giving a cost of £181.33 
per cycle, for a mean of 3.93 cycles); appears reasonable
• Monitoring costs of £39.30 (assuming £10 per cycle for a mean of 3.93 
cycles); maybe low. Does not include imaging (chest radiograph or CT) while 
on treatment
• Monitoring of patients from treatment cessation till disease progression 
of £758 [assuming an outpatient attendance every 4 weeks, GP visit every 
4 weeks, chest radiograph every 4 weeks and blood tests every 4 weeks. 
Unit costs were £190.51 per outpatient attendance (source), £34.27 per 
GP visit (source), £28.22 per chest radiograph (source) and £3.02 per 
blood test (source). Cost of £9.14 per non-PD day for a mean of 82.9 
days]; chest radiograph for non-treated patients maybe excessive. Clinical 
advisors suggest only use chest radiograph or CT when patients become 
symptomatic
• Costs of treating toxicity – costing non-haematological toxicity on basis 
of reported occurrence (with unit costs estimated by experts) while 
haematological toxicity has been costed on the basis of transfusions, GCSF 
and systemic antibiotic use. Usage as reported in trial
• Costs are reported as composite (as incremental costs in table 4.5 of MS 
and in bottom row of table 4.4) and by each major component (in table 4.4 
of MS)
• Outcomes – appropriate to lifetime horizon, using survival (days) and 
weighting by utilities derived from patients and valued using (UK population) 
tariff
TABLE 67  Critical appraisal checklist66 of economic evaluation (continued)DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Item
Critical 
appraisal Reviewer comment
Is differential timing 
considered?
Yes MS states that 3.5% discount rate has been applied, but with majority of 
survival below 1 year, this has little effect
Is incremental analysis 
performed?
Yes Costs of topotecan acquisition/administration/monitoring and treatment 
of toxicity, plus costs of non-progressive days (after finishing topotecan 
treatment) are only costs included. No costs included for BSC
Incremental life-years and incremental QALYs are calculated and ICERs 
presented for both life-years gained and QALYs gained
Is sensitivity analysis 
undertaken and presented 
clearly? 
Yes Deterministic sensitivity analyses were undertaken on:
• Monitoring costs (from halving to doubling monitoring costs) – little 
variability (26,740–27,019)
• Discount rates (see above comment on relevance of discounting) – little 
variability (26,217–27,250)
• PSS costs (add 3% to mean incremental cost per patient versus add 10% to 
mean incremental cost per patient) – little variability (27,638–29,516)
• Cost of additional non-PD survival (from halving to doubling non-PD costs)  
– medium variability (25,039–30,421)
• Cost of treating adverse events (from halving to doubling adverse event 
costs) – large variability (22,906–34,688)
• QoL (methods of imputation for missing values) large variability (22,512–
33,816)
• Drug administration costs [extreme scenarios of drugs administered on 
single visit to GP (low) versus daily administration in outpatients (high)] large 
variability (24,115–40,253). Inclusion of scenario where patients managed in 
general practice does not seem consistent with SmPC for topotecan stating 
requirement for specialist management
• Bootstrap analyses conducted and reported as scatter plots and summarised 
as means and 95% CIs
TABLE 67  Critical appraisal checklist66 of economic evaluation (continued)Appendix 8
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TABLE 68  External validity of economic studies
Item/study
1. Patient group
Are the patients in the study similar to those of 
interest in England and Wales?
? subgroup of relapsed patients with SCLC
MS estimates at approximately 5% of new SCLC cases per year 
(approximately150 p.a.)
2. Health care system/setting
Comparability to England and Wales?
Comparability of available alternatives?
Similar levels of resources?
Institutional arrangements comparable?

3. Treatment
Comparability with clinical management?

4. Resource costs
Comparability between study and setting/
population of interest?

Resource use from multicentre trial. Unit costs applied for UK – based 
on published national sources or expert opinion from UK practitioners
? = unclear or unknown;  = judged item suitable to generalise to England and Wales with or without some readjustment.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Overall survival
As described in the main body of the text, the survival model adopted for this report was developed 
using linear regression to estimate the parameters of a linear transformation of the observed Kaplan–
Meier estimates for OS from the RCT by O’Brien and colleagues.57 Two parametric survival functions 
were estimated, a Weibull survival function and a log-logistic survival function, which were compared for 
goodness of fit to the observed survival functions for best supportive care and for oral topotecan plus BSC.
For a Weibull distribution the survival function is given by
S t t ( ) exp( ) = −λ
γ
with scale parameter λ and shape γ. Taking the log of both sides gives
log ( ) S t t ( )= −λ
γ
Taking the log of both sides again, gives
log log ( ) log( ) log( ) − ( ) ( )= + S t t λ γ
which is a linear function and can be fit using least squares methods to provide estimates of λ and γ.
Similarly, the log-logistic survival function, given by
S t t ( )= +− 



−
1
1
λ
γ
can be transformed to the linear function
log
( )
( )
log( ) log( )
1− 
 

  = +
S t
S t
t λ β
This can be fit using least squares methods to provide estimates of λ and β.
The following tables report the parameter estimates and measures of goodness of fit for linear regressions, 
estimated using stata, for a Weibull survival function and for a log-logistic survival function. In both cases 
an additional parameter (Treat) was included in the regression – this was a dummy (0,1) variable that 
indicated whether the observed survival data were for the topotecan plus BSC arm (Treat = 1) or the BSC-
only arm (Treat = 0).
Appendix 9  
Survival modelling methodologyAppendix 9
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	 Source	|	SS	 df	 MS	 Number	of	obs	 =	 240
----------+----------------------------------	 F(2,	237)	 =	 2253.43
	 Model	|	304.815408	 2	 152.407704	 Prob	>	 F	 =	 0.0000
	Residual	|	16.0291723	 237	 .067633638	 R-squared	 =	 0.9500
----------+----------------------------------	 Adj	R-squared	 =	 0.9496
	 Total	|	320.84458	 239	 1.3424459	 Root	MSE	 =	 .26006
------------------------------------------------------------------------------
	 weibull	|	Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
----------+--------------------------------------------------------------------
	 ln_time	|	1.093707	 .0163295	 66.98	 0.000	 1.061538	 1.125877
	 treat	|	-.6442615	 .0344367	 –18.71	 0.000	 -.7121027	 -.5764203
	 _cons	|	–5.505614	 .0792441	 –69.48	 0.000	 –5.661727	 –5.349502
------------------------------------------------------------------------------
Regression output for the Weibull survival function:
Goodness of fit
Regression output for the log-logistic survival function:
Goodness of fit
Both models appear to fit the data well, with the log-logistic having a superior fit. This can be more 
readily identified by graphing the survival functions. For each parametric survival function we first plot 
the transformed Kaplan–Meier estimates and the fitted linear regressions. In a second figure we show the 
untransformed Kaplan–Meier estimates and the fitted survival functions for oral topotecan plus BSC and 
for BSC alone.
	 Source	|	 SS	 df	 MS	 Number	of	obs	 =	 240
-------------+------------------------------	 F(2,	237)	 =	 5584.19
	 Model	|	 607.177663	 2	 303.588831	 Prob	>	 F	 =	 0.0000
	 Residual	|	 12.8846967	 237	 .054365809	 R-squared	 =	 0.9792
-------------+------------------------------	 Adj	R-squared	 =	 0.9790
	 Total	|	 620.06236	 239	 2.59440318	 Root	MSE	 =	 .23316
------------------------------------------------------------------------------
	logLogistic	|	 Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
-------------+----------------------------------------------------------------
	 ln_time	|	 1.542566	 .0146404	 105.36	 0.000	 1.513724	 1.571408
	 treat	|	 -.9385921	 .0308748	 –30.40	 0.000	 -.9994161	 -.877768
	 _cons	|	 –6.984087	 .0710474	 –98.30	 0.000	 –7.124053	 –6.844122
------------------------------------------------------------------------------DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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FIGURE 11  Transformed Kaplan–Meier survival curves from O’Brien and colleagues,57 plus linear fit (Weibull).
FIGURE 12   Kaplan–Meier survival curves from O’Brien and colleagues,57 plus Weibull survival curves.Appendix 9
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The transformed log-logistic survival functions appear to be closer to linear functions than the 
transformed Weibull survival functions. The Weibull survival functions are likely to underestimate survival 
probabilities at higher survival durations when compared with the Kaplan–Meier estimates. The modelled 
probability of survival at 100 weeks is very close to zero for the Weibull survival function, whereas the 
Kaplan–Meier estimate is around 5%. In contrast, for the log-logistic survival function the modelled 
probability of survival at 100 weeks is around 4%.
The interpretation of the parameter coefficient for the dummy variable Treat is more obscure in the log-
logistic model than in the Weibull model, where its absolute value can be interpreted as the HR for oral 
topotecan plus BSC relative to BSC alone for OS. This value, 0.644, can be compared directly with the 
unadjusted HR of 0.64 and the adjusted HR of 0.61 reported in the main trial publication by O’Brien and 
colleagues.57
Time to progression
A similar procedure was used to estimate an appropriate function to model the mean TTP. In this case, 
three potential survival functions were modelled, including an exponential function (in addition to the 
Weibull and log-logistic survival functions).
The risk of disease progression was derived from the reported median TTP using an exponential 
approximation72
λ = –ln(S)/t
where S is the proportion of patients surviving (or in this case without disease progression) at time t. For 
the median TTP the value of S in the above equation is set, by definition, at 0.5, while t = 16.3 weeks 
(as presented in Chapter 3 of this report, under Oral topotecan plus BSC versus BSC alone). The mean 
TTP can be calculated by taking the reciprocal of the risk of disease progression (1/λ). This approach was 
used in a previous TAR on second-line chemotherapies for advanced ovarian cancer,69 which included 
topotecan. The accuracy of the estimate of the mean TTP depends on the adequacy of the exponential 
approximation, used to convert the median TTP to a risk of disease progression. The appropriateness of 
this transformation cannot be assessed without reference to the full survival function for TTP, which was 
not reported in the RCT publication by O’Brien and colleagues.57 This represents a substantial source of 
uncertainty in the model.
The economic model submitted with the MS contains participant-level data from the RCT by O’Brien 
and colleagues, including TTP for patients in the oral topotecan group. The figure below charts the 
exponential survival function against the Kaplan–Meier estimates for TTP using the patient-level data 
submitted with manufacturer’s economic model. This suggests that the model fits the observed data 
well, up to the median survival. However, the fit is much poorer beyond that point and may significantly 
underestimate PFS when compared with the Kaplan–Meier estimate.
Based on the area under the curve, the estimated mean TTP using the Kaplan–Meier estimates is 30.3 
weeks compared with an estimate of 23.52 using the exponential function – thus underestimating PFS 
by around 48 days. It should be noted that there is considerable uncertainty in the survival functions at 
longer survival durations, with small numbers of patients included in the analysis above 100 weeks.
To retain compatibility with the methods of estimating the OS functions, the survival function for disease 
progression was estimated from linear transformations of the Kaplan–Meier estimate of the survival 
function for TTP.Appendix 9
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FIGURE 15  Kaplan–Meier survival estimate for time to progression with 95% confidence interval, with modelled exponential suvival 
function.
Regression output for the Weibull survival function:
Goodness of fit
	 Source	|	SS	 df	 MS	 Number	of	obs	 =	 104
----------+---------------------------------	 F(1,	102)	 =	 940.94
	 Model	|	129.325342	 1	 129.325342	 Prob	>	 F	 =	 0.0000
	Residual	|	14.0191996	 102	 .137443133	 R-squared	 =	 0.9022
----------+---------------------------------	 Adj	R-squared	 =	 0.9012
	 Total	|	143.344542	 103	 1.39169458	 Root	MSE	 =	 .37073
------------------------------------------------------------------------------
	 weibull	|	Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
----------+-------------------------------------------------------------------
	 ln_time	|	1.239133	 .0403959	 30.67	 0.000	 1.159008	 1.319258
	 _cons	|	–6.361008	 .1872409	 –33.97	 0.000	 –6.732399	 –5.989616
------------------------------------------------------------------------------DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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	 Source	|	 SS	 df	 MS	 Number	of	obs	 =	 104
-------------+------------------------------	 F(1,	102)	 =	 2437.28
	 Model	|	 230.206518	 1	 230.206518	 Prob	>	 F	 =	 0.0000
	 Residual	|	 9.63412526	 102	 .094452208	 R-squared	 =	 0.9598
-------------+------------------------------	 Adj	R-squared	 =	 0.9594
	 Total	|	 239.840644	 103	 2.32854994	 Root	MSE	 =	 .30733
------------------------------------------------------------------------------
	 logLogistic	|	 Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
-------------+----------------------------------------------------------------
	 ln_time	|	 1.653237	 .0334875	 49.37	 0.000	 1.586814	 1.719659
	 _cons	|	 –7.803979	 .1552191	 –50.28	 0.000	 –8.111856	 –7.496103
------------------------------------------------------------------------------
Regression output for the log-logistic survival function:
Goodness of fit
As for OS, the modelled survival functions for TTP were plotted against the Kaplan–Meier estimates.
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FIGURE 16  Kaplan–Meier survival estimate for time to progression with 95% confidence interval, with modelled Weibull suvival function.Appendix 9
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FIGURE 17   Kaplan–Meier survival estimate for time to progression with 95% confidence interval, with modelled log-logistic suvival 
function.
The log-logistic function appears to give a better fit than either the simple exponential approximation or 
the regression-based Weibull function. Comparing the mean TTP estimated using each of these functions, 
we get 22.7 weeks with the Weibull function and 28.5 weeks using the log-logistic function. While the log-
logistic survival function clearly fits the observed data better than the alternative functions (Weibull and 
exponential), all three appear to underestimate mean TTP compared with the area under the Kaplan–
Meier curve. However, it should be borne in mind, as noted above, that there is considerable uncertainty 
in the survival functions at longer survival durations, as indicated by the wide 95% CI, with the data 
contributing to estimated PFS above 110 weeks being contributed by two patients.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Overall survival
Correlation between parameters in the OS regression is handled using the Cholesky decomposition 
method.82 The Cholesky decomposition of the variance–covariance matrix for the regression used to fit the 
log-logistic survival function is shown below:
ln(t) Treat ln(λ)
ln(t) 0.014640 0.000000 0.000000
Treat –0.006566 0.030169 0.000000
ln(λ) –0.067545 –0.016090 0.015051
The parameter estimates for the regression are shown below:
ln(t) Treat ln(λ)
1.542566 –0.938592 –6.984087
In each simulation three draws are taken from standard normal distributions (mean = 0, SD = 1), labelled 
here as z1, z2 and z3. Three new variables (Tz1, Tz2 and Tz3) are defined, by multiplying elements of the 
Cholesky decomposition matrix (C) by the values drawn from standard normal distributions (z1, z2 and z3). 
Identifying elements of the Cholesky decomposition matrix as C[i,j] where i is the row number and j the 
column number, then:
Tz1 = z1 × C[1,1]
Tz2 = z1 × C[2,1] + z2 × C[2,2]
Tz3 = z1 × C[3,1] + z2 × C[3,2] + z3 × C[3,3]
For each simulation the sampled values of the parameter estimates are therefore defined as:
Tz1 + ln(t)
Tz2 + Treat
Tz3 + ln(λ)
The same approach was used to handle correlation between parameters in the model used to estimate 
TTP for patients in the oral topotecan cohort.
Probability of adverse events
The probability of adverse events is based on the number of patients experiencing each grade of adverse 
event, as reported in the CSR for study 487 (included as appendix 5 of the MS). These are sampled using 
the procedure outlined in Briggs and colleagues82 for sampling from a Dirichlet distribution. Variables 
x0, x1 … x4 (corresponding to grades 0–4 for a given toxicity) are drawn from independent gamma 
Appendix 10  
Input parameters for probabilistic 
sensitivity analysisAppendix 10
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distributions with shape parameters α0,	α1 …		α4 (corresponding to the count of patients experiencing the 
given grades of toxicity) and a common scale parameter of 1.
Thus the simulated count for each grade (j) of a given toxicity is xj ∼ γ(αj,1).
The simulated proportion is calculated by dividing the simulated count for each grade by the sum of the 
simulated counts for all grades of the relevant toxicity
x
x
j
j j= ∑ 0
4
Health-state utility
The rate of deterioration in QoL per 3-month interval for oral topotecan plus BSC and for BSC is 
sampled across the 95% CI reported by O’Brien and colleagues.57 See table below:
Cohort Point estimate LCI UCI SE Distribution
Topotecan + BSC –0.05 –0.11 0.02 0.03827 Normal
BSC –0.20 –0.27 –0.12 0.03316 Normal
Chemotherapy courses and BSA
The mean (and SE) for the number of courses of oral topotecan and patients’ BSA were estimated from 
data included in the manufacturer’s economic model. These were simulated using normal distributions.
Variable Mean SE Distribution
Number of courses per patient 3.9296 0.2649 Normal
BSA 1.8404 0.0240 Normal
Costs
Costs included in the PSA were those related to outpatient provision of chemotherapy, general medical 
management in outpatients, inpatient and outpatient management of adverse events, and palliative care 
costs. Drug costs were not sampled during the PSA, but were included at values quoted in the BNF.
Costs derived from NHS Reference Costs were sampled using estimated ‘SEs’. These assumed that a 
variation of plus or minus 25% was an appropriate CI for the average reference costs. The estimated SEs 
are shown in column 3 of the table below. Parameters for gamma distributions (shown in columns labelled 
‘Alpha’ and ‘Beta’) were derived using the ‘method of moments’,82 based on the means and estimated ‘SEs’. 
The simulated values were inflated to 2007/08 prices using appropriate inflation indices, as for the base-
case and deterministic sensitivity analyses.
The estimated SE for palliative care costs was derived using the minimum and maximum values presented 
by Oliver and colleagues,49 as these were the only summary data for the distribution of palliative care costs 
reported.DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Item Mean ‘SE’ Alpha Beta Distribution
Oral topotecan (per mg) 30.00
Intravenous topotecan (per course) 1494.75
Outpatient attendance for oral chemotherapy 178.99 15.94 126.07 1.4198 Gamma
FBC 2.90
U&E 4.70
LFT 4.70
Chest radiograph 27.71 2.47 126.07 0.2198 Gamma
Day-case admission 355.43 31.66 126.07 2.8193 Gamma
Inpatient elective excess bed-day 241.76 21.53 126.07 1.9177 Gamma
Inpatient non-elective excess bed-day 181.73 16.18 126.07 1.4415 Gamma
Outpatient attendance 200.78 17.88 126.07 1.5926 Gamma
Intensive care (per day) 989.82 88.15 126.07 7.8513 Gamma
GP visit 36.00
Cost of palliative care (per patient) 3495.00 1168.46 8.95 390.6433 Gamma
Antibody screen 10.40
Electronic cross-match 25.00
Serological cross-match 30.90
Standard red cells (per unit) 133.90
Platelets (per unit) 208.46
Blood transfusion (per transfusion) 78.80
Platelets transfusion (per transfusion) 705.00DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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O
’Brien and colleagues57 and Chen and 
colleagues64 briefly reported on a pooled 
analysis of utility data, collected using the EQ-5D 
and valued using a population tariff, using a mixed 
model (to account for the inclusion of repeated 
observations for trial participants). The CSR for 
Study SK&F-104864/478, submitted to NICE as 
appendix 5 of the MS, contains slightly more 
detail on the methods used. The CSR makes clear 
that the analysis has used EQ-5D utility scores, 
derived using responses from patients in the RCT 
by O’Brien and colleagues57 and valued using the 
tariff reported by Dolan and colleagues.80 The 
EQ-5D was administered at baseline and at each 
clinic visit (every 3 weeks) – missing data for the 
EQ-5D are not reported or discussed in the main 
trial publication (O’Brien and colleagues57) or the 
CSR. The CSR reports that the mixed model was 
estimated using restricted maximum likelihood 
and included treatment, baseline EQ-5D utility, 
time and a treatment-by-time interaction as fixed 
covariates. The random effects were intercept 
and time, while course of therapy was included 
as a repeated effect. An unstructured covariance 
structure was used for the random effects and a 
spatial covariance structure for the repeated effect. 
No further detail of this analysis is provided in the 
CSR.
Both O’Brien and colleagues57 and Chen and 
colleagues64 state that the ‘rate of deterioration’ 
in utility was –0.05 per 3-month period for oral 
topotecan plus BSC, and –0.20 per 3-month period 
for BSC. We interpreted this to indicate that for 
each 3-month period the mean utility reduces from 
baseline by 5% for the oral topotecan plus BSC 
cohort and by 20% for the cohort receiving BSC 
alone.
Assuming a baseline utility for patients in both 
cohorts of 0.70, based on the reported baseline 
utility of patients in the RCT by O’Brien and 
colleagues who contributed data to the pooled 
analysis (0.72 for oral topotecan plus BSC and 0.68 
for BSC), we estimated mean utility over time for 
each arm over a period of 12 months as:
Time (months)
Oral 
topotecan + BSC BSC
0 0.7000 0.7000
3 0.6650 0.5600
6 0.6318 0.4480
9 0.6002 0.3584
12 0.5702 0.2867
To estimate a daily rate of deterioration in utility 
we subtracted the natural log of the baseline utility 
from the natural log of the value at 3 months, for 
each arm:
–0.4080 – –0.3567 = –0.0513 (for oral topotecan 
plus BSC), and
–0.5798 – –0.3567 = –0.2231 (for BSC)
Dividing these values by the mean number of days 
in 3 months (91.3125) gives –0.000562 for oral 
topotecan plus BSC and –0.002444 for BSC. To 
estimate the utility at a given number of days from 
baseline, simply enter the appropriate values in the 
following formula:
–0.3567 + utility decrement × days
(where –0.3567 is the natural log of 0.7, the 
assumed baseline utility value) and exponentiate 
the result. For example, to calculate the utility value 
for oral topotecan plus BSC and for BSC at 1 year:
exp(ln(0.7) + –0.000562*(365.25)) = 0.5702 
(for oral topotecan plus BSC), and
exp(ln(0.7) + –0.002444*(365.25)) = 0.2867 
(for BSC)
Appendix 11  
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Specific questions regarding the management of patients being treated with topotecan (in oral or i.v. form) 
are listed below:
What tests would be required prior to starting treatment with topotecan?
Assume that a FBC is required as the SmPC states that ‘prior to administration of the first course of 
topotecan, patients must have a baseline neutrophil count of ≥ 1.5 × 109/l, a platelet count of ≥ 100 × 109/l 
and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary)’.
•  Would any other tests be required prior to starting treatment with topotecan?
What tests would be used to monitor patients receiving chemotherapy 
with topotecan?
Assume that haematological toxicity is assessed by FBC.
•  Would this be assessed only at start of each treatment cycle or would this happen more frequently?
•  Would assessment/frequency of assessment for haematological toxicity differ between oral versus i.v. 
topotecan?
•  What tests would be routinely requested for assessing other toxicities? Please specify types of test, the 
frequency of testing and toxicities being assessed.
•  Would patients receiving oral topotecan have additional monitoring in primary care (e.g. visits by 
district nurses)? How frequently would patients receiving oral topotecan attend for treatment or 
monitoring during each treatment cycle?
Would patients attending for topotecan be required to take any 
premedications or concomitant medication?
•  Would patients require premedication prior to topotecan by i.v. infusion?
•  Would patients require premedication prior to oral topotecan?
•  Would patients require concomitant medication with topotecan by i.v. infusion?
•  Would patients require concomitant medication with oral topotecan?
•  The trial report by O’Brien and colleagues specifically refers to a proportion (3%) of patients receiving 
GCSF – would this be prescribed as prophylaxis against neutropenia?
•  The trial report by O’Brien and colleagues specifically refers to a proportion of patients (3%) receiving 
erythropoietin – would this be prescribed as prophylaxis?
Topotecan for i.v. infusion is supplied as powder for reconstitution.
SmPC states ‘saline (0.9% w/v sodium chloride i.v. infusion or 5% w/v glucose i.v. infusion) is required for 
reconstitution of powder to a final concentration of between 25 and 50 microgram/ml’.
•  Can you indicate the quantity of saline required to achieve this concentration for a patient requiring a 
dose of 2.7 mg per day (i.e. dosage of 1.5 mg/m2 per day for a patient with a BSA of 1.8 m2)?
Appendix 13  
Questions to clinical experts – management of 
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and management of treatment-related toxicityAppendix 13
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Dose escalation/dose reduction
•  If a patient has their chemotherapy dose increased, due to lack of efficacy, in one cycle, does the dose 
remain at the escalated level for their remaining cycles of treatment on a given agent?
•  If a patient has their chemotherapy dose reduced, due to toxicity, in one cycle, does the dose remain 
at the reduced level for their remaining cycles of treatment on a given agent?
If the exact dosage of oral topotecan is not available would you 
recommend rounding the dosage up or down?
For example, the exact dosage for a patient with BSA of 1.8 m2 would be 4.14 mg per day, at a dosing 
schedule of 2.3 mg/m2 per day. With oral topotecan available in 1- and 0.25-mg capsules would you 
recommend rounding up to 4.25 mg per day or rounding down to 4.00 mg per day?
Treatment of toxicity/adverse events
A previous review conducted for NICE [Main and colleagues, Health Technol Assess 2006; 10(9)], which 
included topotecan, reported estimates of the costs of managing treatment-related toxicity. While the 
review was concerned with the use of topotecan for treatment of advanced ovarian cancer, we are aware 
that the dosage, frequency of administration and cycle length are the same for advanced ovarian cancer 
and for SSLC.
Would it be reasonable to adopt similar assumptions for managing 
(topotecan) treatment-related toxicity in relapsed patients with SCLC as 
for advanced ovarian cancer patients?
The assumptions and costs adopted in the advanced ovarian cancer review (which were derived from one 
of the manufacturers’ submissions to the NICE appraisal) are listed below. First, we list the assumptions 
with regard to how patients are managed, as outpatient, day case or inpatient, and, second, the 
assumptions regarding drug treatment or specific interventions (such as transfusions) provided.
TABLE 73  Management of haematological toxicity
Toxicity/adverse event Grade Managed as: Length of stay
Neutropenia 3 Outpatient Single attendance by 50% of affected patients
4 Inpatient 3.5 days (range 2–5 days)
Thrombocytopenia 3 No treatment
4 Day case All patients attend for platelet transfusion
Anaemia 3 Day case Single attendance for all affected patients
4 Day case Single attendance for all affected patients
Sepsis 3 Inpatient Average 4.5 days (range 3–6 days)
4 Inpatient Total stay of 10 days on average, with an average of 5 days 
(range 3–7 days) in ICU and 5 days (range 3–7 days) on 
the ward
No assumptions were listed for febrile neutropenia – would it be reasonable to regard these as a subset of 
Grade 4 neutropenia and apply the same management assumptions?DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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TABLE 74  Management of non-haematological toxicity
Toxicity/adverse event Grade Managed as Length of stay
Diarrhoea 3 Inpatient 5 days
4 Inpatient 5 days 
Vomiting 3 Outpatient Single attendance for all affected patients
4 Inpatient 5 days
TABLE 75  Drug treatment or specific interventions for haematological toxicity
Toxicity/adverse event Grade Drug/intervention Quantity (total cost)
Neutropenia 3 Ciprofloxacin 6 (£1.50)
4 Ciprofloxacin
GCSF
6 (£1.50)
5 (£77.03)
Thrombocytopenia 3 No treatment
4 Platelet transfusion
Type and cross
1 (£78.80)
1 (£18.00)
Anaemia 3 Platelet transfusion
Type and cross
1 (£78.80)
1 (£18.00)
4 Platelet transfusion
Type and cross
1 (£78.80)
1 (£18.00)
Sepsis 3 Gentamicin
Tazocin
1 (£61.25)
1 (£368.48)
4 Gentamicin
Tazocin
Saline
Fluconzole i.v.
1 (£61.25)
1 (£368.48)
1 (£42.00)
1 (£204.96)
TABLE 76  Drug treatment or specific interventions non-haematological toxicity
Toxicity/adverse event Grade Drug/intervention Quantity (total cost)
Diarrhoea 3 Buscopan
Ciprofloxacin
Codeine
Loperamide
1 (£1.39)
6 (£1.50)
1 (£0.33)
2.5 (£0.08)
4 Buscopan
Ciprofloxacin
Codeine
Loperamide
1 (£1.39)
6 (£1.50)
1 (£0.33)
2.5 (£0.08)
Vomiting 3 Dexamethasone
Granisetron
6 (£0.51)
1 (£383.95)
4 Saline
Dexamethasone i.v.
Granisetron i.v.
Cyclizine
1 (£42.00)
1 (£6.60)
1 (£360.00)
1 (£8.55)DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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Appendix 14  
Relative risks of adverse events 
– i.v. versus oral topotecan
Haematological adverse event
Neutropenia RR SE(lnRR)
95% CI
Lower Upper
Grade 3 Eckardt 0.9035 0.2019 0.6083 1.3420 75.2
von Pawel 1.2483 0.3514 0.6269 2.4856 24.8
Pooled 0.9789 0.1750 0.6946 1.3796
Grade 4 Eckardt 1.3663 0.1065 1.1089 1.6835 80.0
von Pawel 1.9071 0.2128 1.2567 2.8941 20.0
Pooled 1.4607 0.0952 1.2119 1.7605
Thrombocytopenia RR SE(lnRR)
95% CI
Weight (%) Lower Upper
Grade 3 Eckardt 1.2667 0.2152 0.8308 1.9313 71.4
von Pawel 0.9623 0.3397 0.4945 1.8725 28.6
Pooled 1.1708 0.1818 0.8198 1.6719
Grade 4 Eckardt 0.6279 0.2167 0.4106 0.9602 70.1
von Pawel 0.8935 0.3315 0.4666 1.7110 29.9
Pooled 0.6979 0.1814 0.4891 0.9958
Anaemia RR SE(lnRR)
95% CI
Weight (%) Lower Upper
Grade 3 Eckardt 1.6154 0.2212 1.0471 2.4922 62.9
von Pawel 1.3747 0.2880 0.7817 2.4174 37.1
Pooled 1.5215 0.1754 1.0788 2.1459
Grade 4 Eckardt 0.5000 0.6014 0.1538 1.6251 72.7
von Pawel 0.9623 0.9806 0.1408 6.5760 27.3
Pooled 0.5980 0.5127 0.2189 1.6333Appendix 14
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Non-haematological adverse events
Diarrhoea RR SE(lnRR)
95% CI
Weight (%) Lower Upper
Grade 2 Eckardt 0.3524 0.3942 0.1627 0.7631 87.91
von Pawel 0.1606 1.0628 0.0200 1.2896 12.09
Pooled 0.3205 0.3696 0.1553 0.6613
Grade 3 Eckardt 0.1689 0.7552 0.0384 0.7418 67.10
von Pawel 0.1927 1.0784 0.0233 1.5954 32.90
Pooled 0.1764 0.6186 0.0525 0.5929
Grade 4 Eckardt 1.0132 0.9934 0.1446 7.1006 66.54
von Pawel 0.9636 1.4011 0.0618 15.0138 33.46
Pooled 0.9963 0.8104 0.2035 4.8776
Nausea RR SE(lnRR)
95% CI
Weight (%) Lower Upper
Grade 3 Eckardt 0.5789 0.6163 0.1730 1.9373 62.38
von Pawel 0.9636 0.7935 0.2035 4.5638 37.62
Pooled 0.7013 0.4867 0.2701 1.8205
Grade 4 Eckardt 2.0263 1.2194 0.1857 22.1136 56.90
von Pawel 0.9636 1.4011 0.0618 15.0138 43.10
Pooled 1.4709 0.9198 0.2425 8.9232
Vomiting RR SE(lnRR)
95% CI
Weight (%) Lower Upper
Grade 3 Eckardt 0.6079 0.7213 0.1479 2.4992 45.77
von Pawel 0.4130 0.6627 0.1127 1.5136 54.23
Pooled 0.4929 0.4880 0.1894 1.2828
Grade 4 Eckardt 1.0132 0.9934 0.1446 7.1006 66.54
von Pawel 0.9636 1.4011 0.0618 15.0138 33.46
Pooled 0.9963 0.8104 0.2035 4.8776DOI: 10.3310/hta14190  Health Technology Assessment 2010; Vol. 14: No. 19
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P
lots of the Kaplan–Meier estimates of TTP for patients treated with oral topotecan or i.v. topotecan 
in the RCTs reported by von Pawel and colleagues58 and Eckardt and colleagues56 were scanned 
using techdig software and then imported into microsoft excel. These were transformed, as described in 
Appendix 9, to be fit using least squares methods and the data were analysed using stata 9.
A log-logistic survival function for TTP was estimated, as for oral topotecan (described in Appendix 9), 
with the addition of a dummy (0,1) variable to indicate whether the data were for the oral topotecan arm 
(IV_Topo = 0) or the i.v. topotecan arm (IV_Topo = 1).
Regression output for log-logistic survival function for TTP in the RCT reported by von Pawel and 
colleagues:58
Regression output for log-logistic survival function for TTP in the RCT reported by Eckardt and 
colleagues:56
The coefficient for the dummy variable, IV_Topo, has opposite signs in the two regressions – as would 
be expected since the two trials gave inconsistent results in terms of the relative TTP with i.v. and oral 
formulations of topotecan. In the RCT reported by von Pawel and colleagues58 median TTP was shorter 
for i.v. topotecan (13 weeks compared with 15 weeks for i.v. and oral topotecan, respectively), whereas 
in the RCT reported by Eckardt and colleagues56 median TTP was longer for i.v. topotecan (14.6 weeks 
compared with 11.9 weeks for i.v. and oral topotecan, respectively). Median TTP for oral topotecan in 
Appendix 15  
Estimating relative TTP for i.v. 
topotecan versus oral topotecan
	 Source	|	 SS	 df	 MS	 Number	of	obs	 =	 118
-------------+------------------------------	 F(2,	115)	 =	 1117.30
	 Model	|	 352.437589	 2	 176.218795	 Prob	>	 F	 =	 0.0000
	 Residual	|	 18.1375774	 115	 .157718064	 R-squared	 =	 0.9511
-------------+------------------------------	 Adj	R-squared	 =	 0.9502
	 Total	|	 370.575167	 117	 3.16730912	 Root	MSE	 =	 .39714
------------------------------------------------------------------------------
	logLogistic	|	 Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
-------------+----------------------------------------------------------------
	 ln_time	|	 2.00121	 .0423367	 47.27	 0.000	 1.917349	 2.085071
	 IV_Topo	|.2709251	 .07345	 3.69	 0.000	 .1254348	 .4164153
	 _cons	|	 –5.217638	 .125721	 –41.50	 0.000	 –5.466667	 –4.968609
------------------------------------------------------------------------------
	 Source	|	 SS	 df	 MS	 Number	of	obs	 =	 148
-------------+------------------------------	 F(2,	145)	 =	 1848.82
	 Model	|	 435.650575	 2	 217.825288	 Prob	>	 F	 =	 0.0000
	 Residual	|	 17.0837308	 145	 .117818833	 R-squared	 =	 0.9623
-------------+------------------------------	 Adj	R-squared	 =	 0.9617
	 Total	|	 452.734306	 147	 3.07982521	 Root	MSE	 =	 .34325
------------------------------------------------------------------------------
	logLogistic	|	 Coef.	 Std.	Err.	 t	 P>|t|	 [95%	Conf.	Interval]
-------------+----------------------------------------------------------------
	 ln_time	|	 1.812713	 .0298959	 60.63	 0.000	 1.753625	 1.871801
	 IV_Topo	|	 -.2290531	 .0587501	 –3.90	 0.000	 -.3451704	 -.1129359
	 _cons	|	 –4.810578	 .0955714	 –50.33	 0.000	 –4.999472	 –4.621685
------------------------------------------------------------------------------Appendix 15
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both trials is shorter than that reported in the RCT by O’Brien and colleagues,57 where median TTP for 
oral topotecan was 16.3 weeks.
IV_Topo was included as an additional covariate in the regression model estimated for TTP (described in 
Appendix 9), taking values estimated in the regressions above, to estimate the TTP for patients included 
in the model for oral topotecan, if they were treated with i.v. topotecan. This variable affects only the 
duration of post-treatment, non-progressive disease survival. Estimated median TTP using the model is 
reported in Table 77 below.
TABLE 77  Estimating median TTP using the regression model
Median TTP (weeks) Mean TTP (weeks)
Oral topotecan 16.03 28.30
Intravenous topotecan (based on von Pawel and colleagues58) 13.61 24.37
Intravenous topotecan (based on Eckardt and colleagues56) 18.41 32.07Health Technology Assessment reports 
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